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ABSTRACT OF DISSERTATION 
 
 
 
METHYLPHENIDATE AND ATOMOXETINE TREATMENT DURING ADOLESCENCE 
IN THE SPONTANEOUSLY HYPERTENSIVE RAT:  
MECHANISMS UNDERLYING HIGH COCAINE ABUSE LIABILITY  
IN ATTENTION DEFICIT/HYPERACTIVITY DISORDER 
 
 
Effects of pharmacotherapies for Attention Deficit/Hyperactivity Disorder 
(ADHD) on cocaine abuse liability in ADHD are not understood. Spontaneously 
Hypertensive Rats (SHR), an ADHD model, exhibited greater cocaine self-administration 
than control Wistar-Kyoto and Wistar rats. Methylphenidate, but not atomoxetine 
during adolescence enhanced cocaine self-administration in adult SHRs compared to 
controls. The mesocortical dopaminergic system, including medial prefrontal (mPFC) 
and orbitofrontal (OFC) cortices, is important for ADHD and cocaine addiction. 
Dopamine and norepinephrine transporter (DAT and NET) are molecular targets for 
methylphenidate, atomoxetine and cocaine action.  
In the current studies, SHR, Wistar-Kyoto and Wistar were administered 
methylphenidate (1.5 mg/kg/day, p.o.), atomoxetine (0.3 mg/kg/day, i.p.) or vehicle 
during adolescence (postnatal day 28-55). During adulthood (>77 days), DAT and NET 
functions in mPFC and OFC were determined as neurochemical mechanisms and 
locomotor sensitization to cocaine, and impulsivity under differential reinforcement of 
low rates 30-second (DRL30) schedule were evaluated as behavioral mechanisms 
associated with greater cocaine self-administration in methylphenidate-treated SHRs.   
Maximal velocity of [3H]dopamine uptake (Vmax) by DAT and DAT cellular 
distribution in mPFC and OFC did not differ between vehicle-control, adult SHR, Wistar-
Kyoto and Wistar. Methylphenidate increased DAT Vmax, but not cell-surface 
expression, in SHR mPFC. In contrast, atomoxetine decreased Vmax and cell-surface 
expression in SHR OFC. Compared to control strains, norepinephrine uptake by NET in 
the OFC was increased in vehicle-administered SHR; methylphenidate during 
adolescence normalized NET function in SHR OFC. Locomotor sensitization was greater 
in SHR compared to control, and was not altered by methylphenidate.  Under DRL30, 
 
 
methylphenidate increased burst responses in adult SHR compared to vehicle control as 
well as methylphenidate-treated Wistar-Kyoto and Wistar, indicating increased 
impulsivity.  
Increased OFC NET function, increased impulsivity and cocaine sensitivity may be 
the neurobehavioral mechanisms associated with the increased cocaine self-
administration in SHR. Increased mPFC DAT function may underlie the enhanced 
impulsivity and cocaine self-administration in SHR administered methylphenidate during 
adolescence. Decreased OFC DAT function from atomoxetine-treated SHR may explain 
the reduced cocaine self-administration relative to methylphenidate. Thus, 
methylphenidate during adolescence in ADHD may increase risk for cocaine abuse, while 
atomoxetine may represent a therapeutic alternative for at-risk adolescents with ADHD.  
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Dopamine Transporter, Impulsivity 
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1 CHAPTER ONE: INTRODUCTION 
 
1.1 Attention deficit hyperactivity disorder (ADHD) 
Attention deficit hyperactivity disorder (ADHD) is a neurobehavioral disorder 
characterized by inattention and/or hyperactivity-impulsivity that is persistent and is 
more frequent and more severe than age-matched controls. ADHD was recognized 
about a century ago, as “hyperactivity” or “hyperkinetic disorder of childhood” that 
resulted from a biological condition and not from poor parenting (Still, 1902). This 
disorder was first represented in the Diagnostic and Statistical Manual of Mental 
Disorders, Third Edition (DSM-III) as Attention Deficit Disorder with or without 
Hyperactivity (American Psychiatric Association., 1980).  
ADHD is a highly debilitating disorder that directly exerts negative impact on the 
individuals’ social, academic and occupational activities, which if left untreated, may 
lead to several undesirable outcomes (Meijer et al, 2009). A recent study evaluated 
clinical and functional outcomes of ADHD in adult males three decades after childhood 
diagnosis (Klein et al, 2012). The later study reported that compared to their non-ADHD 
counterparts, ADHD probands had significantly fewer years of schooling, greater divorce 
rates, incarcerations, hospitalization and death rates, as well as more frequent diagnosis 
of psychiatric disorders such as antisocial personality disorders and non-alcohol-related 
substance disorders. The high rates of criminal conviction, diagnoses of antisocial 
personality disorders and substance use disorders in adults diagnosed with ADHD during 
childhood, have been replicated by other independent clinical studies (Barkley et al, 
2004; Dalsgaard et al, 2013; Mannuzza et al, 1998; Rasmussen and Gillberg, 2000). 
Further, results from a WHO World Mental Health (WMH) Survey Initiative indicated 
that ADHD was associated with a statistically significant 22.1 annual days of lost role 
performance compared to their non-ADHD counterparts (de Graaf et al, 2008). 
Consequently, ADHD is a major economic burden. The cost of ongoing care for 
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adolescents with ADHD in the United Kingdom including health, social and educational 
services is estimated to be 670 million pounds annually (Telford et al, 2013). In the 
United States (US), the estimated societal economic burden associated with ADHD in 
2005 was $36 billion and $52.4 billion  (Pelham et al, 2007). Taken together, ADHD has is 
an economic burden on US, as well as the world. 
 
1.1.1 Diagnosis and subtypes 
ADHD is diagnosed based on the presence of the hallmark symptoms, including 
inattention, impulsivity and hyperactivity. The standard for ADHD diagnosis particularly 
in the US, is detailed by the Diagnostic and Statistical Manual of Mental Disorders 
Fourth Edition, Text Revision (DSM IV-TR; American Psychiatric Association., 2000). The 
Fifth Edition of DSM was released recently, and is expected to replace DSM IV-TR 
(American Psychiatric Association., 2013c). Both the manuals list a series of nine 
symptoms of inattention and hyperactivity-impulsivity each. Example of inattention 
includes ‘difficulty sustaining attention in tasks or play activities’, not listening ‘when 
spoken to directly’ and ‘difficulty organizing tasks and activities’. Examples of 
hyperactive-impulsivity includes fidgeting, ‘difficulty playing or engaging in leisure 
activities quietly’, ‘difficulty awaiting for his/her turn’ and frequently ‘interrupting or 
intruding on others’ 
For an ADHD diagnosis, at least six of the nine symptoms in a category must be 
presented at a degree that is maladaptive and inconsistent with developmental level, 
and is persistent for at least 6 months. Furthermore, impairments have to be present in 
two or more settings (e.g., at work/school and at home), and should clearly impede 
social, academic, and occupational functioning. Additionally, the impairments should 
not be better accounted for by another mental disorder (e.g., Pervasive Developmental 
Disorder, Mood Disorder or Dissociative Disorder). Based on these criteria, ADHD is 
classified into Predominantly Inattentive Type and Predominantly Hyperactive-Impulsive 
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Type, depending on whether the criteria for either inattention or hyperactive/impulsive 
are presented. ADHD, Combined Type is diagnosed if criteria for both inattention and 
hyperactive/impulsive are presented. 
There are two other diagnostic tools for ADHD; Classification of Child and 
Adolescent Mental Diagnosis in Primary Care: Diagnosis and Statistical Manual for 
Primary Care (DSM-PC), and the International Classification of Diseases, 10th revision 
(ICD-10). Unlike the DSM IV-TR, ICD-10 uses the term attention deficit/hyperkinetic 
disorder and is often used by insurance companies. The DSM-PC is designed for primary 
care for children and adolescents and details differential diagnoses for commonly 
coexisting comorbidities (Sabeti et al, 2003). However, DSM IV-TR, DSM-PC and ICD-10 
all diagnose ADHD based on presentation of certain clinically observable symptoms, and 
therefore are subjective tools. Currently, there are not objective diagnostic tools for 
ADHD and this is an area of active research (Sabeti et al, 2002). 
 
 
1.1.2 Prevalence and life-time persistence 
Meta-analysis uses a statistical tool called meta-regression to examine the effect 
of moderator variables, such as sample size, on effect size in a study and combine a set 
of studies from different sources thereby providing results that more closely resemble 
the population compared to that obtained from a single study (Paxinos and Watson, 
1998). A recent meta-regression analysis of population surveys from North America, 
South America, Europe, Africa, Asia, Oceania, and the Middle East revealed that the 
prevalence of ADHD is about 5% in children in most cultures (Polanczyk et al, 2007). 
Also, ADHD was found to be more frequent in males than in females (~ 2:1 ratio in 
children), with females being diagnosed with the Predominantly Inattentive Type more 
frequently (Polanczyk et al. 2007). Another meta-analytical review reported comparable 
prevalence rates as the latter study, and indicated that the Predominantly Inattentive 
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Type is the most prevalent ADHD subtype, but individuals with combined subtype are 
the most likely to be referred for clinical services (Willcutt, 2012).   
In the US, the prevalence rates for ADHD are higher than that seen world-wide. A 
National Health and Nutrition Examination Survey (Chai et al, 2012) reported that the 
prevalence of ADHD in the US is about 8.7%, with an estimated 2.4 million individuals 
who meet the DSM-IV criteria (Froehlich et al, 2007). Further, the gender ratio of ADHD 
is the same as that seen world-wide (i.e., 2:1); however boys had an increased likelihood 
of meeting DSM-IV criteria for all ADHD subtypes (Froehlich et al, 2007). Data from the 
National Ambulatory Medical Care Survey (Yetnikoff and Arvanitogiannis, 2013) for the 
years 1990-95, found that the a diagnosis of ADHD for children aged 5-18 years 
increased from 947,208 in 1990, to 2,357,833 in 1995 (i.e., by 232%) calculated using 
the population-adjusted rate of office-based visits (Robison et al, 1999). These 
increasing trends during early ‘90s appeared to be related, partially, to the increase in 
ADHD diagnosis in girls and, partially, to the increasing age of the ADHD patient. Since 
then, the prevalence rate for ADHD in the US has stabilized, which may be attributable 
in part to the uniformity in diagnostic and methodological practices subsequent to the 
release of the DSM-IV in 1996.  
Typically, ADHD is identified during childhood (i.e., during elementary school 
years), which is probably the reason for including the clause that some ADHD symptoms 
and impairment should be “present before age 7 years” (Criteria B, DSM-IV TR;  
(American Psychiatric Association., 2000). The early age of diagnosis may be due to high 
prevalence rates among children of the readily identifiable Predominantly Hyperactive-
Impulsive type of ADHD (Froehlich et al, 2007). The disorder is relatively stable through 
early adolescence. Generally, symptoms of hyperactivity become less obvious with 
increasing age, but problems with restlessness, inattention, poor planning, and 
impulsivity may persist into adolescence and adulthood (Faraone et al, 2006; Turgay et 
al, 2012). Based on the National Comorbidity Survey Replication, the prevalence of adult 
ADHD in the US was estimated to be about 4.4% with a male:female ratio of ~1.6:1 
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(Kessler et al, 2006). A meta-analytical review found that the pooled prevalence of 
ADHD in adults worldwide was approximately 2.5% (Simon et al, 2009). Controversy 
exists as to whether the adult ADHD rates are underestimated currently, which is 
partially, due to the variation in results based on the reporting source (Barkley et al, 
2002). Specifically, compared to parent-reports, the persistence of ADHD into adulthood 
is substantially underestimated in studies based on self-reports. Another reason for the 
supposed underestimation of adult ADHD is the controversy regarding the insensitivity 
of DSM-IV diagnostic criteria to developmental-changes in ADHD (Simon et al, 2009). 
Furthermore, comorbid conditions such as conduct disorder, antisocial behavior, 
oppositional defiant disorders (see Table 1) that are expressed during adolescence and 
adulthood further complicate  ADHD diagnosis during adulthood (Biederman et al, 
1993). All these factors may contribute towards discontinuation of ADHD medications 
during adolescence and adulthood, and may subsequently exert a negative impact on an 
individual’s social and occupational activities.  
 
1.1.3 Disease mechanisms 
1.1.3.1 Genetic mechanisms 
ADHD is a heritable disorder; family and twin studies indicate that genetics 
explains about 76% of the phenotypic variance in ADHD (Biederman and Faraone, 
2005a). However, no biological markers have been identified for the ADHD diagnosis; 
probably because of heterogeneity of phenotypes that are encompassed by this 
disorder.  
Candidate gene studies of ADHD, and meta-analyses thereof, have identified that 
several genetic factors contribute to the disease etiology, each having a small-to-
moderate effect size (Faraone et al, 2005). Specifically, functional polymorphisms in 
genes coding for proteins regulating dopaminergic function, including dopamine 
receptors D4 (DRD4) and D5 (DRD5), catechol-O-methyltransferase (COMT) and the 
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dopamine transporter (DAT1; or SLC6A3), have been implicated in ADHD etiology (Table 
1.1). Other candidate genes implicated in ADHD include those coding for synaptosomal-
associated proteins of 25 KDa (SNAP-25), the noradrenergic receptor α2A (ADRA2A) and 
monoamine oxidase-B (MAO-B) (Faraone et al, 2005; Gizer et al, 2009). Taken together, 
these studies indicate that a dysfunctional catecholaminergic system underlies the 
etiology of ADHD.  
Results from candidate gene-based association studies have shown limited 
overlap with the results from genome-wide association studies (GWAS; Franke et al, 
2009). Further, a recent meta-analytical review of GWAS studies focusing on single 
nucleotide polymorphisms (SNPs) within the exonic or intronic regions of genes with an 
association at p < 0.0001 found that about 53% of the top 85 gene candidates for ADHD 
were involved in neurite outgrowth (Poelmans et al, 2011), suggesting that reduced 
efficiency of neurite outgrowth may underlie ADHD etiology. Furthermore, from the 
latter pool of 85 candidate genes, only the gene for nitric oxide synthase could be 
directly placed in the putative ADHD network (Cappellacci et al, 2006; Tanda et al, 
2009). One potential association between the results from candidate gene-based 
association studies and GWAS, may be that the a dysfunctional catecholaminergic 
system underlies the reduced efficiency of neurite outgrowth (Poelmans et al, 2011); 
however this putative mechanism has not been validated empirically. 
Recent efforts from the Psychiatric Genomics Consortium involved pooling data 
from several large scale genetics projects for meta-analysis to boost statistical power to 
identify genetic-phenotypic associations at a genome-wide significance level.  
Surprisingly, the results revealed no genome-wide significant associations (Neale et al, 
2010a; Neale et al, 2010b).  More importantly, of the several specific genes correlated 
with ADHD, none were either necessary or sufficient to be causally linked with ADHD 
(Gizer et al, 2009). Interestingly, patients with Prader-Willy Syndrome, Turner Syndrome 
and Fragile-X-Syndrome, despite their divergent neurogenetic etiologies, exhibit ADHD-
like symptoms (Lo-Castro et al, 2011).  Taken together, the genetic abnormalities 
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associated with the latter disorders may converge on common downstream signaling 
pathways or neurological circuitry, and thereby express ADHD-like symptoms. A recent 
meta-analysis examining shared genetic etiology between different psychiatric disorders 
reported a genetic correlation between major depressive disorder and ADHD (Cross-
Disorder Group of the Psychiatric Genomics et al, 2013). Specifically, based on weighted 
prevalence of common SNPs, significant genetic correlation was obtained between 
ADHD and major depressive disorder. However significant genetic overlap was not 
found when ADHD was compared to autism spectrum disorder, schizophrenia and 
bipolar disorder (Cross-Disorder Group of the Psychiatric Genomics et al, 2013).   Taken 
together, the most parsimonious explanation for the genetic basis of ADHD etiology is 
that it involves polygenic interactions with complex transmission patterns to yield 
genotypic and phenotypic heterogeneity in ADHD (Curatolo et al, 2010; Sharp et al, 
2009). 
  
 
Table 1.1 Genetics of ADHD 
Genetic polymorphisms associated with ADHD etiology and pharmacogenomics; transporters, receptors and other proteins 
that regulate dopamine (DA) and norepinephrine (NE) neurotransmission. Odds-ratio (OR) was used as the statistical 
measure for the association of the polymorphism with ADHD. 
   Functional effect in 
ADHD etiology 
Association with 
disease etiology 
Pharmacogenetics 
D
o
p
am
in
er
gi
c 
sy
st
em
 
Dopamine 
transporter 
(DAT, 
SLC63A) 
10-repeat allele at 3’UTR Increased striatal DAT 
density  
(Michelhaugh et al, 
2001; VanNess et al, 
2005); see also 
(Martinez et al, 2001) 
OR– 1.13 *a  10/10 genotypes were less 
likely to respond to 
methylphenidate (MPH; 
Roman et al, 2002; 
Winsberg and Comings, 
1999) 
9 repeat allele  N.A. 9/9 poor responders for 
MPH (Joober et al, 2007); 
9/10 genotype showed 
fewer side-effects 
compared to 9/9 and 
10/10 genotypes (Gruber 
et al, 2009) 
DA receptors D4 
7-repeat allele in exon III 
Blunted response to 
dopamine  
(Asghari et al, 1995) 
OR – 1.45 * a 
Associated with 
childhood inattention 
(Rowe et al, 2001) 
Excess transmission of the 
7-repeat allele compared 
to the 2- and 4-repeat 
individuals in MPH 
responders (Seeger et al, 
2001; Tahir et al, 2000) 
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N
o
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d
re
n
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c 
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Receptor 
α2A 
Promoter region SNP 
C1291G 
 ADHD and conduct 
disorder (Comings et 
al, 1999); inattention 
(Roman et al, 2003) 
G/G have improved MPH 
response at reducing 
inattentive scores (Cheon 
et al, 2009; da Silva et al, 
2008) 
NET, SLC6A2 SNP in exon 9, intron 9 
and intron 13 
- Not associated with 
ADHD (Barr et al, 
2002; McEvoy et al, 
2002) 
No associations met the 
genome-wide threshold 
for statistical significance 
(Kieling et al, 2010) 
      
C
at
ec
h
o
la
m
in
er
gi
c 
sy
st
em
 
Dopamine-β-
hydroxylase 
TaqI A1 polymorphism 
in 5’-intron 
 OR – 1.96*  
(Smith et al, 2003)  
- 
COMT Val108Met 
polymorphism 
Met-enzyme has a 50-
70% reduced 
enzymatic activity 
than the Val-enzyme  
(Lotta et al, 1995) 
OR – 1.0 a Pharmacogenetic effects 
were not strong (Kieling et 
al, 2010; except Cheon et 
al, 2008) 
SNAP25 Three markers- 
In the putative promoter 
– an SNP -2015 A/T; A 
microsatellite in intron 
1; SNP in intron 7 - 
80609 G/A 
Reduce calcium 
dependent dopamine 
release  
(Wilson, 2000) 
OR – 1.19 *a - 
* OR was statistically significant for association with ADHD diagnosis; N.A. OR data was not available; a as reported in 
(Faraone et al, 2005) 
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1.1.3.2 Environmental and gene-environment interaction mechanisms 
Several groups have proposed that environmental factors as well as complex 
gene-environment interaction underlies ADHD etiology. Prenatal factors such as 
maternal life-style during pregnancy have been associated with ADHD. Prenatal 
exposure to alcohol and smoking have been associated with ADHD symptoms including 
hyperactivity and impulsivity (D'Onofrio et al, 2007; Linnet et al, 2003; Milberger et al, 
1996; Sen and Swaminathan, 2007). Furthermore, prenatal substance exposures are 
associated with increased risk for autism spectrum disorder which is often comorbid 
with ADHD (See Table 1.2). These effects of prenatal exposure to abused substances, in 
part, may be due to the changes in the developmental trajectory of the central 
catecholaminergic system (Zhu et al, 2012), which is developmentally sensitive during 
gestation (Lee et al, 2012). 
Recent studies evaluating the combined effects of prenatal substance exposures 
and DNA polymorphisms in dopamine pathway-related genes, reported that the 
genetically susceptible children (i.e., with the 7-repeat DRD4 alleles, 9-repeat DAT1 
allele, but not the 10-repeat DAT1 allele) had a higher risk for developing ADHD, 
combined type when prenatally exposed to nicotine (Neuman et al, 2007). Another 
study found that the 10-repeat DAT1 allele was associated with greater hyperactivity-
impulsivity (Becker et al, 2008). Early deprivation of social environment during the 
postnatal period also may have significant effects on hyperactivity (McLaughlin et al, 
2010; Yates et al, 2012). Taken together, these studies support that complex gene-
environment interactions contributes to the etiological heterogeneity in ADHD.
  
Table 1.2 Examples of overlapping diagnosis with ADHD and comorbidities with ADHD 
Disorder Similar Features Differentiating features References for clinical 
comorbidity 
Tourette’s 
disorder 
Developmental 
disorder, motoric 
activity 
Expressed in bouts of tics, and not general 
“fidgetiness” 
(Melchior et al, 2013) 
Oppositional 
defiant 
disorder 
Aversion to school or 
work 
Resist conforming with other’s demands, 
no sustained attention deficit 
(Biederman et al, 
1993) 
Conduct 
disorder 
Appearance of 
impulsivity, impaired 
academic/occupational 
performance 
Antisocial behavior (Biederman et al, 
1993; Hamshere et al, 
2013; Willcutt, 2012) 
Autism 
spectrum 
disorder 
Impaired social 
interaction 
Due to indifference to facial an tonal 
communication cues, instead of peer 
rejection in ADHD 
(Cross-Disorder Group 
of the Psychiatric 
Genomics et al, 2013) 
Tantrums Due to change from their expected course 
of events, and not impulsivity 
Disruptive 
mood 
dysregulation 
disorder 
Impulsivity and 
disorganized attention 
Pervasive irritability and intolerance of 
frustration 
(Biederman et al, 
1993) 
Personality 
disorders 
Adult ADHD symptoms; 
social intrusiveness, 
cognitive dysregulation 
ADHD do not necessarily exhibit fear of 
abandonment, self-injury, extreme 
ambivalence 
(Barkley et al, 2004; 
Mannuzza et al, 1998) 
 
1
1
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1.1.3.3 Neurological mechanisms 
The neurobiological etiology of ADHD is not understood completely (Tripp and 
Wickens, 2009). However, converging evidence from structural and functional 
neuroimaging research indicate a pivotal role for a hypofunctional corticostriatal system 
in mediating the deficits in higher-order functions, as well as the behavioral and 
emotional regulation deficits commonly observed in ADHD. 
Structural neuroimaging: 
ADHD patients have a reduced cerebral volume in the prefrontal cortex (PFC), 
dorsal anterior cingulate cortex, as well as in subcortical areas including striatum (Aston-
Jones and Cohen, 2005; Crunelle et al, 2013). The right frontal lobes including PFC 
(Castellanos et al, 1996; Hynd et al, 1990) and the caudate nucleus (subregion of dorsal 
striatum) of children with ADHD were smaller in volume than controls, suggesting a 
neurodevelopmental lag in the maturation of the associated neuronal pathways and 
their connectivity (Castellanos et al, 1996). Further, the age of attaining peak cortical 
thickness in the cerebrum was delayed children with ADHD compared to controls 
(Chandler et al, 2013b; Matecka et al, 1997b).  
A popular hypothesis regarding ADHD etiology is a disrupted connectivity 
between neuronal networks. Diffusion tensor imaging (DTI) is a structural magnetic 
resonance imaging (MRI) technique to map white matter tracts for assessing structural 
abnormalities in neuronal networks (for review; Doughty and Richards, 2002b). DTI 
studies revealed that compared to controls, individuals with ADHD had reduced white 
matter tracts in the intra-cortical areas associated with higher-order executive function 
(Corominas-Roso et al, 2013). Further, the frontolimbic white matter tracts, involved 
with emotional regulation, were reduced in children with ADHD compared to control 
(Sanchez-Mora et al, 2013). Taken together, intra-cortical and frontolimbic networks 
have structural impairments in children with ADHD that may contribute to reduced 
speed of neuronal communication compared to age-matched controls. 
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Functional neuroimaging: 
Evidence for functional impairments in the prefrontal cortex (PFC) of individuals 
with ADHD is provided by functional neuroimaging studies. Functional imaging studies 
include evaluation of brain activation using changes in blood oxygen level dependent 
(BOLD) signals monitored in real-time with functional magnetic resonance imaging 
(fMRI). In the absence of medications, functional deficits in orbitofrontal cortex (OFC), 
dorsolateral PFC (DLPFC), and medial PFC (mPFC) have been linked to the behavioral 
deficits observed in individuals with ADHD. For example, compared to control subjects, 
boys (9-16 years old) with ADHD showed decreased BOLD signal in the OFC during a 
delayed discounting task that measures impulsivity (Rubia et al, 2009a). In male and 
female adults with ADHD, dysregulated OFC activation was reported during a risky 
decision making task, suggesting that impairments in OFC function are associated with 
motivational and emotional challenges faced by ADHD adults  (Wilbertz et al, 2012). 
Decreased DLPFC activation was associated with working memory deficits on a Color-
Word Stroop test in adults with ADHD (Burgess et al, 2010). In the absence of 
medications, adolescents with ADHD exhibited enhanced attenuation of BOLD signals in 
the mPFC during the Stroop test with emotional interference, compared to 
demographically matched control (Posner et al, 2011). Taken together, OFC, DLPFC and 
mPFC functions are associated with the deficits in behavioral and emotional regulation 
observed in adolescents and adults with ADHD. 
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Table 1.3 Subregions of the primate frontal cortex and their functions 
Subregion Functionality Reference 
Dorsolateral 
prefrontal 
cortex (DLPFC)  
Higher order cognition, short and long 
term memory, impulse control and 
problem solving  
(Petrides, 1994; 
Vogeley et al, 
2004) 
Orbitofrontal 
cortex (OFC) 
Processing the value of natural reinforcer, 
higher order reward and reinforcement, 
assessment of short- and long-term 
gain/loss, inhibition, detection of 
irregularities 
(Bechara, 2001) 
(Aron et al, 2004; 
Huettel and 
McCarthy, 2004) 
Ventromedial 
cortex (vmPFC); 
(includes 
cingulate gyrus) 
Processing decision outcomes, cognitive 
control, inhibition, suppression of 
inappropriate behavior 
(Elliott and Dolan, 
1998; Forstmann 
et al, 2008; Vogt 
et al, 1992) 
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Although the bulk of functional imaging studies use fMRI, the results from these 
studies do not provide information about the specific neurochemical systems involved 
in the disease etiology. In this respect, positron emitted tomography (PET) and single-
photon emission computed tomography (SPECT) are superior at revealing 
neurochemical substrates involved in disease etiology (da Silva et al, 2011). A significant 
negative correlation between DAT density (evaluated using SPECT) in striatum and 
cerebral blood flow in the cingulate gyrus, frontal lobe, temporal lobe of the cortex was 
found in a group of medication-naïve adolescents with ADHD (da Silva et al, 2011). 
Another  PET study revealed that in medication-naïve ADHD adults, striatal DAT and 
dopamine D2/D3 receptor densities were correlated with motivational deficits 
evaluated using a personality questionnaire (Goldstein et al, 2001); the results were 
interpreted to suggest that the core symptoms of ADHD such as inattention are related 
to the broader concept of motivational process. The mesocorticolimbic pathway is 
involved in reinforcement learning and motivated (also called goal-directed) behavior.  
The mesocorticolimbic pathway consists of dopaminergic projections from the ventral 
tegmental area (VTA) to the nucleus accumbens (NAc or ventral striatum) and to the 
PFC (Fig 1.1). Maturation of corticostriatal connectivity is dependent on mesocortical 
dopaminergic signals (Galinanes et al, 2009). The nigrostriatal pathway, which projects 
from substantia nigra to dorsal striatum (Fig 1.1), has been implicated in motor control, 
and deficits in this pathway are considered to underlie hyperactivity in ADHD (Engert 
and Pruessner, 2008). The dorsal striatum receives inputs from PFC, which are 
associated with attentional control (Robbins et al, 1998), and hence, may contribute to 
inattention, a hallmark of ADHD. Taken together, these results of these studies suggest 
a critical role for deficits in dopaminergic function in the mesocorticolimbic and 
nigrostriatal pathways in the etiopathology of ADHD.  
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Figure 1.1 Graphical representation of the mesocorticolimbic and nigrostriatal 
dopaminergic circuitry and of the noradrenergic projections in rat brain 
PFC – PFC, NAc – nucleus accumbens, VTA – ventral tegmental area, STN – substantia 
nigra, LC – locus coeruleus. 
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In terms of directionality, the elevated striatal DAT expression in ADHD (Gill et al, 
1997), suggested increased clearance of extracellular dopamine, and thereby lead to the 
hypodopaminergic hypothesis of ADHD. Further support for the hypodopaminergic 
hypothesis was provided by genetic polymorphisms in D4, COMT and DAT that 
potentially lead to reduced dopaminergic signaling have been associated with ADHD 
(Faraone, Perlis et al. 2005).  However, a recently published meta-analysis of DAT 
expression concluded that un-medicated ADHD adults (~30 years old) have lower striatal 
DAT expression, while previously medicated ADHD adults have higher striatal DAT 
density compared to non-ADHD individuals (Fusar-Poli et al, 2012). These result suggest 
that the increase in DAT expression is an outcome of treatment and not etiopathology. 
Thus, ADHD may not be attibutable entirely to decreased dopaminergic function. 
A seminal review of neuroimaging studies, both clinical and preclinical studies 
dispelled the hypothesis “suggesting ’too much’ or ’too little’ of a single 
neurotransmitter” underlies ADHD etiology (Pliszka et al, 1996). A multistage hypothesis 
was proposed that suggests a complex interaction of dopamine and norepinephrine and 
other neurotransmitter systems in the modulation of attention and impulse control, 
which is disrupted in ADHD. Thus, the most popular hypothesis regarding ADHD 
etiopathology involves deficits in both dopamine and norepinephrine neurotransmission 
(Arnsten, 2009; Fernandez-Castillo et al, 2013; Levy, 2009).  
The primary central noradrenergic pathways project from locus coeruleus (LC) to 
several regions of brain, including amygdala, ventral striatum and PFC (see Fig 1.1). 
These projections are involved in arousal and cognitive function (Green et al, 2003b; 
Kalivas and Barnes, 1988). Attentional set-shifting tasks evaluate behavioural flexibility 
and attention, two functions that are impaired in ADHD (Arnsten, 2009; Viggiano et al, 
2004a). Reduced noradrenergic function in mPFC is sufficient to produce impaired 
attentional set-shifting (Newman et al, 2008). Further evidence supporting the 
catecholaminergic hypothesis comes from neuropharmacological studies (described in 
 18 
  
section 1.2) and that a large majority of medications efficacious in managing ADHD 
engage both dopaminergic and noradrenergic systems. 
Other neurochemical mechanisms, including cholinergic and glutamatergic 
pathways, also contribute to ADHD etiopathology (Doughty et al, 2002b). For example, 
1H-magnetic resonance spectroscopy revealed reduced glutamate levels in the 
prefrontal cortex of previously medicated adults with ADHD compared to non-ADHD 
healthy controls (DeBow and Colbourne, 2003). Furthermore, MPH treatment in ADHD 
adult was reported to decrease cortical concentration of choline containing compounds 
(Hebert et al, 1999b). Furthermore, cortical dopaminergic function is known to 
modulate glutamate and cholinergic neurotransmission in the PFC and striatum 
(Doughty et al, 2002b; Hebert and Gerhardt, 1999a). The latter studies contribute to a 
growing body of literature that suggest that ADHD etiology involves a complex 
interaction of several neurotransmitter systems. 
 
1.2 ADHD medications  
1.2.1 Classifications 
Based on overall pharmacology, ADHD medications may be broadly classified 
into ‘stimulants’ and ‘non-stimulants’. A brief mechanism of action for the currently 
approved ADHD medications is provided in Table 1.4. Stimulants or psychostimulants 
are drugs that induce locomotor hyperactivity and promote dopamine release in ventral 
and/or dorsal striatum (Berridge and Devilbiss, 2011; Wilens, 2006). Examples of 
stimulant medications for ADHD are amphetamine and its isomers and MPH and its 
isomers. On the other hand, non-stimulant drugs do not induce striatal dopamine 
release and do not induce locomotor activation (Swanson et al, 2006). Examples of non-
stimulant medications are atomoxetine (ATO), guanfacine and clonidine. Further details 
regarding the mechanism of action and pharmacology of MPH and ATO is provided in 
section 1.8 and 1.9.  
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Since the serendipitous discovery of benzedrine for the treatment of “children 
with learning and behavioral problems” in the 1930s (Bradley, 1950), the 
psychostimulants, such as amphetamine and MPH have been the drugs of choice for 
symptomatic treatment of ADHD. Stimulants have been found to be effective at 
managing ADHD symptoms in 70-80% of ADHD patients (Elia et al, 1999). Stimulants are 
the most widely prescribed ADHD medications; ~3 million prescriptions per quarter are 
filed for extended release oral MPH preparations alone (Sembower et al, 2013). 
However, doubts have been raised about whether stimulants are safe especially for 
chronic administration to children and adolescents (Greenhill et al, 2001). Specifically, 
stimulants have established abuse potential that raises concern regarding prescribing 
stimulants to adolescents with ADHD (Manchikanti, 2007; Sweeney et al, 2013). As a 
consequence, several formulations have been developed with modified 
pharmacokinetic properties that minimize the abuse liability of these drugs (Spencer et 
al, 2011; Szobot et al, 2008b); see Table 1.5 for details).  
Over the past six decades, efforts made by both the pharmaceutical industry and 
academia have led to the development and approval of two non-stimulant ADHD 
medications, ATO and guanfacine (for review; Heal et al, 2012). In particular, for ADHD 
cases where stimulants are not efficacious or cause unpleasant side effects, non-
stimulants have been beneficial. ATO was the first non-stimulant medication approved 
by the Food and Drug Administration (FDA), for use in children, adolescents, and adults 
(http://www.fda.gov/Drugs/DrugSafety). FDA approved a second non-stimulant drug 
guanfacine in 2011, for children and teens between ages 6 and 17. Also, the non-
stimulant clonidine was approved by FDA in 2009 for use either alone or in combination 
with a stimulant to enhance its effectiveness. These medications have all shown efficacy 
in improving attention and impulse control; however the efficacy of these non-
stimulants were lower than that for stimulants. Specifically, compared to placebo, 
efficacy is ~50-60% for ATO in contrast to >70% for stimulants (Garnock-Jones and 
Keating, 2010; Scahill et al, 2001). 
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Bupropion and modafinil are used off-label and often prescribed for managing 
ADHD symptoms. Bupropion is a non-stimulant drug, and is a norepinepherine and 
serotonin uptake inhibitor. Bupropion has been shown to be efficacious compared to 
placebo in ameliorating ADHD symptoms (efficacy ~20% compared to placebo; 
Maneeton et al, 2011), and has low potential for abuse (Rush et al, 1998). On the other 
hand, modafinil has shown potential as an alternative psychostimulant to amphetamine 
and MPH for treatment of ADHD (efficacy ~50-60% compared to placebo; Biederman et 
al, 2005b; Heal et al, 2012). Unlike amphetamine and MPH, modafinil is not associated 
with side effects such as abuse potential and locomotor excitability (Deroche-Gamonet 
et al, 2002); however the biochemical mechanisms of action for modafinil is not well 
understood (Morgan et al, 2007). 
Cognitive control is defined as the ability to suppress inappropriate behavior in 
response to contextual and temporal cues and adjust behavior accordingly. Because 
ADHD includes cognitive deficits that are debilitating, especially under academic settings 
(Berridge et al, 2011; Wallace et al, 2011), a number of novel ADHD therapeutics are 
targeted towards remediating the cognitive dysfunction in ADHD.  Moreover, according 
to one school of thought, impaired cognitive control may be the fundamental 
disturbance underlying the hallmark features of ADHD (Nigg and Casey, 2005). A review 
of 40 placebo-controlled clinical studies revealed that MPH improved cognitive flexibility 
and attention/vigilance in majority of the studies (Pietrzak et al, 2006). Interestingly 
cholinergic drugs, including varenicline and lobeline, that improve attention and 
working memory by activating the nicotinic acetylcholine receptors (α4β2 and α7 
subtypes) have been evaluated for therapeutic efficacy in ADHD (Howe et al, 2010; 
Rollema et al, 2009; Wallace et al, 2011). Histamine is known also to play a role in 
cognition, attention and alertness (Leurs et al, 2005). MPH (1 mg/kg subcutaneous) and 
ATO (1 mg/kg subcutaneous) increase extracellular concentrations of histamine in the 
PFC of awake rats (Horner et al, 2007). Thus, an increase in cortical histamine may 
contribute to the pharmacotherapeutic effects of MPH and ATO that leads to improved 
cognition and alertness in ADHD. Histamine H3 receptors are presynaptic autoreceptors 
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that inhibit histamine release from histaminergic neurons in rat brain (Arrang et al, 
1983). H3 antagonist, ciproxifan, improved short-term memory and attention and 
decreased impulsivity in outbred rats (Day et al, 2007; Giovannini et al, 1999). Not 
surprisingly, novel therapeutic strategies for ADHD include antagonists for histamine H3 
receptor that are currently in various phases of clinical trials (Wallace et al, 2011). 
    
 
Table 1.4 Mechanism of action of ADHD drugs  
Drug Pharmacological 
class 
Neurotransmitter 
target 
Site of action Selectivity Psychostimulant 
D-Amphetamine Releasing agent DA, NE, 5HT 
 
Monoamine release DA >= NE Yes  
Monoamine uptake 
inhibition 
  
MAO inhibition   
L-Amphetamine Releasing agent DA, NE, 5HT Monoamine release DA = NE Yes  
Monoamine uptake 
inhibition 
  
MAO inhibition   
DL-MPH and D-MPH 
(Ritalin) 
Uptake 
inhibition 
DA, NE 
 
Monoamine uptake 
inhibition 
DA = NE Yes  
Bupropion 
(Wellbutrin, Zyban) 
Uptake 
inhibition 
DA 
(NE) 
Monoamine uptake 
inhibition 
DA = NE No  
Atomoxetine 
(Strattera) 
Uptake 
inhibition 
NE 
(DA in the PFC) 
Monoamine uptake 
inhibition 
(DA) = NE No 
Guanfacine 
(Intuniv) 
α2A-agonist NE Adrenoreceptor 
agonist 
NE No 
Modafinil 
(Provigil) 
Undefined  NE, DA, 
(histamine) 
  Equivocal  
adapted from Heal et al, 2012 
(DA) – Atomoxetine induced increase in extracellular DA in the PFC is an outcome of NET inhibition. 
 
 
2
2
 
    
 
Figure 1.2 Molecular targets of methylphenidate and atomoxetine. 
Methylphenidate inhibits dopamine transporters (DAT) and norepinephrine transporter (NET), while atomoxetine is a 
selective NET inhibitor. VMAT2 – vesicular monoamine transporter type 2, MAO-B – monoamine oxidase B, α1and α2 – 
norepinephrine receptor type 1 and 2, respectively, D1 and D2 – dopamine receptor type 1 and 2, respectively. 
 
2
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Table 1.5 Approved ADHD medications and formulations 
Formulations of the currently approved ADHD medications and the efficacies, adapted from (Curatolo et al, 2010) 
Pharmacotherapy Formulation Market name Efficacy 
Stimulant medication    
    
Methylphenidate Immediate release Ritalin, Focalin 0.92 (0.8, 1.05)a 
 Osmotic release Concerta 0.90 (0.76, 1.05) 
 Extended release Ritalin LA, Concerta 0.85 (0.65, 1.05) 
 Long-acting Ritalin-SR 0.96 (0.75, 1.16) 
 Dexmethylphenidate Focalin, Attenade 0.76 (0.45, 1.08) 
    
Dextroamphetamine Immediate release Dexedrine, Dextrostat 1.24 (0.88, 1.60) 
 Extended release Accurate 1.13 (0.57, 1.69) 
 Prodrug Lisdexamfetamine 1.52 (1.34, 1.71) 
    
Mixed amphetamine salts Immediate release Adderall 1.34 (0.95, 1.72) 
 Extended release Adderall XR 0.77 (0.59, 0.94) 
Non-stimulant medications    
    
Atomoxetine Immediate release Strattera 0.63 (0.57, 0.69) 
    
Guanfacine Immediate release Tenex  
 Extended release Intuniv 0.8 (0.53, 1.07) 
a Efficacies of the formulation (compared to placebo) and 95% confidence intervals; the values are based on meta-analytical 
review (Curatolo et al, 2010; Kirshenbaum et al, 2008)
2
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1.2.2 Prescription rates and relative efficacies 
Currently, USA is the world’s largest consumer of ADHD medications (Scheffler et 
al, 2007). Stimulants, including MPH and amphetamine, are the first line of 
pharmacotherapy for ADHD, primarily due to their superior efficacy relative to other 
approved and non-approved ADHD medications (Table 1.4). The population-adjusted 
rate of stimulant prescription among ADHD patients between 5 to 18 years of age was 
increased 2.9-fold from 1990 to 1995 (Robison et al, 1999). The prescription rate for 
MPH increased 2.6-fold in the same period and MPH accounted for 87.6% of all 
medications prescribed to ADHD individuals (Robison et al, 1999). A recent report based 
in the IMS Health National Disease and Therapeutic Index, reported that between 2005 
and 2010, ADHD individuals under 18 years were prescribed stimulants and ATO in 85-
90% and 6-13% cases, respectively (Garfield et al, 2012). Furthermore, among the 
stimulants, MPH containing preparations were prescribed in 52-62% of the cases, while 
amphetamine preparations were prescribed for the rest of the cases (Garfield et al, 
2012), thus making MPH one of the most widely prescribed ADHD therapeutics for 
children and adolescents. 
Several attempts have been made to evaluate factors underlying the variability 
in therapeutic efficacy of ADHD medications. Specifically, in neuropsychiatric disorders 
such as ADHD, there is a paucity of research regarding the predictors of treatment 
response and side effects (Kieling et al, 2010). Pharmacogenomics analyzes how genetic 
makeup of an individual influences their response to drugs, taking into consideration 
both the efficacy and side effects of the therapeutic agents. Pharmacogenomics 
combines the fields of pharmacology and genetics to provide this powerful tool that 
may expedite the advent of ‘personalized medicine’.  
Since the efficacious ADHD therapeutics such as MPH and ATO target the 
catecholaminergic pathways (Table 1.4), the genetic heterogeneity for these molecular 
targets in the ADHD population may be responsible at least in part for the variability in 
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response to treatment. Some of the recent pharmacogenetic association studies have 
been tabulated (Table 1.1) to increase our understanding of why all ADHD individuals 
are not effectively treated with the current ADHD therapeutics. Again, genetic 
associations predicting therapeutic efficacy of MPH are not consistent between studies 
(for review; Kieling et al, 2010), which may be due to methodological differences such as 
heterogeneity in experimental design, differences in baseline scores for ADHD 
symptoms between studies, non-standardized definition for “clinically significant 
genetic predictors of treatment effect” (Kieling and Rohde, 2008; Polanczyk et al, 2008). 
Taken together, MPH is one of the most widely prescribed ADHD therapeutic; however 
several factors including genetics and ADHD subtype and severity contribute to the 
outcomes (efficacy and side-effects) of MPH treatment. 
 
1.2.3 Mechanisms underlying ADHD etiology: importance of prefrontal cortex 
Integration of a wealth of knowledge generated through clinical and preclinical 
studies employing ADHD medications have culminated in several hypotheses regarding 
the etiopathology of ADHD. Regulation of behavior and emotion is referred to as 
“executive functions”. The executive dysfunction hypothesis of ADHD suggests that the 
core ADHD symptoms arise from primary cognitive/executive impairments (Arnsten, 
2009; Sonuga-Barke and Fairchild, 2012). The dual pathway hypothesis posits a 
combination of executive functional deficits and reward/motivational impairments as 
responsible for ADHD pathophysiology (Blum et al, 2008; Sagvolden et al, 1998a; 
Sonuga-Barke, 2005). A more recent theory in ADHD etiology builds on the dual 
pathway model by adding the deficit in temporal processing circuitry as an added 
complexity contributing to the heterogeneity in ADHD (Sonuga-Barke et al, 2010). All 
the above hypotheses converge upon the importance of the prefrontal cortex (PFC) in 
the regulation of attention, executive function and motivation driven behavior through 
its projections into the motor and sensory cortex as well as to subcortical areas 
including the nucleus accumbens (NAc), striatum and amygdala (Arnsten, 2009; Levy, 
 27 
 
2008, 2009). The individual processes that are suggested to be dysregulated in ADHD 
have been described in this section. Further examples have been included that describe 
the effect of MPH treatment on these individual processes. 
Regulation of attention: PFC regulates attention based on relevance to the 
context/environment (Arnsten, 2009). Specifically, through its projections to the sensory 
association cortex, the PFC suppresses processing of irrelevant stimuli and thereby 
enhances processing of relevant stimuli (Knight et al, 1995). PFC also helps sustain 
attention to relevant sources and also shift attention to relevant dimensions through its 
many intra-cortical networks (Arnsten and Li, 2005). In ADHD children, MPH normalized 
function in the anterior cingulate cortex and lateral PFC during the suppression of 
interference during Stroop test (Bush et al, 2008; Lee et al, 2010). 
Reward/motivational deficits in ADHD: Using a multiple schedule of alternating 
fixed interval 30 sec/extinction, ADHD individuals were found to have a shorter delay of 
reinforcement gradient compared to non-ADHD control (Sagvolden et al, 1998a). 
Medication naïve ADHD children exhibit increased impulsivity on a delay discounting 
task (Demurie et al, 2012), where impulsivity as increased choice of a smaller immediate 
reward over a larger delayed reward (Paxinos and Watson, 1986). These results support 
the reward deficiency hypothesis of ADHD (Blum et al, 2008) that explains that 
hyperactivity, reduced sustained attention, and increased impulsivity in a delay discount 
task can be explained as reduced motivation for reward. Reward deficiency in ADHD 
individuals is associated with hypodopaminergic striatum as well as decreased BOLD 
signal in the OFC and striatum (Rosa-Neto et al, 2005; Rubia et al, 2009b; Sonuga-Barke, 
2005).   A [11C]raclopride PET imaging study in adolescents with ADHD revealed that 
MPH-evoked changes in striatal extracellular dopamine correlate with reductions in 
inattention and impulsivity using a continuous performance test (Rosa-Neto et al, 2005). 
MPH also normalized OFC activity in medication naïve ADHD children in response to 
reward during a continuous reinforcement task (Rubia et al, 2009b). Taken together, 
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MPH ameliorates the reward/motivational deficits in ADHD by normalizing striatal 
dopaminergic function as well as OFC-striatal activation patterns. 
Regulation of executive function: PFC regulates behavior and emotion, which 
are referred to as executive functions. The dlPFC regulates attention-related motor 
responses through its connections with the basal ganglia and cerebellum (Middleton 
and Strick, 2000; Robbins, 2007). Projections from mPFC and OFC to amygdala, 
hypothalamus, NAc and striatum regulates emotion, response inhibition and error 
detection (Aron, 2007; Aron et al, 2004; Price et al, 1996; Rubia et al, 2003). Go/no-go 
task measures response inhibition capacity as decreased ability to stop in response to a 
relatively infrequent stop-cue that is randomly presented in-between the more frequent 
go-cues (Tannock et al, 1989b). The Stroop test evaluates the effect of interference on 
reaction time to dissociate a complex stimulus (e.g., identify the color of the following 
word, BLUE), thereby evaluating both attention and cognitive flexibility (Paxinos and 
Watson, 2005). Inattention and response inhibition deficits in ADHD children was 
associated with an attenuated decrease in BOLD signals in the PFC regions including 
anterior cingulate cortex compared to age-matched control (Schwarz et al, 2006; 
Stephens et al, 2010; Stephens et al, 2011). MPH has been found to normalize the 
decrease in PFC BOLD signal in ADHD children during go/no-go tasks (Liddle et al, 2011), 
and normalize decreased BOLD signal in anterior cingulate cortex and dlPFC during the 
suppression of interference during the Stroop test (Bush et al, 2008; Lee et al, 2010). 
Taken together, MPH treatment normalizes PFC function to improve response inhibition 
and sustained attention in children with ADHD. Comparing results from clinical studies 
and preclinical rat models, it is important to note that the DLPFC in primates is 
considered to be functionally analogous to the Fr2 and the anterior cingulate cortex 
subregions of mPFC in rodents, and the OFC in humans corresponds to OFC in rodents 
(Uylings et al, 2003). Thus, based on results from human studies, the prefrontal cortical 
subregions, mPFC and OFC, are regions of interest in rodent studies.  
 29 
 
Further support for the role of frontal cortex in ADHD behaviors include that 
lesions of the frontal lobes result in a breakdown of goal directed activity, executive 
function, attention and produce hyperactivity (Benson and Stuss, 1982; Petrides and 
Milner, 1982; Stuss et al, 1982). Predominantly glutamatergic pyramidal neurons project 
from the PFC to the subcortical regions to modulate goal directed activity and executive 
function (Goldman-Rakic, 1995). The dendritic spines on the pyramidal neurons respond 
to small changes in the catecholamine via their noradrenergic α2A receptors and 
dopamine D1 receptors (Sawaguchi and Goldman-Rakic, 1994; Smiley et al, 1994; Wang 
et al, 2007). The catecholaminergic inputs to these neurons arise from the basal ganglia 
and the arousal systems in the brain stem (for review; Engert et al, 2008) and as 
depicted in Fig 1.1. Thus, increasing catecholaminergic neurotransmission in cortical 
areas may be involved in the efficacy of psychostimulants and ATO in ADHD, which 
further lends support to the catecholaminergic hypothesis of ADHD etiopathology. 
With a few exceptions, clinically efficacious ADHD medications potently inhibit 
DAT and/or NET function (see Table 1.4, and Fig 1.2). PET studies reveal that at clinically-
effective doses, MPH inhibits DAT and NET (Volkow et al, 2002). Intracranial 
microdialysis studies in outbred rats report that at clinically or pharmacologically 
relevant doses, ADHD medications elevate extracellular concentrations of dopamine and 
norepinephrine in the PFC (Berridge et al, 2006; Bymaster et al, 2002). ADHD 
medications also increase neuronal firing in PFC (Devilbiss and Berridge, 2008). The MPH 
induced cortical excitability was decreased by α2 adrenergic antagonist (Andrews and 
Lavin, 2006), suggesting the effects of MPH are mediated partially via α2 receptor 
activation. Inhibition of D1 receptors in the PFC of rhesus monkeys decreased working 
memory in occulomotor delayed response tasks (Sawaguchi et al, 1994). In outbred rats, 
the cognitive enhancing effects of therapeutically relevant doses of MPH are inhibited 
by α2 and D1 receptor antagonists intracranially applied to PFC (Arnsten et al, 2005). 
Taken together, these results suggest that the molecular mechanism by which MPH 
exerts its therapeutic effects includes increased cortical α2 and D1 receptor activation 
via increased extracellular norepinephrine and dopamine (Arnsten, 2009). The functions 
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of individual receptor and transporter involved in ADHD etiology and therapeutics have 
been detailed in section 1.6 and 1.7 for dopaminergic and noradrenergic systems, 
respectively. 
 
1.3 Animal models of ADHD 
For the validation of an animal model for a human disorder, specific criteria have 
been suggested (Willner, 1986).  
1) Face validity, i.e., mimicking the symptoms of the human disorder  
2) Construct validity, i.e., sharing common etiology with the human disorder  
3) Predictive validity, i.e., a model conforming to the first two conditions predicts 
the outcomes in the human patient population.  
Since the precise etiology of ADHD is still unclear, the face-validity becomes the 
yard-stick for establishing an ADHD model. Such ADHD models may be viewed as 
experimental preparations developed for the purpose of studying ADHD-related 
phenotypes observed in humans (Koob, 2012). This approach has limitations related to 
extrapolating results to predicting clinically verifiable outcomes regarding both 
therapeutics and etiology.  
A common obstacle for preclinical researchers is the inherent difficulty in 
operationalizing clinical descriptors of a psychiatric disorder (e.g., the symptoms of 
ADHD as described in DSM-IV) into behavioral tasks for rodent models. The second 
challenge is associated with providing a validation for modeling every aspect of a 
complex psychiatric disorders such as ADHD or addiction (Koob, 2012). For ADHD, the 
phenotypic traits of inattention, impulsivity and hyperactivity have been used to 
validate an animal model for this disorder. Also, individuals with ADHD are not 
hyperactive in a novel environment, but rather express hyperactivity in familiar 
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environments (Sagvolden and Sergeant, 1998b). Ideally, the deficits in these core 
symptoms should be ameliorated by stimulant and non-stimulant medications. Taking 
these primary criteria into consideration, several animal models of ADHD have been 
employed.  
 
1.3.1 Spontaneously hypertensive rats (SHR) 
The most widely accepted animal model of ADHD are the spontaneously 
hypertensive rats (SHR), a genetic rat model generated from the inbred Wistar-Kyoto 
(WKY) progenitor strain by inbreeding for hypertension. Historically, SHRs were 
characterized against the WKY control to define the ADHD phenotype. SHRs have been 
studied and characterized extensively to ascertain validity as a model for this 
complicated neuropsychological disorder.   
SHR exhibit several dopaminergic deficits that contribute to its popularity as a 
model of ADHD (see Table 1.6). Specifically, the gene sequence for DAT differs from 
WKY; a 160 basepair insertion is present upstream of exon 3 of DAT in SHR (Mill et al, 
2005). Compared to WKY, striatal DAT expression is decreased in juvenile SHR, and is 
increased in adult SHR (Paxinos and Watson, 2007; Paxinos et al, 1980). Electrically 
evoked [3H]dopamine release is decreased in the dorsal striatum and PFC of adult SHR 
(Russell et al, 1995). Adult SHR also exhibit greater extracellular dopamine in NAc, 
attenuated K+-evoked release compared to WKY; accumbal dopamine release in adult 
SHR is increased with MPH (Carboni et al, 2003). Taken together, SHR exhibit 
corticostriatal dopaminergic deficits compared to WKY which may contribute to the 
increased hyperactivity, impulsivity and inattention (Sagvolden et al, 2005b). SHR also 
exhibit other neurobehavioral deficits (Table 1.6) that further increase their face-validity 
as a model of ADHD.
  
Table 1.6 Validation of Spontaneously Hypertensive Rats (SHR) as a model for ADHD 
ADHD Phenotype Findings in SHR References 
Inattention 
Enhanced responding during extinction trials (responding in the absence 
of cues) in a multiple fixed interval 30 sec/extinction (FI-30/EXT) schedule 
(Sagvolden et al, 2005b) 
Impulsivity 
Increased premature responses during the FI-30/EXT schedule (Sagvolden et al, 2005b)  
Deficits in withholding a prepotent response (Sanabria and Killeen, 2008) 
Increased choice of a small immediate reward over a delayed large 
reward 
(Wooters and Bardo, 2011) 
Hyperactivity 
Operant hyperactivity (Hill et al, 2012b) 
Increased open-field activity (van den Bergh et al, 2006) 
Working memory 
Increased number of errors on an radial maze version of win-shift task 
and win-stay tasks 
(Kantak et al, 2008) 
Behavioral 
flexibility 
Increased sessions to criterion on radial maze version of attentional set-
shift task as well as an operant strategy set-shifting task 
(Harvey et al, 2013; Kantak 
et al, 2008) 
Dopaminergic 
dysfunction in 
striatum 
Decreased electrically evoked [3H]dopamine release  
from caudate putamen slices  
(Russell et al, 1995) 
Greater extracellular dopamine in NAc,  
attenuated K+-evoked release, 
 but enhanced extracellular dopamine release with MPH 
(Carboni et al, 2003) 
Dopaminergic 
dysfunction in 
PFC 
Enhanced electrically evoked [3H]dopamine release from PFC slices (Russell et al, 1995) 
Greater extracellular dopamine in PFC of juvenile SHR (Viggiano et al, 2004b) 
Greater DAT function and expression levels in frontal cortex 
(Pandolfo et al, 2012; 
Roessner et al, 2010) 
Genetics Differ from WKY rats in DAT-1 gene sequence (Mill et al, 2005) 
3
2 
 33 
 
In summary, SHR display the core characteristics of ADHD, i.e., inattention, 
impulsivity and hyperactivity, and also display dopamine dysfunction in striatum and 
PFC. Further, MPH improves attention and behavioral flexibility and decreases 
impulsivity and hyperactivity in SHRs (Harvey et al, 2013; Kantak et al, 2008; Roessner et 
al, 2010; Russell et al, 1998; Sagvolden, 2011). Taken together, SHR display the hallmark 
features as well as other behavioral deficits associated with ADHD thereby proving to be 
a heuristically useful model of ADHD. 
Valuable insights into mechanisms of ADHD pharmacotherapeutics as well as 
etiology may be obtained using an animal model of ADHD. However, appropriate 
interpretation of results obtained from ADHD rat models with strong face validity, such 
as the SHR, requires cautious selection of suitable reference control groups. WKY, being 
another inbred and by definition a genetically homogeneous strain of rats, were later 
found to display several behavioral and neurochemical deficits and as a result is 
currently used as a model of depression (De La Garza and Mahoney, 2004). For example, 
hyperactivity in SHR appears to have been overestimated when the only control 
employed was WKY, because WKY are hypoactive relative to outbred control rats (van 
den Bergh et al, 2006). WKY show altered dopaminergic function compared to outbred 
Wistar (WIS) rats such as decreased striatal DA D1 and D2 receptors (Novick et al, 2008; 
Yaroslavsky et al, 2006) and decreased accumbal DAT expression (Jiao et al, 2003). 
Several of these deficits may exaggerated the observed ADHD phenotype that SHR 
display, and consequently, studies that employ WKY as the only reference control 
(Alsop, 2007b) have been criticized. Therefore, the current studies include both the 
more commonly used WKY control and the WIS control as comparators to SHR. The 
rationale for using two controls was to disambiguate differences between SHR and WKY, 
and thereby provide a more complete understanding of the behavioral and 
neurochemical mechanisms underlying ADHD pathology. 
  
 34 
 
1.3.2 Other models  
Naples High Excitability rats: Naples High Excitability (NHE) rats are either inbred 
rats from outbred Sprague-Dawley rats selected based on behavioral arousal to a novel 
environment (Sadile et al, 1993; Viggiano et al, 2002). These animals are considered to 
model the hyperdopaminergicity and hyperactive mesocortical system activity that may 
underlie the etiology of the inattentive and hyperactive phenotype in a subset of the 
ADHD population (Viggiano et al, 2004b). However, there are no studies demonstrating 
impulsivity in these rats. These rats have several neurochemical and behavioral 
similarities with the SHR model, but are not as widely accepted (Oades et al, 2005).  
Poor 5-CSRT task performers:  In this model, outbred Wistar rats were 
segregated into normal and poor-performers based on insufficient stimulus control in a 
5-choice serial reaction time task (5-CSRT). The 5-CSRT task is based on the continuous 
performance task used for evaluating attention in clinical laboratories (Robbins, 2002). 
In a typical 5-CSRT schedule, a 5 sec delay or inter-trial interval (ITI) is followed by 
illumination of the cue-light in one of the 5 nose-poke holes. Responding on the 
illuminated nose-poke hole is considered a correct response and is reinforced. 
Responding during the 5-sec delay is considered premature responding. A poor 5-CSRT 
performer, as defined using an accuracy of less than 64% on this schedule, models the 
inattention aspect of ADHD.   Low therapeutically relevant doses of MPH improve 
accuracy in the poor-performers, but not normal-performers (Puumala et al, 1996). 
Impulsivity, evaluated as % of premature responding was not different between the 
groups. Also, MPH increased impulsivity in normal-performers, but not in poor-
performers. Another study using a similar 5-CSRT schedule but different selection 
criterion for accuracy, found poor-responders to be more impulsive than control 
(Barbelivien et al, 2001). This study did not test the effect of an ADHD medication on 
behavior, although the uptake of [C14]deoxyglucose in the anterior cingulate and OFC 
was lower in the poor-performers. Poor 5-CSRT task performers model is considered to 
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resemble the predominantly inattentive subtype of ADHD (Koffarnus and Katz, 2011; 
Puumala et al, 1996).  
Transgenic models: These models utilized a top-down approach, where proteins with 
associated genetic polymorphisms in the clinical population of ADHD were over-
expressed or under-expressed to evaluate their role in attention, impulsivity or 
hyperactivity.  
DAT knockout and knockdown mice: Several transgenic DAT mutants have been 
evaluated for ADHD phenotype, the oldest being the DAT knockout mice (Gainetdinov, 
2008). For example, homozygous DAT knockout mice were ~6-times more active and 
required ~100-times longer to clear extracellular dopamine compared to heterozygous 
and wild-type mice (Giros et al, 1996). Also, hyperactivity in the DAT knockout mice is 
reduced by administration of amphetamine and dopamine receptor agonist 
(Gainetdinov and Caron, 2000; Zhuang et al, 2001). However, there are no published 
studies showing impulsivity or inattention in these mutants. The importance of this 
model is that it shows that DAT deficiency is neither necessary, nor sufficient, for 
inducing ADHD, lending further credence to the complicated multistep 
catecholaminergic interaction hypothesis of ADHD etiopathology. 
Coloboma mice with SNAP-25 deficient mutation: Heterozygous mutant mice 
expressing coloboma mutation on chromosome 2 (region coding for SNAP25) have been 
proposed as an ADHD model. The SNAP25 coboloma mice exhibit spontaneous 
locomotor hyperactivity. These mutant mice also display a learning deficiency in 
achieving complex neonatal motor abilities as a consequence of reduced calcium-
dependent dopamine release in dorsal striatum (Wilson, 2000). Compared to wild-type 
agouti mice, the coboloma mutant mice display greater sensitivity for delay in a delay 
discounting task as well as impaired attention evaluated as attenuated latent inhibition 
for acquiring conditioned taste aversion (Bruno et al, 2007). However, the effect of a 
stimulant medication on these behaviors has not been tested. Overall, the results with 
this mouse model together with the genetic association studies in subjects with ADHD 
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(Faraone et al, 2005) suggest that functional deficiency of SNAP-25 may contribute to 
ADHD. 
Chemically-induced model, neonatal 6-hydroxydopamine lesioned rats have 
been proposed as a useful model of the hyperactive aspects of ADHD; however they do 
not display impulsivity (Luthman et al, 1989a; Luthman et al, 1989b; Shaywitz et al, 
1978). These studies demonstrate that the dopaminergic, but not noradrenergic 
depletion was associated with hyperactivity in adult rats.  
Environmental models: Environmental effects including, maternal lifestyle, 
stress and nicotine exposure during gestation have been associated with cognitive 
deficits including those associated with ADHD (Cornelius and Day, 2009; Linnet et al, 
2003). A mouse model for prenatal nicotine exposure displayed hyperactivity, reduced 
cortical volume and dopaminergic deficits in frontal cortex (Zhu et al, 2012). A rat model 
of variable prenatal stress expressed working memory deficits, impulsivity and 
inattention under certain behavioral paradigms (Wilson et al, 2012). Rats raised in 
environmentally impoverished conditions also express impulsivity, hyperactivity and 
altered cortical dopaminergic function (Yates et al, 2012). These models, while limited in 
terms of face-validity and construct validity, are important preparations for parsing out 
environmental effects in ADHD etiology and may be valuable predictive tools for 
developing treatment strategies in individuals in whom such an environmental basis for 
ADHD is anticipated. 
 
1.4 Cocaine abuse liability in the ADHD population  
The mesocorticolimbic dopaminergic pathway dysfunction implicated in ADHD is 
also the target of drugs of abuse including cocaine (Ernst and Fudge, 2009; Koob and 
Volkow, 2010).  Not surprisingly, adults with ADHD have a higher risk of developing 
substance use disorders compared to non-ADHD individuals, and cocaine abuse is often 
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comorbid with ADHD (Biederman et al, 1998; Wilens et al, 1998a). The mechanistic basis 
for this observation is not understood completely. 
In this section, a brief review of the clinical literature on ADHD and cocaine 
addiction comorbidity will be discussed, followed by a brief description of the preclinical 
preparations available for evaluating factors influencing abuse liability under carefully 
controlled experimental conditions. The last section will delineate the possible 
behavioral, neurochemical and neurobiological mechanisms in the overlap between 
ADHD and cocaine abuse.  
   
1.4.1 Clinical literature on liability for substance abuse  
ADHD is usually overrepresented among individuals with substance use disorder 
(Carroll and Rounsaville, 1993; Szobot and Bukstein, 2008a; Szobot et al, 2007). 
Individuals with ADHD have 35% higher incidence of cocaine abuse compared to the 
general population (Carroll et al, 1993; Levin et al, 1999). ADHD is present much earlier 
than the usual age for initiation of experimentation with drugs of abuse; ADHD is 
identified during childhood (i.e., during elementary school years), or at least impairment 
are “present before age 7 years” (Criteria B, DSM-IV TR, American Psychiatric 
Association., 2000). Taken together, ADHD has been suggested to be a risk factor for 
developing substance use disorders.  
A report derived from 18–44 year old respondents of the National Comorbidity 
Survey Replication (NCS-R) suggested that compared to non-ADHD, adults with ADHD 
(~4.4% of respondents) had substantial role impairment (e.g., high divorce rates, and 
current unemployment status) as well as high comorbid with other NCS-R/DSM-IV 
disorders, including but not limited to, substance use disorder (Kessler et al, 2006). 
Thus, the association between ADHD and risk of cocaine abuse may be complicated by 
the presence of other comorbid conditions and social factors.   
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ADHD is associated with social impairments such as peer rejection and academic 
problems through childhood and adolescence (Elia et al, 1999; Greene et al, 2001). 
These social impairments may contribute to the high substance abuse liability in ADHD, 
particularly during adolescence (Greene et al, 1997; Tarter, 2002). ADHD treatments 
reduce the risk of developing these social problems, and could be expected to reduce 
substance abuse liability. However, the prevalence of prescription of MPH and ATO for 
ADHD individuals between ages 15 to 21 has declined more rapidly than the previously 
reported age-related decreases in ADHD symptoms (McCarthy et al, 2009), suggesting 
that treatment may be prematurely discontinued in some young adults. Further, the 
clinical literature is divided on the correlation between cocaine abuse and previous 
treatment of ADHD (Greene et al, 1999; Kollins, 2008a, b). This issue is discussed further 
in sections 1.8.4 and 1.9.4. 
ADHD is highly comorbid with other psychiatric conditions such as oppositional 
defiant disorder and conduct disorder (Biederman et al, 1991; Reinhardt and Reinhardt, 
2013), which may be present at childhood (see Table 1 for comorbid conditions) or may 
develop later during adulthood (Miller et al, 2007). These comorbid conditions have 
been implicated in substance abuse liability even in individuals without ADHD (Molina 
and Pelham, 2003). Additional evidence that complicates the disentanglement of 
causality is that compared to age-matched controls, children with ADHD have a higher 
likelihood of developing conduct disorder during adolescence and antisocial personality 
disorder during adulthood (Mannuzza et al, 1998). Thus, elevated substance abuse 
liability (as well as the development of other risky behaviors, including criminality) in 
ADHD may be mediated by the development of comorbid conduct disorder, antisocial 
personality disorder or oppositional defiant disorder (Dalsgaard et al, 2013; Klein et al, 
2012). Indeed a longitudinal study found that ADHD is associated with a greater 
incidence of  substance abuse liability in adolescents only in the presence of 
oppositional defiant disorder or conduct disorder (August et al, 2006). In contrast, 
another longitudinal study found that ADHD is associated independently with substance 
use disorder (Gau et al, 2007). Taken together, comorbid conditions may increase the 
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vulnerability of substance use disorder, but do not necessarily mediate substance abuse 
in individuals with ADHD. 
Indeed, the hallmark symptoms of ADHD have been established as predictors for 
the development of substance use disorder. Specifically, a longitudinal study in non-
ADHD individuals found that lower baseline attention and executive function scores 
significantly predicted substance use and dependence 8 years later (Tapert et al, 2002). 
Further, impairments in behavioral inhibition in childhood (10-12 years of age) predicted 
substance use frequency 4-6 years later and substance use disorders 7-9 years later 
(Tarter et al, 2003). High impulsivity has also been established as a predictor for 
substance use disorders, and specifically, cocaine abuse liability (Bechara and Martin, 
2004; Vonmoos et al, 2013). Interestingly, cocaine abuse may exacerbate ADHD 
symptoms (Vonmoos et al, 2013). ADHD patients with cocaine dependence were more 
impulsive compared to ADHD individuals without comorbid cocaine dependence as well 
as compared to healthy controls (Crunelle et al, 2013). 
 
1.4.2 Brain imaging studies that provide insights into mechanism underlying ADHD 
and comorbid drug abuse 
A working hypothesis regarding ADHD-cocaine abuse comorbidity is that 
executive function deficits in individuals with ADHD impair evaluation of risks and 
negative consequences associated with drug use, and interferes with inhibition of drug 
taking behavior despite negative consequences (Goldstein et al, 2009; Nigg et al, 2005; 
Szobot et al, 2008a). An alternate hypothesis is that altered reward and reinforcement 
mechanisms, a putative basis of ADHD, also mediate high substance abuse liability 
(Kalivas and Volkow, 2005b; Sagvolden et al, 1998a). Thus, the ADHD phenotype may 
enhance the behavioral response to the initial cocaine experience (Lambert et al, 2006); 
which is likely because the neuronal circuitry involved in ADHD (Fig 1.1) is involved in 
cocaine addiction (Adinoff et al, 2003; Bolla et al., 2003; Kaufman et al, 2003).   
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The mesocorticolimbic dopaminergic pathway (Fig 1.1) is also a part of the brain 
reward circuitry that is hijacked by drugs of abuse including cocaine (Ikemoto, 2007; 
Koob et al, 2010). DLPFC, OFC and the vmPFC mediate executive functions (Table 1.6) 
that are relevant for drug abuse and relapse (Aron and Paulus, 2007). Functional 
changes in these three areas of the frontal cortex are expected to underlie the deficits in 
executive function such as compulsive cocaine seeking, cocaine use, atypical pattern of 
evaluating reward expectancy and decision making observed in cocaine users (Bechara 
et al, 2004; Goldstein et al, 2009). Not surprising, cocaine users display “hypofrontality” 
or decreased functioning in these prefrontal cortical areas, as demonstrated by lower 
rates of glucose utilization measured using PET and [F18]-fluorodeoxyglucose  (Goldstein 
and Volkow, 2002).  
As seen with ADHD, persistent decreases in striatal D2 receptor availability has 
been observed also in cocaine abusers compared to control (Volkow et al, 1993; Volkow 
et al, 2007b). Compared to age-matched controls, cocaine abusers displayed reduced 
glucose metabolism in frontal cortical areas such as OFC and cingulate gyrus compared 
to control (Volkow et al, 1993). The connectivity between the cingulate gyrus, OFC and 
ventral striatum is thought to underlie the increased reactivity to cocaine cues in 
cocaine-dependent subjects relative to naturally appetitive stimuli (Wilcox et al, 2011). 
Specifically, compared to age- and education-matched healthy control individuals, 
cocaine-dependent subjects showed increased activation (BOLD signals) in OFC and 
DLPFC and decreased activation of cingulate gyrus following cocaine cues relative. 
Imaging using fMRI during a decision making task (Iowa Gambling task) revealed greater 
activation of OFC and decreased activation of DLPFC and medial prefrontal cortex 
(mPFC) in cocaine abusers compared to control (Bolla et al, 2003). This compromised 
decision making is thought to contribute to the development of addiction and 
undermine efforts for abstinence. Go/No-Go task is commonly used to evaluate 
impulsivity which requires the subject to emit a simple motor response to a ‘Go’ 
stimulus and inhibit that response in the presence of a ‘No-Go’ stimulus (Wooters et al, 
2006). Compared to cocaine-naïve controls, chronic cocaine users show reduced 
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activation of cingulate and insula during successful inhibition of responding during a no-
go trial (i.e. correct no-go responses) and during an incorrect no-go response (i.e., 
commission errors) in a Go/No-Go task  (Kaufman et al, 2003). Taken together, these 
results suggest that the brain structures required for higher-order cognitive control of 
behavior are disrupted in individuals using cocaine. As discussed previously (section 
1.2.3), impulse control and decision making functions are impaired in individuals with 
ADHD, and thus may be the neurological vulnerability that underlies the high cocaine 
abuse liability in ADHD.  
 
1.4.3 Animal preparations for evaluating cocaine abuse liability  
 
Animal models are useful for testing intoxication, withdrawal and preoccupation 
or craving stages of addiction described in the DSM IV (American Psychiatric and 
American Psychiatric Association. Task Force on, 2000). Abuse liability and abuse 
potential of drugs are typically evaluated using several behavioral paradigms 
(http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Gu
idances/UCM198650.pdf), which primarily model binge/intoxication and craving stages 
of the addiction cycle (Koob, 2012). 
 
Self-administration studies assess the reinforcing properties of a drug under a 
non-dependent state. If animals work actively in an operant task to receive a dose of the 
drug, this result indicates that the drug will likely exert reinforcing properties in humans 
(Collins et al, 1984; O'Connor et al, 2011). Thus, if a certain disease condition is clinically 
associated greater risk for substance abuse, the animal model of the said disorder is 
expected to exhibit greater cocaine self-administration compared to control. 
Modifications of the schedule of reinforcement reveal useful information about the 
reinforcing properties of the drug and may be linked to different addiction symptoms 
described in DSM IV (American Psychiatric Association., 2000). For example, a shift in 
the dose-response functions under a fixed-ratio of responding (i.e., number of 
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responses for single reinforcement is constant during the schedule) for a drug of abuse 
indicates a difference in the efficacy of reinforcement of the drug. Further, increased 
responding during a progressive-ratio schedule, where the number of responses to 
obtain a single reinforcement is progressively increased, has been linked with drug 
craving described as spending a “great deal of time” obtaining substance of abuse 
(American Psychiatric Association., 2000; Arnold and Roberts, 1997). Second order 
schedules of reinforcement are used to evaluate differential reactivity for cues that 
predict availability of a drug (Di Ciano and Everitt, 2005; Schindler et al, 2002). Under 
the second order schedules, animals learn a complex sequence of responding; each step 
in the sequence is reinforced by a conditioned reinforcer and completion of the 
sequence results in delivery of the primary reinforcer (Cain et al, 2004). The later 
procedure is especially important model for drug addiction vulnerability because of the 
strong association between responding for drug-cues and context and likelihood of 
relapse (Childress et al, 1988; McLellan et al, 1986).  
 
Conditioned place preference (CPP) is used to evaluate rewarding effect of a 
drug of abuse in the absence of the drug itself (Bardo and Bevins, 2000). The animal is 
exposed to two distinct environments, one of which is paired with the drug, and the 
other with saline through several training sessions. Subsequently, the animal is given the 
choice to spend time in either of the two environments in the absence of the drug.  
Spending more time in the drug-paired chamber indicates greater rewarding properties 
of the drug. However, negative results do not necessarily suggest the absence of abuse 
potential, given that “psychedelic” drugs such as 5-HT2 agonist hallucinogens and 
cannabinoids do not produce CPP in rodent models (Vlachou et al, 2007). Another 
disadvantage of the CPP procedure is that unlike self-administration, it often does not 
exhibit a clear dose-response relationship (Bardo et al, 2000). 
 
Drug discrimination evaluates interoceptive cues produced by a test compound, 
i.e. it is a method in which the animal indicates whether a test drug produces physical or 
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psychological perceptions similar to those produced by a known drug of abuse  (Ator 
and Griffiths, 2003; Preston, 1991). In this paradigm, rats are trained to produce a 
particular response (e.g., press right lever in an operant chamber) in the presence of the 
drug to obtain a food reinforcer and produce a different response (e.g., press left lever) 
under placebo condition to obtain the same reinforcer. Subsequently, the response 
produced by different doses of a test compound reveals whether the rat perceives the 
test compound as drug-like or placebo-like with respect to the interoceptive cue 
properties of the training drug (Koob, 2012). This schedule may also be used to evaluate 
if a test compound can enhance or inhibit the interoceptive cues associated with the 
drug of abuse (Borta and Schwarting, 2004). 
 
Psychomotor tests assess the ability of drugs to enhance motor functioning in 
rats, as has been demonstrated by well-characterized drugs of abuse including cocaine 
and amphetamines (Eisener-Dorman et al, 2011; Nordquist et al, 2008). Repeated 
administration of drugs of abuse, including cocaine, is known to enhance the 
psychomotor response elicited by the drug via a phenomenon termed psychomotor 
sensitization (Castner and Williams, 2007). Sensitization has been suggested to enhance 
the probability of relapse (evaluated using preparations like reinstatement of self-
administration), long after the discontinuation of drug use (Robinson and Berridge, 
2001). The neuropsychological basis for this association has been offered through the 
concept of “incentive sensitization” (Robinson and Berridge, 1993, 2000). In the words 
of the authors,  
i. ‘Potentially addictive drugs share the ability to produce long-lasting changes in 
brain organization.  
 
ii. The brain systems that are changed include those normally involved in the 
process of incentive motivation and reward.  
 
iii. The critical neuroadaptations for addiction render these brain reward systems 
hypersensitive (“sensitized”) to drugs and drug-associated stimuli. 
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iv. The brain systems that are sensitized do not mediate the pleasurable or euphoric 
effects of drugs (drug “liking”), but instead they mediate a subcomponent of 
reward we have termed incentive salience or “wanting”.’ 
 
Further, “incentive salience” has been suggested as the factor responsible for the 
“instrumental responding for the drug (i.e. drug-taking and drug-seeking)”. However, 
this concept has been a source of controversy in the field of drug addiction, where some 
research supports this contention (Lambert et al, 2006; LeBlanc et al, 2013), while 
others argue against it (Small et al, 2009).  
 
1.4.4 Preclinical studies evaluating factors mediating cocaine abuse in ADHD  
Preclinical studies also support the idea that the comorbidity of ADHD and 
cocaine abuse may be the result of commonalities in neuronal substrates. The mPFC in 
rodents is functionally analogous to DLPFC and portions of vmPFC in primates (Uylings 
et al, 2003). With respect to rodents, behavioral flexibility, working memory and 
sustained attention are regulated by the mPFC and OFC (Floresco et al, 2009; Ragozzino, 
2007).  
Both primates and rodents displaying cocaine addiction-like behavior show 
impaired cognitive control and executive function, suggesting functional impairments of 
mPFC and OFC (Beveridge et al, 2008; Harvey et al, 2009; Kantak et al, 2009). 
Importantly, mPFC and OFC also regulate cocaine-seeking behavior in outbred rats self-
administering cocaine (Di Pietro et al, 2006; Grakalic et al, 2010; Kantak et al, 2013; 
Mashhoon et al, 2010). Cellular adaptations in the glutamatergic projections from the 
PFC to the NAc, including decreased D2 and increased D1 signaling in the PFC and 
decreased glutamate release in accumbens observed in cocaine withdrawn rats (for 
review, have been suggested to underlie addiction-like behavior (Kalivas et al, 2005a; 
Volkow et al, 2005b). By extrapolation, the latter adaptations in the cortico-striatal 
glutamatergic neurons are proposed to mediate the motivation to obtain drugs of abuse 
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following the presentation of drug-associated stimuli, which is hallmark diagnostic 
criteria for drug addiction (American Psychiatric Association., 2000).  
The dorsal striatum mediates procedural learning and habit formation (Ikemoto, 
2007; Squire et al, 1993). Cocaine self-administration studies in primates have shown 
that although the initial adaptations following cocaine use is predominantly in the 
accumbens (decreased DAT expression and glucose utilization), chronic self-
administration is associated with adaptations in the dorsal striatum, including increased 
DAT expression and decreased glucose utilization in the caudate and putamen 
(Letchworth et al, 2001; Porrino et al, 2004).  Striatum plays a role in motor control and 
compulsive or habitual drug seeking (Goldstein et al, 2009; Kantak et al, 2005).  Taken 
together, these results suggest that cocaine abuse is associated with functional 
adaptations, particularly in the dopaminergic transmission, in the PFC and striatum. 
Further, ADHD medications may alter cocaine abuse liability by altering dopaminergic 
function in PFC and striatum. 
 
1.5 Impulsivity  
1.5.1 Definition and classifications 
Impulsivity is a complex multidimensional phenotype encompassing a wide 
variety of maladaptive behavior, including but not limited to, actions that are poorly 
conceived, prematurely executed, unnecessarily risky, inappropriate, and often with 
undesirable outcomes (Evenden, 1999b). Impulsivity includes several distinct and 
discreet components, each of which may have different neurological and genetic 
underpinnings. However, the high levels of impulsivity in individuals with ADHD are 
considered to predispose these individuals for future drug abuse vulnerability (Groman 
et al, 2009).  
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For decades, efforts have been made to fractionate the broad construct of 
impulsivity. From the psychological perspective, three separate and potentially 
independent ways have been identified in which impulsivity can modify behavior: in 
preparation for action, in execution of behavior patterns and in assessment of the 
consequences of an action (Evenden, 1999b). The majority of the clinical research in 
impulsivity has relied upon self-reported questionnaires that were developed based on 
different personality theories, which categorizes impulsivity in a relatively-overlapping 
manner (Patton et al, 1995; Whiteside and Lynam, 2001). As a result, impulsivity 
suffered from “jingle” fallacy, where two different constructs have equivalent label, as 
well as from “jangle’ fallacy, where a similar construct has two different labels (Block, 
1995). One conceptually founded and well accepted method for deconstructing 
impulsivity is the UPPS Impulsive Behavior Scale (UPPS; Whiteside et al, 2001)) which is 
based on the Five Factor Model of personality (Merritt and Bachtell, 2013; Russell, 
2003). UPPS scale measures four pathways to measure impulsivity: the urgency, (lack of) 
premeditation, (lack of) perseveration and sensation seeking (Whiteside et al, 2001). 
Urgency refers to the tendency to act impulsively under a positive or negative affect. 
Lack of Premeditation refers to a tendency to act without sufficient forethought. Lack of 
Perseverance refers to an inability to focus or follow through on mundane or 
challenging tasks. Sensation Seeking refers to a tendency to pursue activities that are 
exciting and often dangerous (Whiteside et al, 2005). The UPPS Impulsive Behavior Scale 
successfully differentiated the ADHD subtypes, ADHD-combined, ADHD-predominantly 
inattentive and ADHD with comorbid oppositional defiant disorder (Carter and Griffiths, 
2009). The latter study also identified the impulsivity factors that differentiated the 
ADHD subtypes. Given the superiority of the UPPS scale for evaluating impulsivity 
clinical subjects, efforts to operationalize the impulsivity factors for preclinical studies 
are currently underway. 
Another approach to simplify the construct of impulsivity is by defining 
endophenotypes of impulsivity; endophenotypes are a part of the biological pathway 
that links genes with a complex clinical phenotype (Bearden et al, 2004; Gottesman and 
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Gould, 2003). Endophenotypes help establish specific gene-behavior linkages and 
therefore may assist in identifying the molecular basis of impulsivity in ADHD (Almasy 
and Blangero, 2001; Crosbie et al, 2008). The defining criteria for an endophenotype are 
sensitivity and specificity to disease (Crosbie et al, 2008; Goos et al, 2009). For example, 
an ADHD-related impulsivity endophenotype must be present in ADHD individuals 
(sensitivity) and uncommon among the non-ADHD population (specificity). Furthermore, 
the endophenotype must be present in the genetic relatives of the individuals with  
ADHD even though they do not have ADHD themselves (Almasy et al, 2001). 
Endophenotypes, once established, can be trait markers for susceptibility for disease 
(Doyle et al, 2005b; Goos et al, 2009). Also endophenotypes may allow the 
categorization of ADHD into genetically homogeneous subgroups with distinct etiologies 
(Doyle et al, 2005b; Goos et al, 2009). However, given the complexity of executive 
function deficits in ADHD (Doyle et al, 2005a), evaluating endophenotypes of 
impulsivity, ADHD and cocaine addiction comorbidity is expected to be challenging.  
 
1.5.2 Role in ADHD and cocaine abuse comorbidity 
Genetic polymorphisms observed in patients with ADHD, such as DAT and D4 
polymorphisms, are thought also to be the genetic basis of impulsivity (Congdon and 
Canli, 2008).  As discussed previously, elevated impulsivity is a hallmark of ADHD 
(section 1.1.1). ADHD medications such as d-amphetamine, MPH and ATO have been 
shown to reduce impulsivity in clinical studies (Newman et al, 2008; Rubia et al, 2009a) 
and also have been shown to have beneficial effects in other neuropsychological 
disorders such as substance use disorders for managing impulsivity.  
Clinical research on ADHD has employed a number of behavioral tasks for 
empirically evaluating impulsivity, many of which have strong face-validity and are easily 
translated to preclinical research (Evenden, 1999a; Evenden, 1999b). Two such tasks, 
the Choice-Delay Task, measuring preference for a larger, but delayed reward over an 
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immediate small reward,  and the Stop Signal task, measuring the ability to inhibit a 
prepotent action, form very specific and sensitive predictors of ADHD (Solanto et al, 
2001). However, there is very little correlation between performance on the latter tasks 
(Solanto et al, 2001), probably because Choice-Delay Task and the Stop Signal task 
measure two different forms of impulsivity that engage different, but overlapping 
neural substrates. The behavioral tasks evaluating impulsivity have been broadly 
categorized into those measuring ‘impulsive action or motor-impulsivity’ and those 
evaluating ‘impulsive choice or cognitive/non-planning impulsivity’ (Winstanley et al, 
2010a). Motor impulsivity is described as inability to withhold from making a response, 
while impulsive choice is described as making decisions that are not beneficial for the 
future (Evenden 1999; Winstanley, Eagle et al. 2006). While each of these methods of 
classification has their own advantages and disadvantages, there is a need to 
standardize the rules for categorization to facilitate translational research between 
clinical and preclinical studies (Wickens et al, 2011; Winstanley et al, 2006a). 
Impulsive action has been associated with initiation and acquisition of drug-
taking behavior, while impulsive choice has been associated drug-seeking and 
reinstatement of self-administration (Diergaarde et al, 2008; Winstanley et al, 2010a).  
Compared to age-matched controls, individuals with ADHD select a less-likely but larger 
reward over a certain small reward (Drechsler et al, 2010a; Ernst et al, 2006). 
Conceptually, the latter risky decisions making is independent of delay aversion 
evaluated using Choice-Delay Task, but the two constructs share common neural 
substrates (Cardinal, 2006; Drechsler et al, 2010b).  Both risky decision making and delay 
aversion step from deficit processing of negative feedback, and may impair judgment 
and realistic assessment of the risks associated with actions (Cardinal, 2006; Drechsler et 
al, 2010b). Enhanced risk-taking behavior is associated with current and future drug use 
and abuse (Doremus-Fitzwater et al, 2010).  
Chronic drug taking has been shown also to increase various facets of impulsivity 
(Cardinal, 2006).  The working hypothesis in the field is that psychostimulants, such as 
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cocaine, enhance impulsivity as a feed-forward mechanism (Winstanley et al, 2010a). 
Specifically, the enhanced impulsivity impairing attempts to quit using drugs and 
exacerbating psychological effects of withdrawal, thereby leading to continuation and 
escalation of drug abuse (Koob et al, 2010; Winstanley et al, 2010a). Taken together, 
both ADHD and cocaine abuse are associated with increased impulsivity. However, the 
long-term effect of chronic administration of the stimulant ADHD medication, MPH, in 
individuals with ADHD on impulsivity later in life has not been empirically evaluated. 
 
1.5.3 Brain regions/Neurotransmitters involved 
Dopaminergic transmission in PFC and striatum are associated with impulsivity, 
risk-taking behavior and drug abuse (Cardinal, 2006; Koob et al, 2010; Perry et al, 2011; 
St Onge and Floresco, 2009, 2010).  Inactivation of dopamine terminals in NAc leads to a 
shift in choice preference from a larger less-likely reward  to smaller certain rewards and 
blocks acquisition of cocaine self-administration (Cardinal and Howes, 2005; McGregor 
and Roberts, 1993), thus demonstrating that a functional NAc dopaminergic system is 
necessary for impulsive choice as well as cocaine seeking.   
OFC lesions increase impulsive action and impair learning about the relative 
value of larger reward, under probabilistic as well as delayed delivery conditions (Eagle 
and Baunez, 2010; Mobini et al, 2002).  mPFC mediates goal-directed behavior and 
attention (Dalley et al, 2004), and regulates ability of rats to use within-session cues to 
update their choice according to recent reward contingencies (St Onge et al, 2010).  
Thus, OFC and mPFC functions critically mediate impulsive decision making as well as 
motor impulsivity. 
Dopamine plays an important role in determining the rewarding and reinforcing 
value of stimuli.  Changes in the phasic firing rates of dopamine neurons are thought to 
code for reward prediction errors and carry information about reward uncertainty 
(Tobler et al, 2005).  Stimulants at low doses increase synaptic dopamine levels and 
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decrease impulsive behavior in humans as well as rodents (Richards et al, 1999).  
Systemic administration of D1-type receptor antagonists does not affect delay 
discounting tasks while D2-type receptor antagonists increase impulsive choice (Wade 
et al, 2000).  Thus, dopaminergic signaling in mesocorticolimbic system may be a link 
between enhanced impulsivity and cocaine abuse liability in ADHD. 
Other neurotransmitter systems implicated in impulsivity are serotonin and 
norepinephrine. Disruption of serotonergic function by intra-raphe administration of 
5,7-dihudroxytryptamine in rats  increases preference for the smaller immediate reward 
over larger delayed reward (Mobini et al, 2000). While SSRIs have been useful in 
managing impulse control disorders such as pathological gambling, these drugs have not 
been effective at managing ADHD symptoms, suggesting that altered serotonin 
transmission is not central to ADHD etiology (Winstanley et al, 2006a).  
On the other hand, inhibition of norepinephrine transporters and activation of 
noradrenergic α2A receptors have been shown to reduce ADHD symptoms including 
impulsivity (Fernando et al, 2012; Robinson et al, 2008a). Based on differences in 
sensitivity to delay in a delay discounting task, one study divided SHR into impulsive and 
non-impulsive subtypes (Adriani et al, 2003). The latter study found that the impulsive 
SHR sub-population had lower extracellular norepinephrine in the cingulate gyrus and 
mPFC. However, the role of norepinephrine neurotransmission in impulsivity has been 
relatively underexplored. Of note, local infusion of α1 and α2 receptor agonist into the 
mPFC and OFC did not alter impulsive decision making (Pardey et al, 2013). In terms of 
impulsive action using 5-CSRT task, systemic administration of α2 receptor antagonist 
increased premature responding (Onali et al, 1988), and β-adrenergic antagonist 
decreased MPH-mediated increased premature responding (Milstein et al, 2010). Taken 
together these results suggest that noradrenergic transmission modulates impulsivity, 
however, further studies are needed to evaluate whether PFC noradrenergic receptors 
are involved. 
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1.6 Dopamine system 
1.6.1 Dopamine biochemistry and neurotransmission 
Dopamine is synthesized in the presynaptic neuron from amino acid tyrosine. 
Tyrosine hydroxylase converts tyrosine to L-dihydroxyphenyl alanine (L-DOPA), and this 
step is rate-limiting in the biosynthesis of dopamine. L-DOPA is further decarboxylated 
by DOPA decarboxylase to dopamine. Dopamine is packaged via vesicular monoamine 
transporter-2 (VMAT2) into presynaptic vesicles, where it is stored for release. In 
response to an action potential, the synaptic vesicles fuse with the presynaptic 
membrane and release dopamine into the synaptic space.  
The basal striatal extracellular dopamine concentration is ~4 nM, which 
transiently rises ~60-fold to 250 nM following dopamine release during a standard nerve 
impulse (Tannock et al, 1989a). Dopamine released into the synaptic space binds to 
postsynaptic D1-like receptors and D2-like receptors to produce their downstream 
signaling cascade. The extracellular concentration of dopamine returns to ~4 nM within 
milliseconds, primarily by diffusion of the transmitter into the extracellular space and 
assisted by uptake by DAT which translocates the dopamine back into the presynaptic 
terminal.  
The low basal level of extracellular dopamine concentration is thought to 
maintain presynaptic D2 autoreceptors at a steady-state partial activation. D2 
autoreceptors detect changes in extracellular dopamine and counter regulate it by 
modulating tyrosine hydroxylase activity, tonic release of dopamine and DAT mediated 
uptake. This phenomenon is called tonic dopamine regulation (Costa et al, 1990; Dalley 
and Kelleher, 1966; Siegler et al, 1990). Dopamine taken up by DAT into the presynaptic 
neuron is either metabolized by monoamine oxidase (MAO) into dihydroxyphenyl acetic 
acid (DOPAC) or repackaged and stored into synaptic vesicles. Extracellular dopamine is 
metabolized by catechol-O-methyltransferase (COMT) to 3-methoxytyramine. DOPAC 
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and 3-methoxytyramine are further metabolized into homovanillic acid by COMT and 
MAO, respectively. 
 
 
 
Figure 1.3 Dopaminergic neurotransmission at an ordinary synaptosome 
VMAT2 – vesicular monoamine transporter type 2, MAO-B – monoamine oxidase B, D1 
and D2 – dopamine receptor type 1 and 2, respectively, and Dopamine transporter – 
DAT 
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1.6.1.1 Role in ADHD and cocaine abuse 
When DAT is blocked by therapeutically relevant doses of MPH, extracellular 
dopamine in the striatum is increased by ~6-fold. This elevated resting state 
extracellular concentration of dopamine increases D2 autoreceptor activation and 
reduces action potential evoked dopamine release in striatum (Tannock et al, 1989a; 
Trobst et al, 2000). The decreased background firing of striatal neurons results in 
strengthening of corticostriatal signal via the glutamatergic prefrontal cortical afferents 
(McCrae et al, 2008). Taken together, the increased change in signal-to-noise ratio in the 
striatum is thought to mediate the increased attention and reduced distractibility 
following MPH treatment. Further support for the role of striatal D2-receptors in ADHD 
etiology and cocaine addiction comes from imaging studies. Specifically, striatal D2/D3 
receptor availability is lower in ADHD compared to non-ADHD individuals (Volkow et al, 
2007b) and in cocaine abusers (Volkow et al, 1993) compared to control. Cocaine is 
thought to exert its primary rewarding and reinforcing properties by increasing 
extracellular dopamine in NAc, while the striatum, mPFC and OFC are involved in the 
development and expression of drug addiction (Koob et al, 2010), also see section 
1.4.3). 
As discussed previously (Table 2), genetic studies revealed that hypofunctional 
D4 receptor polymorphisms are associated with ADHD etiology. Unlike other D2-like 
receptors, D4 does not have autoreceptor function. D4 receptors are expressed on 
neuronal presynaptic terminals that do not co-express tyrosine hydroxylase (Rivera et al, 
2008). This suggests that the primary function of D4 signaling is modulation of release of 
non-dopamine neurotransmitters, i.e. D4 functions as a heteroreceptor (Svingos et al, 
2000). Dopamine and norepinephrine are equal affinity agonists for D4 receptors 
(NewmanTancredi et al, 1997). In the dorsal striatum and the NAc, D4 is expressed on 
medium spiny neurons and modulates glutamatergic signaling (Mrzljak et al, 1996; 
Thomas et al, 2009). Taken together, D4 receptors appear to be important modulators 
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of striatal dopaminergic signaling, and hence, play a critical role in ADHD and cocaine 
addiction. 
D2-like receptors in PFC also are important for ADHD etiology and therapeutics. 
D2 receptors have a significant presynaptic autoreceptor role in the mPFC (Cubeddu et 
al, 1990). Specifically, the D2 agonist quinpirole reduced electrically-evoked 
[3H]dopamine release from mPFC slice preparation (Cubeddu et al, 1990).  D2 receptor 
stimulation in PFC modulates response-related firing of PFC neurons (Wang et al, 2004). 
Further, activation of D2 on pyramidal glutamate neurons modulates cocaine-induced 
behavior by exerting inhibitory control over cocaine-induced dopamine release in NAc 
(Beyer and Steketee, 2000, 2001; Liu and Steketee, 2011). D4 postsynaptic receptors are 
responsible for suppression of GABA-containing inhibitory interneurons (Rivera et al, 
2008; Wang et al, 2002). Thus, hypoactivation of D4 may result in excessive inhibition of 
firing of PFC networks. 
D1 receptors are the most abundant dopaminergic receptor in the PFC (Lidow et 
al, 1991). Stimulation of D1 receptors by cortical dopamine weakens firing of 
inappropriate connections (Arnsten et al, 2005). Thus, insufficient D1 receptor activation 
impairs PFC function by ineffectively blocking “noise”. Moderate levels of D1 stimulation 
suppresses irrelevant inputs or “noise” to layer IV and V cortical neurons and thereby, 
improve PFC function, including attention and working memory (Gamo et al, 2010; 
Vijayraghavan et al, 2007; Yang and Seamans, 1996). However over-stimulation of D1 
receptors by high concentrations of stimulants (observed during abuse of drugs such as 
cocaine), weakens PFC function by suppressing too many network connections 
(Vijayraghavan et al, 2007).   
 
1.6.1.2 Ontological changes in dopaminergic transmission, emphasis on adolescence 
During early adolescence (~PND 28-35 in rats), a transient generalized increase in 
D1 receptor density and arborization of glutamatergic pyramidal neurons in PFC results 
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in decreased cortical control over reward related behavior, which results in higher 
impulsivity and risk taking (Casey and Jones, 2010; Ernst et al, 2009; Somerville and 
Casey, 2010a; Somerville et al, 2011).  Fine-tuning of cortical control is achieved with 
synaptic pruning and selective down regulation of D1 receptors (Brenhouse et al, 2008; 
Doremus-Fitzwater et al, 2010) thus, contributing to an age-dependent decrease in 
impulsivity (Andrzejewski et al, 2011; Laviola et al, 2003). D1 receptor function in cortex 
is a therapeutic target for MPH action (Gamo et al, 2010). D2 and D4 receptors in PFC 
also are upregulated between postnatal day 7 (PND7) to PND28, and subsequently, 
downregulated between PND35-60 (Tarazi and Baldessarini, 2000). Currently, no reports 
are available that evaluate age-dependent changes in DAT expression or function in 
cortical areas. 
In contrast to the PFC, ontogenic changes in dopaminergic reward circuitry 
follow a different developmental trajectory. In the rodent NAc, density of dopamine D1, 
D2 and D4 receptor peaks by 4 weeks of age and is pruned subsequently during early 
adulthood (PND60) (Tarazi et al, 2000). In contrast, DAT density in NAc and dorsal 
striatum peaks by PND60 and is not down regulated in adult rats (Tarazi et al, 1998).  
 
1.6.2 Dopamine transporter (DAT) 
1.6.2.1 Involvement in ADHD and cocaine abuse comorbidity  
DAT has been associated with several neuropsychiatric disorders ever since the 
discovery of a 40-basepair variable number of tandem repeats (VNTR) polymorphism in 
the 3’-untranslated region of the DAT1 gene (Vandenbergh et al, 1992a; Vandenbergh et 
al, 1992b). As discussed in the previous sections, DAT play a critical role in ADHD 
etiology and therapeutics as well cocaine abuse and addiction. DAT inhibition is one of 
the primary mechanisms of action by which MPH exerts its therapeutic effects in ADHD 
and by which cocaine exerts its reinforcing properties. Genetic variations of DAT in 
ADHD etiology and therapeutics have been described previously (see Table 2).  
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Striatal DAT density evaluated using SPECT with [123I]altropane revealed a 70% 
elevated DAT density in ADHD individuals compared to non-ADHD proband (Dougherty 
et al, 1999). A recent meta-analytical review showed that previously medicated ADHD 
individuals have higher striatal DAT density compared to non-ADHD individuals (Fusar-
Poli et al, 2012). However, cortical DAT expression in ADHD relative to control has not 
been reported.  
Molecular mechanisms and pharmacological properties of ADHD medication, 
including MPH, are comparable to cocaine (Volkow et al, 1995); the Ki of cocaine and 
MPH for inhibition of DAT is 640 nM and 390 nM, respectively, and intravenous 
administration produces comparable DAT occupancy and subjective effects in humans. 
Striatal DAT function is elevated also in cocaine users (Mash et al, 2002). However, 
cortical DAT expression in cocaine users has not been reported.   
 
1.6.2.2 Structure, Function and regulation of trafficking 
Neuronal DAT is responsible for ensuring that dopaminergic signals are 
restricted, temporally and spatially (Melikian, 2004). DAT is coded by the DAT1 gene 
(SLC6A3) on chromosome 5 (Vandenbergh et al, 1992b). DAT is a member of the high 
affinity, sodium-and chloride-dependent solute transporter SLC6 gene family. DAT is a 
transmembrane protein the crystal structure of which is not available currently. 
Information about DAT structure is derived from in silico modeling that is currently 
based on X-ray structure of the homologous bacterial leucine transporter, LeuT 
(Manepalli et al, 2012).  
DAT, like the other members of the SLC6 family, are thought to have 12 
membrane-spanning domains with intracellular amino- and carboxy-terminals and a 
large, glycosylated extracellular loop between transmembrane domains 3 and 4 
(Melikian, 2004). DAT is thought to have two substrate binding site, one lodged in the 
interior of the transmembrane domains, called S1 and the second on the “extracellular 
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vestibule”, called S2 (Manepalli et al, 2012). DAT inhibitors including cocaine and MPH 
are expected to dock at the S2 site and impair dopamine transport by blocking access to 
the S1 site (Huang et al, 2009). 
At the presynaptic surface, DAT functions as regulators of extracellular dopamine 
concentration. A considerable pool of DAT is present in the intracellular portion of 
vesicular structures (Nirenberg et al, 1997). Immunocytochemical studies suggest that 
DAT is present on the presynaptic nerve terminal and in the cell bodies of the 
dopaminergic neurons (Hersch et al, 1997). Several stimuli regulate DAT function 
through trafficking dependent mechanisms that ultimately change the expression of 
DAT at the cell surface (Melikian, 2004). Specific examples of such mechanism include 
inhibition of DAT recycling by inhibition of phosphoinositol-3-kinase, increasing DAT 
endocytosis by PKC-mediated phosphorylation and several protein-protein interactions 
(Melikian, 2004; Sager and Torres, 2011).  Importantly, increases in D2 receptor 
activation and excess  concentrations of transporter substrate downregulates surface 
DAT expression (Gulley and Zahniser, 2003). Thus, chronic increases in extracellular 
dopamine by inhibition of DAT and NET in the PFC and by inhibition of DAT in the 
striatum by drugs including MPH, ATO and cocaine may lead to lasting adaptations in 
the cellular distribution of DAT. 
 
 
1.7 Norepinephrine system 
Norepinephrine is structurally similar to dopamine. The most important 
noradrenergic system neurons originate from locus coeruleus (LC) located in the dorsal 
pons. Axons of these neurons project to several areas of the brain, including but not 
limited to cortex, thalamus, hypothalamus, cingulate gyrus, hippocampus, and amygdala 
(see Fig 1.1). ADHD medications as well as cocaine are known to modulate firing of 
noradrenergic LC neurons (Gamo et al, 2010).  
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Figure 1.4 Noradrenergic neurotransmission at an ordinary synaptosome 
VMAT2 – vesicular monoamine transporter type 2, MAO-B – monoamine oxidase B, 
α1and α2 – norepinephrine receptor type 1 and 2, respectively, NET – norepinephrine 
transporter 
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1.7.1 Norepinephrine biochemistry and neurotransmission 
Norepinephrine is synthesized from dopamine in synaptic vesicles. Dopamine is 
hydroxylated by dopamine-β-hydroxylase (DβH), simultaneous with the reduction of an 
ascorbic acid molecule. Norepinephrine is released following an action potential from 
the presynaptic terminal and is subsequently cleared from the synaptic space by uptake 
by norepinephrine transporters (NET) and by metabolism by the extracellular enzyme 
COMT. Norepinephrine in the presynaptic terminal is either repackaged into synaptic 
vesicles, or metabolized by MAO. Norepinephrine is converted to normetanephrine and 
dihydroxymandelic acid by COMT and MAO, respectively. These metabolites are 
converted subsequently to vanillylmandelic acid by the complementary enzyme from 
the previous biochemical step in the metabolic pathway. 
1.7.1.1 Role of noradrenergic transmission in ADHD in cocaine abuse 
Clinical studies have found that polymorphisms in NET, COMT, D4 and DβH 
enzymes are associated with ADHD (see Table 2). NET clears both dopamine and 
norepinephrine (Moron et al, 2002), and is especially important for dopamine clearance 
in the cortical areas (regions of importance to ADHD etiology). DβH is the neuronal 
enzyme responsible for the conversion of dopamine to norepinephrine. COMT 
metabolizes extracellular dopamine and norepinephrine. Dopamine D4 receptors share 
equal affinity dopamine and norepinephrine, although not expressed on DβH expressing 
neurons in PFC (Rivera et al, 2008).   
ADHD medications such as d-amphetamine, MPH, and ATO increase 
norepinephrine levels in cortical areas. Further, guanfacine is a α2A adrenergic agonist. 
All effective ADHD medications increase norepinephrine neurotransmission. Moreover 
MPH and d-amphetamine at clinically relevant doses increase dopamine and 
norepinephrine levels in PFC, with the % increase in norepinephrine concentrations 
being greater than the % increase in dopamine concentration. Extracellular 
concentration of norepinephrine in PFC is ~0.9 nM (Bymaster et al, 2002). MPH at 
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0.5mg/kg, i.p. increases extracellular norepinephrine in PFC by 280% above baseline 
(Berridge et al, 2006). In contrast, in the subcortical region like medial septal area, MPH 
at 0.5 mg/kg i.p. increased extracellular norepinephrine to 122% of baseline of baseline 
(Berridge et al, 2006). 
ADHD is thought to be the result of reduced norepinephrine neurotransmission 
in PFC. Inhibition of α2 receptors (A, B and C subtypes) with intra-cortical administration 
of yohimbine has been shown to induce an ADHD profile in primates (Li and Mei, 1994; 
Ma et al, 2005; Ma et al, 2003). Inattention, impulsivity and emotional dysregulation 
may be due to decreased norepinephrine mediated PFC regulation of function of 
sensory and motor cortices, and dorsal and ventral striatum.  
Increasing cortical norepinephrine signal via increasing norepinephrine or 
activation of α2A receptors (by both stimulants and non-stimulants) is thought to 
improved PFC-mediated functions including attention and impulsivity (Arnsten et al, 
2005; Bari et al, 2011). At moderate levels extracellular norepinephrine activates α2A 
receptors, decreases intracellular cAMP, and consequently enhances the strength and 
duration of firing of cortical pyramidal neurons (Wang et al, 2007).  
Extracellular concentrations norepinephrine produce an inverted-U shaped dose 
response curve for modulation of PFC function; higher cortical norepinephrine engage 
the low-affinity α1-adrenoreceptors, increase intraneuronal cAMP, and protein kinase C 
activity and suppress firing of PFC cortical neurons (Birnbaum et al, 2004). Thus, 
stimulants at higher doses (comparable to that seen during drug abuse) are detrimental 
to cortical function.  
Cocaine is an inhibitor of monoamine transporters DAT, NET and serotonin 
transporter, and cocaine administration leads to increases in norepinephrine 
concentrations in brain (Amara and Sonders, 1998). Systemic administration of α1-
agonist, prazosin, has been shown to increase motivation for cocaine self-administration 
(Wee et al, 2008). However, DAT inhibition, and not NET inhibition by cocaine is thought 
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to mediate the reinforcing properties of cocaine (Dewit and Wise, 1977; Ritz et al, 1987; 
Wilson and Schuster, 1974). Norepinepherine neurotransmission is engaged by aversive 
and conditioned appetitive stimuli (Feenstra et al, 1999; Mingote et al, 2004). 
Norepinephrine depletion in mPFC has been shown to block cocaine-induced increase in 
dopamine in NAc and conditioned place preference in mice (Ventura et al, 2007). In 
contrast, inhibition of α1 receptors in mPFC or in VTA did not alter cocaine self-
administration (Ecke et al, 2012). Taken together, these results suggest that NET in 
cortical areas is involved in ADHD etiology and therapeutics but may not be directly 
related to cocaine abuse liability.  
 
1.7.1.2 Ontological changes in noradrenergic transmission, emphasis on adolescence 
Cortical norepinephrine concentration in rhesus monkeys exhibited a steady 
increase from birth to adulthood, and during adulthood, cortical norepinephrine far 
exceeded dopamine and serotonin concentrations (Goldman-Rakic and Brown, 1982). In 
the rodent LC, NET expression was high during the early postnatal period, and 
significantly decreases from adolescence to early adulthood (Sanders et al, 2005; Zhu et 
al, 2005b). Downregulation of DβH in the LC occurs more gradually and is not 
significantly lower until 2 years of age (Zhu et al, 2005b). In contrast, in the forebrain, 
NET expression increased from birth to PND 15, and these levels were typically 
maintained through adulthood (Sanders et al, 2005). The latter age-dependent changes 
in NET expression are consistent with developmental changes in cortical NET function 
(Coyle and Axelrod, 1971). α2 adrenergic receptors followed a similar developmental 
trajectory in rat cortex (Happe et al, 2004). Taken together, these studies suggest that 
cortical noradrenergic systems are not as plastic as the dopaminergic system during 
adolescence. Thus, the cortical noradrenergic system is not developmentally vulnerable 
during adolescence, and is not expected to be altered by mild pharmacological 
manipulations, such as treatment with therapeutically relevant low doses of MPH and 
ATO. 
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1.7.2 NE transporter (NET) 
The basal dopamine and norepinephrine extracellular concentrations in PFC are 
0.4 nM and 0.9 nM, respectively (Bymaster et al, 2002). ATO, a selective NET inhibitor, 
at 0.3 mg/kg, i.p. increases PFC extracellular norepinephrine and dopamine by 170% and 
50%, respectively, of baseline (Bymaster et al, 2002). 
 
1.7.2.1 Structure, Function and regulation of NET 
Neuronal NET is responsible for ensuring that noradrenergic signals are 
restricted, temporally and spatially (Melikian, 2004). NET is coded by the NET1 gene 
(SLC6A2) on chromosome 16 (Pacholczyk et al, 1991); NET is a member of the high 
affinity, sodium-and chloride-dependent solute transporter SLC6 gene family. The 
polypeptide sequence for NET shares 67% homology with DAT, and as a consequence 
most of the information about NET structure is derived from DAT models (Manepalli et 
al, 2012). 
NET, like the other members of the SLC6 family, is thought to have 12 
membrane-spanning domains with intracellular amino- and carboxy-terminals (Melikian, 
2004). Like DAT, NET too has two substrate binding site, one lodged in the interior of the 
transmembrane domains, called S1 and the second on the “extracellular vestibule”, 
called S2 (Manepalli et al, 2012). NET inhibitors including cocaine, as well as specific NET 
inhibitors including desipramine are expected to dock on the S2 site and impair 
dopamine transport by blocking access to the S1 site (Hill et al, 2011). 
NET at the synaptic surface functions as regulators of extracellular 
norepinephrine; surface NET in the cortex regulates extracellular dopamine 
concentrations (Bymaster et al, 2002). Unlike striatal and accumbal DAT, during the 
resting stage, NET is predominantly located in the intracellular compartment in the 
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prefrontal cortex (Miner et al, 2003) and is redistributed to the cell surface when 
conditions, such as stress, increase extracellular norepinephrine (Miner et al, 2006). 
Several proteins regulate trafficking of NET to and from the cell surface, including but 
not limited to proteinphosphatase2A, syntaxin1A, tyrosine kinase and mitogen-activated 
protein kinase (Apparsundaram et al, 2001; Gulley et al, 2003; Sager et al, 2011). 
 
1.8 Methylphenidate  
MPH is a piperidine-derived chemical moiety with two chiral centers (Fig 1.5). Of 
the 4 stereoisomers, d-threo MPH is the pharmacologically active stereoisomer 
(Challman and Lipsky, 2000; Heal et al, 2008). The chemical name for MPH is (±)-methyl 
α-phenyl-α-(2-piperidyl)acetate hydrochloride. The mechanism of action and 
pharmacology of MPH will be described in the subsequent sections. 
 
Figure 1.5 Methylphenidate 
The structure of d-threo (2R, 2’R)-methylphenidate, the pharmacologically active 
stereoisomer (Challman et al, 2000).  
MPH, following its synthesis in 1944, was used originally as an analeptic to 
reverse barbiturate induced coma (Wax, 1997). MPH is approved by FDA for treatment 
of ADHD, narcolepsy and postural orthostatic tachycardia syndrome. Off-label clinical 
uses of MPH include treatment of lethargy, biopolar depression, major depressive 
disorder and obesity. MPH is the first line of pharmacological treatment for ADHD in 
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children, adolescents, and adults (Dodson, 2005; Rosler et al, 2010; 2009), partially 
because of its superior efficacy (~70% cases) compared to placebo (Castells et al, 2011; 
Koesters et al, 2009), as well as its relative safety and mild side-effects (Godfrey, 2009; 
Merkel, 2010; Merkel and Kuchibhatla, 2009). However, MPH is not approved for use in 
children under 6 years of age (Vitiello, 2001) since the long-term effects of MPH on the 
developing brain are not understood clearly. Currently, several formulations of MPH are 
available in the US and world market (See table 4) each of which has its own set of 
advantages and disadvantages.  
  
1.8.1 Mechanism of action  
MPH is an inhibitor of DAT and NET, with Ki for inhibition of uptake of 
[3H]dopamine and [3H]norepinephrine about 160 nM and 40 nM, respectively (Richelson 
and Pfenning, 1984). MPH acts by enhancing extracellular concentrations of DA and NE 
in cortical areas (see Fig 1.2). Stimulation of postsynaptic α2A-receptors by NE is 
thought to strengthen appropriate network connections by extending the duration of 
the “signal”. On the other hand stimulation of D1 receptors is thought to weaken 
inappropriate connections and thereby weaken “noise” (Arnsten et al, 2005). 
 
1.8.2 Pharmacology  
Following oral administration of the immediate release formulations, maximal 
plasma concentrations of MPH are observed within 1-3 hours (Tmax) and a half-life (T1/2) 
of 1.5 to 2.5 hours has been reported (Faraj et al, 1974). For sustained release 
formulations, the Tmax and T1/2 for MPH was 3-4 hrs and 4 hrs, respectively (Birmaher et 
al, 1989). MPH is primarily metabolized to ritalinic acid by enzymatic de-esterification; 
alternate metabolic degradation pathways include trans-esterification to 
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ethylphenidate, hydroxylation of thephenyl-ring or oxidation of the piperidine-ring to 
form lactams. Less than 1% of MPH is excreted unchanged (Markowitz et al, 2003).  
Clinically, MPH exerts its therapeutic actions at low plasma concentrations of 8-
40 ng/mL by occupying >50% DAT in brain, and SPECT studies show that the highest 
MPH concentrations occur in striatum (Ding et al, 1997; Volkow et al, 1998a). Striatal 
DAT inhibition and subsequent increases in extracellular dopamine mediate the 
therapeutic actions of MPH (Volkow et al, 2012).  The latter study used changes in 
[11C]raclopride binding in the striatum to infer changes in extracellular dopamine 
concentration and reported that MPH-induced (0.5 mg/kg, i.v.) increases in extracellular 
striatal dopamine correlated with reductions in inattention ratings in ADHD individuals 
(Volkow et al, 2012). 
MPH has been shown to normalize deficits in cortical function in ADHD 
individuals. Specifically, during an emotional Stroop task, the activation and deactivation 
patterns in the mPFC following the presentation of a positive- and negative-valence 
distraction, respectively, were enhanced in adolescents with ADHD compared to control 
subjects and MPH normalized these aberrant activation patterns in individuals with 
ADHD (Posner et al, 2011). In another study, MPH improved reaction time during a 
working memory task in adolescents with ADHD and simultaneously strengthened 
connectivity in the frontoparietal regions of cortex (McCrae et al, 1986b). In another 
study, MPH normalized the elevated rates of omission errors, but not commission 
errors, during a continuous performance task in medication naïve children with ADHD, 
suggesting that acute MPH ameliorates inattention, but not impulsivity in children with 
ADHD (Rubia et al, 2009b). Behavioral effects in the latter study were associated with 
activation of the dysfunctional mPFC-striato-cerebellar attentional networks and a 
deactivation of the hypersensitive OFC activation for reward processing. Taken together, 
the above studies provide further evidence that the therapeutic efficacy of MPH is 
mediated, in part, by altering the function of neural networks including those in 
striatum, mPFC and OFC.  
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Clinically relevant MPH doses produce peak plasma concentration of 8-40 ng/mL 
(Wargin et al, 1983). Comparable plasma concentrations of MPH are observed in 
rodents following intraperitoneal injection of 0.25 - 1.0 mg/kg or oral administration of 
0.75 - 3.0 mg/kg (Berridge et al, 2006; Kuczenski and Segal, 2002). Low oral doses of 
MPH (2.0 mg/kg, p.o) preferentially increased dopamine in PFC (125% above baseline) 
rather than in NAc (50% above baseline; Berridge et al, 2006). The latter study also 
found that therapeutically relevant doses of MPH (0.5 mg/kg, i.p.) increased 
extracellular norepinephrine preferentially in PFC (280% above baseline) compared to 
the subcortical medial septal area (122% above baseline). Further, within the PFC, the 
magnitude of increase in extracellular norepinephrine was greater than dopamine 
(280% versus 130% above baseline) following 0.5 mg/kg, intraperitoneally. MPH 
improved working memory by increasing activation of cortical α2A adrenergic and D1 
dopaminergic receptors in non-human primates and rats (Arnsten, 2009; Gamo et al, 
2010). MRI studies in outbred rats revealed that MPH (2.0 mg/kg, i.p.) produced positive 
BOLD signals in NAc, substantial nigra and OFC, and produced negative BOLD signals in 
motor and somatosensory cortices, caudate putamen, globus pallidus and bed nucleus 
of stria terminals (Easton et al, 2009). This pattern of changing brain activation was 
observed also with ATO, suggesting some similarities in the outcome of ADHD 
medications (Easton et al, 2007). Taken together, these results from animal studies 
show that the pharmacological actions of therapeutically relevant doses of MPH, in part, 
involve enhanced catecholamine signaling in PFC and the modulation of mPFC, OFC and 
striatal activation. 
 
1.8.2.1 Cardiovascular effects 
Concerns have been raised about potential cardiovascular side effects including 
myocardial infarction, stroke and sudden death, associated with use of prescription 
stimulants such as MPH. The reasons behind such concerns regarding prescription 
stimulants are that prescription stimulants: 
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1. increase blood pressure and heart rate (Findling et al, 2001; Wilens et al, 2005) 
2. increase circulating levels of catecholamines that can induce vasospasm (Bromberg-
Marin et al, 2007; Rumbaugh et al, 1971; Thompson and Thompson, 2010) 
3. induce  formation of proinflammatory immunoactive gylcation end products that 
can cause vasculitis (Rumbaugh et al, 1971; Rumbaugh et al, 1976; Schteinschnaider 
et al, 2000; Treweek et al, 2009) 
4. prolong cardiac QT interval that may increase the risk for torsades de pointes 
(Reimherr et al, 2007; Yap and Camm, 2003). 
The concern for adverse cardiovascular events is higher in the adult population 
compared to children and adolescents primarily due to comorbid conditions, higher 
dose of stimulants administered, slower rates of systemic elimination and higher 
background rate of cardiovascular events (Castle et al, 2007; Olfson et al, 2008). A 
recent review of the clinical literature found that MPH and ATO treatments in children 
and adolescents with ADHD were not associated with increased risk of adverse 
cardiovascular events (Westover and Halm, 2012). However, caution must be exercised 
while interpreting these results; since the incidence of cardiovascular events in this age-
group is low, the possibility of type-II error (false negative outcome) is high.  In contrast 
to the effects in adolescents, results from studies evaluating cardiovascular events in 
adults were mixed, such that some indicated that stimulant treatments were safe (Habel 
et al, 2011) while others found an increased risk for adverse cardiovascular events 
(Holick et al, 2009; Schelleman et al, 2012). The later reports indicated an increased risk 
of events, such as transient ischemic attack among individuals prescribed ATO (Holick et 
al, 2009), and increased risk for ventricular arrhythmia and sudden death among those 
prescribed MPH (Schelleman et al, 2012). However, there is a paucity of clinical studies 
evaluating predefined clinical endpoints such as, myocardial infarction, stroke and 
death, as primary outcomes as opposed to soft endpoints such as stimulant induced 
increased blood-pressure or heart-rate. The former more definitive endpoints are 
particularly important because there isn’t a well-established causative relation of the 
latter soft-endpoints with adverse cardiovascular events (Psaty et al, 2001). Therefore, 
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further studies are required to ascertain whether chronic treatment with MPH and ATO 
during childhood and adolescence alters the risk of cardiovascular events during 
adulthood (Westover et al, 2012). 
 
1.8.3 Abuse liability 
Although MPH has been approved for medical use, it is classified as a schedule II 
drug by the US Controlled Substance Act (CSA; 21 U.S.C. 811(b), 811(c)). Schedule II 
controlled substances have high abuse potential 
(http://www.deadiversion.usdoj.gov/schedules/index.html). The Center for Drug 
Evaluation and Research (CDER) of the Food and Drug Administration (FDA) describes 
abuse liability as “used in nonmedical situations, repeatedly or even sporadically, for the 
positive psychoactive effects it produces.” 
(http://www.fda.gov/cder/guidance/index.htm). A survey revealed that children and 
adolescents prescribed MPH are often approached to sell or trade their medications 
(Musser et al, 1998). The nonprescription use of MPH increased from 1.2% to 2% 
between 2000-2006, with a doubling of non-prescription use in the college-age students 
(18-25 yrs old) in this period (Bogle and Smith, 2009). The mechanism of action of MPH 
is comparable to cocaine, a drug of abuse (Kollins et al, 2001). Specifically, both MPH 
and cocaine inhibit DAT and increase extracellular dopamine in nucleus accumbens, the 
reward center of the brain (Ritz et al, 1987). The brain distribution of MPH and it’s in 
vivo potency at inhibiting striatal DAT in humans is comparable to that for cocaine 
(Volkow et al, 1995; Volkow et al, 1998b). Humans have been shown to self-administer 
MPH, which produced significant positive effects and drug-liking scores compared to 
placebo on the Addiction Research Center Inventory (ARCI) subject-rated drug-effect 
questionnaire (Jasinski et al, 2008). Taken together, these results establish that MPH has 
significant abuse liability, and as a consequence is diverted for non-medical use, 
including to individuals without ADHD (United States. Substance Abuse and Mental 
Health Services Administration. Office of Applied Studies., 2006).  
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An internet-based survey revealed that ~7% of adults report using MPH for non-
medical reasons at least once in their life-time (Novak et al, 2007). However, the 
prevalence of nonmedical use was more for short-acting formulations. These results 
indicate that different mechanisms underlie the therapeutic and reinforcing effects of 
MPH. As described above (section 1.4.4), stimulants produce have addictive properties 
by increasing dopamine release in striatum. The therapeutic actions of MPH also 
depend, at least in part, upon an increase in extracellular dopamine in striatum (section 
1.2.3). 
One of the factors that differentiate the reinforcing and therapeutic effects of 
MPH is dose. Low, therapeutically relevant doses of MPH do not act as a stimulant; i.e., 
do not increase locomotor activity or increase accumbal and striatal extracellular 
dopamine concentrations (Berridge et al, 2006). Rather, low doses of MPH reduce 
home-cage activity in rodents, and preferentially increase cortical dopamine and 
norepinephrine concentrations (Berridge et al, 2006; Kuczenski et al, 2002) thereby 
resulting in therapeutic efficacy.  
Pharmacokinetic profile associated with the route of administration of MPH 
contributes to the reinforcing effect. Compared to cocaine, intravenously administered 
MPH resulted in comparable Tmax and temporal profile of subjective self-reports of 
“high”; however the half-life of [11C]MPH was longer than that of [11C]cocaine (90 min vs 
20 min; Volkow et al, 1995).  The therapeutically relevant oral route of administration of 
MPH resulted in a longer Tmax, and as a consequence, did not produce the subjective 
self-reported “high” despite comparable increases in extracellular dopamine in striatum 
found with intravenous administration (Volkow and Swanson, 2003). These results 
suggest that formulations that result in rapid increase in plasma concentration of MPH 
have a greater abuse potential compared to formulations that have a low rate of 
systemic absorption. 
A third factor to consider is individual differences; i.e., some individuals are more 
sensitive to the rewarding and reinforcing effects of MPH than others (Volkow et al, 
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2003). For example, preexisting conditions including history of drug abuse, impulsivity, 
and ADHD (section 1.4.1) may confer higher abuse liability. Taken together, dose, route 
of administration and individual differences contribute to the abuse liability of MPH and 
must be taken into consideration while evaluating the risks of MPH treatment in 
children and adolescents with ADHD. 
 
1.8.4 Impact of methylphenidate treatment on ADHD/cocaine abuse comorbidity 
The high comorbidity of cocaine abuse in individuals with ADHD is well 
documented in the clinical literature (see section 1.4). Individuals with ADHD have 35% 
higher incidence of cocaine abuse compared to the general population (Carroll et al, 
1993; Levin et al, 1999). However, the effects of MPH on this comorbidity are highly 
debated and controversial. Clinical reports suggest that MPH treatment initiated in 
childhood may be protective against cocaine addiction (Fischer and Barkley, 2003; 
Wilens et al, 2003), or not modify cocaine abuse liability in individuals with ADHD 
(Molina et al, 2013). Another study reported that MPH treated adolescents and adults 
with ADHD showed higher abuse and dependence on stimulants, including cocaine and 
tobacco, compared to untreated and age-matched non-ADHD subjects (Lambert and 
Hartsough, 1998). The latter study has been criticized. The authors did not control for 
comorbid conduct disorder, which is critical given the strong association of conduct 
disorder with drug abuse liability (Burke et al, 2001). Another study that controlled for 
lifetime severity of conduct disorder found that MPH treatment >1 year during 
childhood was associated with greater likelihood of ever using cocaine, but only in the 
presence of comorbid conduct disorder (Barkley et al, 2003). In contrast, a study that 
excluded children with conduct disorder found a positive correlation between age of 
initiation of MPH treatment and cocaine abuse during adulthood (Mannuzza et al, 
2008), such that lifetime rates of cocaine abuse were higher when treatment was 
initiated in early adolescence. Thus, the age of intiation of MPH treatment may be a 
critical factor modulating cocaine abuse liability in individuals with ADHD. 
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Adolescence is an vulnerable developmental period, and treatment with 
stimulant medication at this age may lead to several lasting detrimental outcomes 
(Spear, 2000b); also see section 1.5.5).  ADHD is typically diagnosed during childhood, 
especially given the diagnostic criteria that ADHD symptoms and impairment should be 
“present before age 7 years” (American Psychiatric Association., 2000). However, 
several factors, including ADHD subtype and socioeconomic status, may delay the age of 
ADHD diagnosis (Froehlich et al, 2007), and consequently, delay the age of initiation of 
MPH treatment. Also, older children (12-15 years) have a greater likelihood of initiating 
treatment compared to younger children (Froehlich et al, 2007). Another study reported 
that although the typical age of ADHD diagnosis was <8 years, ~12% of newly diagnosed 
ADHD individuals were in the 12-17 years age range (Chen et al, 2011). Further, later 
initiation of MPH treatment in this cohort was associated with increased discontinuation 
of treatment. A recent review documented high rates of non-adherence to ADHD 
medications and peak rates of discontinuation of MPH after 5 years of treatment 
initiation in children and adolescents (Adler and Nierenberg, 2010). Taken together, 
these studies suggest that initiation of MPH treatment during adolescence as well as 
discontinuations of MPH treatment are common clinical observations, and its impact on 
drug abuse liability needs to be evaluated. 
Another question raised by the clinical studies is why did specifically cocaine 
abuse liability stand out in these studies with MPH treatment in ADHD subjects? The 
commonalities in the mode of action of MPH and cocaine may underlie, in part, the 
increased cocaine abuse liability following MPH treatment. Both drugs are 
psychostimulants that block DAT and NET and increase extracellular dopamine 
concentration in brain reward circuitry (see section above, 1.8.3).  Thus, MPH treatment 
may lead to enhanced sensitivity for later stimulant exposure, which is reported to be a 
predictor of cocaine dependence and life-time use (Lambert et al, 2006).  However, 
whether enhanced sensitization for cocaine preceded cocaine abuse in MPH-treated 
individuals is difficult to address in clinical studies; preclinical studies with carefully 
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controlled experimental conditions are advantageous for systematically addressing 
these questions. 
 
1.8.5 Relevance of adolescence 
The developing brain is more vulnerable to pharmacological insult than the fully 
developed brain, and drugs at doses well below the toxic concentrations are capable of 
producing long-lasting alterations in a developmentally malleable system. Adolescence 
represents a developmentally critical period for the neurocircuitry regulating motivation 
and decision-making (Chambers et al, 2003). Because of reduced impulse control, 
adolescence is associated with enhanced sensation seeking and risk-taking behaviors 
(Adriani and Laviola, 2004; Arnett, 1992). Furthermore, first use of psychoactive 
substances during early adolescence has been associated with higher life-time rates of 
drug-use, rapid development of dependence and higher rates of psychopathological 
comorbidities (Clark et al, 1998). However, these effects are a consequence of a 
combination of biological and social factors, and as such, animal models provide a better 
control to evaluate the contribution individual factors associated with enhanced drug 
abuse vulnerability during adolescence (Adriani et al, 2004).  
An MRI study revealed age-related differences in neuronal activation patterns 
following acute MPH in adult and adolescent outbred rats (Canese et al, 2009). 
Specifically, in adult rats, a high dose MPH (4 mg/kg, i.p.) increased BOLD signals in NAc 
and PFC. In contrast, in adolescent rats, the same MPH dose reduced BOLD signal in NAc 
and PFC, suggesting that neurological effects of pharmacological manipulations differ 
between adolescent and adult rats.  
Development of higher cognitive function, including inhibitory control occurs 
throughout adolescence concurrently with the maturation of PFC (Casey et al, 2005).  
Specifically, maturation of cognitive capacity coincides with extensive synaptic pruning 
of glutamatergic pyramidal neurons in PFC and simultaneous strengthening of the 
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remaining synaptic connections. For example, during early adolescence, a transient 
increase in D1 receptor density suppresses cortico-amygdalar emotional control and 
simultaneously, increases cortical drive controlling reward-related behavior. (Casey et 
al, 2010; Ernst et al, 2009; Somerville et al, 2010a; Somerville et al, 2011). Fine-tuning of 
cortical drive is achieved with synaptic pruning and selective down regulation of D1 
receptors (Brenhouse et al, 2008; Doremus-Fitzwater et al, 2010), leading to a decrease 
in impulsivity by adulthood. Expression of D2 and D4 receptors in PFC are also 
upregulated between PND7-28, and subsequently, downregulated between PND35-60 
(Tarazi et al, 2000). DAT expression in the cortical areas is sparse; limitations of 
detection of the currently available methods, such as autoradiographic binding, do not 
provide information about the developmental changes in the cortical areas during 
adolescence (Moll et al, 2000). Chronic treatment with MPH during adolescence may 
alter the developmental trajectory of cortical dopaminergic system. 
During adolescence, the reward circuitry also undergoes changes; in the rodent 
NAc, dopamine D1, D2 and D4 receptor density peaks by 4 weeks of age and is 
subsequently pruned in early adulthood (PND60; Tarazi et al, 2000). In contrast, DAT 
density in the NAc and dorsal striatum peaks by PND60 and does not get down 
regulated in outbred rats (Tarazi et al, 1998). Since the nigrostriatal pathway and the 
mesolimbic pathways are implicated in motor activity and altered responsiveness to 
reward-related learning in ADHD (see section 1.2.3), MPH treatment also alters function 
in these areas. Taken together, the development-related neuronal plasticity confers 
additional vulnerability, such that MPH at doses well below stimulant concentrations 
may permanently enhance sensitivity for future drug abuse vulnerability. 
Chronic treatment with low doses of MPH during adolescence was associated 
with decreased cocaine CPP, and decreased cocaine self-administration in adult outbred 
rats (Carlezon et al, 2003; Thanos et al, 2007). In contrast, another study reported that a 
low dose of MPH during early adolescence did not alter psychomotor response to 
cocaine, but increased cocaine self-administration evaluated during late adolescence 
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(Brandon et al, 2001). Furthermore, MPH treatment in juvenile primates followed by 
treatment discontinuation did not enhance cocaine self-administration during 
adulthood (Gill et al, 2012). A limitation of these studies was that the subjects involved 
did not have an ADHD phenotype. Chronic treatment with MPH during adolescence may 
produce different effects in subjects with an already compromised dopaminergic 
system, as found in patients with ADHD. Thus, subjects with the ADHD-like phenotype 
are needed to evaluate the effect chronic MPH treatment during adolescence on future 
cocaine abuse liability. 
Studies using the SHR model for ADHD found several interesting results with 
MPH treatment. Chronic administration of MPH (0.6 mg/kg, i.p.) during adolescence did 
not cause sensitization in adolescent rats, but led to sensitization in adult rats (Barron et 
al, 2009). In contrast, MPH treatment (2.5 mg/kg, i.p.) during adolescence (PND35-45) 
led to decreased CPP for cocaine in adult SHRs (Augustyniak et al, 2006). Another study 
found that MPH (1 mg/kg, i.p.) treatment during peri-adolescence (PND 21-35) 
decreased CPP for MPH in adolescent SHR (>PND 45) and increased CPP in adolescent 
Wistar rats (dela Pena et al, 2012a).  CPP evaluates rewarding effects of drugs; however, 
self-administration is the strongest predictor of abuse liability of drug (McCrae and 
Costa, 1995). In adult rats, MPH pretreatment (2 mg/kg, i.p.; 14 days) did not alter MPH 
self-administration in SHR, but increased MPH self-administration in adult Wistars (dela 
Pena et al, 2012b). In contrast, when MPH (1.5 mg/kg, p.o.) was administered during 
adolescence (PND 28-55), SHRs showed increased cocaine self-administration during 
adulthood (PND >77) (Harvey et al, 2011). Specifically, compared to WKY and WIS 
controls, SHR treated with MPH orally (1.5 mg/kg) during adolescence exhibited more 
rapid acquisition of cocaine self-administration, greater responding across a range of 
cocaine doses, and higher progressive ratio breakpoints (refer Fig 1.6). The increase in 
cocaine self-administration was associated with decreased DAT function in whole 
prefrontal cortex, which includes both mPFC and OFC. mPFC and OFC are distinct based 
on cytoarchitecture and behavioral function, but are also highly interconnected (Gilbert 
and Burgess, 2008; Lawrence et al, 2009). Taken together, MPH treatment during 
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adolescence increased later vulnerability to cocaine addiction and altered cortical DAT 
function may underlie these effects. Furthermore, these reports emphasize that a rat 
strain exhibiting an ADHD phenotype is required for addressing a key controversial 
question regarding the impact of MPH treatment during adolescence on later cocaine 
addiction vulnerability.  Further studies are required for evaluating behavioral and 
neurochemical mechanisms mediating the increased cocaine self-administration in SHR 
to inform therapeutic strategies for adolescents with ADHD and to protect against 
future cocaine abuse. 
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Fig 1.6. Cocaine self-administration: In adult SHR, discontinuation of methylphenidate (MPH) treatment after adolescence 
expedites acquisition (left) of cocaine self-administration, and leads to upward shifts in the cocaine dose-response under 
Fixed-Ratio 1 (center) and Progressive Ratio (PR) breakpoint (right) schedules, indicating that cocaine is a more efficacious 
reinforcer in SHR. In adult WIS, discontinuation of MPH treatment after adolescence increases the number of sessions to 
acquisition criterion. Data are presented as percentage of WKY-VEH control (left) and as a percentage of WKY-VEH receiving 
cocaine 0.3 mg/kg/infusion as control (center and right). *p<0.05 compared SHR-VEH, WIS-MPH and WKY-MPH; #p<0.05 
compared to respective vehicle control, εp<0.05 main effect of strain, compared to WKY and WIS. Figure adapted from 
Harvey et al, 2011. 
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1.9 Atomoxetine 
Stimulants such as MPH and amphetamine have been the first line of 
pharmacotherapy for ADHD in children, adolescents and adults (Dodson, 2005; Rosler et 
al, 2010; 2009). Stimulants are efficacious controlling ADHD symptoms in ~70% patients 
(Spencer et al, 1996). However, about 10-30% of the individuals with ADHD do not 
benefit from either MPH or amphetamine treatments as they are non-responders or 
intolerant to psychostimulant therapy (Barkley, 1977; Elia et al, 1991). Psychostimulants 
are controlled substances with documented abuse liability (Holman, 1994). As a 
consequence, there is a need to develop pharmacotherapies with different mechanism 
of action that may not have abuse liability.  
Increase in extracellular dopamine and norepinephrine in the PFC which is 
associated with the therapeutic efficacy of stimulants, while increase in dopamine in the 
nucleus accumbens contributes to the reinforcing effects of stimulants (Gamo et al, 
2010; Heal et al, 2008). Selective inhibitors of NET increase extracellular dopamine and 
norepinephrine in the PFC, but not in the nucleus accumbens (Bymaster et al, 2002; 
Moron et al, 2002). Thus compared to stimulants, NET inhibitors exhibit a 
neurochemical profile that mitigates ADHD symptoms without the risk of abuse and 
diversion. 
Tricyclic antidepressants such as desipramine and nortriptyline, which have a 
higher affinity for NET compared to DAT and serotonin transporters (Wong et al, 1995) 
emerged as “off-label” therapeutics for ADHD (Biederman et al, 1989; Spencer et al, 
1996; Wilens et al, 1996). However, tricyclic antidepressants are associated with 
persistent side effects such as cognitive impairments, sedation, dry mouth, weight-gain 
and cardiovascular events due to their affinity for α1-adrenergic receptors, cholinergic 
receptors and histaminergic receptors (Cookson, 1993; Walsh et al, 1994; Wong et al, 
1995). Subsequent efforts to identify an ADHD therapeutic with improved selectivity for 
NET led to ATO (Spencer et al, 1998).   
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Figure 1.7 Atomoxetine 
Alternate names: tomoxetine, LY139603. IUPAC (3R)-N-methyl-3-(2-methylphenoxy)-3-
phenylpropan-1-amine; other chemical names - (R)-N-methyl-3-phenyl-3-(o-
tolyloxy)propan-1-amine; (+/-)-N-methyl-gamma-(2-methylphenoxy) phenylpropylamine 
hydrochloride. 
 ATO was efficacious in the treatment of ADHD over placebo in adults (Spencer 
et al, 1998). Also, ATO reduced core symptoms of ADHD in children and adolescence, 
produced a graded dose-response, and was found to be well tolerated in this age group 
(Michelson et al, 2001; Spencer et al, 2001). The efficacy of ATO was found to be 
comparable to the immediate release formulations of MPH, but was less than that of 
extended-release formulation OROS MPH (Garnock-Jones and Keating, 2009).  
 
1.9.1 Mechanism of action 
ATO is a selective, potent competitive inhibitor of NET with a Ki of 0.1 nM 
inhibiting norepinephrine uptake into rat hypothalamic synaptosomes (Bolden-Watson 
and Richelson, 1993; Wong et al, 1982). The latter studies also demonstrated that ATO 
was highly selective for NET. Specifically, ATO has very low affinity for DAT and 
serotonin transporters, with Ki’s of ~1600 nM and ~750 nM, respectively, for inhibiting 
monoamine uptake. With respect to noradrenergic receptors, the IC50 for inhibition of 
binding of [3H]WB4101 to α1-adrenergic receptors and binding of [3H]clonidine to α2-
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adrenergic receptors on membranes isolated from crude synaptosomal fractions of rat 
cerebral cortex were 10 and 56 µM, respectively. IC50 for inhibition of [
3H]pyrilamine to 
histamine H1 receptor, and of [
3H]3-quincylindinyl benzilate to  muscarinic receptors 
was 6.4 and 21 µM, respectively. ATO at 10 µM failed to inhibit binding of [3H]serotonin 
into rat PFC. Furthermore, ATO produced less than 10% inhibition in binding of 
[3H]dihyroalaprenolol, flunitrazepam and GABA in membranes from calf cerebellum, 
suggesting that ATO has little to no affinity for β-adrenergic receptors, GABAA and other 
GABAergic receptors (Wong et al, 1982).  
ATO inhibited radioligand binding in membrane preparations from heterologous 
expression systems transfected with human NET, SERT and DAT with Ki values of 5, 77 
and ~1450 nM, respectively (Bymaster et al, 2002), suggesting that the mechanism of 
action of ATO is comparable between rats and humans. Using in vivo microdialysis in 
freely moving rats, ATO (0.3 to 3 mg/kg i.p.) was reported to increase extracellular 
norepinephrine in PFC to ~300% of basal NE concentrations (Bymaster et al, 2002). ATO 
also increased cortical extracellular dopamine concentrations to ~300% of basal DA 
concentrations (Bymaster et al, 2002). The extracellular 5-HT concentration in PFC was 
not significantly increased by ATO at doses up to 3 mg/kg i.p. (Bymaster et al, 2002). 
Further, ATO (3 to 10 mg/kg i.p.) did not increase extracellular dopamine in the nucleus 
accumbens or striatum of freely moving rats (Bymaster et al, 2002). Taken together, 
these results suggest that ATO increased extracellular dopamine in PFC by inhibiting 
uptake of dopamine into noradrenergic terminals via NET (Moron et al, 2002).  
 
1.9.2 Pharmacology 
NET inhibition by ATO increases extracellular dopamine and norepinephrine 
concentration in the PFC. ATO exerts its therapeutic action via enhanced catecholamine 
neurotransmission in PFC (Bymaster et al, 2002; Gamo et al, 2010). ATO reduces 
impulsivity in outbred rats evidenced by reduced premature responding using 5-CSRTT 
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and increased preference for a delayed larger reward in a delay-discounting task 
(Robinson et al, 2008a). ATO also improved behavioral flexibility in rats with 
noradrenergic-lesions in the mPFC (Newman et al, 2008). ATO also decreased locomotor 
activity of SHRs, but not WKY, in open- field chambers (Umehara et al, 2013a). Taken 
together, these results from preclinical studies suggest that ATO ameliorates ADHD 
related symptoms. 
Increased extracellular dopamine concentration in PFC activates D1 receptors 
and enhances working memory (Sawaguchi et al, 1994). Further, activation of cortical 
areas impacts neuronal projections to subcortical areas such as striatum, VTA and NAc 
(Taber et al, 1995; Taber and Fibiger, 1993). Thus, deficits in subcortical function 
associated with ADHD, such as altered processing of reward and reinforcement 
(Sagvolden et al, 1998a; Williams et al, 2009b) are ameliorated, partially, by activation 
of D1 receptors in the PFC. 
Increased cortical norepinephrine by ATO leads to activation of α2A receptors 
(Gamo et al, 2010), which in turn mediates improvement in PFC function (Arnsten et al, 
2005). Activation of α2A receptors decreases intracellular cAMP, disinhibits cAMP-HCN 
channels and thereby result in enhanced strength and duration of firing of cortical 
pyramidal neurons (Wang et al, 2007). The latter mechanism of action is thought to 
underlie the efficacy of ADHD medications for increasing attention and reducing 
impulsivity and working memory deficits (Sagvolden, 2006; Wang et al, 2007).  
A MRI study using outbred Sprague Dawley rats found negative BOLD response 
in the caudate putamen (dorsal striatum), which may indicate decreased neural activity 
in the striatum (Allison et al, 2000; Easton et al, 2007). Further, negative BOLD response 
in the brain areas associated with the cortico-basal thalamic loop circuit and positive 
BOLD response in the OFC was obtained following acute ATO administration (Easton et 
al, 2007). These results, although observed in anesthetized outbred rats, may indicate 
the pharmacological mechanisms by which ATO reduces hyperactivity and enhance 
behavioral control in ADHD.   
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Alternate mechanisms which may contribute to enhanced attention and working 
memory following ATO (1 mg/kg, i.p.) treatment are increased extracellular 
acetylcholine and histamine in the mPFC (Horner et al, 2007; Tzavara et al, 2006). The 
ATO-induced increase in cortical acetylcholine was reversed by SCH23390, a D1 
antagonist and by prazosin, an α2A antagonist (Tzavara et al, 2006). Thus, ATO induced 
increased cortical catecholamines may mediate the increased extracellular 
acetylcholine. Taken together, these results suggest that ATO treatment recruits several 
neurological circuits to produce its therapeutic efficacy, and that increased cortical 
dopamine and norepinephrine is central to the mechanism of action of ATO. 
 
1.9.3 Abuse liability 
As a screening strategy for abuse liability, CDER recommends several binding 
studies to evaluate the interaction of new drugs with neurotransmitter systems 
associated with abuse potential (http://www.fda.gov/cder/guidance/index.htm), 
including dopamine, norepinephrine, serotonin, GABA, acetylcholine, opioid, NMDA and 
cannabinoids. Based on the results from the recommended binding studies (Bymaster et 
al, 2002), ATO was approved by the US FDA as an uncontrolled, non-stimulant 
treatment for pediatric adolescent and adult ADHD.  
In terms of direct effects on the reward circuitry, ATO does not increase 
extracellular dopamine concentrations in NAc or striatum (Bymaster et al, 2002). These 
microdialysis results have a high translational validity for predicting abuse liability since 
increases in extracellular dopamine concentrations and DAT occupancy in striatum are 
closely related to reinforcing effects (Murnane and Howell, 2011). In contrast to the 
stimulant MPH, ATO increased the number of Fos-positive cells in PFC, but not in 
striatum or nucleus accumbens (Bymaster et al, 2002). Taken together, these results 
support the interpretation that ATO exerts its pharmacotherapeutic action via 
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modulation of catecholaminergic neurotransmission locally in cortex, and not via 
activation of the mesocorticolimbic dopaminergic system.  
Preclinical behavioral studies including self-administration and drug-
discrimination paradigms are used typically for evaluating abuse potential. Using drug 
discrimination preparations in rats and rhesus monkeys, ATO generalized to cocaine 
only under conditions employing low training doses of cocaine, but not when cocaine 
doses were increased to levels that produce psychomotor stimulation (Terry et al, 
1994). Also, high doses of ATO substituted for methamphetamine in squirrel monkeys; 
however, these doses produced substantial decreases in response rates (Tidey and 
Bergman, 1998), suggesting a non-specific behavioral suppression at high doses. In 
contrast to ATO, the stimulant MPH produced dose-related cocaine-appropriate 
responding with complete substitution for cocaine in drug discrimination studies 
(McCrae and Costa, 1986a). In self-administration studies, ATO did not support self-
administration, whereas MPH served as positive reinforcer at doses of 0.03 mg/kg, i.v. 
(Gasior et al, 2005). Taken together, these results also suggest limited abuse liability of 
ATO. 
In a cohort of non-dependent, light drug users, the subjective effects of ATO (20, 
45 and 90 mg) were not different from placebo, except for a significantly higher “bad” 
and “sick” score at the highest dose (Heil et al, 2002). In another cohort of stimulant-
preferring individuals with a history of drug abuse, significant “liking” scores were 
reported with MPH (90 mg dose), but not with ATO (45, 90 and 180 mg dose) (Jasinski et 
al, 2008). Further, abrupt discontinuation of ATO in children and adults with ADHD was 
not associated with drug withdrawal syndrome (Wernicke et al, 2004), suggesting that 
ATO treatment does not lead to drug dependence. To date, there are no published 
studies evaluating abuse potential of ATO in individuals with ADHD. Taken together, 
converging evidence from in vitro and in vivo animal studies and from human studies 
supports that the low-abuse liability of ATO, indicating that this medication is a valuable 
alternative for patients who choose not to be treated with a controlled substance. 
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1.9.4 Impact on ADHD/cocaine abuse comorbidity 
ATO does not increase dopamine in NAc or the striatum (Bymaster et al, 2002). In 
a clinical study evaluating the discriminative and subjective effects of ATO in subjects 
with a substance abuse history, ATO at a 90 mg dose significantly increased drug-
appropriate responding for MPH relative to placebo. This partial substitution of ATO for 
MPH may suggest also that ATO is a useful candidate for a replacement therapy for 
stimulant abuse (Lile et al, 2006). In cocaine-dependent volunteers, ATO was well 
tolerated, did not alter cocaine pharmacokinetics, improved working memory and 
sustained attention, and decreased the subjective effects of cocaine (Cantilena et al, 
2012), further supporting the utility of ATO as an agonist replacement therapy for 
cocaine abuse. 
ATO is effective as an ADHD therapeutic and has favorable safety profile and 
negligible risk of abuse or misuse in clinic (Garnock-Jones et al, 2010). ATO reduced 
symptoms in adult ADHD patients with comorbid ethanol abuse/dependence (Wilens et 
al, 2008). In the same cohort, reductions in ADHD symptoms were not altered despite 
relapse to alcohol abuse (Wilens et al, 2011). In a small cohort of cocaine dependent 
subjects comorbid for ADHD, ATO reduced ADHD symptoms, but the high drop-out rate 
from the study of cocaine-dependent subjects and the lack of effect on cocaine use 
through the trial, indicates that the utility of ATO in this patient population may be 
limited (Levin et al, 2009).  Thus far, no clinical studies have been reported that 
determine whether ATO treatment of individuals with ADHD prospectively alters liability 
for future cocaine abuse liability. Using a heuristically useful animal model of ADHD, 
chronic ATO treatment during adolescence was not found to alter cocaine self-
administration during adulthood compared to vehicle control (Somkuwar et al, 2013b); 
Fig 1.8). Taken together, these results suggest that ATO may be a valuable alternative 
for ADHD patients at risk for substance abuse or who choose not to be administered a 
controlled substance. 
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Figure 1.6 Cocaine self-administration in adult rats following atomoxetine treatment during adolescence 
In adult SHR, discontinuation of atomoxetine (ATO) treatment after adolescence does not alter acquisition (left) of cocaine 
self-administration, dose-response of cocaine under fixed-ratio 1 (center) and progressive ration (PR; right) schedules. SHR 
required fewer sessions to acquire cocaine self-administration, and showed upward shifted dose-response for cocaine under 
fixed-ratio 1 and PR schedules compared to WKY and WIS (data not shown). In adult WKY, discontinuation of ATO treatment 
after adolescence decreased the number of sessions to acquisition of cocaine self-administration. Data are presented as 
percentage of WKY-VEH control (left) and as a percentage of WKY-VEH receiving cocaine 0.3 mg/kg/infusion as control 
(center and right). *p<0.05 compared SHR-VEH, WIS-MPH and WKY-MPH; #p<0.05 compared to respective vehicle control, 
εp<0.05 main effect of strain, compared to WKY and WIS. Figure adapted from Somkuwar et al., 2013. 
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1.10 Overall hypothesis and specific aims 
Mechanisms underlying the high cocaine abuse liability in ADHD are not well 
understood. Clinical studies are ambiguous about whether MPH treatment in children 
and adolescents with ADHD increase or decrease cocaine abuse liability. Thus far, no 
clinical studies have been reported that show that ATO treatment in individuals with 
ADHD alters liability for future cocaine abuse. Our previous studies using the 
Spontaneously Hypertensive Rats (SHR), a validated animal model of ADHD, also model 
the high cocaine abuse liability reported in ADHD (Harvey et al, 2011). Specifically, SHRs 
acquired cocaine self-administration faster and showed greater motivation for lower 
doses of cocaine compared to control strains Wistar-Kyoto and Wistar. Treatment of 
adolescent rats (PND28-55) with a therapeutically relevant dose of MPH (1.5 mg/kg/day, 
p.o.), followed by discontinuation of treatment after adolescence led to an enhanced 
cocaine self-administration during adulthood (>77 days old) in the MPH-treated SHR 
compared to vehicle-administered SHR as well as MPH-treated Wistar-Kyoto and Wistar 
rats (Harvey et al, 2011) see Fig 6). Specifically, MPH treatment reduced the number of 
sessions to acquire cocaine self-administration in SHR, with upward shifts in cocaine 
dose-response curve under fixed-ratio and progressive-ratio schedules. Our study also 
found that MPH treatment decreased DAT function in PFC of adult SHR, but did not alter 
DAT function in striatum. Using an identical experimental design, we showed that ATO 
treatment (0.3 mg/kg/day, i.p.) did not increase cocaine self-administration in adult SHR 
(Somkuwar et al, 2013b), see Fig 8). The purpose of this dissertation research is to 
identify neurochemical and behavioral mechanisms associated with the increased 
cocaine self-administration in MPH-treated SHRs, and determine the protective effects 
of ATO treatment from further exacerbating cocaine self-administration in SHR. 
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The overall hypothesis of this dissertation research is that in SHR, MPH 
treatment during adolescence increases cocaine self-administration in SHR which is 
associated with  
 increased DAT function and cell surface expression in the mPFC and OFC,  
 altered NET function in the mPFC and OFC 
 increased sensitivity to the psychomotor effects of cocaine  
 increased impulsivity under differential reinforcement of low rate schedule 
ATO treatment, on the other hand, will not increase cocaine-self administration 
in SHR and will not increase DAT function in mPFC and OFC. 
 
Hypothesis 1: MPH treatment during adolescence, followed by treatment 
discontinuation, will increase DAT function and cell surface distribution in the mPFC and 
OFC of adult SHR, while ATO will not. 
Specific Aim 1 (Chapter 2) Determine the effects of MPH during adolescence on 
DAT function and cellular distribution in mPFC, OFC and striatum during adulthood. DAT 
function was evaluated using [3H]dopamine uptake and synaptosomal preparation, DAT 
cellular distribution was evaluated using biotinylation of synaptosomal preparations 
followed by western blotting analyses. 
Specific Aim 2 (Chapter 3) Determine the effects of ATO during adolescence on 
DAT function and cellular distribution in mPFC, OFC and striatum during adulthood. DAT 
function was evaluated using [3H]dopamine uptake and synaptosomal preparation, DAT 
cellular distribution was evaluated using biotinylation of synaptosomal preparations 
followed by western blotting analyses. 
 
Hypothesis 2: MPH treatment during adolescence, followed by treatment 
discontinuation, will alter NET function in the mPFC and OFC of adult SHR. 
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Specific Aim 3 (Chapter 4) Determine the effects of MPH during adolescence on 
NET function in mPFC, OFC and striatum during adulthood.  
a. Optimize an in vivo voltammetry protocol for evaluating clearance of 
exogenously applied norepinephrine from mPFC and OFC of anesthetized rats 
b. Determine NET function in the mPFC and OFC of adult rats that were treated 
with MPH or vehicle during adolescence. 
 
Hypothesis 3: MPH treatment during adolescence, followed by treatment 
discontinuation, will increase sensitivity to the psychomotor effects of cocaine in adult 
SHR 
Specific Aim 4 (Chapter 5) Determine the effects of MPH treatment during 
adolescence on 
a. sensitivity to cocaine-induced locomotor activation 
b. development of sensitization to repeated cocaine administration 
c. expression of sensitization to the locomotor effects of cocaine 
 
Hypothesis 4: MPH treatment during adolescence, followed by treatment 
discontinuation, will increase impulsivity in adult SHR 
Specific Aim 5 Determine the effects of MPH during adolescence on impulsivity 
during adulthood using differential reinforcement of low-rate (DRL) schedules.  
Chapter 6 describes a set of experiments were conducted to optimize the assay 
and analysis to identify effects of strain and treatment on behavior; 
a. Determine strain differences between SHR, Wistar-Kyoto and Wistar using two 
DRL schedules and optimize the analysis of impulsivity endophenotypes using 
mathematical modeling approach  
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b. Determine the effects of MPH treatment in adolescent rats on impulsivity 
endophenotypes 
Chapter 7 describes experiments that were designed to address hypothesis; 
c. Determine the effects of chronic MPH treatment in adolescent rats on 
impulsivity during adulthood 
d. Determine the effects of chronic MPH treatment in adult rats on impulsivity 
during adulthood 
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2 CHAPTER TWO 
Adolescence methylphenidate treatment in a rodent model of attention 
deficit/hyperactivity disorder: Dopamine transporter function and cell surface 
distribution in adulthood 
Portions of this chapter have been published in the manuscript: 
Somkuwar S.S., Kantak K.M., Dwoskin L.P. Adolescence methylphenidate treatment in a 
rodent model of attention deficit/hyperactivity disorder: Dopamine transporter function 
and cellular distribution in adulthood. Biochemical Pharmacology, 2013 Jul; 86(2):309-
16. 
Chapter reprinted with permission of Biochemical Pharmacology. All rights reserved 
2.1 Introduction 
Attention deficit/hyperactivity disorder (ADHD) is a highly debilitating, 
heterogeneous disorder typically diagnosed in childhood, and characterized by age-
inappropriate levels of inattention, impulsivity and hyperactivity. The neurobiological 
etiology of this disease is not understood completely (Tripp et al, 2009).  ADHD is 
ascribed partially to dopaminergic deficits in prefrontal cortex (Arnsten, 2009; Levy, 
2009; Sonuga-Barke, 2005).  Further, ADHD is associated with increased dopamine 
transporter (DAT) expression in striatum and with specific polymorphisms in the DAT 
gene (Faraone et al, 2005; Mill et al, 2002). 
The Spontaneously Hypertensive Rat (SHR) is the most widely accepted rodent 
model of ADHD and displays all of the behavioral diagnostic characteristics of ADHD 
(Kantak et al, 2008; Sagvolden et al, 2005b).  SHR display diminished dopamine (DA) 
release from prefrontal cortical and striatal slices in vitro (Russell et al, 1995), but 
greater DA release from nucleus accumbens in vivo (Heal et al, 2008).  Also, DAT 
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function and expression levels in frontal cortex and striatum were greater in SHR than in 
control rats (Pandolfo et al, 2012; Roessner et al, 2010).  Taken together, these previous 
findings strengthen the predictive value of the SHR for evaluating the consequences of 
long-term pharmacotherapeutic treatment of ADHD on DA neurochemistry and related 
behaviors. 
Methylphenidate (MPH; Ritalin®) is a gold standard treatment for ADHD, 
providing successful relief from ADHD symptoms. In SHR, MPH improves attention and 
decreases hyperactivity (Kantak et al, 2008; Sagvolden et al, 2005b).  In terms of 
underlying neurochemical mechanisms of action, MPH acts as an inhibitor of striatal 
DAT function and prefrontal cortical DAT and norepinephrine transporter (NET) 
function, increasing extracellular DA concentrations and DA receptor occupancy  
(Andersen, 1989; Engert et al, 2008; Richelson et al, 1984; Volkow et al, 2005a).  
Furthermore, MPH decreases basal firing rates of striatal neurons (Engert et al, 2008), 
which has been suggested to strengthen corticostriatal signals, thus contributing to its 
pharmacological effects.  Based on these findings, DAT is critically involved in the 
dopaminergic dysfunction associated with ADHD and serves as an important molecular 
target for the treatment of ADHD.  
Adults with ADHD have been reported to have a higher risk of developing 
substance use disorders compared to individuals without ADHD (Wilens et al, 1998b).  In 
comparison to the general population, those with ADHD have a 35% higher incidence of 
cocaine abuse (Levin et al, 1999).  However, the impact of prior treatment with MPH on 
cocaine abuse liability in this population is controversial. While some studies suggest 
MPH treatment is protective against cocaine abuse (Fischer et al, 2003; Wilens et al, 
2003; Winters et al, 2011), others indicate that MPH exposure during adolescence may 
increase cocaine abuse liability (Barkley et al, 2003; Lambert et al, 1998; Mannuzza et al, 
2008).  Also, the mechanisms underlying the high comorbidity between ADHD and 
cocaine abuse are not well understood. Since cocaine competitively inhibits DAT, which 
leads to a compensatory increase in DAT cell surface expression and function (Daws et 
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al, 2002; Huang et al, 2009; Mandt and Zahniser, 2010), one explanation for the 
comorbitity of ADHD and cocaine abuse may be a greater DAT expression and function 
in these individuals. 
Another explanation for the comorbidity of ADHD and cocaine abuse may be the 
preexisting impairments in cortically-controlled executive function, including increased 
impulsivity and risk-taking behavior in this population (Groman et al, 2009; Winstanley 
et al, 2010a).  Compared to control subjects, boys with ADHD showed decreased 
orbitofrontal cortex (OFC) activation using fMRI during a delayed discounting task that 
measures impulsivity (Rubia et al, 2009a).  Also, decreased dorsolateral prefrontal 
cortex (DLPFC) activation was associated with working memory deficits in ADHD 
individuals compared to controls (Burgess et al, 2010).  Unmedicated ADHD individuals 
also showed increased deactivation of fMRI signals in the medial prefrontal cortex 
(mPFC) assessed during the Stroop test with emotional interference, compared to 
medicated ADHD and control individuals (Posner et al, 2011).  With respect to 
understanding molecular mechanisms in cortical areas involved in ADHD, it is important 
to note that the DLPFC in primates is considered to be functionally analogous to the 
subregions of mPFC in rodents, including the Fr2 and the anterior cingulate cortex 
(Uylings et al, 2003). Thus, functional impairments in these cortical regions (OFC, DLPFC 
and mPFC) are strongly associated with behavioral deficits in ADHD; however, few 
studies have evaluated molecular mechanisms in the OFC and mPFC of SHR. 
Of importance, cocaine abuse is associated with impulsive behavior and with 
lasting neurochemical changes in these same cortical regions (Beveridge et al, 2008).  
Individuals abusing cocaine display reduced response inhibition in the Stroop test and 
increased glucose metabolism in OFC, compared with demographically-matched 
controls (Goldstein et al, 2001).  In cocaine users, reduced inhibitory control in the Go-
No Go tasks was associated with decreased mPFC activation using fMRI (Kaufman et al, 
2003).  In contrast, increased activation of DLPFC was found in cocaine-dependent 
individuals during the Stroop test and in response to cocaine-related cues (Brewer et al, 
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2008; Maas et al, 1998).  With respect to animal models, outbred rats self-administering 
cocaine showed decreased cocaine-seeking and taking behavior following inactivation of 
OFC and mPFC (Di Pietro et al, 2006; Grakalic et al, 2010; Kantak et al, 2013; Mashhoon 
et al, 2010), thereby supporting the critical involvement of OFC and mPFC function in 
cocaine abuse. Thus, both impulsivity and functional impairments of the OFC, DLPFC and 
mPFC are associated with ADHD and cocaine abuse, and these commonalities may in 
part underlie their comorbidity. 
Valuable insights into the mechanisms underlying comorbidity of ADHD and 
cocaine abuse may be obtained using an animal model of ADHD that exhibits high 
cocaine self-administration behavior. However, appropriate interpretation of results 
obtained from ADHD rat models with strong face validity, such as SHRs, requires 
cautious selection of suitable reference control groups (Sagvolden et al, 2009).  Studies 
that employ the SHR-progenitor strain, Wistar-Kyoto (WKY) as the only reference 
control (Sagvolden et al, 2005b) have been criticized. For example, hyperactivity in SHR 
appears to have been overestimated when the only control employed was WKY, 
because WKY are hypoactive relative to outbred control rats (Alsop, 2007a; van den 
Bergh et al, 2006).  Neurochemical studies also reveal differences between WKY and 
outbred control rat strains. WKY show altered dopaminergic function compared to 
outbred Wistar (WIS) rats (e.g., decreased striatal DA D1 and D2 receptors and 
increased striatal D3 receptors (Novick et al, 2008; Yaroslavsky et al, 2006); decreased 
accumbal DAT expression (Jiao et al, 2003); and decreased mPFC DA content (De La 
Garza et al, 2004)).  Thus, inclusion of both the more commonly used WKY control and 
the WIS control as comparators to SHR provides a more complete understanding of the 
behavioral and neurochemical mechanisms underlying ADHD pathology and of the 
effects of long term ADHD pharmacotherapeutics.  
Using this optimized experimental design, our previous results showed that SHR 
treated with a therapeutically relevant oral dose of MPH during adolescence exhibit 
increased cocaine self-administration in adulthood compared to vehicle-administered 
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SHR and MPH-administered WKY and WIS controls (Harvey et al, 2011).  The increase in 
cocaine self-administration was associated with decreased DAT function in whole 
prefrontal cortex, which includes both OFC and mPFC. OFC and mPFC are distinct based 
on cytoarchitecture and behavioral function, but are also highly interconnected (Gilbert 
et al, 2008; Lawrence et al, 2009).  Thus, the current study determined DAT function and 
expression in OFC and mPFC in adult SHR following a therapeutically relevant oral dose 
of MPH administered during adolescence.  
 
2.2 Materials and methods: 
2.2.1 Materials   
(±)-MPH hydrochloride, desipramine hydrochloride, paroxetine hydrochloride, 
nomifensine maleate, pargyline, ascorbic acid, ethylenediaminetetraacetic acid (EDTA), 
sucrose, β-mercaptoethanol, 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
(HEPES), 3-hydroxytyramine (DA), sodium chloride and magnesium sulfate were 
purchased from Sigma-Aldrich (St. Louis, MO). The current experiments used racemic 
MPH, which also is administered to ADHD patients under the trade name Ritalin®. α-d-
Glucose, L-ascorbic acid, and monobasic potassium phosphate were purchased from 
Aldrich Chemical Co. (Milwaukee, WI), AnalaR-BHD Ltd. (Poole, UK) and Mallinckrodt (St. 
Louis, MO), respectively. [3H]DA (dihydroxyphenylethylamine,3,4-[7-3H]; specific 
activity, 30.3 Ci/mmol) was obtained from PerkinElmer Life and Analytical Sciences Inc. 
(Boston, MA). All other chemicals in the uptake assay buffers were purchased from 
Fisher Scientific Co. (Pittsburgh, PA).   
For the cell surface localization assays, antibodies recognizing rat DAT (C-20; goat 
polyclonal antibody), demethylated protein phosphatase 2A-C (PP2A-C; 4B7; mouse 
monoclonal antibody), anti-mouse IgG conjugated with horseradish peroxidase (IgG-
HRP; sc2954 chicken polyclonal antibody) and anti-goat IgG-HRP (sc2020; donkey 
polyclonal antibody) were purchased from Santa Cruz Biotechnology, Inc. (Santa Cruz, 
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CA). Antibodies against alpha-1 Na+/K+ ATPase type-1 (mouse monoclonal antibody) 
were obtained from Abcam (Cambridge, MA).  Antibodies recognizing β-actin (A 5441, 
mouse monoclonal antibody) were purchased from Sigma-Aldrich (St. Louis, MO). 
Sulfosuccinimidobiotin (sulfo-NHS-biotin), d-biotin and immunoPure immobilized 
monomeric avidin gel were purchased from Pierce Chemical (Rockford, IL).  Complete 
protease inhibitor cocktail tablets were obtained from Roche diagnostics (Indianapolis, 
IN).  Immunobilon-P PVDF membranes were procured from Millipore. HyGLO Quickspray 
Chemiluminescent HRP Antibody Detection Reagent and HyblotCL autoradiography films 
were purchased from Denville Scientific Inc. (Metuchen, NJ). All other chemicals in the 
buffers for cell surface localization assays were purchased from Bio-Rad Laboratories, 
Inc. (Hercules, CA). 
2.2.2 Animals and Treatments 
Male SHR and WKY (inbred control) rats at postnatal day 25 (P25) were obtained 
from Charles River Laboratories (Kingston, NY), and male WIS (outbred control) rats at 
P25 were obtained from Charles River Laboratories (Raleigh, NC).  Rats were individually 
housed with free access to food and water in a colony room maintained on a 12-h 
light:dark cycle (lights on 07:00 h) in the Division of Laboratory Animal Resources 
(University of Kentucky, Lexington, KY). From P28 to P55, rats were administered MPH 
(1.5 mg/kg, p.o. in oyster crackers, Monday - Friday) or vehicle (1 ml/kg, tap water in 
oyster crackers) to mimic the clinically relevant plasma concentrations, route of 
administration and weekly pattern of dosing (1996; Berridge et al, 2006; Kantak et al, 
2008; Kuczenski et al, 2002).  Specifically, a dose of 1.5 mg/kg delivered orally produces 
peak plasma levels of MPH in rats comparable to plasma levels (8-40 μg/ml) obtained in 
the ADHD population (Berridge et al, 2006; Kuczenski et al, 2002). Oyster crackers 
containing MPH or water were placed in the individual home cage and consumption was 
monitored to ensure reproducible dosing between days and between animals. Rats 
consumed the crackers within 3 min of presentation. P28 to P55 includes a time period 
from early adolescence to late adolescence (Doremus-Fitzwater et al, 2010; Spear, 
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2000a), the typical age during which MPH is administered clinically. Rats were also 
maintained under mild food restriction (90% of their free-feeding body weight) to mimic 
the conditions of our previously published studies (Harvey et al, 2011) to allow for 
comparison of current neurochemical findings with those previously reported. Further, 
all rats consumed the entire daily allotment of food, and body weight did not differ 
between the MPH- and vehicle-treated groups (data not shown). After P55, MPH 
treatment ended and ad libitum access to food was reinstated. The number of days 
varied between the last day of treatment (P55) and the day (P77-P84) that the 
neurochemical assay was conducted. Separate cohorts of rats were used for the DA 
uptake assays and the DAT cellular distribution assays. Rat handling procedures were 
approved by the Institutional Animal Care and Use Committee at the University of 
Kentucky and were performed in accordance with the 1996 version of the National 
Institutes of Health Guide for the Care and Use of Laboratory Animals. 
 
2.2.3 DA Uptake Assay   
DAT function was assessed using kinetic analysis of [3H]DA uptake into OFC, 
mPFC and striatal synaptosomes using a previously published procedure (Marusich et al, 
2011) with minor modifications. For each experiment, OFC, mPFC and striatum from 
both hemispheres of one MPH-treated and of one vehicle-treated rat of the same strain 
and age (P77-P84) were homogenized in separate glass homogenizers, each containing 
20 ml of ice-cold sucrose solution (0.32 M sucrose and 5 mM sodium bicarbonate, pH 
7.4) with 16-20 passes of a Teflon pestle. Synaptosomal suspensions were subjected to 
two centrifugation steps (2,000g, 10 min, 4 °C followed by 20,000g, 17 min, 4 °C) using 
an Avanti-J30I centrifuge (Beckman Coulter, Brea, CA). Resulting pellets were 
resuspended in 2.2 ml (OFC and mPFC synaptosomes) or 2.4 ml (striatal synaptosomes) 
ice-cold uptake buffer (125 mM NaCl, 5 mM KCl, 1.5 mM MgSO4, 1.25 mM CaCl2, 1.5 
mM KH2PO4, 10 mM glucose, 25 mM HEPES, 0.1 mM EDTA, 0.1 mM pargyline, and 0.1 
mM L-ascorbic acid, saturated with 95% O2/5% CO2, pH 7.4). OFC and mPFC samples 
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(100 µl aliquots of the 2.2 ml synaptosomal suspensions) and striatal samples (30 µl 
aliquot of the 2.4 ml synaptosomal suspension) were incubated for 5 min in a metabolic 
shaker (Dubnoff incubator; Precision Scientific, Winchester, VA) at 34 °C in a saturated 
95% O2/5% CO2 atmosphere in the absence or presence of 10 µM nomifensine. 
Nomifensine, a DAT inhibitor, was used to obtain nonspecific [3H]DA uptake. OFC and 
mPFC suspensions also contained 5 nM each of paroxetine and desipramine to prevent 
[3H]DA uptake by serotonin transporters and NETs, respectively.  Subsequently, 1 of 7 
final concentrations (0.01-1.0 µM) of [3H]DA was added to the buffer, and incubation of 
the mPFC, OFC and striatal synaptosomal suspensions continued for 5, 5 and 10 min, 
respectively. [3H]DA uptake was terminated by addition of 3 ml of ice-cold assay buffer, 
immediately followed by filtration through Whatman GF/B glass fiber filters (presoaked 
with 1 mM pyrocatechol for 3 hr at 4 °C) using a cell harvester (Biochemical Research 
and Development Laboratories, Gaithersburg, MD).  Values for total and nonspecific 
[3H]DA uptake were obtained from the amount of radioactivity retained on the filters as 
determined by liquid scintillation spectrometry (model B1600TR; PerkinElmer Life and 
Analytical Sciences, Downers Grove, IL).  Protein concentrations were determined with 
bovine serum albumin standards using the Bradford method (Bradford, 1976).  Specific 
[3H]DA uptake was obtained by subtracting nonspecific uptake from total uptake, and 
the values were used to determine kinetic parameters (Vmax and Km) by employing the 
commercially-available GraphPad Prism 5.0 program (GraphPad Software Inc., San 
Diego, CA).  
 
2.2.4 DAT cellular distribution assay  
Synaptosomal pellets of OFC, mPFC and striatum were resuspended in 1.25 ml 
(OFC and mPFC) or in 3 ml (striatum) of ice-cold sucrose solution. Synaptosomal protein 
concentrations were determined as previously described. Biotinylation and Western 
blotting assays were performed using a previously published method (Zhu et al, 2005a).  
Briefly, synaptosomal suspensions contained about 1 mg protein (OFC and mPFC) or 500 
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µg protein (striatum). Suspensions were incubated with shaking for 1 hr at 4 °C in 500 µl 
of 1.5 mg/ml sulfo-NHS biotin in PBS/Ca/Mg buffer (138 mM NaCl, 2.7 mM KCl, 1.5 mM 
KH2PO4, 9.6 mM Na2HPO4, 1 mM MgCl2, 0.1 mM CaCl2, pH 7.4), which labels all surface 
proteins with biotin. Free sulfo-NHS biotin was removed by centrifugation (8000g, 4 
min, 4 °C) using a model 5417R centrifuge (Eppendorf, Hauppauge, NY) followed by 
washing with 1 ml ice-cold 100 mM glycine in PBS/Ca/Mg buffer, and these steps were 
repeated twice. Then, samples were centrifuged using the same conditions and washed 
with 1 ml ice-cold PBS/Ca/Mg buffer, and these steps were repeated twice. 
Subsequently, OFC, mPFC and striatal synaptosomes were lysed by sonication for 2-4 s 
followed by incubation, with continuous shaking for 20 min at 4 °C in Triton X-100 buffer 
(150, 150 and 300 μl, respectively; 10 mM Tris, 150 mM NaCl, 1 mM EDTA, 1.0% Triton 
X-100, 1 μg/ml aprotinin, 1 μg/ml leupeptin, 1 μM pepstatin, 250 μM 
phenylmethysulfonyl fluoride, pH 7.4). Lysates underwent centrifugation (21,000g, 20 
min, 4 °C). Supernatants constituted the total protein fraction. To obtain the cell surface 
and intracellular fractions, 2/3 of the supernatant was incubated with Avidin beads with 
shaking for 1 hr at room temperature, and samples centrifuged (17,000g, 4 min, 4 °C). 
Supernatants constituted the non-biotinylated fraction (intracellular fraction). Pellets 
contained the Avidin-conjugated biotinylated proteins (cell surface fraction). Pellets 
were washed three times with 1% Triton-X-100 and incubated with Lamelli buffer 
containing 5% v/v β-mecaptoethanol to free the cell surface proteins from the Avidin-
biotin complex. Total, non-biotinylated and biotinylated fractions were frozen at -20 °C 
until Western blot analysis.  
The total, non-biotinylated and biotinylated fractions were thawed and 
subjected to gel electrophoresis and Western blotting as described previously (Salvatore 
et al, 2003) using a gel running apparatus and  Trans-Blot® SD Semi-Dry Transfer Cell, 
respectively (Bio-Rad Laboratories, Inc., Hercules, CA).  Blots were incubated (overnight, 
4 °C) with primary antibody for DAT, followed by secondary antibody (1 hr, room 
temperature). DAT protein was detected using enhanced chemiluminescence and 
HyblotCL autoradiography films (Denville Scientific Inc.). Blots were probed 
 98 
 
simultaneously for detection of Na+/K+ ATPase (a plasma-membrane enriched protein), 
PP2A (an intracellular protein) for determining efficiency of biotinylation of surface 
proteins, and β-actin (a cytoskeletal protein) to control for loading of proteins. Band 
densities, expressed as relative optical density (arbitrary units), were determined for 
DAT and β-actin in total, non-biotinylated and biotinylated fractions using ImageJ 
software (http://imagej.nih.gov/ij).   
 
2.2.5 Statistical Analysis   
Data analyses were conducted using SPSS Statistics Version 19 (SPSS Inc., IBM Company, 
Armonk, NY). Data are reported as mean ± S.E.M. and n represents the number of rats 
per group. To determine if there was a between group difference in the number of days 
between the cessation of treatment and the conduct of the neurochemical assay, post-
treatment periods were analyzed by two-way ANOVAs, with strain and treatment as 
between-subject factors. Km values for DA were expressed as µM and were log 
transformed to adjust for the skewed distribution, and then analyzed by two-way 
ANOVA, with strain and treatment as between-subject factors. Vmax values were 
expressed as pmol/mg/min. Vmax values for the individuals in the MPH-treated group 
were expressed as a percent of the mean Vmax value for the vehicle-treated control 
group and analyzed using one-way ANOVAs followed by Tukey’s post-hoc test to 
compare between MPH-treated strains.  Within each strain, Vmax values from MPH-
treated rats were compared to the vehicle-control (100%) using Student’s one-sample t-
test for matched subjects (Vadum and Rankin, 1998).  For cellular distribution assays, 
total, non-biotinylated and biotinylated fractions were analyzed using mixed-model 
ANOVAs with strain and treatment as between-subject factors. Day of experiment was 
used as a covariate to account for day-to-day variations in experimental conditions 
(Verbeke and Molenberghs, 2000).  Outliers were eliminated using the Grubbs test 
(GraphPad Software; http://www.graphpad.com/quickcalcs/Grubbs1.cfm). When 
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appropriate, Tukey’s post-hoc analyses were used to determine between group 
differences. 
 
2.3 Results 
2.3.1 Maximum Velocity (Vmax) of DA Uptake by DAT  
No between-group differences and no interaction of MPH x strain were found for 
the number of days between the cessation of treatment and the DA uptake assays 
(interaction terms: OFC F[2, 38] = 0.51; mPFC (F[2, 45] = 0.08; striatum F[2, 30] = 0.10; ps 
> 0.05). In the vehicle-control groups, no strain differences in Vmax of [3H]DA uptake for 
either OFC (F[2, 17] = 0.34, p > 0.05),  mPFC (F[2, 24] = 0.70, p > 0.05) or striatum (F[2, 
16] = 0.30, p > 0.05; Table 1) were found. Figure 1 shows the strain comparisons after 
MPH treatment. MPH treatment during adolescence increased (164 ± 21.6% of control) 
Vmax in the mPFC of adult SHR compared to SHR vehicle-control (t[6] = 2.98, p < 0.05; 
Figure 1). Also, Vmax in mPFC was greater in MPH-treated SHR compared to MPH-
treated WKY and WIS (F[2, 18] = 4.36, p < 0.05; Figure 1b). Vmax was decreased (74.0 ± 
5.12% of control) in OFC of the MPH-treated WKY group compared with the WKY 
vehicle-control (t[7] = 5.09, p < 0.005), but was not different from the MPH-treated WIS 
and SHR (F[2, 20] = 2.55, p > 0.05; Figure 1). MPH treatment during adolescence did not 
alter DAT function in adult striatum (F[2,14] = 0.92, p > 0.05; Figure 1).  
 
2.3.2 Affinity (Km) for DA at DAT 
In mPFC and striatum, no MPH x strain interaction for the Km for [3H]DA at DAT 
was found (mPFC, F[2, 45] = 1.08; striatum, F[2, 29] = 0.20; ps > 0.05; Figure 2).  In OFC, 
a MPH x strain interaction (F[2, 38] = 6.14, p < 0.005) was found, but main effects of 
strain (F[2, 38] = 0.18, p > 0.05) and treatment (F[1, 38] = 2.33, p > 0.05) were not 
obtained (Figure 2). Post-hoc evaluation of the interaction term revealed that MPH 
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treatment during adolescence decreased the Km value by 50% in WIS compared to the 
WIS vehicle-control group (p < 0.01). 
 
2.3.3 DAT cell surface distribution  
No between-group differences and no MPH X strain interaction was found for 
the number of days between the cessation of treatment and the DAT cell surface 
distribution assays (F[2, 36] = 0.0, p > 0.05). DAT expression and distribution did not 
differ between treatment groups or between strains for either the total, non-
biotinylated or biotinylated fractions in OFC (Figure 3), mPFC (Figure 4) or striatum 
(Figure 5). Results from the statistical analyses of the strain x treatment interaction, and 
the main effects of treatment and strain are provided in Table 2. 
 
2.4 Discussion 
In the current study, effects of MPH treatment during adolescence on DAT 
function and expression in adulthood were determined in the SHR model of ADHD.  WKY 
and WIS rats served as inbred and outbred control groups, respectively. Surprisingly, 
treatment of the WIS and WKY during adolescence with a therapeutically relevant dose 
of MPH, and then cessation of MPH treatment in adulthood, resulted in lasting changes 
in DAT function in OFC. Specifically, in OFC from WIS, an increase in affinity of DAT for 
DA was found, with no alteration in maximal uptake of DA. In contrast, in OFC from 
WKY, the MPH treatment paradigm resulted in no change in affinity for DA, and a 
decreased maximal DA uptake, which was trafficking independent. These results suggest 
that a misdiagnosis of ADHD, and subsequent treatment with MPH during adolescence, 
could result in lasting alterations in OFC DAT function. Thus, with respect to the current 
data, the outbred control (Wistar) has greater value than the inbred control (WKY) for 
comparisons to SHR, due to the greater stability of DAT function despite MPH treatment 
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in the outbred control. Moreover, in the SHR model of ADHD, the MPH treatment 
regimen produced persistent increases in mPFC DAT function that were trafficking 
independent. Thus, the increase in mPFC DAT function was a long term consequence of 
MPH treatment during adolescence, was specific to the SHR strain, and may be 
responsible for the treatment-induced alterations in behavior. Furthermore, the current 
results emphasize the importance of the ADHD animal model, and the appropriate 
control strains, for investigations of neurochemical mechanisms underlying long-term 
effects of ADHD pharmacotherapeutics.   
The current study found that DAT function and cellular distribution in mPFC, OFC 
and striatum did not differ between SHR, WKY and WIS vehicle-control groups. With 
regard to striatum, the current results support previous findings showing no difference 
in total DAT expression and function between SHR and WKY (Harvey et al, 2011; Li et al, 
2007; Miller et al, 2012; Womersley et al, 2011).  The current results further extend 
these previous findings by showing that cell surface DAT distribution similarly is not 
different between these inbred strains. In contrast, others have reported greater DAT 
function and greater total DAT expression in SHR compared to WKY (Pandolfo et al, 
2012; Roessner et al, 2010).  Inconsistencies in the results may be explained in that 
greater DAT function in adult SHR was observed following exposure of striatal 
synaptosomes to a single concentration (0.022 µM) of [3H]DA (Pandolfo et al, 2012) 
whereas, the current results were obtained from a comprehensive analysis of DAT 
kinetic parameters (Km and Vmax) using a wide [3H]DA concentration range (0.01-1.0 
µM). No differences in the kinetic parameters for DAT were found between SHR, WKY 
and WIS. Furthermore, inconsistencies in the levels of striatal DAT expression may be 
explained by the use of [3H]GBR 12935 to assess expression, since this radioliand binds 
to both intracellular and cell surface DAT protein (Roessner et al, 2010).  However, an 
explanation for the discrepancy in the analysis of striatal DAT protein by Western blot is 
not apparent currently. Close inspection of the clinical literature also reveals 
inconsistencies regarding striatal DAT levels in ADHD. While greater striatal DAT 
expression has been observed (Faraone et al, 2005) others report that DAT levels are 
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lower in left caudate in ADHD individuals, and not different from control in other 
subregions of striatum (Volkow et al, 2007a).  A recent meta analysis reported that 
striatal DAT levels in ADHD individuals may depend on previous stimulant treatment, 
with lower DAT density in medication naïve and higher DAT density in previously 
medicated ADHD individuals (Fusar-Poli et al, 2012).   Thus, ADHD is a complicated 
condition that cannot be confined to an explanation regarding alterations in DAT 
function and/or expression in striatum. 
Compared to WKY and WIS controls, SHR treated with MPH during adolescence 
exhibited improvements in neurocognitive function in adolescence, as demonstrated by 
performance on maze- and operant-based visual discrimination learning tasks, and 
increased cocaine self-administration in adulthood (Harvey et al, 2011).  Specifically, the 
increase in cocaine self-administration was characterized as a more rapid acquisition of 
cocaine self-administration, greater responding across a range of cocaine doses, and 
higher progressive ratio breakpoints. Further, MPH dose and treatment during 
adolescence resulted in a decrease in DAT function in whole prefrontal cortex in SHR 
and an increase in DAT function in this brain region in WKY and WIS, compared to the 
respective vehicle controls (Harvey et al, 2011).  In contrast, the identical MPH 
treatment regimen in the current study resulted in an increased DAT function in SHR 
mPFC, whereas no changes were observed in OFC, compared to vehicle control. These 
subregions of prefrontal cortex have distinct cytoarchitecture, connectivity and 
differentially contribute to behavioral processes including decision making and 
impulsivity (Gilbert et al, 2008; Perry et al, 2011).  As such, the apparent discrepancy 
with respect to DAT function between the previous and current results may be due to 
MPH effects in specific cortical subregions. Evidence that mPFC and OFC are critically 
involved in cocaine self-administration comes from studies in which local inactivation 
with lidocaine decreased cocaine-seeking and taking behavior (Di Pietro et al, 2006; 
Grakalic et al, 2010; Kantak et al, 2013; Mashhoon et al, 2010).  Following MPH 
treatment during adolescence, the increase in mPFC DAT function would be expected to 
decrease extracellular DA concentration in mPFC. Consistent with these findings, mPFC 
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DA depletion resulted in an increased motivation for and increased sensitivity to cocaine 
(McGregor et al, 1996; Schenk et al, 1991).  Thus, mPFC may be at the intersection of 
MPH effects on DAT function and the increased cocaine self-administration observed 
following adolescent MPH treatment. 
A limitation of the current study was that a single dose of MPH was tested. 
Nevertheless, this dose of MPH is therapeutically-relevant (Berridge et al, 2006; 
Kuczenski et al, 2002) and has been shown to ameliorate behavioral deficits in the adult 
and adolescent SHR in working memory and behavioral flexibility tasks (Harvey et al, 
2013; Kantak et al, 2008). The increased DAT function in SHR mPFC in the current study 
did not correspond with a concomitant increase in cell surface localization of DAT. Thus, 
the MPH-induced long-term changes in DAT function in mPFC were not dependent on 
trafficking of DAT to the plasma membrane. Although the biotinylation method of 
evaluating protein trafficking differentiates intracellular and cell surface proteins 
(Sorkina et al, 2005; Zahniser and Sorkin, 2009), this method does not differentiate 
between cholesterol-rich lipid raft and cholesterol-deficient non-raft regions of the cell 
surface membrane (Adkins et al, 2007; Foster et al, 2008).  DAT expressed in the lipid 
raft membrane compartment is more sensitive to protein kinase C mediated 
phosphorylation (Foster et al, 2008).  Increased phosphorylation of DAT results in 
reduced DA uptake, and conversely, decreased DAT phosphorylation results in increased 
DAT function (Ramamoorthy et al, 2010; Samuvel et al, 2008; Zhu et al, 1997).  
Furthermore, phosphorylation at serine7 in DAT transitions the protein into a low 
affinity state (Moritz et al, 2013).  Taken together, the MPH-induced increase in DAT 
function in mPFC in SHR rats observed in the current study may be explained by 
localized DAT expression in the cholesterol-deficient non-raft regions of the cell surface 
membrane in mPFC, reducing DAT phosphorylation and increasing function.   
In conclusion, the present study demonstrates that MPH treatment during 
adolescence increases DAT function during adulthood in the mPFC of SHR, the ADHD 
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model, and not in the control strains.  The increased DAT function in mPFC may underlie 
the increased cocaine self-administration observed in MPH-treated SHR. 
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2.5 Tables 
 
Table 2.1 Maximal velocity of [3H]DA uptake by DAT in OFC, mPFC and striatum in 
vehicle-treated adult SWKY, SHR and WIS rats 
Brain regions a WKY  SHR  WIS  
OFC  4.3 ± 0.8  3.0 ± 0.8  2.8 ± 0.7  
mPFC  4.0 ± 0.5  3.3 ± 0.6  3.0 ± 0.6  
striatum  19.1 ± 2.5  17.1 ± 2.5   21.0 ± 3.4  
a Values are mean ± S.E.M. in pmol/mg/min.  n = 6/group for striatal samples, and n = 8-
10/group for OFC and mPFC samples 
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Table 2.2 Statistics comparing DAT levels in total, non-biotinylated (Non-biot) and 
biotinylated (Biot) fractions of mPFC, OFC and striatum from methylphenidate- and 
vehicle-treated adult SHR, WKY and WIS rats 
F-statistics 
Treatment main 
effect (Ft) 
Strain  
main effect (Fs) 
Treatment x Strain 
interaction (Fi) 
OFC 
Total Ft[1, 17] = 0.65 Fs[2, 17] = 0.15 Fi[2, 17] = 0.13 
Non-biot Ft[1, 17] = 0.00 Fs[2, 17] = 0.54 Fi[2, 17] = 1.13 
Biot Ft[1, 16] = 0.06 Fs[2, 16] = 2.12 Fi[2, 16] = 0.97 
mPFC 
Total Ft[1, 18] = 1.74 Fs[2, 18] = 0.46
  Fi[2, 18] = 0.82 
Non-biot Ft[1, 18] = 0.06 Fs[2, 18] = 3.11 Fi[2, 18] = 0.62 
Biot Ft[1, 18] = 0.04 Fs[2, 18] = 1.36 Fi[2, 17] = 0.37 
striatum 
Total Ft[1, 14] = 0.75 Fs[2, 14] = 1.03 Fi[2,14] = 0.66 
Non-biot Ft[1, 14] = 2.50 Fs[2, 14] = 0.75 Fi[2,14] = 1.22 
Biot Ft[1, 13] = 0.09 Fs[2, 13] = 0.41 Fi[2,13] = 1.64 
The main effect of treatment (Ft), strain (Fs) and treatment x strain interaction (Fi) have 
been reported individually; ps > 0.05.
  
2.6 Figures 
 
Figure 2.1 Effect of MPH on the Vmax of DAT in OFC, mPFC and striatum 
 
Fig. 2.1. Vmax for DAT in OFC, mPFC and striatum from methylphenidate-treated WKY (grey bars), SHR (black bars) and WIS 
(open bars) rats expressed as pmol/mg/min as a percentage of vehicle control (dotted line). Values are mean ± S.E.M. # 
Different from the vehicle control, p < 0.05.  * Different from WKY and WIS, p < 0.05. n = 8-10/group for OFC and mPFC; n = 
6/group for striatum. 
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Figure 2.2 Effects of MPH treatment on Km of DAT in OFC, mPFC and striatum 
 
Fig. 2.2. Km for DAT in OFC, mPFC and striatum from methylphenidate-treated (striped) and vehicle-treated (plain) WKY (grey 
bars), SHR (black bars) and WIS (open bars) rats.  Values are expressed in µM as mean ± S.E.M.  # Different from vehicle, p < 
0.05. n = 8-10/group for OFC and mPFC; n = 6/group for striatum. 
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Figure 2.3 Effects of MPH treatment on cellular distribution of DAT in the OFC 
 
Fig. 2.3 (A) Representative blots for cellular distribution of DAT in OFC synaptosomes 
from methylphenidate-treated (M) and vehicle-treated (V) WKY, SHR and WIS rats.  
Actin was used to monitor uniform protein-loading while Na+/K+ ATPase and PP2A 
served to ascertain the efficiency of biotinylation of surface proteins.  (B) Distribution of 
DAT between total, non-biotinylated (Non-Biot; intracellular) and biotinylated (Biot; cell 
surface) fractions of OFC synaptosomes from methylphenidate-treated (striped) and 
vehicle-treated (plain) WKY (grey bars), SHR (black bars) and WIS (open bars) rats.  
Values are mean ± S.E.M in arbitrary units. n = 6-7/group.  
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Figure 2.4 Effects of MPH treatment on cellular distribution of DAT in the mPFC 
  
Fig 2.4 (A) Representative blots for cellular distribution of DAT in mPFC synaptosomes 
from methylphenidate-treated (M) and vehicle-treated (V) WKY, SHR and WIS rats.  
Actin was used to monitor uniform protein-loading while Na+/K+ ATPase and PP2A 
served to ascertain the efficiency of biotinylation of surface proteins.  (B) Distribution of 
DAT between total, non-biotinylated (Non-Biot; intracellular) and biotinylated (Biot; cell 
surface) fractions of mPFC synaptosomes from methylphenidate-treated (striped) and 
vehicle-treated (plain) WKY (grey bars), SHR (black bars) and WIS (open bars) rats.  
Values are mean ± S.E.M in arbitrary units. n = 6-7/group. 
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Figure 2.5 Effects of MPH treatment on cellular distribution of DAT in the striatum 
 
 
Fig. 2.5 (A) Representative blots for cellular distribution of DAT in striatal synaptosomes 
from methylphenidate-treated (M) and vehicle-treated (V) WKY, SHR and WIS rats.  
Actin was used to monitor uniform protein-loading while Na+/K+ ATPase and PP2A 
served to ascertain the efficiency of biotinylation of surface proteins.  (B) Distribution of 
DAT between total, non-biotinylated (Non-Biot; intracellular) and biotinylated (Biot; cell 
surface) fractions of striatal synaptosomes from methylphenidate-treated (striped) and 
vehicle-treated (plain) WKY (grey bars), SHR (black bars) and WIS (open bars) rats.  
Values are mean ± S.E.M in arbitrary units. n = 5-6/group.  
 
Copyright © Sucharita S. Somkuwar 2013 
 112 
 
3 CHAPTER THREE 
Adolescent atomoxetine treatment in a rodent model of ADHD: Effects on cocaine 
self-administration and dopamine transporters in frontostriatal regions 
Portions of this chapter have been published in the manuscript: 
Somkuwar S.S., Jordan C.J., Kantak K.M., Dwoskin L.P. Adolescent atomoxetine 
treatment in a rodent model of ADHD: Effects on cocaine self-administration and 
dopamine transporters in frontostriatal regions. Neuropsychopharmacology 2013, 
Dec;38(13):2588-97. 
Chapter reprinted with permission of Neuropsychopharmacology. All rights reserved 
3.1 Introduction     
Attention deficit/hyperactivity disorder (ADHD) affects 8-12% of children, and up 
to 5% of adults, making it one of the most prevalent disorders (Biederman et al, 2010). 
Adults with ADHD have a higher risk of developing substance use disorders compared to 
individuals without ADHD (Wilens et al, 1998). In particular, individuals with ADHD have 
a 35% higher incidence of cocaine abuse compared to the general population (Levin et 
al, 1999), and children with ADHD are twice as likely to use cocaine during adulthood 
(Lee et al, 2011).  
One explanation for comorbid ADHD and cocaine abuse may be commonalities 
in neuronal substrates. Hypoactivation of the orbitofrontal cortex (OFC) and dorsolateral 
prefrontal cortex (DLPFC) is evident in both disorders and leads to deficits in working 
memory, decision-making, and response inhibition (Adinoff et al, 2003; Bolla et al, 2003; 
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Burgess et al, 2010; Cubillo et al, 2011; Wilcox et al, 2011).  With respect to rodents, 
behavioral flexibility, working memory and sustained attention are regulated by both 
the medial prefrontal cortex (mPFC) and OFC (Floresco et al, 2009). Moreover, mPFC 
and OFC also regulate cocaine-seeking behavior in outbred rats self-administering 
cocaine (Di Pietro et al, 2006; Kantak et al, 2013). As parts of the mPFC in rodents is 
functionally analogous to DLPFC in primates (Uylings et al, 2003), these findings suggest 
that mPFC and OFC function is critical for understanding the mechanisms underlying 
comorbid ADHD and cocaine abuse. 
There is a paucity of information concerning the effects of ADHD medications on 
the comorbidity of ADHD and cocaine abuse.  Primarily, two categories of medications 
are used to treat ADHD: stimulants (e.g., methylphenidate; MPH) and non-stimulants 
(e.g., atomoxetine; ATO). MPH is a dopamine and norepinephrine transporter (DAT and 
NET, respectively) inhibitor (Richelson and Pfenning, 1984), whereas ATO is a selective 
NET inhibitor (Bolden-Watson and Richelson, 1993). While MPH is the first-line 
treatment for ADHD, ATO has efficacy nearly comparable to MPH in reducing ADHD 
symptoms (Garnock-Jones and Keating, 2009).  
Clinical reports suggest that MPH treatment initiated in childhood may be 
protective against cocaine addiction (Wilens et al, 2003), or alternatively, not modify 
cocaine abuse liability in ADHD individuals (Molina et al, 2013). However, a positive 
correlation was reported between age of initiation of MPH treatment and cocaine abuse 
during adulthood (Mannuzza et al, 2008), such that lifetime rates of cocaine abuse were 
higher when treatment was initiated in early adolescence. Preclinical models employing 
carefully controlled experimental conditions may be valuable for evaluating mechanisms 
underlying these controversial clinical results. Previous work using spontanously 
hypertensive rats (SHR), a well established model of ADHD (Kantak et al, 2008; 
Sagvolden et al, 2005), found that MPH treatment during adolescence increased cocaine 
self-administration in adult SHR compared to untreated SHR and compared to MPH-
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treated Wistar-Kyoto (WKY) or Wistar (WIS) control rats (Harvey et al, 2011).  In the 
latter report, repeated administration of MPH during adolescence increased the self-
administration efficacy for a range of doses of cocaine, without altering sensitivity for 
cocaine in SHR. Increased vulnerability to cocaine self-administration in SHR may be due 
to MPH-induced increases in DAT function in mPFC relative to untreated SHR and MPH-
treated WKY or WIS (Somkuwar et al, 2013). These findings from the SHR model are 
complimentary with observations in humans, such that previously medicated ADHD 
individuals have higher striatal DAT density compared to non-ADHD individuals (Fusar-
Poli et al, 2012). Striatal DAT function is elevated also in cocaine users (Mash et al, 
2002). However, cortical DAT expression in ADHD and in cocaine users has not been 
reported.   
ATO, unlike MPH, has very low affinity for DAT (Heal et al, 2008). However, 
selective inhibition of NET by ATO increases extracellular concentrations of both 
norepinephrine and dopamine in PFC (Arnsten, 2009), because NET is responsible 
primarily for dopamine clearance in this brain region (Moron et al, 2002). In outbred 
rats, ATO reduces cocaine seeking and cocaine cue-induced reinstatement (Economidou 
et al, 2011; Janak et al, 2012).  However, effects of ATO on cocaine self-administration 
and on DAT function and cell surface expression in SHR have not been determined. The 
current study tests the hypothesis that, in contrast to the effects of MPH treatment, 
treatment with a pharmacologically relevant dose of ATO (Bymaster et al, 2002) during 
adolescence does not increase vulnerability for cocaine self-administration in adult SHR 
after the ATO treatment has been discontinued. To identify long-term changes in 
dopaminergic systems, DAT function and expression in mPFC, OFC, and striatum in adult 
SHRs were evaluated following the administration of a pharmacologically relevant dose 
of ATO during adolescence. Further, to identify changes in DAT function that may 
influence cocaine self-administration, neurochemical studies were conducted in rats at 
the same age at which cocaine self-administration was initiated.  
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3.2 Materials and Methods  
3.2.1 Subjects 
Male Wistar (WIS)/Cr, Wistar-Kyoto (WKY)/Cr and Spontaneously Hypertensive (SHR)/Cr 
rats (Charles River Laboratories, Wilmington, MA, Kingston, NY or Raleigh, NC) arrived 
on postnatal day 25 (P25). SHR served as an animal model of ADHD; and WKY and WIS 
as inbred and outbred comparator strains, respectively. Experiments 1, 2 and 3 
employed the same group of rats. Experiment 4 employed a separate group of rats. 
Experiment 5 again employed a separate group of rats. Housing has been described 
previously (Harvey et al, 2011) and in the Supplemetary Materials. From P28 through 
P55, rats received ATO or vehicle (see below) Monday through Friday to mimic the 
weekend “medication holiday” often recommended for individuals with ADHD 
(American Academy of Pediatrics, 1996). For rats used in the behavioral studies, an 
intravenous catheter was implanted on P67 (see Supplementary Materials for details). 
Protocols were approved by the Institutional Animal Care and Use Committee at Boston 
University and at the University of Kentucky, and were performed in accordance with 
the 1996 version of the NIH Guide for the Care and Use of Laboratory Animals. 
 
3.2.2 Drugs 
Atomoxetine ((R)-N-methyl-γ-(2-methylphenoxy)-benzenepropanamine hydrochloride; 
Tocris Biosciences, Ellisville, MO; 0.3 mg/ml) was dissolved in 0.9% sterile physiological 
saline and injected i.p. at a dose of 0.3 mg/kg. This relatively low dose was chosen to 
increase extracellular norepinephrine concentrations in PFC, although this dose also has 
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been shown to increase extracellular dopamine concentrations in PFC through inhibition 
of NET (Bymaster et al, 2002). An i.p. route was utilized due to poor oral bioavailability 
of ATO in rats (Mattiuz et al, 2003). For intravenous self-administration studies, cocaine 
hydrochloride (NIDA, Bethesda MD) was dissolved in sterile 0.9% physiological saline 
containing 3 IU of heparin/ml. A cocaine unit dose of 0.3 mg/kg was used for training, 
and doses from 0.003 to 1.0 mg/kg were used to evaluate dose-response functions. 
 
3.2.3 Experiment 1: Acquisition of Cocaine Self-administration (Fixed Ratio).  
Experiment 1 determined the speed at which WIS, WKY, and SHR acquired cocaine self-
administration, and evaluated strain-dependent effects of adolescent ATO treatment on 
acquisition. Sessions (2 hr) were conducted daily Monday – Friday beginning on P77 in 
lighted chambers described in Supplementary Materials. Rats were allowed to press the 
active lever (left or right, counterbalanced across rats) for a 0.3 mg/kg cocaine infusion 
under a fixed ratio 1 (FR1) schedule of reinforcement. Responses on the inactive lever 
were recorded, but had no consequences. Animals received no external inducements to 
respond on either lever (spontaneous acquisition). A stimulus light located above the 
active lever was illuminated upon receipt of a cocaine infusion and remained 
illuminated during a 20 sec timeout period during which additional infusions could not 
be earned, but lever responses were counted. The house light was extinguished during 
the timeout. Acquisition of cocaine self-administration was defined as earning ≥20 
infusions in a 2-hr session for two consecutive sessions, and discriminating the active 
from inactive lever by a factor of 2 or greater (Harvey et al, 2011).  
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3.2.4 Experiment 2: Cocaine Dose-Response Functions (Fixed-Ratio).  
Experiment 2 evaluated the efficacy of cocaine reinforcement in WIS, WKY, and SHR, 
and identified strain-dependent effects of adolescent ATO treatment on responding 
maintained by a range of cocaine doses under an FR1 schedule. Following achievement 
of acquisition criterion, rats continued under an FR1 schedule of 0.3 mg/kg cocaine 
delivery until active lever responses and infusions varied less than 10% across 5 
consecutive sessions. A range of cocaine unit doses (0.003, 0.01. 0.03, 0.1, and 1.0 
mg/kg/infusion) was then substituted in random order twice each week (Tuesdays and 
Fridays). The 0.3 mg/kg training dose was available on intervening days. Following 
determination of FR1 cocaine dose-response functions, baseline responding was 
reestablished for the 0.3 mg/kg dose for 2-3 days prior to beginning Experiment 3.  
 
3.2.5 Experiment 3: Cocaine Dose-Response Functions (Progressive Ratio).  
Experiment 3 assessed the motivating influence of cocaine reinforcement in WIS, WKY, 
and SHR, and identified strain-dependent effects of ATO treatment during adolescence 
on progressive ratio (PR) breakpoints across a range of cocaine unit doses. The PR 
schedule of Loh & Roberts (1990) was implemented, such that response requirements 
on the active lever increased exponentially for each subsequent cocaine infusion. Self-
administration sessions terminated when rats failed to meet the response requirement 
within 1 hr. The last FR completed was defined as the PR breakpoint. Baseline 
responding under the PR was established for the 0.3 mg/kg dose for 5 consecutive 
sessions, after which test doses (1.0, 0.1, and 0.01 mg/kg/infusion) were substituted in 
descending order.  
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3.2.6 Experiment 4: Dopamine Uptake Assay.  
Experiment 4 assessed DAT function in mPFC, OFC and striatum of WIS, WKY, and SHR 
treated with ATO or vehicle. Kinetic analysis of [3H]dopamine uptake into mPFC, OFC 
and striatal synaptosomes was conducted using a previously published procedure 
(Marusich et al, 2011) with minor modifications. Purified synaptosomal suspensions 
from mPFC, OFC and striatum from one ATO- and one vehicle-treated rat of the same 
strain and age (P77-P84) were prepared as detailed in Supplementary Materials. Briefly, 
mPFC, OFC and striatal samples were incubated for 5 min in the absence or presence of 
an excess concentration of nomifensine, a DAT inhibitor, to determine nonspecific 
[3H]dopamine uptake, and paroxetine and desipramine to prevent [3H]dopamine uptake 
by serotonin and norepinephrine transporters, respectively. Subsequently, 1 of 7 final 
concentrations (0.01-1.0 µM) of [3H]dopamine was added to the assay buffer and 
incubations continued for mPFC (5 min), OFC (5 min) and striatal (10 min) synaptosomal 
suspensions. Specific [3H]dopamine uptake was obtained by subtracting nonspecific 
uptake from total uptake; these values were used to determine kinetic parameters (Vmax 
and Km) using the commercially available GraphPad Prism 5.0 program (GraphPad 
Software Inc., San Diego, CA).    
 
3.2.7 Experiment 5: DAT Cellular Distribution Assay.  
Experiment 5 assessed DAT cellular distribution in mPFC, OFC and striatum of WIS, WKY, 
and SHR treated with ATO or vehicle.  Synaptosomal pellets of mPFC, OFC and striatum 
were resuspended in 1.25 ml (mPFC and OFC) or in 3 ml (striatum) of ice-cold sucrose 
solution. Biotinylation and Western blotting assays were performed using a previously 
published method (Somkuwar et al, 2013) detailed in Supplementary Materials. Briefly, 
synaptosomal suspensions were incubated with sulfo-NHS biotin to label all surface 
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proteins.  Synaptosomes were lysed by sonication and incubation in Triton X-100 buffer.  
Total protein fractions were obtained by centrifugation. Two-thirds of the total protein 
fractions were incubated with Avidin beads to separate non-biotinylated (supernatant) 
from Avidin-conjugated biotinylated fractions (pellet). Total, non-biotinylated and 
biotinylated fractions were subjected to gel electrophoresis and Western blotting and 
subsequently probed for  DAT protein, Na+/K+ ATPase (plasma-membrane enriched 
protein) and PP2A (intracellular protein) for determining efficiency of biotinylation, and 
β-actin (cytoskeletal protein, loading control) to ascertain protein loading.  Band density, 
expressed as relative optical density, was determined for DAT and β-actin using ImageJ 
software (http://imagej.nih.gov/ij).   
3.2.8 Data Analyses 
 Dependent measures for self-administration experiments included sessions to 
reach acquisition criterion (square root transformed prior to analysis), cocaine infusions 
earned, active and inactive lever responses, and progressive ratio breakpoints. 
Dependent measures for DAT functional assays included Km (log transformed prior to 
analysis) and Vmax (pmol/mg/min; ATO-treated rats were normalized as percent of 
vehicle-treated control of the same strain). For the cellular distribution assay, DAT from 
each fraction (total, intracellular and surface) for each brain region was normalized to β-
actin levels in the same sample. Dependent measures were analyzed by 1-factor (strain), 
2-factor (strain X treatment, drug dose X treatment, or drug dose X strain) or 3-factor 
(drug dose X strain X treatment) ANOVAs, with repeated measures for dose. Post-hoc 
Tukey’s tests were used in behavioral studies and Tukey’s or one-sample t-tests 
(compared to a hypothetical value of 100) for matched subjects in neurochemical 
studies. Outliers in neurochemical studies were removed prior to analysis using the 
Grubbs test (GraphPad Software; http://www.graphpad.com/quickcalcs/Grubbs1.cfm). 
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3.3 Results   
3.3.1 Experiment 1: Acquisition of Cocaine Self-Administration (Fixed-Ratio).  
Sessions to reach the acquisition criterion for the 0.3 mg/kg dose is shown in Figure 1. 
Strains differed significantly (F[2, 47] = 7.0, p≤ 0.002), and there was a trend for a strain 
X treatment interaction (F[2, 47] = 2.7, p≤ 0.07). Overall, SHR acquired cocaine self-
administration faster than WKY and WIS (p≤ 0.04 and 0.002, respectively). Treatment 
comparisons within each strain revealed that in WKY, acquisition of cocaine self-
administration was faster after ATO than vehicle (p≤ 0.03). ATO did not alter acquisition 
speed in SHR or WIS. Strain comparisons within each treatment revealed that in vehicle-
treated rats, SHR acquired cocaine self-administration faster than WKY (p≤ 0.02). In 
ATO-treated rats, both SHR and WKY acquired cocaine self-administration faster than 
WIS (p≤ 0.01 and 0.05, respectively).  
Analyses of active and inactive responses as well as infusions earned at criterion 
also were performed (Table S1 and Figure S1). These analyses confirm strain-level 
differences, with SHR emitting more active lever responses and earning more cocaine 
infusions than WKY or WIS, overall. These analyses also revealed that at criterion, ATO 
treatment increased active lever responses exclusively in SHR. Moreover, numbers of 
inactive lever responses emitted were not different between strains and between 
treatment conditions, and rats discriminated the active from inactive lever by a factor of 
2 or greater (Table S1).   
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3.3.2 Experiment 2: Cocaine Dose-Response Functions (Fixed-Ratio).  
Cocaine dose-response functions based on number of infusions earned under FR1 are 
shown in Figure 2A. For the 3-way ANOVA, strain (F[2, 43] = 18.4, p≤ 0.001) and dose 
(F[5, 215] = 185.5, p≤ 0.001) differed, and there was a strain X dose interaction (F[10, 
215] = 9.3, p≤ 0.001). The treatment factor and its interactions with strain and/or dose 
were not significant. Overall, SHR earned more cocaine infusions than WKY and WIS (p≤ 
0.001). Further testing of the strain X dose interaction indicated that SHR earned more 
infusions than WKY for cocaine doses ranging from 0.003 to 0.3 mg/kg (p≤ 0.04), and 
more infusions than WIS for cocaine doses ranging from 0.003 to 0.1 mg/kg (p≤ 0.01 
except at 0.01 mg/kg, where p≤ 0.08). In addition, WIS earned more infusions than WKY 
at 0.1 mg/kg (p≤ 0.001). No strain differences were observed at 1.0 mg/kg. Analyses of 
the cocaine dose-response functions based on number of active lever responses were 
similar to the above number of infusions earned (Figure S2).  
    
3.3.3 Experiment 3: Cocaine Dose-Response Functions (Progressive Ratio).  
Cocaine dose-response functions based on the last FR completed under the PR schedule 
are shown in Figure 2B. For the 3-way ANOVA, strain (F[2, 42] = 10.1, p≤ 0.001) and dose 
(F[3, 126] = 53.3, p≤ 0.001) differed. The treatment factor and its interactions with strain 
and/or dose were not significant. Overall, SHR had higher breakpoints than WKY and 
WIS (p≤ 0.001 and 0.01, respectively). Further analysis of the dose factor revealed that 
animals maintained the highest breakpoints at 1.0 mg/kg, which differed from all other 
doses, and maintained the lowest breakpoints at 0.01 mg/kg, which also differed from 
all other doses (p≤ 0.001 to 0.03).  Breakpoints maintained by 0.3 mg/kg and 0.1 mg/kg 
did not differ from each other. PR breakpoints based on infusions earned and active 
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lever responses also were analyzed and results were similar to the last FR completed 
measure (Figures S3 and S4).   
 
3.3.4 Experiment 4: Dopamine Uptake.   
Km values for [
3H]dopamine uptake in mPFC, OFC and striatum did not differ among 
strain or treatment groups (Table S2). Also, the Vmax for [
3H]dopamine uptake by DAT in 
mPFC, OFC and striatum did not differ between strains treated with vehicle (Figures 3A-
5A).  ATO treatment did not alter Vmax in mPFC in any strain when compared to the 
corresponding vehicle control. Also, there were no differences in Vmax in mPFC between 
strains treated with ATO (Figure 3A). Conversely, with respect to the OFC, ATO 
decreased Vmax for [
3H]dopamine uptake in SHR (t[7] = 2.42, p≤ 0.05) and WIS (t[5] = 
5.67, p≤ 0.005) by 25% and 51% of vehicle control, respectively (Figure 4A). 
Furthermore, there were strain differences in OFC in the ATO treated groups. 
Specifically, Vmax was lower for ATO-treated SHR and WIS (14% and 55%, respectively) 
compared to ATO-treated WKY (F[2, 21] = 8.22, p≤ 0.005). ATO also decreased Vmax in 
SHR striatum (t[6] = 2.74, p≤ 0.05) by 18% of vehicle control (Figure 5A). However, Vmax 
in striatum did not differ among the ATO-treated groups.  
 
3.3.5 Experiment 5: DAT Cellular Distribution Assay.  
In the vehicle-treated groups, no between-strain differences in DAT cellular distribution 
were found in mPFC, OFC and striatum (Table S3). ATO treatment did not alter DAT 
cellular distribution in mPFC (Figures 3B and 3C). However in OFC, ATO treatment 
significantly decreased (22% of vehicle control) DAT expression in the surface fraction 
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only in SHR (Figures 4B and 4C; t[7] = 2.50, p≤ 0.05). DAT cellular distribution in OFC in 
the ATO-treated groups was not different between the strains (Figures 4B and 4C). In 
striatum, ATO treatment during adolescence increased total DAT expression in SHR (18% 
of vehicle control; t[7] = 2.76, p≤ 0.05) and WIS (12% of vehicle control; t[6] = 4.35, p≤ 
0.05; Figures 5B and 5C). Also, surface DAT in striatum of WKY was increased (13% of 
vehicle control; t[7] = 2.88, p≤ 0.05; Figures 5B and 5C). DAT cellular distribution in 
striatum did not differ among ATO-treated groups (Figures 5B and 5C).  
 
3.4 Discussion  
3.4.1 Strain Differences in Behavior and DAT Neurochemistry 
 Compared to inbred WKY and outbred WIS comparator strains, SHR acquired 
cocaine self-administration faster, and showed greater intake and higher breakpoints 
across a range of cocaine unit doses under FR1 and PR schedules. These results suggest 
that SHR exhibit a vulnerable cocaine self-administration phenotype, characterized by 
faster acquisition, higher efficacy and a greater motivating influence of cocaine 
reinforcement. Vulnerability is reflected by vertical shifts in FR and PR dose-response 
functions (Piazza et al, 2000).  Thus, the current findings further verify the utility of the 
SHR for modeling comorbid cocaine abuse and ADHD (Harvey et al, 2011). 
Comparator strains did not differ, except that WIS had greater cocaine intake 
and made more active lever responses than WKY for 0.1 mg/kg cocaine under FR1. This 
dose produced peak rates of responding in all strains. Cocaine doses commonly abused 
in people and those associated with peak rates of responding in rhesus monkeys 
produce similar levels of striatal DAT occupancy (Wilcox et al, 2002).  This suggests that 
strain differences in cocaine self-administration may reflect strain differences in DAT 
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function or expression. Compared to WIS, WKY have decreased DAT density in nucleus 
accumbens (Jiao et al, 2003). In the present study, however, there were no strain 
differences in DAT function in mPFC, OFC or striatum under vehicle conditions. Further, 
no differences were found in DAT cellular distribution in mPFC, OFC and striatum among 
SHR, WKY and WIS, which is in agreement with some previous findings (Jiao et al, 2003; 
Li et al, 2007), but not others (Pandolfo et al, 2012; Roessner et al, 2010). 
Inconsistencies in striatal DAT expression may be explained by use of [3H]GBR 12935 to 
assess expression, since this radioligand binds to both intracellular and cell surface DAT 
protein (Roessner et al, 2010). Further, prior history of the subjects, including 
participation in behavioral assays, may explain some inconsistencies between studies in 
striatal DAT function and expression (Pandolfo et al, 2012).  With respect to striatal cell 
surface DAT expression, there was a trend suggesting WKY had lower DAT expression 
than SHR and WIS, although this was not associated with differences in striatal DAT 
function (Harvey et al, 2011; Womersley et al, 2011). Thus, cocaine may be a more 
efficacious reinforcer in SHR and WIS than WKY, due to greater DAT cell surface 
expression within the reward circuit in SHR and WIS.  
 
3.4.2 Effects of Atomoxetine Treatment 
 Following discontinuation of MPH treatment in adolescent SHR, an increase in 
cocaine self-administration was observed; and importantly, this was not observed in the 
control WKY and Wistar rats (Harvey et al, 2011). These findings appear to differ from 
those of other investigators reporting no increase in cocaine self-administration after 
discontinuing MPH treatment (Gill et al, 2012; Thanos et al, 2007); however, rats or 
monkeys that did not have an ADHD phenotype were employed in these studies. Thus, 
our results with the control strains (not expressing the ADHD phenotype) are in 
agreement with the latter findings. Further, our results employing SHR, which display 
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the ADHD phenotype, extend the literature, and moreover, are in agreement with 
clinical reports that teens with ADHD treated with stimulant medication have greater 
liability for cocaine abuse (Harvey et al, 2011; Mannuzza et al, 2008). Interestingly, 
when the ADHD stimulant treatment was initiated during childhood, a decreased drug 
abuse liability was found in adulthood (Wilens et al, 2003). Taken together, the current 
approach using an animal model of ADHD is appropriate and clinically relevant for 
determining the effects of alternate ADHD medications such as ATO. 
Adolescent ATO treatment did not alter cocaine self-administration behavior in 
SHR, with one exception. ATO-treated SHR made more active lever responses at the 
acquisition criterion under FR1, without having greater cocaine intake. This indicates 
that SHR made more responses during the 20 sec timeout/cue light presentation period 
following each cocaine infusion. Acute ATO pretreatment has cognitive enhancing 
effects via increased noradrenergic transmission (Gamo et al, 2010; Janak and Corbit, 
2011). Thus, it is possible that chronic ATO treatment increased the salience of cocaine-
paired cues in SHR during acquisition of cocaine self-administration via inhibition of 
norepinephrine uptake. As chronic ATO treatment during adolescence selectively 
increases NET mRNA in the OFC during adulthood (Sun et al, 2012), the OFC may be an 
important site of action for ATO-induced changes in cocaine cue salience.  
 The results of the current report suggest that alterations in DAT function and 
expression in OFC after ATO treatment may also be of importance to cocaine self-
administration behavior. Adolescent ATO treatment increased the speed of acquisition 
of cocaine self-administration in adult WKY, but not SHR and WIS, and correspondingly 
decreased DAT function in OFC of SHR and WIS, but not WKY. In our previous work, ATO 
treatment during adolescence was shown to differentially influence performance on a 
strategy set shifting task as well (Harvey et al, 2013). Specifically, learning speed during 
the initial discrimination phase was decreased in SHR and increased in WKY and WIS 
after ATO. During the set shift phase, ATO improved learning accuracy exclusively in 
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SHR, suggesting strain-dependent effects of ATO on prefrontal cortical functions 
(Floresco et al, 2009). In addition to decreases in Vmax of dopamine uptake at DAT in 
OFC, ATO decreased cell surface expression of DAT in OFC in SHR, revealing an 
underlying trafficking-dependent mechanism for the observed decrease in OFC DAT 
function. It has been shown that repeated application of dopamine decreases DAT 
function and expression in striatum in vivo and in a heterologous expression system in 
vitro (Gulley et al, 2002). Since dopamine is cleared by NET in mPFC and OFC, chronic 
ATO treatment will increase extracellular dopamine concentrations in these brain 
regions, which may lead to decreased DAT surface expression, and subsequently to 
decreased DAT function as observed in the SHR OFC. In WIS, the identical ATO 
treatment decreased DAT function in OFC, but did not decrease DAT cell surface 
expression, indicating a trafficking-independent mechanism. Taken together, these 
results suggest ATO may be protective against further enhancement of vulnerability to 
cocaine self-administration in SHR, via a long-lived reduction in DAT function and/or 
surface expression in OFC. Another variable that may confer this protection in SHR is the 
failure of adolescent ATO treatment in SHR to increase DAT function in mPFC during 
adulthood. In our previous studies, adolescent MPH treatment increased mPFC DAT 
function in SHR (Somkuwar et al, 2013) and further enhanced vulnerability to cocaine 
self-administration in SHR (Harvey et al, 2011) during adulthood.  
ATO unexpectedly decreased DAT function and increased total DAT expression in 
SHR striatum. The increase in total striatal DAT expression may be a compensatory 
response to the decrease in DAT function. Also, ATO increased total DAT expression in 
WIS and surface expression in WKY. Thus, ATO alterations in striatal DAT expression 
were not specific to the strain with the ADHD phenotype.  These results may reveal 
neuronal cross talk between dopaminergic neurons in striatum and noradrenergic 
neurons in cortex, where ATO has a direct effect at NET (Swanson et al, 2006).   
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3.4.3 Conclusions 
 The present study demonstrates that the SHR phenotype models comorbid 
cocaine abuse and ADHD. Contrary to previous findings with MPH, ATO treatment did 
not further enhance vulnerability to cocaine self-administration in SHR. Though 
additional work is needed to confirm mechanisms and signaling pathways involved, our 
work suggests that the protection by ATO against further enhanced cocaine abuse 
vulnerability in SHR may occur through decreased DAT function and decreased DAT cell 
surface localization in OFC, and sustained DAT function in mPFC. Taken together, the 
behavioral and neurochemical results suggest that ATO may be a suitable alternative to 
stimulant treatment in ADHD teens in whom the risk of drug abuse may be a concern. 
Moreover, while these studies do not raise critical concerns about the safety of ATO, 
they do emphasize the importance of accurate diagnosis of ADHD. In the WKY control, 
ATO speeded acquisition of cocaine self-administration and did not alter OFC DAT. 
Misdiagnosis of ADHD, and subsequent ATO treatment in teens could result in a more 
rapid development of abuse of cocaine.  
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3.5 Figures 
 
Figure 3.1 Number of sessions to reach criterion for acquisition of cocaine self-
administration 
 
Experiments were performed using adult Wistar (WIS; white bars), Wistar-Kyoto (WKY; 
black bars), and Spontaneously Hyperactive (SHR; grey bars) rats after discontinuation of 
adolescent treatment with atomoxetine (ATO; striped bars) or vehicle (VEH; solid bars). 
Values are mean ± S.E.M. (n=8-11/strain and treatment). * p ≤ 0.05 compared to SHR 
(denoted by horizontal line under the symbol). # p ≤ 0.05 compared to VEH-treated 
WKY. § p ≤ 0.05 compared to ATO-treated WKY and SHR. 
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3.2 Cocaine dose-response functions under fixed-ratio and progressive-ratio schedules 
 
 
Figure 2. (A) Cocaine dose-response functions based on number of infusions earned 
under an FR1 schedule (n=8-9/strain and treatment). (B) Progressive ratio breakpoints 
based on the last FR completed (n=8/strain and treatment). Experiments were 
performed using adult Wistar (WIS), Wistar-Kyoto (WKY), and Spontaneously 
Hypertensive (SHR) rats following discontinuation of adolescent treatment with 
atomoxetine (ATO; squares, dashed lines) or vehicle (VEH; circles, solid lines). Values are 
mean ± S.E.M. * p ≤ 0.05 compared to SHR overall (denoted by horizontal line under the 
symbol). # p ≤ 0.05 compared to the same dose in WIS. 
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3.3 Effects of atomoxetine on DAT function and cellular distribution in mPFC 
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Figure 3.  Dopamine transporter Vmax and cell surface distribution in the medial 
prefrontal cortex (mPFC) of adult Wistar (WIS), Wistar-Kyoto (WKY) rats and 
Spontaneously Hypertensive Rats (SHRs) following discontinuation of adolescent 
treatment with atomoxetine (ATO) or vehicle (VEH). (A) Vmax values are mean ± S.E.M. 
pmol/mg/min expressed as a percent of vehicle control; (n = 6-10/strain and treatment). 
Vmax values for WIS, WKY and SHR vehicle control groups were 3.0 ± 0.4, 2.4 ± 0.3 and 
3.9 ± 0.7 pmol/mg/min, respectively, and were not different from each other. (B) DAT 
expression values are mean ± S.E.M. arbitrary units for DAT density following ATO 
treatment expressed as a percentage of vehicle control (dotted line, see Supplementary 
Materials for vehicle control values). (C) Representative blots for DAT cellular 
distribution between total, non-biotinylated (Non-Biot; intracellular) and biotinylated 
(Biot; cell surface) fractions in mPFC synaptosomes from ATO-treated (A) and vehicle-
treated (V) WIS, WKY and SHRs. Actin was used to normalize DAT expression for each 
individual sample while Na+/K+ ATPase and PP2A served to ascertain efficiency of 
biotinyation of the surface proteins; (n = 6-7/strain and treatment). 
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Figure 3.4 Effects of atomoxetine on DAT function and cellular distribution in OFC 
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Figure 4. Dopamine transporter Vmax and cell surface distribution in the orbitofrontal 
cortex (OFC) of adult Wistar (WIS), Wistar-Kyoto (WKY) rats and Spontaneously 
Hypertensive Rats (SHRs) following discontinuation of adolescent treatment with 
atomoxetine (ATO) or vehicle (VEH). (A) DAT Vmax values are mean ± S.E.M. 
pmol/mg/min expressed as a percent of vehicle control; (n = 6-10/strain and treatment). 
Vmax values for WIS, WKY and SHR vehicle control groups were 3.5 ± 0.4, 2.8 ± 0.5 and 
4.3 ± 0.9 pmol/mg/min, respectively, and were not different from each other. (B) DAT 
expression values are mean ± S.E.M. arbitrary units for DAT density following ATO 
treatment expressed as a percentage of vehicle control (dotted line, see Supplementary 
Materials for vehicle control values). (C) Representative blots for distribution of DAT 
between total, non-biotinylated (Non-Biot; intracellular) and biotinylated (Biot; cell 
surface) fractions in OFC synaptosomes from ATO-treated (A) and vehicle-treated (V) 
WIS, WKY and SHRs. Actin was used to normalize DAT expression for each individual 
sample, while Na+/K+ ATPase and PP2A served to ascertain the efficiency of biotinyation 
of surface proteins; (n = 6-7/strain and treatment). * p ≤ 0.05 compared to the vehicle 
control value of 100%, # p ≤ 0.05 compared to ATO-treated WIS and SHR. 
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Figure 3.5 Effects of atomoxetine on DAT function and cellular distribution in striatum 
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Figure 5. Dopamine transporter Vmax and cell surface distribution in the striatum of adult 
Wistar (WIS), Wistar-Kyoto (WKY) rats and Spontaneously Hypertensive Rats (SHRs) 
following discontinuation of adolescent treatment with atomoxetine (ATO) or vehicle 
(VEH). (A) DAT Vmax values are mean ± S.E.M. pmol/mg/min expressed as a percent of 
vehicle control; (n = 5-6/strain and treatment). Vmax values for WIS, WKY and SHR 
vehicle control groups were 19.0 ± 1.7, 15.4 ± 2.3 and 17.3 ± 1.8 pmol/mg/min, 
respectively, and were not different from each other. (B) DAT expression values are 
mean ± S.E.M. arbitrary units for DAT density following ATO treatment expressed as a 
percentage of vehicle control (dotted line, see Supplementary Materials for vehicle 
control values). (C) Representative blots for distribution of DAT between total, non-
biotinylated (Non-Biot; intracellular) and biotinylated (Biot; cell surface) fractions in 
striatal synaptosomes from ATO-treated (A) and vehicle-treated (V) WIS, WKY and SHRs. 
Actin was used to normalize DAT expression for each individual sample while Na+/K+ 
ATPase and PP2A served to ascertain the efficiency of biotinyation of surface proteins; 
(n = 5-6/strain and treatment). * p ≤ 0.05 compared to the vehicle control value of 
100%. 
  
 136 
 
3.6 Supplementary Materials and Methods 
 
Housing conditions and treatment: Male Wistar (WIS)/Cr, Wistar-Kyoto (WKY)/Cr and 
Spontaneously Hypertensive (SHR) rats (Charles River Laboratories, Wilmington, MA, 
Kingston, NY or Raleigh, NC) arrived on postnatal day 25 (P25). The rats were housed 
individually. Rats were not given environmental enrichment because past research has 
demonstrated that environmental enrichment reduces ADHD-like symptoms in the SHR 
strain (Pamplona et al, 2009). For the rats used in the cocaine self-administration assays, 
rats received ATO (0.3 mg/kg, i.p., dissolved in 0.9% sterile physiological saline) or saline 
(2.0 ml/kg, i.p.) from P28 until P55. For the rats used in dopamine transporter function 
and cellular distribution assays, rats received ATO (0.3 mg/kg, i.p., dissolved in 0.9% 
sterile physiological saline) or saline (2.0 ml/kg, i.p.) from P28 until P55.   Double volume 
was used to enable complete dissolution of ATO. Administration was from Monday 
through Friday to mimic the weekend “medication holiday” often recommended for 
individuals with ADHD (1996). In addition, rats were mildly food restricted (85-90% of 
their free-feeding body weight) to enable comparison with our previously published 
results (Harvey et al, 2011). After P55, treatment was terminated, ad libitum food access 
was reinstated, and no environmental enrichment was provided in the home cage. The 
3-day acclimation period is standard protocol in animal studies assessing cocaine self-
administration (Roberts et al, 2002), neurochemistry (Mateo et al, 2005) as well as in 
studies using adolescent rats (Levin et al, 2007). Since the objective of the current study 
was to identify the effects ATO treatment across the entire period of adolescence, the 
treatment was initiated at postnatal day 28. One way to include a longer acclimation 
period in the experimental design would be to wean the rat pups early prior to 
shipment. However, early weaning itself is stressful and is known to produce 
neurological modifications (Ferdman et al, 2007). Of particular concern is that maternal 
separation in SHR is known to decrease striatal DAT function (Womersley et al, 2011). 
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Surgery for Behavioral Studies: Animals were anesthetized with i.p. injections of 90 
mg/kg ketamine and 10 mg/kg xylazine. Buprenex (0.05 mg/kg s.c.; Bulter Schein, 
Columbus, OH, USA) was given as a preemptive analgesic 5 min prior to anesthetization. 
Incisions were made to expose the right femoral vein and skull. A catheter constructed 
of silicon tubing (I.D. = 0.020 in, O.D. = 0.037 in) was inserted s.c. between these 
incisions. The proximal end of the catheter was inserted into the right femoral vein and 
anchored to tissue underlying the vein using surgical silk and 0.5 mm square Teflon 
mesh (C.R. Bard Inc., Charlotte, N.C.). The distal end of the catheter was attached to a 
22-gauge pedestal mount (Plastics One, Roanoke, VA). The pedestal and four stainless-
steel screws were attached to the skull with dental cement. The stainless steel tubing 
exiting the pedestal was plugged with a sealed piece of Teflon tubing and covered with a 
protective plastic outer screw cap. Rats were treated for 3-5 days post-surgery with i.v. 
Baytril (5 mg/kg; Bayer Health Supply, Kansas City, KS) to reduce risk of systemic 
infection, for 3 days with s.c. Meloxicam (0.3 mg/kg; Butler Schein, Columbus, OH, USA) 
to reduce inflammation, as well as twice daily with s.c. Buprenex (0.025 mg/kg; Bulter 
Schein, Columbus, OH, USA) for 48 hr following surgery, and as needed. Catheters were 
flushed daily Monday-Friday with 0.1 ml of 0.9% saline solution containing 0.3 IU 
heparin (Baxter Healthcare, Deerfield, IL, USA) and 6.7 mg of Timentin (Glaxo-
SmithKline, Research Triangle Park, NC, USA). On weekends, a locking solution 
containing 100% glycerol and 1000 IU/ml of undiluted heparin (3:1) was infused into the 
catheters to fill dead space and minimize the occurrence of blockages, thus prolonging 
the longevity of the catheter. On Mondays, the locking solution was withdrawn and 
replaced with 0.1 ml of 0.9% saline and 0.3 IU heparin. Catheter patency was checked 
weekly both by withdrawal of blood and by monitoring for sedation following an 
intravenous infusion of 1.0 mg of methohexital sodium (0.1 ml, Brevital, JHP 
Pharmaceuticals, Rochester, MI). If a catheter was found to be non-functional, a new 
catheter was implanted into the left femoral vein or into the right or left jugular vein. 
The animals were allowed to recover before resuming cocaine self-administration 
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experiments. As a result, no animals were excluded from statistical analyses due to loss 
of patency. 
 
Apparatus 
For behavioral studies, eight experimental chambers (model ENV-008CT; Med 
Associates, St. Albans, VT) were equipped with two response levers, a white stimulus 
light above the active lever, and a house light. Chambers were outfitted with a single-
channel fluid swivel (Instech Solomon, Plymouth Meeting, PA, USA) connected to a 
spring leash and counterbalanced arm assembly (Med Associates). Motor-driven syringe 
pumps located outside the chamber were used for i.v. drug delivery. Chambers were 
enclosed in a sound-attenuating cubicle (model ENV-018 M; Med Associates) equipped 
with a ventilation fan and 8-ohm speaker to provide background white noise. A personal 
computer programmed in Medstate Notation and connected to a Med Associates 
interface controlled experimental events. 
 
Neurochemical Studies 
Materials: For the dopamine uptake assay, desipramine hydrochloride, paroxetine 
hydrochloride, nomifensine maleate, pargyline, ascorbic acid, 
ethylenediaminetetraacetic acid (EDTA), sucrose, β-mercaptoethanol, 4-(2-
hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES), 3-hydroxytyramine (dopamine), 
sodium chloride and magnesium sulfate were purchased from Sigma-Aldrich (St. Louis, 
MO). α-d-Glucose, L-ascorbic acid, and monobasic potassium phosphate were 
purchased from Aldrich Chemical Co. (Milwaukee, WI), AnalaR-BHD Ltd. (Poole, UK) and 
Mallinckrodt (St. Louis, MO), respectively. [3H]Dopamine 
(dihydroxyphenylethylamine,3,4-[7-3H]; specific activity, 30.3 Ci/mmol) was purchased 
from PerkinElmer Life and Analytical Sciences Inc. (Boston, MA). All other chemicals in 
the uptake assay buffers were purchased from Fisher Scientific Co. (Pittsburgh, PA). 
 For the cell surface localization assays, antibodies recognizing rat DAT (C-20; goat 
polyclonal antibody), demethylated protein phosphatase 2A-C (PP2A-C; 4B7; mouse 
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monoclonal antibody), anti-mouse IgG conjugated with horseradish peroxidase (IgG-
HRP; sc2954 chicken polyclonal antibody) and anti-goat IgG-HRP (sc2020; donkey 
polyclonal antibody) were purchased from Santa Cruz Biotechnology, Inc. (Santa Cruz, 
CA). Antibodies against alpha-1 Na+/K+ ATPase type-1 (mouse monoclonal antibody) 
were obtained from Abcam (Cambridge, MA). Antibodies recognizing β-actin (A 5441, 
mouse monoclonal antibody) were purchased from Sigma-Aldrich (St. Louis, MO). 
Sulfosuccinimidobiotin (sulfo-NHS-biotin), d-biotin and immunoPure immobilized 
monomeric avidin gel were purchased from Pierce Chemical (Rockford, IL). Complete 
protease inhibitor cocktail tablets were obtained from Roche Diagnostics (Indianapolis, 
IN). Immunobilon-P PVDF membranes were purchased from Millipore. HyGLO 
Quickspray Chemiluminescent HRP Antibody Detection Reagent and HyblotCL 
autoradiography films were purchased from Denville Scientific Inc. (Metuchen, NJ).  
 
Dopamine Uptake Assay: DAT function was assessed using kinetic analysis of 
[3H]dopamine uptake into mPFC, OFC and striatal synaptosomes employing a previously 
published procedure (Marusich et al, 2011) with minor modifications. For each 
experiment, mPFC, OFC and striatum of one ATO-treated and one vehicle-treated rat of 
the same strain and age (P77-P84)  were homogenized in separate glass homogenizers, 
each containing 20 ml of ice-cold sucrose solution (0.32 M sucrose and 5 mM sodium 
bicarbonate, pH 7.4) with 16-20 passes of a Teflon pestle. Synaptosomal suspensions 
were subjected to two centrifugation steps (2,000g, 10 min, 4 °C followed by 20,000g, 
17 min, 4 °C) using an Avanti-J30I centrifuge (Beckman Coulter, Brea, CA). Resulting 
pellets were resuspended in 2.2 ml (mPFC and OFC synaptosomes) or 2.4 ml (striatal 
synaptosomes) ice-cold uptake buffer (125 mM NaCl, 5 mM KCl, 1.5 mM MgSO4, 1.25 
mM CaCl2, 1.5 mM KH2PO4, 10 mM glucose, 25 mM HEPES, 0.1 mM EDTA, 0.1 mM 
pargyline, and 0.1 mM L-ascorbic acid, saturated with 95% O2/5% CO2, pH 7.4). mPFC 
and OFC samples (100 µl aliquots of the 2.2 ml synaptosomal suspensions) and striatal 
samples (30 µl aliquot of the 2.4 ml synaptosomal suspension) were incubated for 5 min 
in a Dubnoff metabolic shaker (Precision Scientific, Winchester, VA) at 34 °C in a 
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saturated 95% O2/5% CO2 atmosphere in the absence or presence of 10 µM 
nomifensine, a DAT inhibitor, which was used to obtain nonspecific [3H]dopamine 
uptake. mPFC and OFC suspensions also contained 5 nM each of paroxetine and 
desipramine to prevent [3H]dopamine uptake by serotonin transporters and NETs, 
respectively. Subsequently, 1 of 7 final concentrations (0.01-1.0 µM) of [3H]dopamine 
was added to the buffer and incubation of the mPFC, OFC and striatal synaptosomal 
suspensions continued for 5, 5 and 10 min, respectively. [3H]Dopamine uptake was 
terminated by addition of 3 ml of ice-cold assay buffer, immediately followed by 
filtration through Whatman GF/B glass fiber filters (presoaked with 1 mM pyrocatechol 
for 3 hr at 4 °C) using a cell harvester (Biochemical Research and Development 
Laboratories, Gaithersburg, MD). Values for total and nonspecific [3H]dopamine uptake 
were obtained from the amount of radioactivity retained on the filters as determined by 
liquid scintillation spectrometry (model B1600TR; PerkinElmer Life and Analytical 
Sciences, Downers Grove, IL). Protein concentrations were determined with bovine 
serum albumin standards using the Bradford method (Bradford, 1976). Specific 
[3H]dopamine uptake was obtained by subtracting nonspecific uptake from total uptake, 
and the values were used to determine kinetic parameters (Vmax and Km) by employing 
the commercially-available GraphPad Prism 5.0 program (GraphPad Software Inc., San 
Diego, CA).    
 
DAT cellular distribution assay: Synaptosomal pellets were resuspended in ice-cold 
sucrose solution (1.25 ml for mPFC and OFC, and 3 ml for striatum). Synaptosomal 
protein concentrations were determined as previously described. Biotinylation and 
Western blotting assay were performed using a previously published method 
(Somkuwar et al, 2013).  Briefly, synaptosomal suspensions contained 1 mg protein for 
mPFC and OFC and 500 µg protein for striatum.  Suspensions were incubated with 
shaking for 1 hr at 4 °C in 500 µl of 1.5 mg/ml sulfo-NHS biotin in PBS/Ca/Mg buffer (138 
mM NaCl, 2.7 mM KCl, 1.5 mM KH2PO4, 9.6 mM Na2HPO4, 1 mM MgCl2, 0.1 mM CaCl2, 
pH 7.4), which labels all surface proteins with biotin. Free sulfo-NHS biotin was removed 
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by centrifugation (8000g, 4 min, 4 °C) using a model 5417R centrifuge (Eppendorf, 
Hauppauge, NY) followed by washing with 1 ml ice-cold 100 mM glycine in PBS/Ca/Mg 
buffer, and these steps were repeated twice.  Then, samples were centrifuged using the 
same conditions and washed with 1 ml ice-cold PBS/Ca/Mg buffer, and these steps were 
repeated twice. Subsequently, synaptosomes were lysed by sonication for 2-4 s followed 
by incubation, with continuous shaking, for 20 min at 4 °C in Triton X-100 buffer (150 μl 
for mPFC and OFC synaptosomes, and 300 μl for striatal synaptosomes; 10 mM Tris, 150 
mM NaCl, 1 mM EDTA, 1.0% Triton X-100, 1 μg/ml aprotinin, 1 μg/ml leupeptin, 1 μM 
pepstatin, 250 μM phenylmethysulfonyl fluoride, pH 7.4).  Lysates underwent 
centrifugation (21,000g, 20 min, 4 °C). Supernatants constituted the total protein 
fraction.  To obtain the cell surface and intracellular fractions, 2/3 of the supernatant 
was incubated with Avidin beads with shaking for 1 hr at room temperature, and 
samples centrifuged (17,000g, 4 min, 4 °C). Supernatants constituted the non-
biotinylated fraction (intracellular fraction).  Pellets contained the Avidin-conjugated 
biotinylated proteins (cell surface fraction).  Pellets were washed three times with 1% 
Triton-X-100 and then incubated for 20 min at room temperature with Lamelli buffer 
containing 5% v/v β-mecaptoethanol to free the cell surface proteins from the Avidin-
biotin complex. Total, non-biotinylated and biotinylated fractions were frozen at -20 °C 
until Western blot analysis.  
Total, non-biotinylated and biotinylated fractions were thawed and subjected to 
gel electrophoresis using a gel running apparatus Western blotting using  Trans-Blot® SD 
Semi-Dry Transfer Cells (Bio-Rad Laboratories, Inc., Hercules, CA).  Blots were incubated 
(overnight, 4 °C) with primary antibody for DAT, followed by secondary antibody (1 hr, 
room temperature).  DAT protein (72 kDa) was detected using enhanced 
chemiluminescence and HyblotCL autoradiography film (Denville Scientific Inc.).  Blots 
were probed simultaneously for detection of Na+/K+ ATPase (a plasma-membrane 
enriched protein; 100 kDa), PP2A (an intracellular protein; 34 kDa) for determining 
efficiency of biotinylation of surface proteins, and β-actin (a cytoskeletal protein; 42 
kDa) to control for loading of proteins. Band densities, expressed as relative optical 
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density, were determined for DAT and β-actin in total, non-biotinylated and biotinylated 
fractions using ImageJ software (http://imagej.nih.gov/ij).   
 
 
Supplementary Results 
Experiment 1: Acquisition of Cocaine Self-Administration (Fixed-Ratio).  
The number of cocaine infusions earned at criterion for the 0.3 mg/kg training dose of 
cocaine is shown in Figure S1. Strains differed significantly (F [2, 47] = 6.2, p ≤ 0.004). 
The treatment factor and its interaction with strain were not significant.  Post-hoc 
comparisons showed that, overall, SHR earned more infusions than WKY (p ≤ 0.003), and 
there was a trend towards more infusions compared to WIS (p ≤ 0.09).  Active lever 
responses at criterion are shown in Table S1. Strains significantly differed (F [2, 47] = 4.5, 
p ≤ 0.02), and there was a trend towards a strain X treatment interaction (F [2, 47] = 2.7, 
p ≤ 0.08). Post-hoc comparisons showed that, overall, SHR made more active lever 
responses than WKY (p ≤ .02), and there was a trend towards more active lever 
responses compared to WIS (p ≤ .07). Treatment comparisons within each strain 
revealed that in SHR, active lever responses were greater after ATO than vehicle (p ≤ 
0.006). Strain comparisons within each treatment condition revealed that in ATO-
treated rats, SHR made more active lever responses than WKY and WIS (p ≤ 0.003 and 
0.006, respectively). There were no strain differences in active lever responses among 
vehicle-treated rats at criterion.  With respect to inactive lever responses, there were no 
strain or treatment differences at criterion (Table S1). In addition, each strain 
discriminated the active from inactive lever by a factor of 2 or greater (9:1 for WKY, 20:1 
for WIS, and 4:1 for SHR, on average).  
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Figure S1. Infusions earned at the 0.3 mg/kg cocaine training dose after reaching the 
acquisition criterion. Values were obtained in adult Wistar-Kyoto (WKY; white bars), 
Wistar (WIS; black bars), and Spontaneously Hypertensive (SHR; grey bars) rats after 
discontinuation of adolescent treatment with atomoxetine (ATO; striped bars) or vehicle 
(VEH; solid bars). Values are mean ± S.E.M. (n=8-11/strain and treatment).  * p ≤ 0.05 
compared to SHR overall (denoted by horizontal line under the symbol). 
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Table S1. Active and inactive lever responses maintained by 0.3 mg/kg cocaine after 
reaching the acquisition criterion in adult Wistar (WIS), Wistar-Kyoto (WKY) and 
Spontaneously Hypertensive (SHR) rats following discontinuation of adolescent 
treatment with atomoxetine or vehicle. Values are mean ± S.E.M. (n=8-11/strain and 
treatment). * p ≤ 0.05 compared to vehicle treatment in SHR.   
 
 
 
 
 
 
 
 
  
Strain Treatment 
Lever Responses 
Active Inactive 
WIS  
Vehicle  
 
70 ± 17 4.0  ± 1.3 
Atomoxetine 
 
70 ± 21 3.0  ± 1.6 
WKY  
Vehicle 
 
51 ± 18 6.0  ± 2.0 
Atomoxetine 
 
51 ± 6.3 5.0  ± 1.9 
SHR  
Vehicle 
 
74 ± 7.9 37 ± 34 
Atomoxetine 180 ± 46 * 30 ± 24 
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Experiment 2: Cocaine Dose-Response Functions (Fixed-Ratio). 
The cocaine dose-response functions based on the number of active lever responses are 
shown in Figure S2. For the 3-way ANOVA, strain (F [2, 43] = 4.9, p ≤ 0.01) and dose (F 
[5, 215] = 36.9, p ≤ 0.001) differed significantly, and there was a dose X strain interaction 
(F [10, 215] = 3.2, p ≤ 0.001). The treatment factor and its interactions with strain and/or 
dose were not significant. Post-hoc comparisons showed that SHR overall made more 
active lever responses than WKY (p ≤ 0.01), but SHR were not different from WIS. 
Further testing of the strain X dose interaction revealed that SHR made more active 
lever responses at the 0.03 and 0.1 mg/kg doses than WKY and WIS (p ≤ 0.05). 
Furthermore, WIS made more active lever responses at 0.1 mg/kg than WKY (p ≤ 0.003). 
No strain differences at the other doses were found. 
 
Figure S2. Cocaine dose-response functions under the FR1 schedule, based on the 
number of active lever responses. Values were obtained in adult Wistar (WIS), Wistar-
Kyoto (WKY) and Spontaneously Hypertensive (SHR) rats after discontinuation of 
adolescent treatment with atomoxetine (ATO; squares, dashed lines) or vehicle (VEH; 
circles, solid lines). Values are mean ± S.E.M. (n=8-9/strain and treatment).  * p ≤ 0.05 
compared to SHR overall (denoted by horizontal line under the symbol). # p ≤ 0.05 
compared to the same dose in WIS. 
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Experiment 3: Cocaine Dose-Response Functions (Progressive Ratio). 
The PR breakpoints based on the number of infusions earned are shown in Figure S3. 
For the 3-way ANOVA, strain (F [2, 42] = 17.1, p ≤ 0.001) and dose differed significantly 
(F [3, 126] = 158.4, p ≤ 0.001). The treatment factor and its interactions with strain 
and/or dose were not significant. Post-hoc tests showed that, overall, SHR had higher PR 
breakpoints than WKY and WIS (p ≤ 0.001). Further analysis of the dose factor showed 
that animals had the highest PR breakpoint at the 1.0 mg/kg dose compared to the 
three other doses (p ≤ 0.001), and the lowest PR breakpoint at the 0.01 mg/kg dose 
compared to the three other doses (p ≤ 0.001). In addition, there was a higher PR 
breakpoint at the 0.3 mg/kg dose than at the 0.1 mg/kg dose (p ≤ 0.001). 
  
The PR breakpoints based on active lever responses are shown in Figure S4. For 
the 3-way ANOVA, strain (F [2, 42] = 10.5, p ≤ 0.001) and dose (F [3, 126] = 51.5, p ≤ 
0.001) differed significantly. The treatment factor and its interactions with strain and/or 
dose were not significant. Post-hoc testing showed that, overall, SHR had higher PR 
breakpoints than WKY and WIS (p ≤ 0.001 and p ≤ 0.008, respectively). Further analysis 
of the dose factor revealed that animals had the highest PR breakpoint at the 1.0 mg/kg 
cocaine dose, compared to the three other doses (p ≤ 0.001), and the lowest PR 
breakpoint at the 0.01 mg/kg cocaine dose, compared to the three other doses (p ≤ 
0.001, except at the 0.1 mg/kg dose where p ≤ 0.05). PR breakpoints at the two 
intermediate cocaine doses, 0.3 mg/kg and 0.1 mg/kg, did not differ from each other. 
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 Figure S3. Progressive ratio breakpoints based on the number of cocaine infusions 
earned. Values were obtained in adult Wistar (WIS), Wistar-Kyoto (WKY) and 
Spontaneously Hypertensive (SHR) rats after discontinuation of adolescent treatment 
with atomoxetine (ATO; squares, dashed lines) or vehicle (VEH; circles, solid lines). 
Values are mean ± S.E.M. (n=8/strain and treatment). * p ≤ 0.05 compared to SHR 
overall (denoted by horizontal line under symbol). 
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Figure S4. Progressive ratio breakpoints based on the number of active lever responses. 
Values were obtained in adult Wistar (WIS), Wistar-Kyoto (WKY) and Spontaneously 
Hypertensive (SHR) rats after discontinuation of adolescent treatment with atomoxetine 
(ATO; squares, dashed lines) or vehicle (VEH; circles, solid lines). Values are mean ± 
S.E.M. (n = 8/strain and treatment). * p ≤ 0.05 compared to SHR overall (denoted by 
horizontal line under symbol). 
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Experiment 4: Dopamine Uptake. 
Atomoxetine did not alter affinity of dopamine for DAT. Two-factor ANOVA comparing 
log transforms of Km values for dopamine did not reveal significant interactions of strain 
X treatment in mPFC (F [2,40] = 0.20, p > 0.05), OFC (F [2,40] = 0.002 , p > 0.05) or 
striatum (F [2,34] = 0.49, p > 0.05). 
 
Table S2. Km values for dopamine uptake at the dopamine transporter in the medial 
prefrontal cortex (mPFC), orbitofrontal cortex (OFC) and striatum of adult Wistar (WIS), 
Wistar-Kyoto (WKY) and Spontaneously Hypertensive Rats (SHRs) following atomoxetine 
(ATO) or vehicle (VEH) treatment during adolescence. Values (nM) are expressed as 
mean ± S.E.M; n = 6-10/strain and treatment. 
 
            WIS           WKY            SHR 
 VEH ATO VEH ATO VEH ATO 
mPFC 77 ± 8.2 110 ± 27  103 ± 18 105 ± 14 75 ± 12 86 ± 4.2 
 
OFC 79 ± 7.5 98 ± 29 81 ± 13 90 ± 16 75 ± 10 82 ± 12 
 
Striatum 33 ± 3.8 30 ± 0.82 36 ± 3.4 36 ± 2.9 33 ± 3.3 28 ± 2.2 
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Experiment 5: DAT Cellular Distribution.  
DAT expression and cellular distribution did not differ between vehicle-treated SHR, 
WKY and WIS.  One-way ANOVAs comparing DAT expression in mPFC, OFC and striatum 
revealed no significant effect of strain in total, non-biotinylated (intracellular) and 
biotinylated (surface) fractions. There was a trend towards a significant strain effect in 
the biotinylated (surface) fraction from striatum. DAT expression in SHR and WIS striatal 
surface tended to be greater than in WKY (see Table S3 for F-statistics). 
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Table S3:  Band density for DAT in the total, non-biotinylated (intracellular) and 
biotinylated (surface) fractions from medial prefrontal cortex (mPFC), orbitofrontal 
cortex (OFC) and striatum of adult Wistar (WIS), Wistar-Kyoto (WKY) and Spontaneously 
Hypertensive Rats (SHRs) that were administered saline during adolescence.  Values are 
expressed as mean ± S.E.M in arbitrary units; n = 6-8/strain. a ps > 0.05; b p = 0.053 
  WIS WKY SHR F-statistics a  
mPFC Total 62 ± 9.4 45 ± 10  85 ± 16  F [2, 17] = 2.5 
Non-biotinylated 36 ± 7.7  20 ± 4.8  39 ± 11  F [2, 17] = 1.5 
Biotinylated 25 ± 8.4  19 ± 4.5  27 ± 4.8  F [2, 18] = 0.41 
OFC Total 63 ± 14  54 ± 11  73 ± 12 F [2, 21] = 0.63 
Non-biotinylated 31 ± 7.7  38 ± 7.6  43 ± 5.5  F [2, 21] = 0.72 
Biotinylated 23 ± 3.1  23 ± 4.9  33 ± 7.1  F [2, 20] = 1.2 
Striatum Total 159 ± 13  179 ± 9.0  182 ± 18  F [2, 19] = 0.85 
Non-biotinylated 96 ± 9.8  74 ± 12  76 ± 15  F [2, 20] = 1.1 
Biotinylated 188 ± 11  153 ± 6.3  186 ± 15  F [2, 20] = 3.4 b 
 
 
 
 
 
 
 
 
 
 
Copyright © Sucharita S. Somkuwar 2013 
  
 152 
 
 
4 CHAPTER FOUR 
 
Norepinephrine transporter function in the prefrontal cortex following 
methylphenidate treatment during adolescence in a rat model of attention 
deficit/hyperactivity disorder 
 
4.1 Introduction 
 
Attention deficit/hyperactivity disorder (ADHD) is one of the most prevalent 
neurobehavioral disorders that affect ~12-15% children worldwide and persists into 
adulthood in ~4-5% individuals (Froehlich et al, 2007; Polanczyk et al, 2007). Although, 
the disease etiology is suspected to be complex multigenetic interaction (Faraone et al, 
2005; Gizer et al, 2009; Kuntsi and Klein, 2012), several lines of evidence suggest that 
deficits in noradrenergic neurotransmission partially underlie ADHD etiopathology 
(Biederman and Spencer, 1999a; Levy, 2009). Polymorphisms of the norepinephrine 
transporter (NET) gene have not been unequivocally associated with the etiology of 
ADHD (Barr et al, 2002; McEvoy et al, 2002), see also (Kollins et al, 2008).  However, 
selective inhibition of NET via ATO has been established as a therapeutically efficacious 
strategy for ADHD children and adolescents (Garnock-Jones et al, 2009; Spencer et al, 
2001; Wilens et al, 2006). Moreover, the currently available FDA-approved therapeutics 
for ADHD increase noradrenergic neurotransmission, either indirectly via inhibition of 
NET (e.g., methylphenidate; MPH) or by directly activating post-synaptic α2A adrenergic 
receptors (e.g., guanfacine) (Berridge et al, 2006; Bymaster et al, 2002; Fernando et al, 
2012; Ma et al, 2005). 
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Reduced noradrenergic neurotransmission, particularly in prefrontal cortex, has 
been strongly associated with hallmark ADHD symptoms of high impulsivity, 
hyperactivity and reduced attention. Inhibition of α2 adrenergic receptors (A, B and C 
receptor subtypes) with intra-cortical administration of yohimbine has been shown to 
produce an ADHD profile in primates (Li et al, 1994; Ma et al, 2005; Ma et al, 2003). 
Further evidence for cortical involvement is provided by studies in rats in which a low 
dose of MPH (2.0mg/kg, i.p.) resulted in positive blood oxygen dependent (BOLD) signals 
in the orbitofrontal cortex (OFC), and resulted in negative BOLD signals in the motor and 
somatosensory cortices (Easton et al, 2009). At therapeutically relevant doses, MPH 
preferentially increased extracellular norepinephrine (NE) in the prefrontal cortex 
compared to both NE in subcortical areas as well as dopamine in the prefrontal cortex 
(Berridge et al, 2006). Moderate increases in extracellular NE activates α2A receptors, 
decreases intracellular second messenger cyclic adenosine monophosphate (cAMP) 
concentrations and thereby enhances the strength and duration of firing of cortical 
pyramidal neurons (Wang et al, 2007). Enhanced pyramidal neuronal firing is 
hypothesized mechanism by which ADHD medications improve attention and reduce 
impulsivity and working memory (Sagvolden, 2006; Wang et al, 2007). Indeed, MPH has 
been shown to increase activation of cortical α2A adrenergic receptors in non-human 
primates and in rats (Arnsten, 2009; Gamo et al, 2010). Taken together, enhancing 
noradrenergic neurotransmission in the cortical areas via inhibition of NET is critical for 
therapeutic action of MPH. However, few studies have investigated the long-term 
consequences of MPH treatment during childhood and adolescence on NET function 
during adulthood. 
The central noradrenergic system undergoes dynamic changes through 
childhood to adulthood. Cortical NE concentration in rhesus monkeys increases steadily 
from birth to adulthood, and during adulthood, cortical NE far exceeded dopamine and 
serotonin concentrations (Goldman-Rakic et al, 1982). In the rodent locus coeruleus, the 
nucleus of origin for NE neurons in brain, NET expression was high during the early 
postnatal period, and significantly decreases following adolescence into early adulthood 
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(Sanders et al, 2005; Zhu et al, 2005b). In contrast, NET expression in the forebrain 
increased from birth to post-natal day 15 (PND 15), and the expression levels were 
maintained through adulthood (Sanders et al, 2005), which was consistent with 
previously reported developmental changes in NET function (Coyle et al, 1971). α2 
adrenergic receptors followed a similar developmental trajectory in rat cortex (Happe et 
al, 2004). Taken together, these studies suggest that the cortical noradrenergic system 
is malleable during early childhood, but not during adolescence. Thus, the cortical 
noradrenergic system is expected to be resilient with respect to mild pharmacological 
manipulations, such as treatment with therapeutically relevant low doses of MPH. 
Results from clinical neuroimaging studies suggest that cortical maturation in 
individuals with ADHD is developmentally delayed (Chandler et al, 2013b; Matecka et al, 
1997b; Sanchez-Mora et al, 2013). As a consequence, the noradrenergic system in the 
ADHD population may be more vulnerable to long-term treatment with MPH during 
adolescence. Previous studies in the Spontaneously Hypertensive Rat (SHR), a well-
established model of ADHD (Sagvolden, 2011; Sagvolden et al, 2005b), have found that 
MPH treatment during adolescence produced lasting changes in dopamine transporter 
(DAT) function in prefrontal cortex and its subregions (Harvey et al, 2011; Somkuwar et 
al, 2013a). Further, MPH treatment during adolescence increased impulsivity and 
cocaine self-administration in SHR compared to control Wistar-Kyoto and Wistar rats 
that did not exhibit the ADHD phenotype (Harvey et al, 2011); Somkuwar et al, 2013 
submitted; Chapter 7). Both MPH and cocaine inhibit NET (Richelson et al, 1984). NE 
depletion in the medial prefrontal cortex (mPFC) inhibits the cocaine-induced increase 
in dopamine in nucleus accumbens and cocaine reward in mice (Ventura et al, 2007). 
Taken together, these results suggest that in SHR, chronic treatment with MPH during 
adolescence may produce lasting alterations in NET function, which in turn may be 
associated with the enhanced impulsivity and reinforcing effects of cocaine during 
adulthood. 
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Clinical verification of the role of NET in the pathophysiology of ADHD is 
currently not well understood (Zimmer, 2009), in part, due to the paucity of suitable 
radioligands for NET for use in positron emitted tomography (PET) studies (for review, 
Ding et al, 2006). Evaluation of NET function has been further stymied by the high non-
specific binding of the standard NET inhibitors such as nisoxetine, desipramine and 
oxaprotilin. The high non-specific binding of NET ligands also has been an impediment 
for evaluating NET function using in vitro preparations such as kinetic analysis of uptake 
of [3H]NE into brain synaptosomes. The current study is aimed at isolating NET function 
using an in vivo approach to overcome these methodological challenges.  
High speed chronoamperometry is an in vivo electrochemical method for 
detecting molecules that readily undergo oxidation and reduction when coming in 
contact with an electrode held at an appropriate voltage (Borland and Michael, 2007). 
Concentrations of such electroactive molecules are directly proportional to the current 
produced during their oxidation and reduction at the electrode surface. NE is one such 
electroactive analyte in which the phenolic ring readily oxidizes to an orthoquinone and 
then reduces back to the phenol ring when a 0-0.55V square-wave pulse is applied in a 
physiological (pH 7.4) media. Under these experimental conditions, specific NET 
function can be inferred from real-time clearance of exogenously applied NE, 
circumventing the potential confound of amount released altering clearance 
measurements (McCrae et al, 2005). The latter study evaluated DAT function by 
determining clearance of exogenously applied dopamine. DAT and NET share functional 
and structural homologies and are comparable in their substrate selectivity (Miller et al, 
2010; Moron et al, 2002; Whiteside et al, 2005). Hence, the electrochemical procedures 
used in the current study relied on methods and approaches of previous studies 
evaluating DAT function (Liu et al, 2009; Ram et al, 2004; Zhu et al, 2007).  
The aim of the current study was to evaluate in vivo NET function in subregions 
of prefrontal cortex, including the cingulate gyrus (CG), prelimbic cortex (PrL), 
infralimbic cortex (IL) and lateral orbitofrontal cortex (LO). The experimental protocol 
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was optimized and employed to identify differences between SHR and controls WKY and 
WIS following MPH or vehicle treatment through adolescence on NET function during 
adulthood. 
 
4.2 Materials and Methods 
4.2.1 Drugs and Reagents 
(±)-MPH was purchased from Sigma-Aldrich (St. Louis, MO). MPH was dissolved in water 
to obtain concentrations of 1.5 mg/ml (prepared daily) and injected into oyster crackers 
(Kantak et al, 2008) to attain a dose of 1.5 mg/kg for oral administration. (±)-
Norepinepherine (+)-bitartarate (NE), GBR12909 (1-2-[bis(4-
fluorophenyl)methoxy]ethyl)-4-(3-phenylpropyl)piperazine dihydrochloride), ascorbic 
acid, sodium chloride and Nafion perflurinated ion-exchange resin (5% solution) were 
purchased from Sigma (Milwaukee, WI). Sodium phosphate dibasic and sodium 
phosphate monobasic were purchased from Fischer Scientific (Fair Lawn, NJ). Urethane 
was purchased Sigma Life-Sciences (St. Louis, MO). Perchloric acid (70%) was purchased 
from Sigma-Aldrich (Milwaukee, WI). Sticky wax was purchased from FDJ/On time 
(Winter Park, FL).   
 
4.2.2 Animals  
For optimization of the NE clearance assay, male and female adult Sprague-
Dawley rats were obtained from the Division of Laboratory Animal Resources (DLAR) at 
University of Kentucky. These rats had history of operant conditioning or Pavlovian 
conditioning including acute morphine injection during adulthood. For the comorbidity 
experiments, drug naive male SHR, WKY and WIS rats at post natal day (P) 25 were 
obtained from Charles River Laboratories (Kingston, NY or Raleigh, NC). Rats were 
individually housed with free access to food and water (unless specified otherwise) in a 
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colony room maintained on a 12-hour light:dark cycle (lights on 07:00 hour) in the DLAR 
(University of Kentucky, Lexington, KY). Rat handling procedures were approved by the 
Institutional Animal Care and Use Committee at the University of Kentucky and were 
performed in accordance with the 1996 version of the National Institutes of Health 
Guide for the Care and Use of Laboratory Animals.    
 
4.2.3 Treatment 
Following three days of habituation, rats were administered MPH (1.5 mg/kg, 
p.o.) or vehicle (VEH, water, 1 ml/kg, p.o. using one oyster cracker) from P28 to P55. P28 
to P55 includes a time period from early adolescence to late adolescence (Doremus-
Fitzwater et al, 2010; Spear, 2000a), the typical age during which MPH is administered 
clinically. MPH or vehicle was administered from Monday to Friday to mimic the 
weekend medication holiday often practiced in the treatment of children and 
adolescents with ADHD (American Psychiatric Association., 2013a). 
The dose of MPH (1.5 mg/kg, p.o.) in outbred rats provides clinically-relevant 
plasma concentrations of MPH (Wargin et al, 1983), that increases extracellular 
dopamine and norepinephrine in the prefrontal cortex, but are below threshold for 
producing locomotor activation or increasing striatal dopamine concentration (Berridge 
et al, 2006; Kuczenski et al, 2002). In the SHR, MPH at 1.5 mg/kg, administered orally, 
through adolescence improves attention and behavioral flexibility (Harvey et al, 2013; 
Harvey et al, 2011; Kantak et al, 2008). From P56 onwards, the rats were individually 
housed with free access to food and water in a colony room until the electrochemical 
experiments were conducted. Between P77-91 rats were anesthetized with urethane 
(1.5 g/kg, i.p.) and placed on a stereotaxic frame (David Kopf Instruments, Tujunga, CA). 
Urethane was chosen because it did not alter DAT function in vivo (Weed, 2004). Body 
temperature was maintained at 34-35°C (the rat core temperature) (DeBow et al, 2003) 
using a heating pad coupled with a rectal thermometer (Harvard Apparatus, Holliston, 
 158 
 
MA). A longitudinal incision on the skin over the scalp and the skin was retracted. 
Bleeding was stopped by local application of epinephrine (5µg/ml, in saline) and a 
styptic-powder with benzocaine (Kwikstop, ARC Laboratories, Atlanta, GA). The excess 
epinephrine was washed away and the exposed skull was air-dried. A small hole was 
drilled in the skull over the posterior cortex for placement of an Ag/AgCl silver reference 
electrode. A larger hole was drilled in the skull overlying the mPFC and OFC and the dura 
removed to expose the cortex. The exposed brain was cleaned of the blood using sterile 
saline. The electrode micropipette assembly was lowered into the CG (+ 2.9mm AP, ± 
0.8 mm ML, -1.6 mm DV), PrL (dorsal +2.9 mm AP, ± 0.8 mm ML, -2.5 mm DV  and 
ventral +2.9 mm AP, ± 0.8 mm ML, -3.2 mm DV), IL (+2.9 mm AP, ± 0.8 mm ML, -4.2 mm 
DV) and LO (+3.2 mm AP, ± 2.6 mm ML, -4.2 mm DV). We chose to target the CG, PrL 
and the IL cortex subregions of mPFC separately because these regions have distinct 
intracortical and subcortical connections (Heidbreder and Groenewegen, 2003; Hoover 
and Vertes, 2007; Vertes, 2006). Specifically, the CG and the dorsal coordinate of PrL are 
thought to project to the motor and sensory cortices, while the ventral PrL and IL 
project to the limbic and associative areas. 
 
4.2.4 In vivo electrochemical measurements 
 
To assess NET function, NE clearance from the extracellular space was 
determined following local ejection of NE into the mPFC or the OFC in urethane 
anesthetized rats using previously published method for evaluation of dopamine 
clearance (Ram et al, 2004; Zhu et al, 2007) with a few modifications. The 
electrochemical recording electrodes (Center for Microelectrode Technology, Lexington, 
KY) consisted of a single carbon fiber (30 µm diameter) sealed in a glass capillary with 
150- to 200-µm length exposed. To enhance the selectivity of the electrode for the 
positively-charged catecholamines over the negatively-charged endogenous moieties 
(e.g., ascorbic acid), the exposed region of the carbon-fiber electrode was coated with 
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Nafion (10 swirls) and cured by heating at 200 °C for 5 min (Gerhardt et al, 1984). 
Electrodes were calibrated in vitro in 0.1 M phosphate buffer saline (pH 7.4) at room 
temperature and showed a linear current by concentration response for NE (2-8 µM) 
with correlation coefficients ranging from 0.98 to 1.00. A Fast16 mkIII system (Fast 
Analytical Sensing Technology, Quanteon, LLC, Nicholasville, KY) was used for electrode 
calibration. The range of selectivity for NE over ascorbic acid was 30 - 6800 to 1 
(n=9/group). The Nafion coating process described above was repeated until the 
selectivity for NE over ascorbic acid reached >30:1. The range of the limit of detection 
for the electrodes used in the current study was 0.01 – 0.51 µM (average = 0.11 µM). 
Each electrode was attached to a single-barrel micropipette (internal diameter of tip, 10 
– 20 µm) with sticky-wax such that the electrode and the micropipette were 100 – 400 
µm apart.  
Immediately before the lowering the recording assembly into the region of 
interest, the micropipette was filled with a non-saturating NE solution (100 or 200 µM) 
with ascorbic acid (100 µM) in saline (0.9% sodium chloride; Hospira Inc, IL) at pH 7.2-
7.4. Although, NET expression is greater than DAT in the prefrontal cortex, NE has a high 
affinity for DAT, and therefore NE may be non-specifically cleared by DAT (Moron et al, 
2002 ). Thus, clearance of NE by DAT was inhibited using a specific DAT inhibitor 
GBR12909 (Andersen, 1989) to isolate NET function. GBR12909 (50 nM) was used at a 
concentration ~15 times the Ki for inhibition of dopamine uptake at DAT (Matecka et al, 
1997a). For the optimization experiments, the concentration of NE (200 µM) selected 
was based on prior studies evaluating dopamine clearance in the mPFC using in vivo 
voltammetry (Zhu et al, 2007). For the comorbidity experiments, the concentration of 
NE (100 µM) was reduced to improve the resolution of the volume of NE applied. 
At 5 min intervals, NE solution was pressure-ejected (20-25 psi) from the 
micropipette using a Picospritzer II (General Valve Corporation, Fairfield, NJ). Volume of 
NE ejected (264 nl/mm) was measured using a reticule with a millimeter scale fitted in 
the eyepiece of a stereomicroscope (Leica Microsystems Inc., Buffalo Grove, IL) that was 
focused on the meniscus of the NE solution in the micropipette. Oxidation potential 
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(+0.55 V for 100 msec) and reduction potential (0 V for 100 msec) were applied 
alternately to produce a square-wave potential. Electrochemical measurements of 
oxidation and reduction currents were made at 5 Hz and averaged to 1 Hz using Fast16 
mkIII system. Stable baseline was defined as 3 consecutive signals for which the maximal 
amplitudes did not differ by ± 10 % following a constant ejection volume of NE solution. 
For each experiment 3 to 5 stable baseline signals were recorded.  
The optimization experiments (n=3-4/group) evaluated the effects of DAT 
inhibition on NE clearance in mPFC and OFC.  For these experiments, NE solution 
included GBR12909 (50 nM) for recording from the one hemisphere and did not include 
GBR12909 for recording in the opposite hemisphere. The sequence of the solution 
applied (with or without GBR12909) as well as brain hemisphere (left or right) was 
randomized between experiments.  
For the comorbidity experiments (n = 6-9/group), a single-barrel micropipette 
containing NE solution (100 µM) with GBR12909 (50 nM) and ascorbic acid (100 µM) in 
saline (pH 7.2-7.4) was attached to the nafion-coated carbon-fiber electrode was 
lowered into mPFC or OFC. NE clearance was recorded from the four regions of interest 
using a within-subject design. The sequence for recording from mPFC and OFC was 
randomized between experiments. Recording from the CG, PrL and IL subregions of 
mPFC were conducted in that sequence by increasing the depths at the same AV-ML 
coordinates. Following 3 to 5 stable baseline signals from one region of interest, the 
electrode-pipette assembly was moved ventral to the next region of interest. 
 
4.2.5 Verification of electrode placement 
Immediately after each recording session, brains were removed and flash-frozen 
using 2-methylbutane, stored at -80°C for histological evaluation of microelectrode 
recording tracks. Brains were sectioned along the coronal plane (20 µm sections) using a 
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Leica 1850 M cryostat (Nussloch, Germany) and sections were thaw mounted onto 
Fisher SuperFrost Plus® slides. The slides were stored overnight at room temperature 
under desiccation and stained with cresyl violet for determination of electrode 
placement. Probe placements were evaluated under a light microscope (1 X 
magnification) by observing the stained sections for tissue displacement (Fig 4.1). Only 
data from histologically confirmed microelectrode placements (Paxinos, 1991) were 
included in the subsequent analyses of results.  
 
4.2.6 Electrochemical data acquisition and statistical analysis 
Data were processed using a customized Matlab®-based analysis package, 
FastAnalysis Version 5.0 (Jason Burmeister Consulting, LLC). The primary parameters for 
evaluating NE clearance obtained from the data were peak amplitude (Amax, in µM), the 
first-order rate constant of the signal (k-1, in sec
-1, Liu et al, 2009) and the area under 
curve for the NE signal (AUC). NE signals were matched for amplitude (ranging from 0.6 
to 1.5 µM). Range of Amax was selected apriori to ensure that the Michelis-Menten 
kinetics properties for NET were not altered by excessive concentration of extracellular 
NE. The rationale for the range of the NE Amax selected were made based on prior 
studies evaluating DA clearance by DAT in striatum (Hebert et al, 1999a). Data from 
each brain region for each rat was averaged to one value. First order uptake rate was 
calculated as the product of peak amplitude and first order rate constant (Amax X k-1, in 
nM/sec) (Ram et al, 2004). Clearance was calculated by dividing the amount of NE 
applied by the area under curve (NEamt/AUC, in L/sec; Zhu et al, 2007). Space between 
the electrode and the micropipette was inferred from the ratio of the amount of NE 
applied through the micropipette and the peak amplitude of NE recorded at the 
electrode (NEamt/Amax, in L). The latter parameter is proposed in the current work based 
on the assumption that in a given brain region, NEamt/Amax will increase proportionately 
with the electrode-micropipette distance. 
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Statistical analyses were conducted using SPSS Statistics Version 19 (SPSS Inc., 
IBM Company, Armonk, NY). Data are reported as mean ± S.E.M. and n represents the 
number of rats per group.  For the optimization experiments, the dependent variables 
were compared using paired t-tests. For the comorbidity experiments, all the dependent 
variables, except for clearance, were compared using two-factor ANOVA (strain X 
treatment), and followed by Bonferroni’s post-hoc comparisons. Outliers were omitted 
using the Grubbs test (GraphPad; http://www.graphpad.com/quickcalcs/Grubbs1.cfm). 
For comparing clearance in the comorbidity experiments two-factor ANCOVA were used 
with strain and treatment as between-subject factors and space between electrode and 
micropipette as the covariate. Significance was set at p < 0.05. Significant interactions 
were probed further using one-factor ANCOVAs to evaluate the effects of MPH 
treatment for individual strain. 
 
4.3 Results 
4.3.1 Histological assessment of electrode placements in mPFC and OFC 
Examples of electrode placement based on tissue-displacement in mPFC and OFC 
are presented in Fig 4.1. Approximate location of the electrode tips in the LO and IL are 
presented in Fig 4.1 middle and bottom panels, respectively. For LO, localization of 
electrodes was between +3.2 to + 4.0 mm anterior to bregma and between 2.4 to 2.7 
mm lateral to bregma. For mPFC, electrode localization was between +2.7 to +3.2 mm 
anterior to bregma and between 0.5 and 1.0 mm lateral to bregma. One rat was 
excluded from the mPFC analyses due to microelectrode placement error, because the 
track marks were outside the range for ML co-ordinates (at + 1.3 mm ML, and not within 
± 1.0 mm ML). 
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4.3.2 Optimization experiments 
No differences in  amount of NE applied and Amax were found between the 
hemispheres in which NE was applied alone and in which NE was applied with 
GBR12909 (50 nM) (Table 1). Average volume of solution that was pressure ejected into 
the brain was 28.6 ± 2.14 nL. In CG, dorsal PrL, ventral PrL, IL and LO subregions, no 
differences were found between the hemispheres in which NE was applied alone and in 
which NE was applied with GBR12909 for either uptake rate or clearance of NE (Fig 4.2, 
top panel and bottom panel, respectively). 
 
4.3.3 Comorbidity experiments 
No differences were found between MPH and VEH administered SHR, WKY and 
WIS in the amount of NE applied and in the Amax (Table 3) for CG, dorsal PrL, ventral PrL, 
IL and LO subregions. The average volume of solution that was pressure ejected into the 
brain regions for all the experiments conducted was 47.8 ± 4.61 nL.  
No differences were found between MPH and VEH administered SHR, WKY and 
WIS in the first order uptake rate of NE in  CG, dorsal PrL, ventral PrL and IL (Fig 4.3). In 
contrast, a strain x treatment interaction was obtained for NE clearance in the IL after 
accounting for the between-experiment variation in electrode-micropipette space 
(Finteraction[2,40] = 5.10, p < 0.05; Fcovariate [1,40] = 144, p < 0.0001; Fig 4.4). Post-
hoc comparison revealed that MPH treatment during adolescence decreased NE 
clearance in the IL cortex of WIS. For the other subregions of mPFC, no effect of MPH 
treatment, strain and interaction were obtained for NE clearance, but a significant effect 
of experimental variation in the electrode-micropipette distance was obtained in CG 
(see Table 4 for statistics). 
For uptake rate in the LO, a significant strain X treatment interaction was 
obtained (Finteraction[2,45] = 4.38, p < 0.05; Fig 4.5). Post-hoc comparisons revealed 
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that the uptake rate for vehicle administered SHR was greater than vehicle administered 
WKY and WIS , and MPH treatment during adolescence reduced the uptake rate in SHR. 
Further, the uptake rate of MPH-treated SHR was not different from MPH-treated WKY 
and WIS. In contrast, no difference was obtained for NE clearance in LO after accounting 
for the between-experiment variation in the electrode-micropipette space 
(Finteraction[2,44] = 1.33, p >0.05; Fcovariate [1,44] = 113, p < 0.0001). However, slopes 
for NE clearance in the LO against volume of brain between electrode-micropipette 
assembly indicated a trend in the same direction as for uptake rate (Fig 4.6). 
 
 
4.4 Discussion 
The optimization experiments revealed that inhibition of DAT by GBR12909 in 
mPFC and OFC subregions did not alter first order uptake rate of NE or NE clearance. 
These results are in agreement with previous findings that GBR12909 did not inhibit 
dopamine uptake into frontal cortical synaptosomes of mice (Moron et al, 2002). 
Compared to WKY and WIS, the uptake rate of NE in the LO subregion of OFC was 
greater in SHR, suggesting that NET function was elevated in SHR. Further, MPH 
treatment during adolescence followed by cessation of treatment during adulthood 
decreased the uptake rate of NE in LO of SHR, such that uptake rate in MPH-treated SHR 
was not different from MPH-treated WKY and WIS rats. Also, MPH treatment during 
adolescence decreased NE clearance in the IL-PFC of outbred WIS rats. No other effects 
of strain or treatment were obtained in either NE uptake rate or in NE clearance. These 
results suggest that increased NET function in the LO may underlie the behavioral 
deficits in SHR and that MPH treatment normalized LO NET function and that this 
normalization persisted long after discontinuation of MPH treatment.  
Although, MPH treatment in adolescent SHR decreased the slope of the linear 
regression for NE clearance from the LO from 0.05 to 0.01 (Fig 4.6) suggesting a 
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decrease in NET function, statistical significance was not reached. In contrast, results for 
the IL-PFC reveal that NE clearance, but not uptake rate of NE in outbred WIS rats was 
significantly decreased by MPH treatment during adolescence. Taken together, these 
results suggest that although uptake rate and clearance of NE both indicate NET 
function, the current study found the two measures to be differentially sensitive to the 
effects of MPH between LO and IL-PFC. These differences may be explained partially by 
methodological consideration. Uptake rate is limited because it does not account for the 
amount of NE applied via the micropipette; amount of NE applied alters Amax which is 
used to calculate uptake rate (Zhu et al, 2007). In contrast, clearance is a classical 
pharmacokinetic parameter providing the efficiency of NE removal by NET; theoretically, 
clearance is expected to a constant value independent of the amount of NE applied (Zhu 
et al, 2007). However, in the current study, the between-experiment variation in the 
volume (or space) between the microelectrode and the micropipette altered the 
observed clearance of NE (evidenced by significant effect of covariate). Therefore, 
clearance was compared between treatment and strains with the electrode-pipette 
volume as a covariate. The lack of statistical significance of strain and treatment 
interaction for clearance of NE in the LO may be explained by the relatively poor fit of 
the regression to the data (R2; Fig 4.6). Thus, the interpretation of the results in this 
brain region is limited by the extent to which NE uptake rate represents NET function. 
Based on uptake rate of NE, SHR have a hypofunctional noradrenergic system in 
the OFC (specifically, the LO), which may underlie some of the behavioral deficits in SHR 
such as impaired reversal learning, strategy shifting, working memory and attention 
(Harvey et al, 2013; Kantak et al, 2008; Sagvolden, 2006). These behavioral deficits may 
be mediated, in part, by weakened OFC projections to the locus coeruleus and ventral 
tegmental area which modulate neuronal firing of noradrenergic and dopaminergic 
neurons, respectively (Aston-Jones et al, 2005; Chandler et al, 2013a). MPH exerts its 
therapeutic effects by increasing extracellular NE in the prefrontal cortex and thereby, 
increasing α2A receptor activation (Berridge et al, 2006; Wang et al, 2007). The current 
results indicate that chronic MPH treatment during adolescence normalizes the elevated 
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NET function in the SHR that persists long after treatment discontinuation. Clinically, 
MPH treatment is often discontinued because several ADHD symptoms diminish with 
age (Faraone et al, 2006; McCarthy et al, 2009). The current results suggest that MPH 
treatment during adolescence may contribute to the observed age-related reduction in 
ADHD symptoms. 
Therapeutically relevant MPH treatment in adolescent SHR followed by 
treatment discontinuation increased cocaine self-administration during adulthood 
(Harvey et al, 2011). In contrast, MPH treatment during adolescence reduced the 
rewarding effects of cocaine in adult SHR as evidenced by rightward shifts in the dose-
response curves for cocaine-induced conditioned place preference (Augustyniak et al, 
2006). The latter study did not find a change in cocaine-evoked dopamine release in 
nucleus accumbens, which is known to be associated with the reinforcing effects of 
cocaine (Dewit et al, 1977; Ritz et al, 1987). These apparent disparities between the 
rewarding and the reinforcing effects of cocaine can be explained by the dichotomy of 
the role of NE neurotransmission between these behaviors. Specifically, NE 
neurotransmission is thought to be engaged by conditioned appetitive (as well as 
aversive) stimuli, but is not the primary mediator of the reinforcing effects of drugs of 
abuse (Feenstra et al, 1999; Mingote et al, 2004; Ritz et al, 1987). Previous studies 
suggest that in the mPFC, NE depletion inhibits cocaine conditioned place preference, 
but inhibition of α1 receptors does not alter cocaine self-administration (Ecke et al, 
2012; Ventura et al, 2007). However, the implications of hypofunctional NE in the OFC, 
and normalization of NE uptake by MPH treatment on cocaine self-administration 
behavior in SHR are not well understood.  
In the prefrontal cortex, NET function contributes to dopamine clearance (Moron 
et al, 2002). Thus, elevated NET function in the SHR may contribute to hypo-
dopaminergic state in the LO. Mechanistically, impulsivity is associated with reduced 
dopamine transmission in the OFC (Winstanley et al, 2010b; Zeeb et al, 2010). Increased 
impulsivity, in turn, is associated with increased cocaine self-administration (Dalley et al, 
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2007; Dalley et al, 2008). Taken together, the elevated NET function in the LO observed 
in the current study may contribute to the increased impulsivity (Chapter 7) and 
increased cocaine self-administration (Harvey et al, 2011; Somkuwar et al, 2013b); see 
Chapter 1) in adult SHR compared to both WKY and WIS. 
Impulsivity is a broad psychological construct that includes impulsive decision 
making, defined by increased choice of a smaller immediate reward over a larger 
delayed reward, as well as response inhibition deficit, defined by a reduced capacity to 
inhibit a prepotent response (Broos et al, 2012; Evenden, 1999b). Chronic NET inhibition 
during adolescence as well as increased dopamine receptor activation in the OFC 
decreased impulsive decision making (Mobini et al, 2002; Pardey et al, 2013; Sun et al, 
2012). However, neither chronic NET inhibition during adolescence nor activation of 
dopaminergic receptors in the OFC altered response inhibition capacity in rats (Sun et al, 
2012; Winstanley et al, 2010b). Alternate neurochemical mechanisms like increased DAT 
function in the mPFC and decreased mPFC dopamine (Sokolowski and Salamone, 1994; 
Somkuwar et al, 2013a) may underlie the increased response inhibition deficit in MPH-
treated SHR (Chapter 7). Initiation of drug taking behavior (rate of acquisition of self-
administration) is associated with increased response inhibition deficit (Diergaarde et al, 
2008). However, maintenance of drug-taking behavior is associated with both impulsive 
decision making and response inhibition deficits. Although normalization of NET 
function in the LO of MPH-treated SHR may be partially protective against impulsive 
decision making, MPH treatment is not protective against cocaine abuse liability 
because of the increased in response inhibition deficit (Chapter 7). 
In contrast the SHR, MPH treatment in adolescent WIS decreased acquisition of 
cocaine self-administration (Harvey et al, 2011). In terms of neurochemistry, MPH 
treatment during adolescence increased DAT function in mPFC of SHR, but not WIS 
(Somkuwar et al, 2013a). In contrast, only in WIS, NET function was decreased in the IL 
sub-region of mPFC by MPH treatment during adolescence, suggesting a localized 
increase in dopaminergic signaling in WIS IL-PFC (Moron et al, 2002). Currently, no 
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empirical evidence is available to support the involvement of IL-PFC in acquisition of 
cocaine self-administration. However, IL-PFC sends projections to the nucleus 
accumbens shell and shares reciprocal innervations with the amygdala (McDonald, 
1996). This particular circuitry has been implicated in extinction learning in both fear 
conditioning as well as cocaine-seeking (Peters et al, 2008; Quirk and Mueller, 2008). 
With respect to cocaine-seeking, reversible inactivation of IL-PFC induced reinstatement 
of cocaine-seeking, while activation of IL-PFC (via AMPA infusion) attenuated cocaine-
induced reinstatement (Peters et al, 2008). Further, disconnection between IL-PFC and 
nucleus accumbens shell induced reinstatement of cocaine-seeking (Peters et al, 2008). 
Therefore, IL-PFC is essential for expression of extinction learning as well as 
consolidation of extinction of cocaine-seeking (LaLumiere et al, 2010). These may be 
indirect mechanisms that contribute to the protective effects of MPH treatment in 
subjects without an ADHD phenotype. Additionally, the PL-PFC is involved in 
reinstatement of responding for cues associated with cocaine (Ball and Slane, 2012; 
McLaughlin and See, 2003). NET function was not altered in the PL-PFC or in the IL-PFC 
of MPH-treated SHR, which support for the observation that MPH treatment during 
adolescence does not alter extinction of cocaine self-administration or cocaine cue-
reactivity in SHR (Fig 8.5; Jordan et al. submitted). Taken together, NET function in the 
mPFC subregions are not associated with the previously observed increased cocaine 
self-administration in SHR (Harvey et al, 2011). 
In conclusion, the current study suggests that increased NET function in the LO 
underlies behavioral deficits in SHR, and chronic MPH treatment during adolescence 
normalized NET function that persisted into adulthood. Although, MPH-treatment 
mediated decreased NET function may be beneficial for reducing some behavioral 
deficits in SHR, MPH-treatment did not confer protection against increased cocaine self-
administration. Thus, alternate therapeutic strategies need to be explored for treating 
adolescents with ADHD in whom increased cocaine abuse liability is a concern. 
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4.5 Tables 
Table 4.1 Maximum amplitude of NE (Amax) and amount of NE applied for the 
optimization experiment 
Maximum amplitude of NE (Amax) and amount of NE applied to cingulate gyrus (CG), 
dorsal and ventral prelimbic cortex (PrL), infralimbic cortex (IL) and lateral orbitofrontal 
cortex (LO) for the optimization experiments. Norepinephrine (NE, 200 µM) was applied 
alone (NE alone) or with GBR 12909 (50 nM; NE + GBR) in these brain regions on 
opposite hemispheres of the brain of individual rats. n = 3-4/group. 
 Amax (µM) Amount of NE applied (pmol) 
 NE alone NE + GBR NE alone NE + GBR 
CG 0.67 ± 0.09a 0.79 ± 0.17 7.2 ± 2.6 8.1 ± 2.9 
Dorsal PrL 1.1 ± 0.04 0.80 ± 0.04 8.3 ± 1.6 4.5 ± 1.1 
Ventral PrL 1.0 ± 0.25 0.83 ± 0.11 4.0 ± 1.4 3.4 ± 1.1 
IL 0.80 ± 0.21 0.99 ± 0.10 2.2 ± 0.86 2.3 ± 0.61 
LO 1.3 ± 0.28 1.7 ± 0.30 6.1 ± 1.8 11 ± 2.2 
a Values are mean ± S.E.M. 
 
  
Table 4.2 Amount of NE applied and maximum amplitude of NE (Amax) for the comorbidity experiment 
Amount of NE applied and maximum amplitude of NE (Amax)  for cingulate gyrus (CG), dorsal and ventral prelimbic cortex 
(PrL), infralimbic cortex (IL) and lateral orbitofrontal cortex (LO) of the adult Spontaneously Hypertensive Rat (SHR), Wistar-
Kyoto (WKY) and Wistar (WIS) rats that were administered methylphenidate (MPH; 1.5 mg/kg, p.o.) or vehicle (VEH) during 
adolescence. Norepinephrine (NE, 100 µM) was applied with GBR 12909 (50 nM) in these brain regions for individual rats 
using a within-subject design. n = 7–9/group for CG, dorsal and ventral PrL and LO; n = 6–8/group for IL. 
  CG Dorsal PrL Ventral PrL IL LO 
NE applied SHR-VEH 7.2 ± 2.6a 3.7 ± 0.90 3.2 ± 1.2 2.3 ± 0.61 7.4 ± 5.0 
(in pmol) SHR-MPH 2.8 ± 1.3 7.6 ± 5.7 2.2 ± 0.86 1.8 ± 0.81 4.9 ± 2.6 
 WKY-VEH 4.4 ± 1.3 4.4 ± 0.84 7.3 ± 3.0 4.1 ± 1.4 5.6 ± 2.0 
 WKY-MPH 8.1 ± 2.9 3.4 ± 1.1 4.5 ± 1.6 3.2 ± 1.1 4.0 ± 1.8 
 WIS-VEH 10 ± 7.0 4.0 ± 1.4 8.3 ± 4.5 5.0 ± 3.1 4.8 ± 1.0 
 WIS-MPH 4.1 ± 2.9 2.3 ± 0.82 4.1 ± 1.2 6.1 ± 2.2 4.3 ± 1.9 
Amax SHR-VEH 0.57 ± 0.11 0.68 ± 0.13 0.69 ± 0.13 0.67 ± 0.09 0.89 ± 0.15 
(in µM) SHR-MPH 0.74 ± 0.13 0.57 ± 0.07 0.68 ± 0.10 0.83 ± 0.17 0.87 ± 0.16 
 WKY-VEH 1.2 ± 0.33 0.81 ± 0.23 0.97 ± 0.37 0.65 ± 0.12 0.69 ± 0.15 
 WKY-MPH 0.67 ± 0.12 0.81 ± 1.4 0.86 ± 0.13 0.72 ± 0.11 0.62 ± 0.11 
 WIS-VEH 1.2 ± 0.28 1.2 ± 0.23 1.3 ± 0.25 1.2 ± 0.38 0.61 ± 0.09 
 WIS-MPH 1.5 ± 0.52 0.96 ± 0.25 0.73 ± 0.12 0.71 ± 0.07 0.95 ± 0.24 
a Values are mean ± S.E.M. 
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Table 4.3 Clearance of NE in cingulate gyrus (CG), and dorsal and ventral prelimbic cortex (PrL) 
Linear regression of clearance for NE (y) by Volume (or space between micropipette and electrode; x) and goodness-of-fit (R2) 
for cingulate gyrus (CG), and dorsal and ventral prelimbic cortex (PrL) of the adult Spontaneously Hypertensive Rat (SHR), 
Wistar-Kyoto (WKY) and Wistar (WIS) rats that were administered methylphenidate (MPH; 1.5 mg/kg, p.o.) or vehicle (VEH) 
during adolescence. Norepinephrine (NE, 100 µM) was applied with GBR 12909 (50 nM) in these brain regions for individual 
rats using a within-subject design. Clearance was calculated as amount of NE applied through the micropipette divided by the 
area-under-curve for the NE signal at the carbon-fiber electrode. Volume was calculated as amount of NE applied through 
the micropipette divided by the maximum amplitude of NE detected at the carbon-fiber electrode. n = 7-9/group for CG, 
dorsal and ventral PrL. 
  SHR WKY WIS F-statistics 
  Regression R2 Regression R2 Regression R2  
CG VEH y = 0.02x - 0.08 0.86 y = 0.02x - 0.01 0.99 y = 0.02x + 0.02 0.98 Finteraction[2,45]=0.74 
 MPH y = 0.01x + 0.01 0.98 y = 0.02x - 0.04 0.98 y = 0.01x + 0.00 1.0 Fcovariate[1,45]=400* 
Dorsal 
PrL 
VEH y = 0.01x + 0.01 0.94 y = 0.01x - 0.00 0.86 y = 0.01x + 0.02 0.70 Finteraction[2,42]=0.39 
MPH y = 0.02x - 0.01 0.70 y = 0.01x + 0.01 0.93 y = 0.02x - 0.02 0.95 Fcovariate[1,42]=200* 
Ventral 
PrL 
VEH y = 0.01x + 0.01 0.97 y = 0.01x + 0.00 0.99 y = 0.01x + 0.01 0.95 Finteraction[2,46]=3.1 
MPH y = 0.01x + 0.00 0.93 y = 0.01x + 0.00 0.92 y = 0.01x - 0.00 0.93 Fcovariate[1,46]=650* 
* p < 0.0001
1
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4.6 Figures 
 
Figure 4.1 Electrode placement 
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Fig 4.1  Neuroanatomical localization of electrodes. The regions of interest for 
evaluating NET function were cingulate gyrus (CG), dorsal and ventral prelimbic cortex 
(PrL), infralimbic cortex (IL) and lateral orbitofrontal cortex (LO; Top panel). 
Dorsoventral coordinates are presented (in mm) from the surface of the rat brain 
(Paxinos, 1991). The placement of the tip of carbon-fiber electrodes within the rodent 
LO (middle panel) and IL (bottom panel). The figure on the left side is a representative of 
the actual track-marks from a cresyl violet stained 20 µm slice for LO and mPFC (middle 
and bottom panels, respectively). The diagram on the right shows the approximate 
location of the tip of the carbon-fiber microelectrodes in the LO and the IL PFC (middle 
and bottom panels, respectively).  
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Figure 4.2 Uptake rate and clearance of NE for the optimization experiments 
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Fig 4.2   Optimization of norepinephrine transporter (NET) function. NET function was 
evaluated using uptake rate (A) and clearance (B) of norepinephrine (NE; 200 µM) 
applied locally to cingulate gyrus (CG), dorsal and ventral prelimbic cortex (PrL), 
infralimbic cortex (IL) and lateral orbitofrontal cortex (LO). For all the brain regions 
evaluated, NE was applied alone (NE alone) or with GBR 12909 (50 nM; NE + GBR) on 
opposite hemispheres of the brain of individual rats. Uptake rate (µM/sec; mean ± 
S.E.M.) as well as clearance (L/sec; mean ± S.E.M.) did not differ between hemispheres. 
n = 3-4/group.  
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Figure 4.3 Uptake rate of NE in the subregions of mPFC for the comorbidity 
experiments 
CG
U
p
ta
k
e
 r
a
te
; 
A
m
a
x
X
 k
-1
(n
M
/s
e
c
)
WIS WKY SHR
0.0
0.5
1.0
1.5
VEH
MPH
dorsal PrL
U
p
ta
k
e
 r
a
te
; 
A
m
a
x
X
 k
-1
(n
M
/s
e
c
)
WIS WKY SHR
0.0
0.5
1.0
1.5
ventral PrL
U
p
ta
k
e
 r
a
te
; 
A
m
a
x
X
 k
-1
(n
M
/s
e
c
)
WIS WKY SHR
0.0
0.5
1.0
1.5
IL
U
p
ta
k
e
 r
a
te
; 
A
m
a
x
X
 k
-1
(n
M
/s
e
c
)
WIS WKY SHR
0.0
0.5
1.0
1.5
A
DC
B
 
Fig 4.3   Uptake rate of norepinephrine (NE) in the mPFC subregions of the adult 
Spontaneously Hypertensive Rat (SHR), Wistar-Kyoto (WKY) and Wistar (WIS) rats that 
were administered methylphenidate (MPH) or vehicle (VEH) during adolescence. NE 
(100 µM; GBR 12909 50 nM) was applied locally to cingulate gyrus (CG; A), dorsal and 
ventral prelimbic cortex (PrL; B and C, respectively) and infralimbic cortex (IL; D) of 
individual rats using a within-subject design. Uptake rate was mean ± S.E.M. of the 
product of the maximum amplitude of the NE signal at the electrode (Amax) and the first 
order fitting of the signal decay (k-1) for group. n = 7-9/group for CG, dorsal and ventral 
PrL; n = 6 – 8/group for IL. 
  
  
Figure 4.4 Clearance of NE in the IL-PFC for the comorbidity experiments 
 
Fig 4.4  Clearance of NE in the infralimbic cortex (IL) of the adult Spontaneously Hypertensive Rat (SHR), Wistar-Kyoto (WKY) 
and Wistar (WIS) rats that were administered methylphenidate (MPH) or vehicle (VEH) during adolescence. Clearance was 
calculated as amount of NE (100 µM, with GBR 12909, 50 nM) applied through the micropipette divided by the area-under-
curve for the NE signal at the carbon-fiber electrode. Volume (or space between electrode and micropipette) calculated as 
amount of NE applied through the micropipette divided by the maximum amplitude of NE detected at the carbon-fiber 
electrode. n = 6 – 8/group; linear regression of clearance (y) as a function of volume (x) and the goodness-of-fit (R2) of the 
regressions are presented. Clearance of NE from the IL of MPH-treated WIS was significantly different from the VEH control. 
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Figure 4.5 Uptake rate of NE in the lateral OFC for the comorbidity experiments 
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Fig 4.5  Uptake rate of norepinephrine (NE) in the lateral orbitofrontal cortex (LO) of the 
adult Spontaneously Hypertensive Rat (SHR), Wistar-Kyoto (WKY) and Wistar (WIS) rats 
that were administered methylphenidate (MPH) or vehicle (VEH) during adolescence. NE 
(100 µM; GBR 12909 50 nM) was applied locally to LO of individual. Uptake rate was 
mean ± S.E.M. of the product of the maximum amplitude of the NE signal at the 
electrode (Amax) and the first order fitting of the signal decay (k-1) for group.  n = 8-
9/group; * p < 0.05 different from the respective vehicle control; # p < 0.05 different 
from the VEH administered WKY and WIS.
  
Figure 4.6 Clearance of NE in the lateral OFC for the comorbidity experiments 
 
Fig 4.6   Clearance of NE in the lateral orbitofrontal cortex (LO) of the adult Spontaneously Hypertensive Rat (SHR), Wistar-
Kyoto (WKY) and Wistar (WIS) rats that were administered methylphenidate (MPH) or vehicle (VEH) during adolescence. 
Clearance was calculated as amount of NE (100 µM, with GBR 12909, 50 nM) applied through the micropipette divided by the 
area-under-curve for the NE signal at the carbon-fiber electrode. Volume was calculated as amount of NE applied through 
the micropipette divided by the maximum amplitude of NE detected at the carbon-fiber electrode. n = 8-9/group; linear 
regression of clearance (y) as a function of volume (x) and the goodness-of-fit (R2) of the regressions are presented. 
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5 CHAPTER FIVE 
 
 
Rat strain differences, but not prior methylphenidate treatment, influences 
sensitization to cocaine during adulthood. 
 
5.1 Introduction 
 
Individuals with attention deficit/hyperactivity disorder (ADHD) are more likely 
to develop cocaine addiction as adults compared to demographically matched controls 
(Levin et al, 1999; Wilens et al, 1998b). Clinical studies suggest that the age of initiation 
of methylphenidate (MPH) treatment in ADHD may influence the outcome of later 
cocaine abuse, such that treatment initiated in childhood may be protective against 
future cocaine addiction (Fischer et al, 2003; Wilens et al, 2003) or not alter cocaine 
abuse liability (Molina et al, 2013), while treatment initiated in adolescence may 
increase cocaine abuse liability (Lambert et al, 1998; Mannuzza et al, 2008). 
 Preclinical studies using outbred rats indicate that MPH treatment in juvenile 
(postnatal day 20-35; P20-35) rats decreases conditioned place preference to cocaine 
during adulthood (Andersen et al, 2002). In contrast, MPH administered to adolescent 
rats increased acquisition rate of cocaine self-administration (Brandon et al, 2001) and 
progressive ratio (PR) breakpoints for cocaine self-administration (Crawford et al, 2011) 
assessed during adulthood. 
Studies employing a widely accepted animal model of ADHD, the spontaneously 
hypertensive rats (Russell et al, 2005), indicate that cocaine self-administration is 
greater in SHR than controls Wistar-Kyoto (WKY; inbred) and Wistar (WIS; outbred) rats 
(Harvey et al, 2011; Somkuwar et al, 2013b). Further, MPH treatment during 
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adolescence improved learning in a visual discrimination task in SHR; however, 
discontinuation of MPH treatment in adulthood enhanced cocaine self-administration in 
SHR compared to vehicle-administered SHR and MPH-treated WKY and WIS (Harvey et 
al, 2011). In the latter study, during adulthood, MPH-treated SHRs acquired cocaine self-
administration behavior more rapidly, maintained greater responding and intake across 
a range of cocaine doses, and exhibited greater PR breakpoints (motivation) for cocaine 
compared to the control groups.  Using a comparable MPH treatment regimen, 
dopamine transporter (DAT) function was increased in the medial prefrontal cortex 
(mPFC) of adult SHR compared to vehicle control and MPH-treated WKY and WIS 
(Somkuwar et al, 2013a). Taken together, cortical dopamine regulation may contribute 
to the enhanced cocaine abuse vulnerability following MPH treatment.  
Dopamine in the mPFC is considered to exert inhibitory control over dopamine 
release in the nucleus accumbens (Beyer and Steketee, 1999), thereby, modulating 
reward and reinforcement of natural reinforcers and drugs of abuse (Tzschentke, 2000; 
Tzschentke and Schmidt, 2000).  Dopamine depletion, via 6-hydroxydopamine lesions in 
mPFC increases cocaine self-administration under fixed-ratio schedules (Schenk et al, 
1991). Another behavioral effect of cocaine mediated by accumbal dopaminergic 
function is hyperactivity, or increase in locomotor activity following cocaine injection 
(Cailhol and Mormede, 1999; Frankowska et al, 2009; Pulvirenti et al, 1989). Dopamine 
depletion in the mPFC enhances cocaine-induced hyperactivity in the open-field (Beyer 
et al, 1999). Further, repeated cocaine exposure progressively enhances cocaine-
induced hyperactivity, this is termed behavioral sensitization (Dumars et al, 1988). 
Behavioral sensitization is associated with a decrease in prefrontal cortical dopaminergic 
function (Liu et al, 2011). Another feature of sensitization is that the context in which 
cocaine is repeatedly administered gets integrated into the sensitization process (Fraioli 
et al, 1999; Robinson et al, 1998). The context acquires incentive salience and 
eventually, can elicit a conditioned response (Robinson et al, 2000, 2001). This process is 
cocaine conditioning, and accumbal dopamine, in part, modulates this effect (Berridge 
and Robinson, 1998). Therefore, increased mPFC DAT function observed in adult SHR 
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following MPH treatment during adolescence may increase sensitivity of SHR to cocaine, 
which in turn, may underlie the previously observed enhanced cocaine self-
administration in SHR (Harvey et al, 2011; Somkuwar et al, 2013b). Further, the 
enhancement in cocaine-induced hyperactivity, cocaine sensitization and conditioned 
response to the cocaine-paired context may serve as surrogates for identifying 
enhanced sensitivity to cocaine in MPH-treated SHRs.   
The current study aims to determine whether MPH treatment during 
adolescence alters sensitivity to cocaine in adult SHR, WKY and WIS. The hypothesis 
tested herein is that MPH treatment during adolescence leads to enhanced cocaine-
induced hyperactivity in adult SHR and augments sensitization to repeated cocaine 
injections in SHR compared to vehicle-administered SHR and MPH-treated WKY and 
WIS.  
 
5.2 Methods 
5.2.1 Drugs 
(±)-Methylphenidate was purchased from Sigma-Aldrich (St. Louis, MO). MPH 
was dissolved in water to obtain concentrations of 1.5 mg/ml (prepared daily) and 
injected into oyster crackers (Kantak et al, 2008) to attain a dose of 1.5 mg/kg for oral 
administration. Cocaine HCl was a gift from the National Institute on Drug Abuse 
(Bethesda, MD, USA) and was dissolved in sterile saline (NaCl, 0.9% w/v). 
 
5.2.2 Animals and Treatments 
Male SHR and WKY at P25 were obtained from Charles River Laboratories 
(Kingston, NY) and male WIS rats at P25 were obtained from Charles River Laboratories 
(Raleigh, NC). The locations listed above are where Charles River Laboratories maintain 
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the breeding colony for the specific strains employed in this study. Rats were 
individually housed with free access to food and water in a colony room maintained on 
a 12-hour light:dark cycle (lights on 07:00 hour) in the Division of Laboratory Animal 
Resources (University of Kentucky, Lexington, KY). Following three days of habituation, 
these rats were orally administered MPH (1.5 mg/kg, p.o.) or vehicle (VEH, water, 1 
ml/kg, p.o. using one oyster cracker) from P28 to P55. This dose of MPH (1.5 mg/kg, 
p.o.) produces clinically-relevant plasma concentrations of MPH (Wargin et al, 1983), 
that increase extracellular dopamine and norepinephrine in prefrontal cortex, but are 
below threshold for producing locomotor activation or increasing striatal dopamine 
concentration (Berridge et al, 2006; Kuczenski et al, 2002). This MPH dose has been 
shown to improve attention and behavioral flexibility in SHRs (Harvey et al, 2013; 
Harvey et al, 2011). P28 to P55 includes a time period from early adolescence to late 
adolescence (Doremus-Fitzwater et al, 2010; Spear, 2000a), the typical age during which 
MPH is administered clinically. Rat handling procedures were approved by the 
Institutional Animal Care and Use Committee at the University of Kentucky and were 
performed in accordance with the 1996 version of the National Institutes of Health 
Guide for the Care and Use of Laboratory Animals.   
 
5.2.3 Acute cocaine-induced hyperactivity 
Typically, when exposed to a novel environment, rats express hyperactivity (Ho 
et al, 2000; Laviola and Adriani, 1998). The novelty-induced hyperactivity decreases 
following repeated exposure to the same environment, which is termed habituation 
(Green et al, 2003a). During adulthood (P134), SHR, WKY and WIS rats were habituated 
for 3 days in the acrylic open-field locomotor chambers (42 × 42 × 30 cm), each with a 
16 × 16 grid of photobeam sensors. Locomotor activity was recorded with a monitoring 
system (AccuScan Instruments Inc., Columbus, OH) and was expressed as total number 
of horizontal beam breaks recorded during each 1-hour session. To determine cocaine-
induced hyperactivity, rats were administered a single injection cocaine (10 mg/kg, i.p.) 
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or saline (1ml/kg, i.p.) in a randomized manner and locomotor activity was recorded for 
an hour. The dose of cocaine chosen has been shown to induce locomotor sensitization 
in adult SHR, WKY and WIS (Cailhol et al, 1999; Frankowska et al, 2009; Frantz et al, 
2007). 
 
5.2.4 Sensitization to repeated cocaine administration 
To evaluate induction of sensitization to repeated cocaine, rats were 
administered cocaine (10 mg/kg, i.p.) and allowed to explore the locomotor chambers 
for 1-hour daily for 10 consecutive days. Upon completion of the 10-day repeated 
treatment phase, rats remained undisturbed in their home cages for a 14-day cocaine-
free period. During this period, rats were not given access to the locomotor chambers.  
On the 15th day, expression of sensitization to cocaine was tested with cocaine, 
0, 5, 10 and 20 mg/kg, i.p. in an ascending dose order within a single session. The half-
life of cocaine in rats is 30 minutes (Pan and Hedaya, 1999). Thus, to obtain the desired 
plasma levels of cocaine at each dose, the following cumulative dosing regimen was 
employed: saline, cocaine 5 mg/kg, 7.5 mg/kg, and 15 mg/kg, i.p. injected at 30-min 
intervals. Following each injection, locomotor activity was monitored for 30 min.  
 
5.2.5 Statistical Analysis 
Outcomes were analyzed using SPSS Statistics Version 19 (SPSS Inc., IBM 
Company, Armonk, NY). Data are reported as mean ± S.E.M, number of horizontal beam 
breaks during 1 hour for cocaine-induced hyperactivity and for the induction of 
sensitization to cocaine. For the expression of sensitization assay, mean ± S.E.M. of the 
number of horizontal beam breaks during the 30-min period after each dose of cocaine 
are reported; n represents the number of rats per group.  Mauchly’s tests of Sphericity 
 184 
 
were employed to validate repeated-measures ANOVA. When the sphericity assumption 
was violated, Greenhouse-Geisser correction was used to determine within-subject 
effects. Data were analyzed using 3-factor ANOVAs with adolescent treatment (2 levels) 
and strain (3 levels) as between-subject factors. Cocaine dose served as within-subject 
factor for hyperactivity (2 levels) and expression of sensitization (4 levels) assays, and 
session number was a within-subject factor in the induction of sensitization assay (10 
levels). Significant main effects and interactions were evaluated using appropriate post-
hoc analyses.  
Linear mixed model analyses were conducted (Verbeke et al, 2000) as a 
complementary approach for evaluating induction of sensitization using session as a 
continuous variable, and not as a discreet variable as in the 3-factor ANOVA. Significant 
session X strain and session x treatment interactions were further probed using linear 
regression analyses, whereby deviation from zero served as an estimate for the 
induction of sensitization. A significant strain x treatment interaction in the absence of 
significant session x strain x treatment interaction indicate a difference in the y-
intercept of the linear regressions between strain and treatment groups (Verbeke and 
Molenberghs, 2000), suggesting that the response to the first cocaine injection was 
different between stain and treatment. Therefore, a significant strain x treatment 
interaction in the linear mixed model analysis was further investigated using a separate 
2-factor ANOVA, with appropriate post-hoc tests, of the horizontal beam-breaks during 
the first session of induction of sensitization assay. 
To evaluate conditioning to cocaine-paired context, total number of horizontal 
beam-breaks following saline injection on the expression of sensitization was compared 
with beam-breaks during the first 30-min of access to the open-field chambers for the 
first day of habituation, following saline injection prior to induction of sensitization and 
that following cocaine injection on the 1st session of induction of sensitization using a 
separate 2-factor ANOVA with strain (3 levels) as a between-subject factor and session-
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type (4 levels) as within-subject factor. Significant interactions and main effects were 
evaluated further using Bonferroni’s post-hoc analyses.  
 
5.3 Results 
5.3.1 Acute cocaine-induced hyperactivity 
In the acute cocaine-induced hyperactivity assay, the interactions of treatment X 
strain X dose (F[2,29] = 0.259, p > 0.05; Fig 5.1) and treatment X dose (F[1,29] = 0.003, p 
> 0.05) and strain X dose (F[2,29] = 0.515, p > 0.05) were not significant. However, a 
main effect of cocaine dose was found (F[1,29] = 19.0, p < 0.001). Horizontal locomotor 
activity following a single cocaine injection was greater than that following saline 
injection for all three strains (ps < 0.05). The increase in locomotor activity following 
acute cocaine injection in WIS, WKY and SHR was 56%, 83% and 33%, respectively, of 
that after saline injection within-subject. 
 
5.3.2 Induction of locomotor sensitization to cocaine 
During the induction of sensitization, treatment X strain X session (F[18,261] = 
0.919, p > 0.05; Fig 5.2A) and the treatment X session (F[9,261] = 1.83, p > 0.05) 
interactions were not significant. However, the strain X session interaction (F[18,261] = 
3.21, p < 0.001) and the main effect of session (F[9,261] = 14.4, p < 0.001) were 
significant. MPH treatment did not alter the induction of sensitization to repeated 
cocaine. Therefore, the sensitization data were collapsed between adolescent VEH and 
MPH groups. Induction of sensitization was evaluated separately for individual strains 
using repeated-measures one-way ANOVAs with Dunnett’s post-hoc analysis compared 
to the first session of cocaine administration. For SHR, locomotor activity was elevated 
(F[9,99] = 15.2, p < 0.0001 Fig 5.2A, right panel) from the 4th to the 10th day compared to 
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the 1st day of repeated cocaine injection (ps < 0.05). For WKY, locomotor activity 
differed by session (F[9,90] = 3.64, p < 0.001; Fig 5.2A, middle panel), but Dunnett’s 
post-hoc analysis did not reveal significant pairwise differences compared to the 1st day 
of repeated cocaine injection. For WIS, locomotor activity was not elevated by repeated 
cocaine injection (F[9,99] = 1.92, p > 0.05 Fig 5.2A, left panel). 
Linear mixed model analysis revealed a significant strain X session interaction 
(F[2,39.1] = 6.21; p < 0.01; Fig 5.2B), but no significant interactions of treatment X 
session (F[1,39.1] = 1.80; p > 0.05) or strain X treatment X session (F[2,39.1] = 0.886; p > 
0.05), indicating that the slope for cocaine sensitization differs between strains, but not 
between treatment groups. Linear regression analyses of the significant strain X session 
interaction revealed that the slopes for induction of sensitization to cocaine were 
significantly different from zero in SHR (1390 ± 185; p<0.0001; Fig 5.2B), WKY (337 ± 
132, p < 0.05) and WIS (445 ± 193, p < 0.05). Further, the slope was greater for SHR 
compared to both WKY and WIS (F[2,344] = 11.9, p < 0.0001).  
The linear mixed model analysis also revealed a significant strain X treatment 
interaction (F[2,124.7] = 3.38; p < 0.05), indicating differences in locomotor activity on 
session #1 of repeated cocaine administration. Two-way ANOVA evaluating locomotor 
activity on session #1 of the induction of sensitization revealed a significant main effect 
of strain (F[2,29] = 4.87, p < 0.05; Fig 5.2C), but not of treatment (F[1,29] = 0.020, p > 
0.05) and not for the strain x treatment interaction (F[2,29] = 0.773, p > 0.05). SHRs 
exhibited greater locomotor activity on session #1 compared to WKY (p < 0.05, Fig 5.2C) 
but not WIS.  
 
5.3.3 Expression of locomotor sensitization to cocaine 
On the test-day for expression of cocaine sensitization, the treatment X strain X 
dose (F[6,87] = 0.374, p > 0.05; Fig 5.3) and the treatment X dose (F[3,87] = 0.862, p > 
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0.05) interactions were not significant. However, a significant strain X dose interaction 
(F[6,87] = 7.12, p < 0.05) was found. Further, a main effect of cocaine dose was found 
(F[3,87] = 28.4, p < 0.001). Post-hoc analyses revealed that in WIS, cocaine 20 mg/kg 
produced greater locomotor activity than 5 mg/kg, but not saline (p < 0.05). In WKY, 
repeated cocaine resulted in a dose-dependent increase in locomotor activity, such that 
saline < cocaine 10 and 20 mg/kg, and cocaine 5 mg/kg < cocaine 20 mg/kg (ps < 0.05). 
In SHR, administration of cocaine resulted in a dose-dependent increase in locomotor 
activity, such that activity after cocaine 5 mg/kg < 10mg/kg < 20 mg/kg; however, only  
the 20 mg/kg dose of cocaine was different from saline (ps < 0.05). 
 
5.3.4 Conditioning to context-paired with repeated cocaine administration 
For conditioning to cocaine-paired context, significant strain X test-day 
interaction (F[6,96] = 6.51, p < 0.0001; Fig 5.4), and significant main effects of strain 
(F[2,96] = 45.3, p < 0.0001) and test-day (F[3,96] = 29.1, p < 0.0001) were obtained. 
Bonferroni’s post hoc analyses for WKY revealed no significant pairwise differences 
between test-days. For WIS, locomotor activity following conditioning to cocaine-paired 
context was greater than locomotor activity after 3 days of habituation (p < 0.05); no 
other significant differences were found. For SHR, locomotor activity following cocaine-
conditioning was greater than locomotor activity with saline injection after habituation 
but prior to induction of sensitization (p < 0.05; Fig 5.4). Also, the conditioned response 
was greater than cocaine-induced hyperactivity (session#1 of induction of sensitization; 
p < 0.05). Further, locomotor activity following conditioned response was greater than 
locomotor activity on the first day of habituation (p < 0.05; Fig 5.4). 
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5.4 Discussion 
The current study tested the hypothesis that chronic MPH treatment in 
adolescent SHR, followed by treatment discontinuation in early adulthood increases the 
sensitivity of adult SHR to the behavioral effects of acute and repeated cocaine 
administration. Contrary to the hypothesis, acute cocaine-induced hyperactivity, and 
induction and expression of sensitization as well as the conditioned response to cocaine 
were not altered in adult SHR following chronic MPH treatment during adolescence. The 
current study only identified strain differences in sensitivity to cocaine. Specifically, 
acute cocaine administration induced hyperactivity in all three rat strains; surprisingly, 
the cocaine induced hyperactivity was the greatest increase in the genetic control, WKY, 
and the smallest increase in SHR. In contrast, repeated administration of a moderate 
dose of cocaine (10 mg/kg, i.p.) produced robust sensitization in SHR, but not in either 
of the control strains. Furthermore, SHR also exhibited an increased conditioned 
response to the cocaine-paired context compared to WKY and WIS. Thus, SHR sensitize 
to cocaine and cocaine-paired context more readily compared to control. Taken 
together, the development of psychomotor sensitization to cocaine is influenced by 
strain/genetic differences between subjects, but MPH treatment in during adolescence 
does not alter the sensitivity to the psychomimetic effects of cocaine.  
Cocaine administered intraperitoneally at the 10 mg/kg dose was reported to 
induce hyperactivity following a single administration and induce behavioral 
sensitization following repeated administration in SHR, WKY and WIS (Cailhol et al, 
1999; Frankowska et al, 2009). In the current study, this dose of cocaine induced 
hyperactivity in all three strains (Fig 5.1), however, sensitization was modest in WKY and 
WIS (Fig 5.2). Specifically, linear regression for the induction of sensitization was 
significantly different from zero, but cocaine induced hyperactivity was not significantly 
increased from session #1 of repeated cocaine administration. One explanation for 
modest effect of cocaine in WIS may be the variability in the induction of sensitization to 
repeated cocaine in outbred rats. Support for this explanation is provided by reports of 
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individual differences in induction of sensitization with low doses of cocaine (Perez et al, 
2010; Pierce et al, 1996a). The latter studies suggest that the expression of sensitization 
depends on increased accumbal glutamatergic transmission. The accumbens of SHR is 
less sensitive to glutamate stimulated dopamine and acetylcholine release compared to 
WKY (Russell, 2003; Tsuda et al, 1996). Taken together, these results suggest that the 
development of sensitization to repeated administration of a low dose of cocaine 
depends on deficient accumbal glutamatergic function. 
Differences in acute cocaine-induced hyperactivity has been employed to 
segregate outbred rats into low-cocaine responders (LCR) and high cocaine responders 
(HCR; Gulley et al, 2003; Mandt et al, 2008). Compared to HCR, LCR develop robust 
behavioral sensitization to repeated cocaine administration, and exhibit greater 
motivation for cocaine self-administration (Mandt et al, 2008). LCRs also express 
greaters striatal DAT and reduced D2 function (Mandt et al, 2010; Merritt et al, 2013). 
SHR have several similarities with the LCR; compared to WKY and outbred control. SHR 
exhibit greater striatal DAT function and reduced D2 function compared to WKY and 
outbred rats (Fujita et al, 2003; Miller et al, 2012). Also, SHRs had a higher rate of 
acquisition of cocaine self-administration with higher PR breakpoints compared to both 
WKY and WIS (Harvey et al, 2011; Somkuwar et al, 2013b). In the current study, SHR 
exhibited lower cocaine-induced hyperactivity and greater induction of sensitization 
following repeated cocaine administration compared to WKY and WIS. Taken together, 
these reports suggest that striatal dopaminergic function contributes to the behavioral 
profile predicting enhanced vulnerability to cocaine.  
Chronic MPH treatment in adolescent SHR, followed by treatment 
discontinuation in early adulthood, resulted in increased cocaine self-administration and 
increased motivation for cocaine, compared to vehicle control and MPH-treated WKY 
and WIS (Harvey et al, 2011). MPH treatment in adolescent SHR increased DAT function 
in mPFC, but did not alter DAT function in striatum (Somkuwar et al, 2013a). As 
discussed above, striatal dopaminergic function has been associated with cocaine 
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sensitization and conditioning to cocaine paired context and cues (Berridge et al, 1998; 
Mandt et al, 2010; Merritt et al, 2013).  Cocaine cue-reactivity, evaluated as 
reinstatement of second order responding for cocaine-cues, in adult SHR was not 
increased following MPH treatment during adolescence (Jordan et al., submitted). Taken 
together, these results suggest that chronic MPH treatment during adolescence may not 
increase the sensitivity of SHR to the psychomotor effects of cocaine. The current results 
are in agreement with this hypothesis. In contrast to MPH, chronic ATO treatment 
during adolescence was reported to decrease striatal DAT function as well as cocaine 
cue-reactivity in adult SHR (Somkuwar et al, 2013b; Jordan et al., submitted). Taken 
together, these results further suggest that striatal DAT function is critically involved in 
the conditioned response to cocaine paired context and cues. 
Self-administration and sensitization models different aspects of cocaine abuse. 
The former models stimulus-response learning in cocaine addiction and evaluates the 
reinforcing properties of a drug under a non-dependent state (Collins et al, 1984; 
O'Connor et al, 2011). The latter models the development of sensitization to the 
incentive motivational effects for cocaine and cocaine-associated cues (Robinson et al, 
1993; Robinson and Berridge, 2008b). Sensitization has been suggested to mediate 
transition from recreational drug use to addiction (Ferrario et al, 2005; Robinson et al, 
2001) but see (Ahmed and Cador, 2006). Thus, neurochemical changes produced by 
prior MPH treatment may enhance future cocaine abuse liability, but may not be 
directly responsible for the development of addiction. The core tenet of the incentive 
sensitization theory is that in susceptible individuals, repeated administration of an 
addictive substance, such as cocaine, leads to attribution of incentive salience to stimuli 
(Brown et al, 2011; Tindell et al, 2005). These changes may then render the subjects 
hypersensitive to cocaine and cocaine-associated cues (Di Ciano, 2008), and the 
enhanced sensitivity persists long after the discontinuation of repeated drug treatment 
(Antelman, 1988; Di Ciano, 2008). SHR show greater motivation for cocaine self-
administration compared to WKY and WIS (Harvey et al, 2011; Somkuwar et al, 2013b). 
SHR were reported to exhibit greater cocaine cue-reactivity than WKY and WIS (Jordan 
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et al., submitted). The importance of context in sensitization is well established, 
particularly with psychostimulants (Fraioli et al, 1999; Robinson et al, 1998). In the 
current study, SHR exhibited greater conditioning to the cocaine-paired context 
compared to WKY and WIS. This increased responding in the cocaine-paired context was 
greater than that elicited by saline injection, suggesting that the enhanced locomotor 
activity was not due to stress associated with injection. Furthermore, only in the SHRs, 
hyperactivity in the open-field chamber following repeated cocaine administration was 
greater that both novelty-induced hyperactivity as well as acute cocaine-induced 
hyperactivity, suggesting a robust effect of cocaine conditioning. Taken together with 
the current results, genetic differences confer sensitivity to the behavioral effects of 
cocaine, however prior MPH treatment does not alter the incentive motivational effects 
of cocaine sensitization.   
In conclusion, the SHR strain is vulnerable to development of psychomotor 
sensitization to cocaine, and prior MPH treatment during adolescence does not alter the 
sensitivity to the psychomotor effects of cocaine in any of the strains. Locomotor 
sensitization to cocaine in SHR may be mediated by increased sensitivity to cocaine and 
by increased sensitivity to the associated context. The increased cocaine sensitivity in 
SHR may be associated with the previously reported higher cocaine self-administration 
and cocaine cue-reactivity in SHR and by extrapolation, may mediate, partially, the high 
cocaine abuse liability in ADHD.  
  
  
5.5 Figures 
 
Figure 5.1. Cocaine-induced hyperactivity 
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Locomotor activity in open-field chambers following cocaine or saline injections in methylphenidate-treated (MPH; striped) 
and vehicle-treated (VEH; plain) WIS, WKY and SHR.  Values are mean ± S.E.M. for number of horizontal photobeam breaks.   
* p < 0.05 compared to respective saline control; n = 6/group for all treatment and strain groups, except vehicle treated WKY, 
where n=5. 
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Figure 5.2 Induction of sensitization to repeated cocaine  
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Locomotor activity in open-field chambers following cocaine injections in 
methylphenidate-treated (MPH; open squares) and vehicle-treated (VEH; closed circles) 
WIS, WKY and SHR for sessions 1-10 (panel A).  Values are mean ± S.E.M. for number of 
horizontal photobeam breaks. Linear regression for locomotor activity across 10 
sessions of repeated cocaine administration for SHR, WKY and WIS (B); values are 
collapsed across VEH and MPH groups. Locomotor activity for individual rats following 
cocaine on session#1 of induction of sensitization (C).  
* p < 0.05 compared to session#1; ε p < 0.05 compared to WKY; n = 6/group for all 
treatment and strain groups, except vehicle treated WKY, where n = 5. 
  
Figure 5.3. Expression of sensitization to cocaine  
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Locomotor activity in open-field chambers following cocaine (5 – 20 mg/kg, i.p.) or saline injections in methylphenidate-
treated (MPH; striped) and vehicle-treated (VEH; plain) WIS, WKY and SHR.  Values are mean ± S.E.M.  for number of 
horizontal photobeam breaks  
a p < 0.05 compared to saline; * p < 0.05 compared to 5 mg/kg cocaine; # p < 0.05 compared to 10 mg/kg cocaine; n = 6/group 
for all treatment and strain groups, except vehicle treated WKY, where n=5. 
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Figure 5.4. Conditioning to the context paired with cocaine  
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Locomotor activity in open-field chambers following saline injections 14 days after 
induction of sensitization (test of conditioning; black bars), following cocaine injection 
during session#1 of induction of sensitization (hyperactivity; dark grey bars), following 
saline injection after 3 days of habituation to the open-field chambers (test of 
habituation; light grey bars) and on the first day of habituation to the locomotor 
chambers (pre-habituation; white bars) in WIS, WKY and SHR.  Values are mean ± S.E.M.  
for number of horizontal photobeam breaks, and are collapsed between 
methylphenidate and vehicle groups. 
* p < 0.05 compared to test of conditioning; n = 12/group for all treatment and strain 
groups, except vehicle treated WKY, where n=11. 
 
Copyright © Sucharita S. Somkuwar 2013 
 196 
 
6 CHAPTER SIX 
Impulsivity endophenotypes identified using differential reinforcement of low rate 
schedules in a rodent model of attention deficit hyperactivity disorder 
 
6.1 Introduction 
Impulsivity is a complex multidimensional phenotype encompassing a wide 
variety of maladaptive behaviors including, but not limited to, actions that are poorly 
conceived, prematurely executed, unnecessarily risky, inappropriate to the situation, 
and often with undesirable outcomes (Evenden, 1999b). Impulsivity is a hallmark of 
attention deficit/hyperactivity disorder (ADHD). Aspects of impulsivity, including having 
“difficulty waiting his/her turn”, “impatience”, and feeling “uncomfortable doing things 
slowly and systematically” serve as diagnostic criteria for ADHD (American Psychiatric 
Association., 2000).  
Impulsivity has been ascribed to impaired response inhibition (Barkley, 1997; 
Dalley et al, 2008).  Response inhibition is an executive control mechanism that prevents 
the execution of an undesirable action (Aron, 2007). Also, impulsivity in ADHD has been 
suggested to be an outcome of a deficiency in timing (Rubia et al, 2009a), in which 
deficits in either motor timing or time perception are expressed as premature 
responding. Certain features of impulsivity are accounted for by either poor inhibitory 
control or poor timing. For instance, “impatience” is an outward manifestation of either 
reluctance to wait (poor response inhibition) or a deficient timing perception (durations 
appear longer than they are in actuality). ADHD patients display deficits in both 
response inhibition and temporal processing (Sonuga-Barke et al, 2010), indicating that 
deficits in response inhibition and timing may be two endophenotypes underlying 
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impulsivity in ADHD. Furthermore, impulsivity associated with ADHD is ameliorated by 
methylphenidate (MPH), a stimulant ADHD medication, which enhances response 
inhibition and reduces neuronal dysfunction associated with disturbed temporal 
processing (Broyd et al, 2005).  
The spontaneously hypertensive rat (SHR) is the most widely used model of 
ADHD (Sagvolden et al, 2005b). However, controversy exists as to whether the SHR 
appropriately models impulsivity associated with ADHD (Wickens et al, 2011). Generally, 
studies using response-withholding preparations indicate that SHR have reduced 
response inhibition, and thus, exhibit greater impulsivity compared to their inbred 
progenitor strain Wistar-Kyoto (WKY), as well as compared to outbred strains (Evenden 
and Meyerson, 1999; Sanabria et al, 2008). However, impulsivity in SHR measured by 
reduced reinforcement in response-withholding preparations such as the differential 
reinforcement of low rate (DRL) schedule and the 5-choice serial reaction time tasks, 
was not decreased as expected by MPH (Ferguson et al, 2007; van den Bergh et al, 
2006), suggesting that the SHR model of ADHD has limitations or that the assessment of 
impulsivity in the latter studies was not adequate (Hill et al, 2012a).  
Clinical studies report an improvement in response inhibition tasks following 
acute MPH administration only in patients who had been prescribed MPH previously 
(Broyd et al, 2005; DeVito et al, 2009), but not in drug naïve ADHD subjects (Rhodes et 
al, 2006; Rubia et al, 2009a). In drug naïve ADHD subjects, chronic MPH treatment 
produced observable improvements in response inhibition and other executive 
functions (Coghill et al, 2007). Further, MPH is most often administered to children and 
adolescents diagnosed with ADHD (Robison et al, 1999), MPH effects may be more 
prominent in younger subjects. MPH reduced impulsivity in adolescent, but not in adult 
WIS rats in a delay-discounting task, where impulsivity is measured as increased choice 
of a smaller immediate reward compared to a larger delayed reward (Bizot et al, 2011). 
In adolescent SHR, acute MPH administration has been reported to reduce the ADHD-
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like phenotype, including impulsivity using a delay-discounting schedule (Adriani et al, 
2003; Umehara et al, 2013b). Chronic MPH administration has been shown to reduce 
working memory deficits and inattention in adolescent SHR (Harvey et al, 2013; Kantak 
et al, 2008). The current research evaluated the effects of chronic MPH treatment on 
impulsivity in adolescent SHR. 
The current research employed DRL schedules, an operant conditioning 
procedure that reinforces only responses (e.g., lever presses) that are separated by an 
experimenter-defined minimum time since the previous response. In this paradigm, 
impulsivity is measured as a reduced efficiency of reinforcement as a consequence of 
early inappropriate responding (Stein and Landis, 1975). Reduced efficiency on a DRL 
schedule may result from reduced response inhibition and/or timing disturbances 
(Doughty and Richards, 2002a; Wiley et al, 2000). SHR show reduced efficiency 
compared to WKY and outbred rats (Bull et al, 2000; Sanabria et al, 2008); extensive 
training on the schedule reduces this difference (Orduna et al, 2009). However, 
information regarding the behavioral response output is lost when only efficiency or 
molar patterns of behavior, defined using arbitrary inter-response time (IRT) cut-offs, 
are considered (Richards et al, 1993). Furthermore, efficiency does not differentiate 
between errors due to response inhibition and timing deficiency.  
IRT distributions obtained under DRL schedules provide valuable information for 
the characterization of the temporal occurrence of behavior (Williams, 1968). Burst 
responding is characterized by short IRTs (generally <2 sec) and indicate a reduced 
capacity to withhold responding.  Burst responding may be a mechanism contributing to 
reduced efficiency (Sagvolden et al, 2005a). SHR exhibit higher burst responding 
compared to control (Boix et al, 1998; Sagvolden et al, 2005a; van den Bergh et al, 
2006); however, other studies report contrasting results (Bull et al, 2000; Ferguson et al, 
2007; Orduna et al, 2009), which may be due to differences in experimental procedures 
and in the molar definition of ‘bursts’.  Mathematical modeling approaches offer a 
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quantitative analysis of IRT distributions by taking into consideration the overall 
distribution of IRTs, and not simply arbitrary summary statistics. As such, response 
inhibition and timing deficiencies in DRL behavior in SHR have been parsed out using a 
modeling approach (Orduna et al, 2009; Sanabria et al, 2008). 
The current study aims to optimize the quantification of IRT distributions to 
parse out individual processes underlying SHR behavior under two DRL schedules, a 
short DRL 5 second with limited hold (DRL5LH) and a long DRL 30 second (DRL30) 
schedule.  Optimization also included the comparison of molar patterns (alterations in 
reinforcement efficacy) with mathematical modeling parameters.  Thus, the current 
research determined the contribution of DRL interval on impulsivity endophenotypes 
expressed by SHR by examining global performance metrics and IRT distribution 
parameters. 
 
6.2 Material and methods 
6.2.1 Subjects 
Male SHR and WKY rats (Charles River Laboratories, Kingston, NY) and male 
Wistar rats (WIS; Raleigh, NC) arrived on postnatal day 70 (P70) or P25. WKY and WIS 
were used as inbred and outbred comparator strains, respectively. Twelve adult rats 
from each strain were used to identify strain differences in endophenotypes of 
impulsivity, except where noted.  Twenty four adolescent rats from each strain were 
used to identify effects of MPH on endophenotypes of impulsivity. Rats were 
maintained on a 12-h light:dark cycle with lights on 07:00 h, individually housed with 
free access to food and water in a colony room (Division of Laboratory Animal 
Resources, University of Kentucky, Lexington, KY, USA). The experiments were 
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conducted during the light-cycle of the rats. After 3 days of habituation, rats were food 
restricted to 90-95% of their expected free-feeding body weight.  All experimental 
protocols were conducted according to the 1996 NIH Guide for the Care and Use of 
Laboratory Animals and were approved by the Institutional Animal Care and Use 
Committee at the University of Kentucky. 
 
6.2.2 Apparatus 
Experiments were conducted in operant conditioning chambers (ENV-001; MED 
Associates, St. Albans, VT, USA) housed in sound attenuating compartments (ENV-018 
M, MED Associates). Operant chambers were connected to a PC interface (SG-6080D, 
MED Associates) and operated using MED-PC TM software. Chambers were equipped 
with a 5 cm × 4.2 cm recessed food receptacle, two retractable metal levers located on 
either side of the food tray and 7.3 cm above a metal grid floor, and a house light 
mounted on the wall opposite the food receptacle. Food pellet reinforcers (45-mg 
Noyes Precision Pellets; Research Diets, Inc., New Brunswick, NJ, USA) were delivered 
via a dispenser (ENV-203, MED Associates) mounted outside of the operant chamber. 
 
6.2.3 Drugs 
(±)-Methylphenidate hydrochloride (Sigma-Aldrich, St Louis, MO) was dissolved 
in water at concentration of 1.5 mg/ml and injected into oyster crackers (Kantak et al, 
2008) providing oral doses of 1.5 mg/kg. Oyster crackers injected with water (1 ml/kg) 
were used as the vehicle control. Solutions were prepared fresh on each experimental 
day and the cracker was provided in the homecage 30 min prior to the operant session. 
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The MPH dose employed results in clinically relevant plasma concentrations (Wargin et 
al, 1983), and was below the threshold for producing locomotor activation (Kuczenski et 
al, 2002). Rats consumed the oyster cracker within 5 min.  
 
6.2.4 Differential reinforcement of low rate schedules 
For evaluating strain differences adult SHR, WKY and WIS were trained on daily 
55-min sessions of DRL5LH, followed by DRL30 schedule, using a previously reported 
training schedule (Sanabria et al, 2008). For both DRL5LH and DRL30 schedules, 
consecutive responses on the active lever greater than 5 or 30 sec apart, respectively, 
were reinforced by delivery of a food pellet reinforcer. Responses on the inactive lever 
were recorded, but had no programmed consequence.  An adjusting limited hold (LH) 
condition was included in the DRL5LH schedule to reduce the probability of reinforcing 
nonscheduled-directed alternate behaviors, such as grooming, which result in long time 
lapses between consecutive responses (McClure and McMillan, 1997). LH was initially 
set at 10 sec. Responding within the LH resulted in a decrease in LH duration by 0.01 
sec. Lack of responding within the LH resulted in an increase in LH duration by 0.03 sec. 
Following stable performance on DRL5LH, which required 12-16 sessions, the dose-
response for MPH treatment was evaluated. Subsequently, the DRL interval was 
increased gradually by 0.75% following each reinforced response within-session. The 
adjusted DRL interval was carried forward from the previous session until DRL30 was 
reached. In DRL30, a LH was not used because the probability of reinforcement of a 
time-insensitive IRT is lower with this schedule. Rats were maintained on DRL30 until 
stable responding was reached, requiring 12-22 sessions.   
Stability under both DRL5LH and DRL30 schedules was defined as less than a 20% 
change in IRT at 5 and 30 sec, respectively, across 5 consecutive sessions. Number of 
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active and inactive lever responses, number of reinforcers earned and IRTs were 
recorded over 5 consecutive sessions of stable behavior. Efficiency was defined as 
pellets earned, calculated as a percent of the total number of responses on the active 
lever. Cut-offs of IRT durations for burst responding for DRL5LH and DRL30 were set at 
1.4 and 2.0 sec, respectively, to segregate the waiting distribution based on procedures 
described in previous reports (Richards et al, 1993). Task delinquent behavior was 
defined for DRL5LH as IRTs longer than 100 sec, which were not reinforced.  For DRL30, 
delinquent behavior, defined as IRTs longer than 120 sec, were reinforced.  
For evaluating the effects of MPH on impulsivity, adolescent SHR, WKY and WIS 
were administered MPH (1.5 mg/kg p.o.) or VEH (water, 1 ml/kg, p.o.) daily from P28-55 
and trained on either DRL5LH or DRL30 (n=6/group/experiment). Training protocols 
used were the same as that described above, with minor modifications. One cohort of 
adolescent rats (n=6/group) was trained to stability on DRL5LH schedule, which required 
12-18 sessions. A separate cohort of adolescent rats (n=6/group) was trained from DRL3 
to DRL30, and then maintained on DRL30 until stable responding was reached, requiring 
12-25 sessions. 
 
6.2.5 Modified temporal regulation (TR) model 
Two non-linear mathematical models were utilized to identify endophenotypes 
of impulsivity in SHR (Hill et al, 2012a; Mika et al, 2012; Sanabria et al, 2008).  Both 
models were fit to the IRT distribution across 5 sessions of stable responding. The first 
model posits that the distribution of IRTs is a mixture of two independent probability 
distributions (see equation 1).  One distribution is sensitive to the DRL contingency 
(waiting-related) and predicted by a gamma function theoretically centered near the 
DRL target time (Supplemental Fig. 1).  The other distribution is not sensitive to the DRL 
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contingency (non-waiting related), and is predicted by an exponential function. The 
second model (see equation 2) posits that the distribution of non-timed IRTs are a 
composite of two processes.  One process results in burst responses characterized by an 
exponential function with a high rate-of-decay (Supplemental Fig. 1).   The second 
process results in task delinquent behavior characterized by an exponential function 
with a low rate-of-decay (Supplemental Fig. 1).       
 
  (     )     (       )   (   )    (   )                                                           
(1) 
 (     )     (       )    (   )    (   )   (   )(   )      (   )    
                                                                                                                                         (2) 
Equation 1 indicates that the probability of IRT duration t sec is a function of five 
parameters: p, N, c, λ and δ; where p is the proportion of timed IRTs and (1–p) is the 
proportion of non-timed IRTs. The shape and scale parameters of the gamma 
distribution Γ are N and c, respectively. λ is the rate of decay of the non-timed IRT or the 
inverse of the mean non-timed IRT. δ is the shortest interval possible and was estimated 
as the shortest IRT emitted (Brackney et al, 2011); it was not a free parameter. Equation 
2 is a modified version of equation 1, where λ has been replaced by three other 
parameters. Here the proportion and rate-of-decay of short non-timed IRTs are q and L, 
respectively, (1-q) and L’ are the proportion and rate-of-decay of the long non-timed 
IRTs. TR parameters were estimated using the method of maximum likelihood (Myung, 
2003). Models were compared for predicting behavior under the two DRL schedules for 
each rat using Akaike’s Information Criterion (AIC; Burnham, 2002); equation 3 was used 
to compare the two AIC values.  
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ΔAIC =  2*(number of parametersequation 2 – number of parametersequation 1) – 
2*(loglikelihoodequation 2 – loglikelihoodequation 1)              
(3) 
Free parameters were estimated for each rat x schedule combination according 
to the model selected by ΔAIC. Equation 1 was selected if the ΔAIC for an individual was 
greater than 10.  Equation 2 was used if ΔAIC for an individual was less than 10. The 
composite ΔAIC for each strain x schedule combination was reported. Response 
threshold θ was calculated as the mean timed IRT divided by the target time, [
   
 
] and 
[
   
  
] for DRL5LH and DRL30, respectively, with c estimated in sec. The Weber fraction 
or coefficient of variation of timed IRTs, ω, was computed as the standard deviation 
divided by the estimated mean, which reduces to [ (
 
 
)]. Further, p, q, N, c, λ, L and L’ 
were considered primary TR parameters and θ and ω were considered secondary or 
derived TR parameters.  
 
6.2.6 Open-field locomotor activity 
Increases in burst responding under the DRL schedules following MPH 
administration may be due to MPH-induced hyperactivity and not due to the effects of 
MPH on response inhibition. To evaluate this possibility, adolescent SHR, WKY and WIS 
were administered MPH or VEH and 30 min later tested for activity in open-field 
chambers. Of note, the rats used in this assay were trained previously on DRL5LH. Three 
days after the completion of DRL studies, locomotor activity was evaluated. Rats were 
habituated for 3 days, for 1-hr each day, in one of 12 open-field chambers 
(42 × 42 × 30 cm), each with a 16 × 16 grid of photobeam sensors with monitoring 
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system (AccuScan Instruments Inc., Columbus, OH). Total number of horizontal beam 
breaks during the third day were recorded and compared between groups. 
 
6.2.7 Data analysis 
Analyses were conducted using SPSS Statistics Version 19 (SPSS Inc., IBM 
Company, Armonk, NY). For evaluating strain differences, dependent variables were as 
follows: 1) active lever responses; 2) reinforcers earned; 3) sessions to train from 
DRL5LH to DRL30; 4) efficiency (% of responses reinforced); 5) limited hold (in sec); 6) 
rate of reinforcement (pellets per min); 7) proportion of burst responses (IRT<1.4 sec for 
DRL5LH and IRT<2.0 sec for DRL30); 8) task delinquency (IRT>100 sec for DRL5LH and 
IRT>120 sec for DRL30); 9) location of the timed peak (x-coordinate of the maxima of 
waiting peak obtained by plotting 1-second and 4-second moving averages for DRL5LH 
and DRL30, respectively; 10) peak spread (width of the waiting-related peak at half-
maximal peak height); and 11) primary and derived parameters from modified TR 
models. For evaluating effects of MPH, dependent variables were as follows: 1) 
efficiency (% of responses reinforced), 2) latency to respond following the delivery of 
reinforcer under DRL5LH, 3) sessions to train from DRL3 to DRL30; 4) primary and 
derived parameters from modified TR models and 5) horizontal activity in open-field 
chambers.  
All data are reported as the mean ± S.E.M. and n represents the number of rats 
per group. Estimates of L, L’, and λ were log transformed to maintain homogeneity of 
variance.  Strain differences were determined using either one-factor ANOVA with 
Tukey’s post-hoc test or unpaired t-test, as appropriate. Further, θ estimates were 
analyzed using Student’s one-sample t-test for matched subjects for comparison with 
the hypothetical value of 1 (Vadum et al, 1998). Reduced accuracy for a strain was 
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indicated by θ less than 1. Strain difference in task delinquency under the DRL30 
schedule was evaluated using a Kruskal-Wallis test with Dunn’s Multiple Comparisons 
post-hoc test. Acute MPH treatment effects for each rat strain were determined using 
repeated-measure one-way ANOVA and Dunnett’s post hoc analysis. Test of sphericity 
was conducted to validate the repeated measures ANOVA (Mauchly, 1940). When the 
assumption of sphericity was violated, Huyhn-Feldt correction was applied to adjust the 
F-statistic (Huynh and Feldt, 1980). Effects of MPH treatment were determined using 
two-factor ANOVA (strain X treatment), followed by Bonferroni’s post-hoc comparisons. 
Main effects of strain or treatment were evaluated using Tukey’s post-hoc comparison. 
Outliers were omitted using the Grubbs test (GraphPad; 
http://www.graphpad.com/quickcalcs/Grubbs1.cfm). 
 
6.3 Results 
6.3.1 Between-strain differences in behavior in adult rats under DRL  
No strain differences were found in the number of sessions required to train rats 
from the DRL5LH to the DRL30 schedule (Supplementary Fig. 2). Number of active lever 
responses and reinforcers earned by SHR under the DRL5LH schedule were greater than 
for WKY, but fewer than WIS (for active lever responses, Fs[2,33]=71.6, p<0.0001;  for 
reinforcers earned Fs[2,33]=124.2, p<0.0001; Table 6.1). In contrast, under DRL30, SHR 
emitted a greater number of active lever responses (Fs[2,33]=40.9, p<0.0001), but 
earned fewer reinforcers compared to both WKY and WIS (Fs[2,33]=43.5, p<0.0001). 
Visual inspection of the mean IRT frequency distributions for SHR, WKY and WIS under 
DRL5LH and DRL30 reveals several strain differences (Fig 6.1A-B). Premature responses 
(left of the dotted line) resulted in loss of reinforcement. Responses (right of the dotted 
line) were reinforced under DRL30; however, only responses within the limited hold 
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were reinforced under DRL5LH. Under DRL5LH, SHR emitted a lower frequency of 
responding at the peak IRT location compared to WIS, and SHR emitted a greater 
frequency of burst responding (IRTs<1.4 sec) compared to WKY (Fig 6.1A, left). 
Quantification of the reinforced responses (efficiency) for DRL5LH revealed no strain 
differences (Fs[2,33]=0.642, p>0.05; Fig 6.1A, right). The rank order for adjusted LH and 
rate of reinforcement under DRL5LH schedule was WIS<SHR<WKY (Fs[2,33]=37.4, 
p<0.0001) and WKY<SHR<WIS (Fs[2,33]=124, p<0.0001), respectively (Fig 6.2). 
Compared to both WKY and WIS, SHR under DRL30 had a lower frequency of 
reinforcement (right of the dotted line), a skewed leftward-shifted waiting distribution, 
and a greater frequency of burst responding (IRTs<2 sec; Fig 6.1B, left).  Under DRL30, 
SHR exhibited a lower reinforcement efficiency compared to WKY and WIS 
(Fs[2,33]=56.0, p<0.001); further, WKY had a higher efficiency than WIS (Fig 6.1B, right).  
 
6.3.2 Strain differences in TR parameters following mathematical modeling of IRT 
distributions 
Because the ΔAIC values for DRL5LH for SHR, WKY and WIS were less than 10 
(ΔAIC values = -1974, -549.7 and -3947, respectively), behavior was predicted by 
equation (2). As expected, both timed responding (i.e., sensitive to the DRL contingency) 
and non-timed responding (exponential functions) were observed under DRL5LH. As 
illustrated by data obtained from representative rats (Supplementary Fig. 3), four IRT 
distribution patterns were observed under DRL5LH.  The waiting pattern was a uni-
modal distribution with responding centered near the 5-second waiting-time that 
achieved an asymptote by 7.5 sec (Supplementary Fig. 3A). The burst pattern was a bi-
modal distribution with the rise to an early plateau delineating burst-related 
responding, followed by waiting (Supplementary Fig. 3B). The task-delinquency pattern 
was a uni-modal distribution in which the waiting IRTs required >15 sec to reach 
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asymptote (Supplementary Fig. 3C). The combination pattern was a composite of a bi-
modal IRT distribution (burst pattern) that required >15 sec to reach asymptote (task-
delinquency pattern; Supplementary Fig. 3D).  
TR parameters for the IRT distributions from SHR, WKY and WIS under the 
DRL5LH schedule illustrated in Fig 6.1A are provided in Table 6.2. With respect to the 
waiting-related distribution, SHR had a higher response threshold (θ; Fs[2,33]=6.33, 
p<0.005) compared to WKY. Also, θ was lower than the hypothetical value of 1 for WKY 
and WIS (t[11]=4.05 and t[11]=3.46, respectively, ps<0.01), demonstrating reduced 
accuracy of estimating the 5-sec waiting time. The coefficient of variation for waiting IRT 
(ω) for SHR was not different from that for the control strains, demonstrating no 
differences in precision; however, ω was greater for WKY compared to WIS 
(Fs[2,33]=3.50, p<0.05). SHR had a lower proportion of waiting-related responding (p) 
compared to WIS, but not compared to WKY (Fs[2,33]=3.36, p<0.05).  
 For non-waiting-related short-IRTs emitted under the DRL5LH schedule, the rate 
of decay (L) was faster for SHR compared to WKY (Fs[2,33]=4.02, p<0.05).  SHR emitted 
shorter bursts (mean length of bursts; 1/L=3.85 sec) than WKY (7.69 sec), but not 
significantly different from WIS (5.26 sec). However, the proportion of short-IRTs was 
not different between strains (q*(1-p); Fs[2,33]=0.149, p>0.05). The between-strain 
differences in the non-waiting-related IRT parameters (L and q*(1-p)) are presented as 
log-transformed exponential functions illustrating that the SHR emitted shorter burst 
responses compared to control (Fig 6.3A). 
For non-waiting-related long-IRTs emitted under the DRL5LH schedule, the rate 
of decay (L’) was slower for SHR (mean length, 1/L’=66.7 sec) and WKY (100 sec) 
compared to WIS (31.3 sec; Fs[2,32]=9.53, p<0.001). Also, the proportion of long-IRTs 
((1-q)*(1-p)) was greater in SHR and WKY compared to WIS (Fs[2,32]=6.48, p<0.005). The 
between-strain differences in the non-waiting-related IRT parameters (L’ and (1-q)*(1-
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p)) are presented as log-transformed exponential functions illustrating that the SHR and 
WKY emitted longer and more frequent task-delinquent responses than WIS (Fig 6.3B). 
Under DRL30, the ΔAIC for SHR, WKY and WIS were -31.6, -120, and +48.0, 
respectively. For SHR and WKY (ΔAICs<10), behavior was predicted by equation (2), 
whereas equation (1) predicted behavior emitted by WIS (ΔAIC>10). Further, the ΔAIC 
for one SHR and two WKY rats were >10; as a consequence, θ, ω, λ and p were 
determined from equation (1). Thus, for WIS rats and for the two WKY and one SHR, the 
non-timed IRTs were not a composite of burst (function of q and L) and task-delinquency 
(function of 1-q and L’) processes. Rather, a single burst-related exponential function (λ) 
sufficiently described the non-timed responding. For statistical analyses, L = λ, and q=1 
for these three rats and for WIS. TR parameters for IRT distributions from SHR, WKY and 
WIS under the DRL30 schedule are provided in Table 6.2. With respect to waiting-
related distributions, WKY had a greater θ than SHR and WIS (Fs[2,33]=44.7, p<0.0001). 
Further, θ deviated from 1 for SHR and WIS (t[11]=16.8 and t[11]=7.26, respectively, 
ps<0.0001), demonstrating reduced accuracy of estimating the 30-sec waiting time. No 
strain differences were found in the coefficient of variation of waiting IRTs (ω; 
Fs[2,33]=0.085, p>0.05), revealing no strain differences in precision. For SHR and WKY, 
the proportion of waiting-related responding (p) was lower than those obtained for WIS 
(Fs[2,33]=7.80, p<0.01).  
For non-waiting-related short-IRTs emitted under the DRL30 schedule, the rate 
of decay was faster for SHR (1/L=0.59 sec) than for WKY (1.27 sec), and slower for WKY 
compared to WIS (0.45 sec; Fs[2,31]=8.13, p<0.0015). Further, the proportion of short 
IRTs was greater for SHR compared to WIS, but not different from those for WKY 
(Fs[2,32]=7.74, p<0.005). Between-strain differences in the non-waiting-related IRT 
parameters (L, λ and q*(1-p), (1-p)) are presented as log-transformed exponential 
functions illustrating that SHR emitted shorter and more frequent bursts compared to 
controls (Fig 6.3C). 
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For non-waiting-related long-IRTs emitted under the DRL30 schedule, the rate of 
decay was faster for SHR (1/L’=0.91 sec) than for WKY (3.75 sec; t[18]=2.10 p=<0.05), 
but the proportion of these IRTs was not different between strains (t[21]=1.49, p>0.05). 
The non-waiting-related IRT parameters (L’, and (1-q)*(1-p)) are presented as log-
transformed exponential functions (Fig 6.3D), illustrating that the distribution for “long-
IRTs” resembled burst-like IRTs in SHR. 
 
6.3.3 Molar IRT distribution parameters 
To determine strain differences for waiting-related responding under DRL5LH 
and DRL30 schedules, the IRT frequency distributions illustrated in Fig 6.1A-B were 
fractionated using visually-defined “molar” behavioral patterns (peak location and peak 
width; Fig 6.4A-D). For waiting-related responding under the DRL5LH schedule, the peak 
location was not different between SHR and WIS; however, the peak location for SHR 
and WIS was longer than that for WKY (Fs[2,33]=7.63, p<0.0005; Fig 6.4A). Further, the 
peak width was greater for SHR compared to WIS (Fs[2,33]=9.67, p<0.0005; Fig 6.4B). 
For waiting-related responding under the DRL30 schedule, the peak location for SHR 
was shorter than that for WKY, but not compared to that for WIS (Fs[2,33]=11.2, 
p<0.0005, Fig 6.4C). Further, the peak location for WKY was greater than that for WIS.  
The peak width under DRL30 was shorter in SHR compared to WKY, but not compared 
to WIS, and peak width for WKY was wider than that for WIS (Fs[2,33]=7.08, p<0.005, Fig 
6.4D).   
Strain differences in non-waiting-related responding under DRL5LH and DRL30 
schedules were characterized using percentage of short-IRTs and long-IRTs (Fig 6.4E-H).  
SHR emitted a greater percentage of short-IRTs (bursts) under DRL5LH (IRT<1.4 sec; 
Fs[2,31]=7.99, p<0.005; Fig 6.4E) and DRL30 (IRT<2.0 sec, Fs[2,32]=17.0, p<0.0001, Fig 
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6.4G) schedules compared to WKY and WIS. Under DRL5LH, both SHR and WKY emitted 
a greater percentage of long-IRTs (task-delinquent responding) compared to WIS 
(IRT>100 sec, Fs[2,33]=10.8, p<0.0001, Fig 6.4F). Under DRL30, long-IRTs were emitted 
by only one SHR, one WIS and nine WKY rats. Between-strain comparisons of the 
percentage of long-IRTs revealed that WKY emitted a greater proportion of long-IRTs 
compared to WIS and SHR (IRT>120 sec; Kruskal-Wallis test, χ2(3)=18, p<0.0001; Fig 
6.4H).  
 
6.3.4 Effects of chronic MPH in adolescent rats under DRL5LH 
Chronic MPH treatment decreased latency to respond following reinforcer 
delivery in the three strains of adolescent rats (Ft[1,29] = 7.86, p<0.01; Fi[2, 29] = 0.842, 
p>0.05; Fig 6.5A), and adolescent SHRs had a lower response latency compared to WKY 
and WIS (Fs[2, 29] = 7.14, p<0.01). Furthermore, the MPH-induced decrease in response 
latency was more pronounced in adolescent SHR (83% of vehicle control; t[10] = 2.64, 
p<0.05) than WKY and WIS (91% and 95%, respectively). Efficiency under DRL5LH was 
not altered by chronic MPH treatment (Table 6.3) in any strain of rat; SHR had reduced 
efficiency compared to WKY and WIS. However, a visual inspection of the mean IRT 
distributions revealed that frequency of waiting-related responding was decreased with 
chronic MPH treatment in all three strains (Fig 6.6A). With respect to modeling 
parameters, chronic MPH treatment decreased the proportion of waiting IRTs (Ft[1, 30] 
= 7.42, p<0.05; Fig 6.6B) and increased burst responses (Ft[1, 30] = 5.54, p<0.05; Fig 
6.6C) in all three strains. No interaction or main effect of strain was revealed for 
proportion of waiting and burst IRTs (Fi[2,30] = 0.792, Fi[2,30] = 0.0774, for waiting and 
burst IRTs, respectively, ps>0.05). Further, no interactions and main effects were 
revealed for mean and proportion of task-delinquent IRTs (Table 6.4), and for precision 
of timed IRTs (Table 6.5).  
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6.3.5 Effects of chronic MPH in adolescent rats under DRL30 
Adolescent SHRs required more sessions to train from DRL3 to DRL30 compared 
to adolescent WKY and WIS (Fi[2,30] = 1.25, p>0.05; Fs[2, 30] = 14.1, p<0.0001; Fig 6.5B). 
Chronic MPH did not alter the number of training sessions in any of the strains (Ft[1,30] 
= 1.41, p>0.05). Efficiency under DRL30 schedule was not altered by chronic MPH 
treatment (Table 6.3) in any of the rat strains; SHR had reduced efficiency compared to 
WKY and WIS, and WKY exhibited greater efficiency compared to WIS (Table 6.3). Visual 
inspection of the mean IRT distributions revealed that frequency of burst responding 
was increased and the peak of timed IRTs was shifted leftwards in adolescent SHR 
treated with MPH; no other differences were observed in the IRT distribution patterns 
between MPH and VEH groups (Fig 6.7A). The parameters derived from fitting the 
mathematical model to the IRT distribution are reported below. 
With respect to the modeling parameters, adolescent SHR showed a reduced 
accuracy of timed IRTs (i.e. mean timed IRTs) compared to WKY and WIS (θ; Fs[2, 30] = 
50.0, p<0.001; Fig 6.7B). Accuracy was further decreased by chronic MPH treatment 
(Ft[1, 30] = 4.71, p<0.05), and this decrease was more pronounced for SHR (78% of 
vehicle control; t[10] = 3.07, p<0.05) than for WKY and WIS (98% and 94%, respectively). 
The mean burst IRTs was increased in MPH-treated SHR compared to vehicle control as 
well as MPH-treated WKY and WIS (1/L; Fi[1, 30] = 3.85, p<0.05; Fig 6.7C). Compared to 
adolescent WKY and WIS, adolescent SHR emitted a greater proportion of burst 
responses, which was further increased by MPH treatment (1-p; Fi[2, 28] = 3.58, p<0.05; 
Fig 6.7D). Further, no interactions nor main effects were revealed for precision of timed 
IRTs for adolescent SHR (Table 6.5) 
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6.3.6 Effects of chronic MPH on locomotor activity in adolescent rats  
In the open-field chambers, the adolescent SHR exhibited greater locomotor 
activity compared to WKY and WIS (Fs[2, 30] = 21.5, p<0.0001; Fig 6.7E). Further, 
locomotor activity for the adolescent WKY was reduced compared to the adolescent 
WIS. However, no interaction or main effect of treatment (Fi[2, 30] = 3.27, Ft[1, 30] = 
3.22, respectively, p>0.05) was obtained in open field locomotor activity in adolescent 
rats. 
 
6.4 Discussion 
In the current study, impulsivity endophenotypes expressed by SHR included 
increased burst responding in both DRL5LH and DRL30 schedules, and reduced wait-
time accuracy in the DRL30 schedule. These endophenotypes contribute to reduced 
reinforcement efficiency, a conventional measure of impulsivity using the DRL task.  
Reinforcement efficiency values for adult SHR were consistent with previous studies 
using DRL30 and DRL5LH (Ferguson et al, 2007; Sanabria et al, 2008; van den Bergh et al, 
2006), but not consistent with DRL5 without a LH condition (Orduna et al, 2009; 
Sanabria et al, 2008). In the current study, SHR attained higher reinforcement rates than 
WKY under the DRL5LH schedule, which was an expected consequence of the observed 
hyperactivity on the active lever in SHRs, and in agreement with previously reported 
hyperactivity in this strain (Hill et al, 2012b). Under the DRL30 schedule, hyperactivity in 
SHR led to a reduced efficiency compared to WKY and WIS. Under the current DRL30 
schedule, WKY were hypoactive compared to WIS, in agreement with previous reports 
(van den Bergh et al, 2006). Also, as a result of fewer active lever responses, WKY had 
the highest reinforcement efficiency under the DRL30 schedule. As a consequence, 
outbred WIS rats proved to be an important control for evaluating impulsivity in SHR, 
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particularly when measures (e.g., efficiency) are normalized by response rates (Alsop, 
2007b). Thus, the current study describes optimized procedures for delineating different 
components of impulsivity, a complex and multifactorial construct.   
 
6.4.1 Optimization using mathematical modeling 
Endophenotypes of impulsivity that contribute to reduced reinforcement 
efficiency in SHR were evaluated by quantification of IRT distribution patterns. Typically, 
IRT patterns have been quantified using molar parameters such as burst ratios and peak 
location, which fragment the IRT distribution (Richards et al, 1993). Although the latter 
molar approach has been informative, current state-of-the-art methods for analyzing 
large data sets often include mathematical modeling, which accounts for the complete 
IRT distribution pattern, rather than simply a fragment of the pattern. Mathematical 
modeling allows informative comparisons of results between different laboratories by 
eliminating the non-standardized cut-offs for IRTs to define the impulsivity 
endophenotypes. In the current study, the results from the mathematical modeling 
approach provided a more informative description than did the molar approach and 
identified the endophenotype of impulsivity expressed as reduced response inhibition in 
the SHR under both schedules.  
Mathematical modeling has been used previously to describe SHR behavior 
under DRL schedules. In the current study, SHR had higher response threshold (θ) 
estimates than WKY under DRL5LH, contrary to previous reports (Orduna et al, 2009; 
Sanabria et al, 2008). This discrepancy may arise from the type of distribution the model 
used to describe the waiting, i.e., normal distribution in the earlier studies versus 
gamma distribution used herein. A recent report suggests that gamma distributions, 
modified from the Erlang distribution for waiting-time, more accurately model waiting 
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behavior under DRL schedules compared with normal distributions (Hill et al, 2012a). In 
the current study, comparison of AIC values from the modified TR equation using the 
normal function (Orduna et al, 2009; Sanabria et al, 2008) with AIC values from Equation 
1 using a gamma function revealed that the latter provided a better fit the waiting 
distribution (Supplementary Table 1). Another possible reason for the inconsistency in 
response threshold may be that Equation (2) includes a second exponential distribution 
of longer non-waiting IRTs, which may have been included with the waiting IRTs in the 
previous studies. Thus, when the long task-delinquency related IRTs were excluded from 
the waiting IRTs, as in the current model (Equation 2), SHR did not differ from WIS in the 
accuracy of estimating the 5 sec waiting time under DRL5LH, emphasizing the 
importance of selecting appropriate modeling tools to draw inferences about 
impulsivity.  
6.4.2 Impulsivity endophenotypes 
For waiting-related responses under DRL5LH, mathematical modeling showed 
that SHR had the highest accuracy of timing (θ), which was different from WKY, but not 
different from WIS.  The current models also showed that SHR were less likely to 
produce waiting responses (p).  Thus, SHR exhibited high accuracy, but a reduced 
tendency to wait.  For non-timed responses, the molar parameter (i.e., percentage 
short-IRTs) indicates that the SHR produced a greater frequency of burst responses. 
However, the mathematical model which accounts for the entire responding pattern 
reveals that  SHR did not emit a greater frequency of bursts (i.e., q*(1-p)), but rather, 
emitted shorter bursts (i.e., 1/L), contributing to a reduced reinforcement efficiency. In 
contrast, in the evaluation of task-delinquency, both molar parameters (i.e., percentage 
long-IRTs) and modeling parameters (i.e., (1-p)*(1-q)) were in agreement and indicated 
that SHR and WKY emitted a greater proportion of delinquent responses compared to 
WIS. Thus, results from the model show that SHR obtain fewer reinforcers under a 
DRL5LH schedule due to a reduced tendency to wait, shorter burst responding, and 
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more frequent and longer task-delinquency behavior.  Reduced tendency to wait and 
shorter bursts indicate that SHR express a specific impulsivity endophenotype.  
Under the DRL30 schedule, SHR exhibited reduced response thresholds, 
indicating either reduced ability to estimate wait-time or impaired time perception. 
Previous research using peak-interval procedures indicate that SHR, WKY and WIS do 
not differ in ability to time 30 sec (Fox et al, 2009; Orduna et al, 2008). Thus, the low 
response threshold (θ) in SHR and WIS may be an outcome of reduced ability to wait, 
indicative of aversion to wait. Moreover, SHR produced a lower proportion (p) of 
waiting-related responses compared with WIS, indicating that reduced response 
inhibition contributed to the low reinforcement efficiency in SHR. Another contributor 
to loss in efficiency was the more frequent burst responding (i.e., q*(1-p)) emitted by 
SHR. Thus, under the DRL30 schedule, SHR obtained fewer reinforcers due to a reduced 
wait-time accuracy (θ) and reduced response inhibition (fewer waiting-related 
responses and more frequent bursts), all of which contribute to impulsivity in SHR. Thus, 
increasing the DRL interval further reveals behavioral deficits associated with 
impulsivity. The current results are consistent with previous findings that low rates of 
reinforcement with variable interval schedules reveal behavioral deficits in SHR (Hill et 
al, 2012a; Williams et al, 2009a). The current results further validate the SHR model of 
ADHD since behavioral deficits in ADHD patients are manifest only under schedules 
providing infrequent reinforcement (Aase and Sagvolden, 2006).   
A limitation of exceedingly-long DRL intervals is the risk of reducing the 
reinforcement frequency to the point where responding is no longer maintained. This 
limitation has been overcome by extensive training (Orduna et al, 2009). Further, not all 
behavioral changes associated with reduced reinforcement frequency are specific to the 
ADHD model. Under low rates of reinforcement, outbred rats are unable to inhibit 
rapid-responding on the active lever (Stein et al, 1975; Williams et al, 2009a; Wultz and 
 217 
 
Sagvolden, 1992). In agreement, increasing wait-time from 5 to 30 sec in the DRL 
schedule resulted in shortening of the burst IRTs in all three rat strains.  
6.4.3 Methylphenidate and DRL behavior 
For animal models of ADHD, the face-validity criterion posits that low doses of 
MPH will reduce impulsivity (Willner, 1986). In adolescent outbred rats, MPH 
administered repeatedly decreased home-cage activity (Kuczenski et al, 2002), but not 
locomotor activity in an open field (Yang et al, 2003; Yang et al, 2011). In adolescent 
SHR, therapeutically relevant low doses of MPH decreased hyperactivity in open-field 
chambers when administered acutely (Umehara et al, 2013a; Umehara et al, 2013b), 
but this effect did not persist following chronic treatment (Yang et al, 2011; Yetnikoff et 
al, 2013). Consistent with these reports, the current study found that chronic MPH 
treatment did not alter locomotor activity in adolescent rats. MPH has been shown to 
improve several prefrontal cortical functions such as behavioral flexibility and 
motivation in outbred rats (Floresco et al, 2009; Yamagata et al, 2012). In adolescent 
SHRs, chronic MPH administration improved learning, attention and non-spatial working 
memory in visual discrimination tasks (Harvey et al, 2011; Kantak et al, 2008), as well as 
behavioral flexibility in strategy set-shifting tasks (Harvey et al, 2013). The current study 
extends the previous findings by showing that chronic MPH treatment in adolescent SHR 
increased motivation to respond (reduced response latency, Fig 6.5A) under DRL5LH. 
Taken together, these results support the adolescent SHR as a model of ADHD. 
In contrast to the effects of MPH on response latency, chronic MPH increased 
impulsivity in adolescent rats. Specifically, MPH increased burst responding in 
adolescent SHR, WKY and WIS under DRL5LH, and also increased burst responding and 
decreased accuracy of estimating the 30-sec wait-time under DRL30 only in SHR. These 
results were contradictory to clinical observation that response inhibition is decreased 
by repeated MPH treatment in children and adolescents with ADHD (Broyd et al, 2005; 
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Lee et al, 2010), and thus may suggest a limitation of the SHR model of ADHD or of DRL 
schedules as a measure of impulsivity.  
The 5-choice serial reaction time task (5CSRT) is a response inhibition task that 
measures impulsivity as increased premature responding (Puumala et al, 1996; Robbins, 
2002). In adult as well as adolescent outbred rats, premature responding under 5CSRT 
schedules has been reported to be increased or not altered by acute MPH at 
therapeutically relevant doses (Economidou et al, 2012; Navarra et al, 2008). In contrast 
to MPH, the non-stimulant ATO decreased premature responding in the 5CSRT 
(Economidou et al, 2012; Navarra et al, 2008). In adult SHR, MPH was found to not alter 
premature responding (van den Bergh et al, 2006); however, effects of MPH or ATO in 
adolescent SHR under 5CSRT tasks have not been reported.  Taken together with the 
current results, response inhibition tasks, such as 5CSRT and the DRL schedules appear 
to be more sensitive to the stimulant properties of MPH, even with doses that were 
below the threshold for increasing locomotor activity (Berridge et al, 2006; Kuczenski et 
al, 2002).  
In conclusion, the current study supports the use of adult and adolescent SHR as 
a model of ADHD. However, the DRL schedules were limited in their ability to model the 
effects MPH on impulsivity. This study extends the literature by demonstrating that 
reduced accuracy of estimating waiting-time and reduced response inhibition 
(composite of reduced proportion of waiting responses and increased burst responses) 
contribute to impulsivity in SHR. These individual processes are differentially sensitive to 
strain, MPH and schedule of reinforcement. Thus, mathematical modeling approach 
may prove to be a valuable tool and may have substantial translational value to extend 
our understanding of DRL behavior in the clinical samples.  
 
  
Table 6.1 Responses on the active and the number of pellets earned by WIS, WKY and SHR under the DRL5LH and DRL30 
schedules of responding. 
  Active lever response Reinforcers earned 
DRL5LH 
SHR 
274 ± 10.4 *
# a 67.7 ± 2.17 * 
#
 
WKY 121 ± 11.4 * 30.4 ± 2.54 * 
WIS 475 ± 32.9  109 ± 5.07 
DRL30 
SHR 
258 ± 13.6 * 
#
 13.8 ± 2.25 * 
#
 
WKY 107 ± 8.19 * 45.5 ± 1.52 * 
WIS 184 ± 13.1 23.5 ± 3.28 
a All values are mean ± S.E.M; * p < 0.05, different from WIS; # p < 0.05 different from WKY; n=12/strain.  
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Table 6.2 Estimates of TR parameters obtained from IRT data from SHR, WKY and WIS on DRL5LH and DRL30 schedules. 
Distribution Waiting-related or timed IRT Burst Task-delinquency 
 Accuracy                θ 
(seconds) 
Precision       
ω (seconds) 
Proportion      p 
Rate of decay 
L (second-1) 
Proportion        
q *(1-p) 
Rate of decay 
L’ (minute-1) 
Proportion       
(1-q)*(1-p) x 10-1 
D
R
L5
LH
 
SHR b 0.99 ± 0.031 # a 0.37 ± 0.053 0.50 ± 0.053 * 0.26 ± 0.091 # 0.44 ± 0.058 0.93 ± 0.12 * 0.60 ± 0.13 ** 
WKY b 0.85 ± 0.038 * † 0.37 ± 0.027 * 0.57 ± 0.042 0.13 ± 0.017 0.41 ± 0.055 0.63 ± 0.20 ***  0.49 ± 0.10 * 
WIS b 0.95 ± 0.015 † 0.27 ± 0.015 0.67 ± 0.036 0.19 ± 0.016 0.30 ± 0.034 1.9 ± 0.42  0.24 ± 0.042 
D
R
L3
0
 
SHR b 0.55 ± 0.027 * ### † 0.51 ± 0.018 0.72 ± 0.044 ** 1.7 ± 0.20 ## 0.22 ± 0.018 ** 66 ± 19 # 0.42 ± 0.22 
WKY b 1.1 ± 0.059 *** 0.51 ± 0.030 0.75 ± 0.037 * 0.73 ± 0.22 ** 0.15 ± 0.025 16 ± 11 0.98 ± 0.29 
WIS c 0.68 ± 0.044 † 0.50 ± 0.021 0.91 ± 0.024 2.2 ± 0.40 c 0.091 ± 0.024  N.A. N.A. 
a Values are mean ± S.E.M. All comparisons are within the same schedule. b Values for the strain for each parameter were 
obtained from equation (2). c Values for the strain for each parameter were obtained from equation (1).* p < 0.05, ** p < 
0.01 and *** p < 0.0001, different from WIS; # p < 0.05, ## p < 0.01 and ### p < 0.0001, different from WKY; †p < 0.05, different 
from unity. N.A. Not applicable, since equation (1) does not include L’ and q. 
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Table 6.3 Adolescent SHR exhibited reduced efficiency under DRL5LH and DRL30 schedules. 
Adolescent SHR exhibited reduced efficiency of earning reinforcers compared to WKY and WIS under DRL5LH and DRL30 
schedules.Under DRL30, adolescent WKY exhibited the greater efficiency compared to WIS. Chronic MPH treatment did not 
alter efficiency of earning reinforcers under either DRL5LH or DRL30 schedules 
   WIS WKY SHR Finteraction Fstrain 
Efficiency DRL5LH VEH 27.4 ± 2.08 a 27.8 ± 1.15 24.4 ± 1.50 F[2,30] = 2.32 F[2,30] = 6.03 b 
  MPH 23.6 ± 1.15 31.6 ± 1.35 22.4 ± 2.89  SHR <WIS = WKY 
 DRL30 VEH 13.1 ± 3.11 16.7 ± 3.14 3.11 ± 0.55 F[2,30] = 0.038 F[2,30] = 23.1 b 
  MPH 11.0 ± 1.79 15.7 ± 1.84 1.40 ± 0.32  SHR < WIS < WKY 
a Values are mean ± S.E.M.  
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Table 6.4 For task-delinquent responding, adolescent SHR exhibited shorter mean delinquent IRTs compared to WKY and 
WIS under DRL5LH 
Adolescent WKY exhibited the longest mean task-delinquent IRTs. Chronic MPH treatment did not alter mean task-
delinquent IRTs. Further, no effects of strain or treatment were obtained for proportion of task-delinquent IRTs under 
DRL5LH. 
   WIS WKY SHR Finteraction Fstrain 
DRL5LH Proportion VEH 0.095 ± 0.036 0.12 ± 0.052 0.13 ± 0.048 F[2,30] = 0.832 F[2,30] = 0.149 
Task-
delinquent 
responding 
(1-p)*(1-q) MPH 0.15 ± 0.052 0.078 ± 0.032 0.079 ± 0.040   
Mean IRT VEH 22.3 ± 8.1 42.6 ± 10.9 6.5 ± 1.8 F[2,26] = 1.39 F[2,26] = 12.1 b 
1/L’ (in sec) MPH 20.7 ± 5.8 49.0 ± 21.0 13.1 ± 4.7  SHR < WIS < WKY 
a Values are mean ± S.E. M. 
b p < 0.05b p < 0.05  
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Table 6.5 For precision of waiting-related responding, no differences were found between MPH and VEH treated groups of 
adolescent SHR, WKY and WIS rats under DRL5LH and DRL30 schedules 
   WIS WKY SHR Finteraction Fstrain 
Precision  DRL5LH VEH 0.41 ± 0.068a 0.45 ± 0.074 0.37 ± 0.056 F[2,30] = 0.371 F[2,30] = 0.300 
(ω)   MPH 0.33 ± 0.027 0.39 ± 0.074 0.39 ± 0.082   
(in sec) DRL30 VEH 0.45 ± 0.032 0.50 ± 0.051 0.54 ± 0.036 F[2,30] = 0.271 F[2,30] = 0.966 
  MPH 0.49 ± 0.025 0.50 ± 0.034 0.52 ± 0.079   
a Values are mean ± S. E.M. 
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Figure 6.1 
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Fig. 6.1: Average frequency distribution of the inter-response times (IRTs) and 
percentage of responses reinforced during responding under DRL5LH (panel A) and 
DRL30 (panel B) schedules for adult Spontaneously Hypertensive Rats (SHR), Wistar-
Kyoto rats (WKY) and Wistar rats (WIS). The frequency of IRTs are presented as the 
mean number of responses in each IRT bin divided by the total number of IRTs emitted 
for WIS (solid curve), WKY (dashed curve) and SHR (dotted curve). The IRT curves are 
presented as 1-second and 5-second moving averages for DRL5LH and DRL30, 
respectively. The vertical dotted lines indicate the minimum waiting time for earning 
reinforcers for each schedule.  Premature responses left of the vertical dotted line 
resulted in loss of reinforcement. Responses to the right of the dotted line were 
reinforced under DRL30; however, only responses within the limited hold were 
reinforced under DRL5LH. Efficiency is presented as the total number of pellets earned 
(mean ± S.E.M) as percentage of the total number of responses on the active lever for 
WIS (black bars), WKY (grey bars) and SHR (white bars).  
* p<0.05, different from WIS;  
# p<0.0001, different from WKY;  
n = 12/strain. 
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Figure 6.2 
Li
m
it
e
d
 h
o
ld
(s
ec
o
n
d
s)
WIS WKYSHR
0
5
10
15
*
**
##
R
a
te
 o
f 
re
in
fo
rc
e
m
e
n
t
(p
el
le
ts
 p
er
 m
in
u
te
)
WIS WKYSHR
0.0
0.5
1.0
1.5
2.0
2.5
**
**
##
A B
 
Fig 6.2 Stable adjusted limited hold (A) and rate of reinforcement (B) for adult 
Spontaneously Hypertensive Rats (SHR), Wistar-Kyoto (WKY) and Wistar (WIS) rats 
under DRL5LH schedule. Stable adjusted limited hold values are mean ± S.E.M. in 
seconds for WIS (black bars), WKY (grey bars) and SHR (white bars). Rate of 
reinforcement for WIS, WKY and SHR are number of pellets earned (mean ± S.E.M.) 
normalized per minute of each 55-minute session (right);  
* p < 0.01, ** p < 0.001, different from WIS;  
## p < 0.001, different from WKY;  
n = 12/strain. 
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Figure 6.3 
IRT bins (sec)
L
o
g
(F
re
q
u
e
n
c
y
)
0 20 40 60
-8
-6
-4
-2
0
SHR
WKY
WIS
IRT bins (sec)
L
o
g
(F
re
q
u
e
n
c
y
)
0 50 100 150 200 250
-7
-6
-5
-4
-3
-2
IRT bins (sec)
L
o
g
(F
re
q
u
e
n
c
y
)
0 10 20 30 40 50 60
-50
-40
-30
-20
-10
0
IRT bins (sec)
L
o
g
(F
re
q
u
e
n
c
y
)
0 50 100 150 200 250
-50
-40
-30
-20
-10
0
BURST TASK-DELINQUENCY
A B
DC
DRL5LHDRL5LH
DRL30DRL30
 
Fig 6.3 The non-waiting-related IRT parameters depicting bursts (left) and task-
delinquent responding (right) emitted by adult Spontaneously Hypertensive Rats (SHR), 
Wistar-Kyoto rats (WKY) and Wistar rats (WIS) under DRL5LH (A and B) and DRL30 (C 
and D) schedules are presented as hypothetical exponential frequency-distribution 
semi-log plots.  The curves were generated from the mean parameter estimates for 
bursts (L and q *(1-p)) and for task delinquency (L’ and (1-q)*(1-p)) under both 
schedules for SHR (dotted curve), WKY (dashed curve) and WIS (solid curve); n = 
12/strain. 
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Figure 6.4 
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Fig 6.4 Molar descriptors for the waiting-related (top) and non-waiting-related (bottom) 
responding emitted by adult Spontaneously Hypertensive Rats (SHR), Wistar-Kyoto 
(WKY) and Wistar (WIS) rats under DRL5LH and DRL30 schedules. For waiting-related 
responding under DRL5LH (A, B) and DRL30 schedules (C, D), the peak location (A, C) and 
peak width (B, D) are mean ± S.E.M. sec for WIS (black bars), WKY (grey bars) and SHR 
(white bars). For non-waiting-related responding, short- and long-IRTs under DRL5LH (E, 
F) and short-IRTs under DRL30 (G) are mean ± S.E.M. expressed as a percentage of the 
total number of IRTs for WIS (black bars), WKY (grey bars) and SHR (white bars). Under 
DRL30 (H), between-strain differences in long-IRTs (>120 sec) were found. 
* p<0.05, different from WIS;  
# p<0.05, different from WKY.  
n = 12/strain (A-G).  
Ω p<0.0001, different from WIS;  
^ p<0.0001, different from WKY.  
n = 1 SHR, 1 WIS, 9 WKY (H). 
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Figure 6.5 
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Fig 6.5  Latency for responding under DRL5LH (A) and number of sessions to train from 
DRL3 to DRL30 (B) for adolescent Spontaneously Hypertensive Rats (SHR), Wistar-Kyoto 
(WKY) and Wistar (WIS) rats that were administered chronic methylphenidate (MPH; 
grey bars) or vehicle (VEH; white bars) 30 min prior to the behavioral session. Latency 
for responding (in sec) and number of training sessions are mean ± S.E.M. in seconds for 
WIS, WKY and SHR.  
s* p < 0.05, main effect of strain, different from WKY and WIS; 
t* p < 0.05, main effect of treatment; 
ε p < 0.05 compared to the respective vehicle control;  
n = 6/group. 
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Figure 6.6 
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Fig 6.6  Average frequency distribution of the inter-response times (IRTs, A) and 
proportion of timed-IRTs (B) and burst-IRTs (C) for adolescent Spontaneously 
Hypertensive Rats (SHR), Wistar-Kyoto rats (WKY) and Wistar rats (WIS) under the 
DRL5LH schedule that were administered chronic methylphenidate (MPH; grey bars) or 
vehicle (VEH; white bars). The frequency of IRTs are presented as the as 1-sec moving 
averages of mean number of responses in each IRT bin divided by the total number of 
IRTs emitted following chronic MPH (dotted curve) or VEH (solid curve) treatments for 
adolescent WIS, WKY and SHR under DRL5LH.  The vertical dotted lines indicate the 
minimum waiting time for earning reinforcers for each schedule.  Premature responses 
left of the vertical dotted line resulted in loss of reinforcement. Values are mean ± 
S.E.M. for proportion of timed-IRTs and proportion of burst-IRTs.  
t* p < 0.05, main effect of treatment;  
n = 6/group. 
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Figure 6.7 
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Fig 6.7  Average frequency distribution of the inter-response times (IRTs, A) and 
mathematically modeled impulsivity parameters (B-D), and hyperactivity (E) for 
adolescent Spontaneously Hypertensive Rats (SHR), Wistar-Kyoto rats (WKY) and Wistar 
rats (WIS) under the DRL30 schedule that were administered chronic methylphenidate 
(MPH; grey bars) or vehicle (VEH; white bars). The frequency of IRTs are presented as 
the as 5-sec moving averages of mean number of responses in each IRT bin divided by 
the total number of IRTs emitted following chronic MPH (dotted curve) or VEH (solid 
curve) treatments for adolescent WIS, WKY and SHR under DRL30.  The vertical dotted 
lines indicate the minimum waiting time for earning reinforcers for each schedule.  
Premature responses left of the vertical dotted line resulted in loss of reinforcement. 
Values are mean ± S.E.M. for accuracy of mean timed-IRTs (B), mean burst IRTs (C; in 
sec) and proportion of burst-IRTs (D) under DRL30 schedule and number of horizontal 
beam-breaks (E) in open-field chambers.   
* p ≤ 0.05 compared to the respective VEH control as well as MPH-treated WKY and 
WIS;  
^ p ≤ 0.05 compared to VEH-treated WKY and WIS;  
ε p ≤ 0.05 compared to the respective VEH  
s* p ≤ 0.05 main effect of strain, different from WKY and WIS;  
# p ≤ 0.05 main effect of strain, different from WIS;  
t* p < 0.05, main effect of treatment;  
n = 6/group. 
  
 235 
 
6.5 Supplementary Materials 
Supplementary Fig. 1 
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Supplementary Fig. 1 Theoretical data representing the individual components of 
equation 2; a timing-related gamma-function (dashed line) that is typically centered on 
the DRL wait time, a fast-decaying exponential function (solid line) describing burst of 
iterative responding and a slow-decaying exponential function (beaded line) describing 
iterative behavior with long pauses between subsequent lever responses. For equation 
1, a single exponential function describes both burst and task-delinquent responding 
(representation not shown). 
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Supplementary Fig. 2 
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Supplementary Fig 2: The number of sessions to train adult rats from DRL5LH to DRL30 
did not differ between Wistar (WIS), Wistar-Kyoto (WKY) and Spontaneously 
Hypertensive Rats (SHR). Training required by WIS (black bars), WKY (grey bars) and 
SHR (white bars) are mean ± S.E.M. in sessions; n=12/strain. 
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Supplementary Fig. 3 
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Supplementary Fig. 3 Representative IRT data from individual rats under DRL5LH 
schedule plotted as cumulative frequency distributions (A-D) illustrating that the 
observed values (closed triangles) are accurately predicted by the mathematical 
model (equation 2; solid red curve). Observed and predicted lines overlap such that 
they cannot be distinguished individually. As illustrated, four IRT distribution patterns 
were observed under DRL5LH. (A) The waiting pattern was a uni-modal distribution with 
responding centered at the 5-second waiting-time that achieved an asymptote by 7.5 
seconds. (B) The burst pattern was a bi-modal distribution with the rise to the early 
plateau delineating burst-related responding, followed by waiting. (C) The task-
delinquency pattern was a uni-modal distribution in which the waiting IRTs required >15 
seconds to reach asymptote. (D) The combination pattern was a composite of a bi-
modal IRT distribution (burst pattern) and required >15 seconds to reach asymptote 
(task-delinquency pattern). 
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Supplementary Table 1: Comparison of gamma- and normal-distribution for predicting 
behavior for Wistar (WIS), Wistar-Kyoto (WKY) and Spontaneously Hypertensive Rats 
(SHR) under DRL5LH schedule of responding. The IRT data for WIS, WKY and SHR under 
DRL5LH schedule were used for mathematical modeling using two equations. In 
equation 1), waiting-related responding was predicted using a normal distribution 
(Orduna et al, 2009; Sanabria et al, 2008). In equation 2), waiting-related responding 
was predicted using a gamma distribution (Hill et al, 2012a). Subsequently, the data-fit 
for equations 1) and 2) were compared using the Akieke Information Criterion (AIC), 
given in equation 3).  
 (     )     (        )   (   )    (   )                                                         
1) 
 (     )     (       )   (   )    (   )                                                            
2) 
ΔAIC =  2*(number of parametersequation 2 – number of parametersequation 1) – 
2*(loglikelihoodequation 2 – loglikelihoodequation 1)             
3) 
 WIS WKY SHR 
DRL5LH -437a -872 -788 
a Values are ΔAIC for each strain, obtained from equation 3 
Since the ΔAIC values for DRL5LH for SHR, WKY and WIS were less than 10, 
behavior was predicted by equation 2). These results are consistent with the 
suggestions from a recent report (Hill et al, 2012), gamma distributions, modified from 
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the Erlang distribution for waiting-time, more accurately modeled waiting behavior 
under DRL5LH compared with normal distributions. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Copyright © Sucharita S. Somkuwar 2013  
 240 
 
 
7 CHAPTER SEVEN 
 
Chronic methylphenidate treatment during adolescence increases impulsivity  
 
that persists into adulthood in the Spontaneously Hypertensive Rat model of ADHD 
 
 
7.1 Introduction 
Attention deficit/hyperactivity disorder (ADHD) is a neurobehavioral disorders 
affecting 8-12% of children and about 5% of adults worldwide (Biederman et al, 2010a). 
The diagnosis of ADHD is based on observable clinical descriptors (hyperactivity, 
impulsivity and inattention) rather than founded on genetic or pathophysiological 
markers (Bearden et al, 2004; Castellanos and Tannock, 2002). Adults with ADHD have a 
higher risk of developing substance use disorders compared to individuals without 
ADHD (Biederman et al, 2010b; Lee et al, 2011; Wilens et al, 1998a). In particular, 
individuals with ADHD have a 35% higher incidence of cocaine abuse compared to the 
general population (Carroll et al, 1993; Levin et al, 1999). Mechanisms underlying the 
comorbidity of ADHD and cocaine abuse have not been elucidated. Methylphenidate 
(MPH) is the most widely prescribed pharmacotherapy for children and adolescents with 
ADHD (Chai et al, 2012; Goldman et al, 1998; Robison et al, 1999).  Controversy exists 
regarding the effects of MPH treatment during childhood and adolescene on 
subsequent cocaine abuse liability (Kollins, 2008b), such that increases, decreases as 
well as no effect have been reported (Barkley et al, 2003; Biederman et al, 1999b; 
Fischer et al, 2003; Lambert et al, 1998; Molina et al, 2013; Wilens et al, 2003). These 
discrepancies may be due to inherent heterogeneity in the ADHD population, varations 
in age and duration of MPH treatment, and complexities associated with comorbid 
conditions such as conduct disorder (Barkley et al, 2003; Molina et al, 2013).  A 
prospective longitudinal study in children with ADHD, but without conduct disorder, 
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reported that initiation of MPH treatment in early adolescence was associated with 
higher lifetime rates of cocaine abuse compared to initiation during childhood 
(Mannuzza et al, 2008). Thus, the age of intiation of MPH treatment may be a critical 
factor modulating cocaine abuse liability in individuals with ADHD.  
Impulsivity, a hallmark of ADHD (American Psychiatric Association., 2000), is an 
established predictor for drug abuse liability, including for cocaine (Belin et al, 2008b; 
Everitt et al, 2008; Winstanley et al, 2010a). Impulsivity is a broad psychological 
construct that encompasses a variety of maladaptive behaviors including, but not 
limited to, actions that are poorly conceived, unnecessarily risky and prematurely 
executed without sufficient forethought (Evenden, 1999b). Experimental measures 
evaluating these facets of impulsivity do not correlate with each other, indicating that 
the construct of impulsivity consists of orthogonal factors (Block, 1995; Broos et al; 
Whiteside et al, 2001; Winstanley et al, 2006a).  
One approach to simplify the construct of impulsivity in ADHD is via the 
identification of endophenotypes, which by definition are proximal markers of gene 
action (Almasy et al, 2001; Gottesman et al, 2003), such as a deficit in response 
inhibition capacity (Crosbie et al, 2008; Slaats-Willemse et al, 2003; Willner, 1986). 
Response inhibition capacity is an executive control mechanism to prevent premature 
execution of an intermittently reinforced action (Aron, 2007; Barkley, 1997). Response 
inhibition capacity was increased in children and adolescents with ADHD during chronic 
MPH treatment (Coghill et al, 2007; Rhodes et al, 2006). However, the long-term effects 
of discontinuation of MPH treatment on response inhibition capacity have not been 
reported (Chen et al, 2011; McCarthy et al, 2009). Cocaine abuse is associated with 
response inhibition deficits (Fillmore and Rush, 2002; Li et al, 2006). Individuals with 
comorbid ADHD and cocaine dependence exhibit greater deficits compared to those 
with ADHD but not cocaine dependence, and compared to demographically-matched 
healthy controls (Crunelle et al, 2013). Thus, response inhibition deficits may be the 
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facet of impulsivity that underlies the greater cocaine abuse liability in individuals with 
ADHD.  
Preclinical studies support that reduced response inhibition is associated with 
increased drug-taking and drug-seeking behavior (Dalley et al, 2011; Diergaarde et al, 
2008; Groman et al, 2009). In outbred animals, low therapeutic doses of MPH decreased 
impulsivity ((Eagle et al, 2007; Hill et al, 2012a; Kuczenski et al, 2002; van den Bergh et 
al, 2006), also see (Fernando et al, 2012; Navarra et al, 2008)).  MPH treatment in 
adolescent outbred animals increased sensitivity to aversive effects of cocaine and 
decreased cocaine self-administration during adulthood (Andersen et al, 2002; Carlezon 
et al, 2003; Thanos et al, 2007). Latter results suggest that MPH treatment may be 
protective against cocaine abuse liability; however, outbred animals do not adequately 
represent the deficits associated with ADHD. Subjects with the ADHD-like phenotype are 
needed to evaluate the complex interaction between chronic MPH treatment and 
response inhibition deficits on cocaine abuse liability. 
The Spontaneously Hypertensive Rat (SHR), the most widely accepted inbred rat 
model of ADHD, displays many of the phenotypic characteristics of ADHD, including 
impulsivity (Adriani et al, 2003; Kantak et al, 2008; Mill et al, 2005; Sagvolden et al, 
2005b; Sanabria et al, 2008).  The inbred progenitor rat strain, Wistar-Kyoto (WKY), also 
exhibits behavioral deficits such as hypoactivity, anxiety and depression (De La Garza et 
al, 2004; Langen and Dost, 2011; van den Bergh et al, 2006). Thus, outbred rat strains, 
such as Wistar (WIS) rats, are included to disambiguate differences between SHR and 
WKY (Alsop, 2007b; Langen et al, 2011; Somkuwar et al, 2013a). Chronic MPH treatment 
in adolescent SHRs improved behavioral deficits including working memory and 
behavioral flexibility relative to vehicle control as well as WKY and WIS (Harvey et al, 
2013; Kantak et al, 2008). 
Compared to WKY and WIS, adult SHR acquire cocaine self-administration faster 
and exhibit upward-shifted dose-response functions for cocaine (Harvey et al, 2011; 
Somkuwar et al, 2013b). Chronic MPH treatment through adolescence followed by 
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treatment discontinuation in early adulthood resulted in a further increase in cocaine 
self-administration in adult SHR compared to SHR administered vehicle and compared 
to the control strains administered MPH (Harvey et al, 2011). Consistent with previous 
studies in outbred animals (Carlezon et al, 2003; Thanos et al, 2007), chronic MPH 
treatment in the WIS rats reduced acquisition of cocaine self-administration compared 
to its vehicle control. Chronic MPH treatment during adolescence in rats with an ADHD 
phenotype (SHR) also increased anxiety, decreased the rewarding effect of MPH, 
increased the cross-sensitization to cocaine, and increased dopamine transporter 
function in the medial prefrontal cortex (dela Pena et al, 2012a; Somkuwar et al, 2013a; 
Vendruscolo et al, 2008; Yetnikoff et al, 2013). The prefrontal cortex undergoes rapid 
development during adolescence, and thus, adolescents differ from adults in their 
response to rewarding as well as aversive stimuli (Casey et al, 2010; Somerville et al, 
2010b). Also, adolescent rats are typically more impulsive compared to adult rats 
(Adriani et al, 2004; Burton and Fletcher, 2012; Proal et al, 2011). Chronic MPH 
treatment in adolescent SHR altered neuronal excitability in adolescent and adult 
prefrontal cortical neurons as well as an increased in cocaine self-administration during 
adulthood (Harvey et al, 2011; Somkuwar et al, 2013a; Urban et al, 2013; Urban et al, 
2012). Thus, chronic MPH treatment during adolescence may have altered the 
developmental trajectory in the prefrontal cortex, ultimately resulting in increased 
cocaine abuse.  
The current study used differential reinforcement of low rate (DRL) schedules to 
determine effects of treatment with a therapeutically relevant dose of MPH during 
adolescence on response inhibition capacity in adult SHR.  MPH-induced changes in 
response inhibition capacity may mediate the increase in cocaine self-administration 
observed previously by altering prefrontal cortical function during development (Harvey 
et al, 2011; Somkuwar et al, 2013a; Urban et al, 2012). Under a DRL schedule, the 
subject must wait a defined time interval between consecutive responses to earn 
reinforcers, i.e., inter-response times (IRT) greater than an experimenter-defined 
minimum time are reinforced  (Monterosso and Ainslie, 1999). Under DRL schedules, 
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response inhibition deficit (or premature responding) is inferred from reduced efficiency 
of earning reinforcers (Stein et al, 1975). Compared to WKY and several outbred strains, 
adult SHR showed reduced efficiency under several DRL schedules (Bull et al, 2000; 
Ferguson et al, 2007; Orduna et al, 2009; Sanabria et al, 2008; van den Bergh et al, 
2006). Surprisingly, therapeutically relevant MPH doses administered acutely did not 
increase efficiency in adult SHR (Ferguson et al, 2007; Orduna et al, 2009; van den Bergh 
et al, 2006), which may be attributed to acute, rather than chronic administration. 
Effects of chronic MPH in either adolescent or adult rats responding on DRL schedules 
have not been evaluated. Additionally, efficiency may not be sensitive to the effects of 
MPH on deficits in response inhibition capacity. Quantitative modeling of IRT-
distribution patterns under DRL schedules provide theoretically based measures of 
response inhibition capacity and may be more sensitive than efficiency to the effects of 
MPH (Hill et al, 2012a; Orduna et al, 2009; Sanabria et al, 2008).  
 
7.2 Methods 
7.2.1 Subjects/Animals 
Three separate cohorts of male SHR and WKY rats (Charles River Laboratories, 
Kingston, NY) and male Wistar rats (WIS; Raleigh, NC) were employed. WKY and WIS 
were used as inbred and outbred comparator strains, respectively. Rats were 
maintained on a 12-h light:dark cycle with lights on 07:00 h, individually housed with 
free access to food and water in a colony room (Division of Laboratory Animal 
Resources, University of Kentucky, Lexington, KY, USA). The experiments were 
conducted during the light-cycle of the rats. Adult rats obtained at postnatal day 70 
(P70), were employed for the pilot experiments (n=12/strain) and for experiment II 
(n=6/group). For experiment I, rats arrived at P25 (n=6/group). After 3 days of 
habituation, rats were food restricted to 90-95% of their expected free-feeding body 
weight. All experimental protocols were conducted according to the 1996 National 
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Institutes of Health Guide for the Care and Use of Laboratory Animals and were 
approved by the Institutional Animal Care and Use Committee at the University of 
Kentucky. 
 
7.2.2 Drugs and treatments 
(±)-Methylphenidate hydrochloride (Sigma-Aldrich, St Louis, MO) was dissolved 
in water at concentrations of 0.3, 0.75, 1.5, 3.0 and 5.0 mg/ml and injected into oyster 
crackers (Kantak et al, 2008) providing oral doses of 0.3 - 5.0 mg/kg. Oyster crackers 
injected with water (1 ml/kg) were used as the vehicle control. Solutions were prepared 
fresh on each experimental day. The MPH dose range results in clinically relevant 
plasma concentrations (Kuczenski et al, 2002; Wargin et al, 1983). With the exception of 
the highest MPH dose, doses administered were below the threshold for producing 
locomotor activation (Kuczenski et al, 2002). For the pilot experiments, the cracker was 
provided in the home-cage 45 min prior to the operant session to attain peak plasma 
levels of MPH immediately before behavioral sessions (Kuczenski et al, 2002). Rats 
consumed the oyster cracker within 5 min of its presentation. 
Previous studies have reported that MPH at 1.5 mg/kg, p.o. reduce working 
memory and learning deficits in the SHR, but not in WKY (Harvey et al, 2011; Kantak et 
al, 2008). Based on the latter reports as well as results from the pilot study (detailed in 
the results section), the 1.5 mg/kg, p.o., dose of MPH was used for experiments I and II. 
For experiment I, rats were treated with MPH or vehicle between P28 to P55, which 
includes early to late adolescence (Doremus-Fitzwater et al, 2010; Spear, 2000a). Rats 
were dosed Monday to Friday to model the weekend “medication holiday” often 
recommended for individuals with ADHD (1996), and evaluated on DRL schedules from 
P77. In experiment II, starting from P77, daily dosing and behavior testing regimen was 
employed to obtain stable operant behavior. Based on preliminary results, MPH was 
administered 30 min before the session.  
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7.2.3 Differential reinforcement of low rate schedules 
Using a previously reported procedure, adult SHR, WKY and WIS were trained on 
daily 55-min sessions of a differential reinforcement of low-rate 5 sec with limited hold 
(DRL5LH) schedule (Sanabria et al, 2008) starting at P77. Experiments were conducted in 
operant conditioning chambers (detailed in Supplementary Materials). For DRL5LH 
schedule, consecutive responses on the active lever greater than 5 sec apart were 
reinforced by delivery of a food pellet. Responses on the inactive lever were recorded, 
but had no programmed consequence.  An adjusting limited hold (LH) condition was 
included in the DRL5LH schedule to reduce the probability of reinforcing nonscheduled-
directed alternate behaviors, such as grooming, which result in long time lapses 
between consecutive responses (McClure et al, 1997). LH was initially set at 10 sec. 
Responding within the LH resulted in a decrease in LH duration by 0.01 sec. Lack of 
responding within the LH resulted in an increase in LH duration by 0.03 sec. Stability 
under the DRL5LH schedule was defined as less than a 10% change in IRT at 5 sec across 
5 consecutive sessions, and typically required 12-16 sessions.  
For the rats in the pilot experiments, after reaching stability, MPH (0.3-5.0 
mg/kg, p.o.) or vehicle (1 ml/kg water in oyster crackers, p.o.) was administered 45 min 
before the session using a randomized Latin-square design with three drug-free sessions 
between each MPH test session. Dose-response function for MPH was not evaluated in 
adolescent SHR because the short four-week window for adolescence (Doremus-
Fitzwater et al, 2012; Spear, 2000b) is inadequate for training and testing rats on the 
DRL schedule using the above experimental design. During these three days of ‘wash-
out’ period between each MPH dose, rats were tested on the DRL5LH schedule without 
any drug treatment to reestablish baseline behavior. Number of active and inactive 
lever responses, number of reinforcers earned and IRTs were recorded. Efficiency was 
defined as pellets earned, calculated as a percentage of the total number of responses 
on the active lever. Following oral delivery, MPH achieves peak plasma concentration 
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within 35-45 min (Gerasimov et al, 2000). MPH is metabolized rapidly in rats, having a 
reported brain and serum half-life of 20 and 50 min, respectively (Patrick et al, 1984). 
Since the purpose of the pilot experiment was to identify an efficacious dose of MPH, 
efficiency during the first 15 min of the DRL5LH session (i.e., during peak plasma levels 
of MPH) was compared between doses for SHR.  
Previous studies suggest that, similar to ADHD individuals, deficits in SHR are 
normalized by higher rates of reinforcement (Aase et al, 2006; Wultz et al, 1992). Thus, 
for experiments I and II, two DRL schedules were used for evaluating response inhibition 
capacity. In the DRL5LH schedule, IRTs>5 sec were reinforced by a food pellet, resulting 
in relatively high reinforcement rates (Sanabria et al, 2008). The training protocol was 
that described above. The timer recording IRT reset to zero following the delivery of a 
pellet. The time between reinforcer delivery and the subsequent lever-response was 
defined as ‘response latency’, which is an indicator of motivation for obtaining the 
reinforcer (Mattila et al, 2011; Meyer et al, 2012). The number of active and inactive 
lever responses, number of pellets earned, response latencies and IRTs were recorded 
over 5 sessions of stable performance. 
For the second schedule, the DRL interval was increased to 30 sec (DRL30), to 
make “waiting” more challenging. A within-session incremental training protocol was 
used in which rats progressed to the 30 sec waiting time at their own pace (Sanabria et 
al, 2008). The timer recording IRT restarted following each response on the active lever, 
and response latency measure and limited hold were not incorporated. The number of 
active and inactive lever responses, number of pellets earned and IRTs were recorded 
over 5 sessions of stable performance. Efficiency was calculated as the number of 
pellets earned expressed as a percent of active lever responses.   
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7.2.4 Open-field locomotor activity 
The purpose of this experiment was to evaluate the effects of chronic MPH during 
adolescence or adulthood on activity in adult rats. Three-five days after the completion 
of DRL studies, locomotor activity was evaluated. Rats were habituated for 3 days, for 1-
hr each day, in one of 12 open-field chambers (detailed in Supplementary Materials). 
Total number of horizontal beam breaks during the third day was recorded and 
compared between groups.  
 
7.2.5 Data analysis  
For pilot experiments 
Analyses were conducted using SPSS Statistics Version 19 (SPSS Inc., IBM Company, 
Armonk, NY). Data are reported as the mean ± S.E.M. and n represents the number of 
rats per group.  A repeated-measure two-way ANOVA was conducted to evaluate the 
interaction of rat strain and MPH dose on percentage of responses reinforced 
(efficiency). Test of sphericity was conducted to validate the repeated measures ANOVA 
(Mauchly, 1940). When the assumption of sphericity was violated, Huyhn-Feldt 
correction was applied to adjust the F-statistic (Huynh et al, 1980). Since the objective of 
the pilot study was to identify a dose of MPH for the subsequent impulsivity studies, 
effects of acute MPH treatment were determined using repeated-measure one-way 
ANOVAs for each rat strain and Dunnett’s post hoc analysis. Furthermore, the initial 15 
min of the behavioral session was evaluated for efficiency (i.e., 45 min after 
administration), when MPH was at peak plasma levels.  
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For experiments I and II: 
Modified temporal regulation (TR) model: Non-linear mathematical models in Equation 
1 and 2 (detailed in Supplementary Materials) were fit to the cumulative-frequency 
distribution of IRTs for each rat under DRL5LH and DRL30, respectively (Hill et al, 2012a; 
Mika et al, 2012; Sanabria et al, 2008). Both of the models segregate the IRT distribution 
between timed-IRTs and non-timed IRTs. The timed-IRTs congregate near the target 
time (for example, at 5 sec for DRL5LH) and the non-timed IRTs are exponentially 
distributed.  
 (     )     (       )    (   )    (   )   (   )(   )      (   )  
(EQ 1; DRL5LH) 
 (     )     (       )   (   )    (   )                                   (EQ 2; 
DRL30) 
The free parameters obtained from the mathematical models served as dependent 
variables, and are described below: 
1. Response threshold θ, θ = (Nxc)/5 sec and (Nxc)/30 sec for DRL5LH and DRL30, respectively, 
where (Nxc) is the mean of timed-IRTs. Smaller value of θ compared to 1, indicates reduced 
accuracy of timed-IRTs. 
2. Proportion of timed-IRTs (p), expressed as a fraction of all IRTs emitted by individual rats. 
Greater value of p indicates greater likelihood of producing timed-responses. 
3. Proportion of burst-IRTs (q* (1-p)) and (1–p) for DRL5LH and DRL30, respectively, expressed 
as a fraction of all IRTs emitted by individual rats. Burst IRTs are a component of the non-
timed IRTs with a relatively short average duration and occur under both the DRL schedules. 
A greater proportion of burst IRTs indicates reduced response inhibition capacity. For 
DRL30, burst responses are complementary to timed IRTs; thus, only bursts IRTs have been 
reported to avoid redundancy. 
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4. In DRL5LH and DRL30, the rate-of-decay of burst-IRTs (L and λ, respectively) is expressed as 
sec-1; the inverse of the rate-of-decay (1/L and 1/λ) is the mean burst IRT in sec.  
5. The model also provides the Weber-fraction (ω) which in an index of the precision of timing. 
Other parameters include the fraction ((1-p)*(1-q)) and rate-of-decay (L’) of the long-IRTs 
under DRL5LH that characterize task-delinquent responses (McClure et al, 1997). Since, task-
delinquent responses are not as prevalent under the DRL30 schedule, the simpler previously 
published mathematical model was used for quantifying IRT distribution for this schedule 
(Hill et al, 2012a). 
Data are reported as the mean ± S.E.M. and n represents the number of rats per group. 
The data were log-transformed to maintain homogeneity of variance when necessary. For 
evaluating effects of MPH treatment, dependent variables were compared using two-factor 
ANOVA (strain X treatment), followed by Bonferroni’s post-hoc comparisons. Main effects of 
strain or treatment were evaluated using Tukey’s post-hoc comparison. One WKY in experiment 
I died due to factors not related to treatment prior to obtaining any data. In experiment I, the 
number of burst IRTs under the DRL30 schedule emitted by one WKY administered vehicle was 
the identified as an outlier using the Grubbs test (GraphPad; 
http://www.graphpad.com/quickcalcs/Grubbs1.cfm). 
 
7.3 Results 
7.3.1 Pilot experiments 
To determine the appropriate dose and time of administration of MPH, percent 
of responses reinforced (or efficiency) was evaluated over the 55-min DRL5LH session. 
No strain X dose interaction was obtained (F[10,165]=1.65, p>0.05); however, the main 
effect of MPH tended to be significant (F[5,165]=2.24, p=0.053). One-way ANOVAs 
revealed that MPH modestly increased the efficiency for SHR and WKY, but not for WIS 
(Table 1).  Analysis of the data during the first 15-min of the DRL5LH session revealed 
that MPH (1.5 mg/kg, p.o.) increased efficiency in SHR compared to vehicle 
(F[5,55]=2.70, p<0.05; Fig 1). Therefore, the dose MPH chosen was 1.5 mg/kg for 
Experiments I and II, and the pretreatment time chosen was 30 min for Experiment II. 
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7.3.2 Methylphenidate treatment during adolescence on behavior during adulthood 
The mean IRT distribution patterns for adult rats under DRL5LH were not 
different between groups administered MPH or vehicle during adolescence (Fig 2A). 
Efficiency was lower in SHR compared to WIS and WKY; however MPH treatment did not 
alter efficiency (Table 3). The proportion of timed-IRTs was increased by MPH treatment 
during adolescence only in WKY (p; Finteraction[2, 29]=5.19, p<0.05; Fig 2B). Furthermore, 
WKY emitted a lesser proportion of timed-IRTs compared to WIS and SHR (Fstrain[2, 
29]=5.11, p<0.05).  No strain X treatment interactions or main effects of treatment were 
obtained for the proportion of burst IRTs (q*(1-p); Fig 2C), as well as for mean timed-
IRTs and mean burst-IRTs (Table 4). Also, parameters from the DRL5LH experiment that 
were not related to impulsivity showed strain differences, but not treatment differences 
(Supplementary Table T1).  Specifically, response latency, proportion and mean of task 
delinquent IRTs, precision of timed-IRTs, and number of sessions to train from DRL5LH 
to DRL30 were not different between treatment groups. However, strain differences 
were found for proportion and mean task delinquent IRTs, which were greater for SHR 
and WKY compared to WIS.  
Under DRL30, differences in the mean IRT distribution pattern were found only 
in adult SHR between groups administered MPH and vehicle during adolescence. Visual 
inspection of the IRT distribution patterns (Fig 3A) reveals that MPH-treated SHR 
emitted a greater proportion of burst responses and fewer timed-IRTs compared to 
vehicle control. Only a main effect of strain was found for efficiency, with lower 
efficiency for SHR than for WKY and WIS (Table 3). With respect to modeling 
parameters, no interactions or main effects were obtained for mean burst-IRTs (Table 4) 
or any other dependent variable under DRL30 (Supplementary Table T1).  However, 
main effects of strain were found, such that accuracy of timed IRTs for SHR was lower 
than for WKY and WIS, and accuracy for WKY was greater than for WIS (θ; Fstrain[2, 
29]=32.9, p<0.0001; Fig 3B). However, there was no strain X treatment interaction or 
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main effect of treatment. In contrast, for proportion of burst IRTs, a strain X treatment 
interaction was found ((1-p); Finteraction[2, 28]=3.58, p<0.05).  Importantly, the vehicle-
administered SHR showed burst IRTs greater than vehicle administered WKY and WIS 
(Fig 3C). Moreover, MPH during adolescence increased burst IRTs only in adult SHR 
significantly above that for the vehicle-administered SHR group (Fig 3C).   
For locomotor activity, main effects of treatment and strain were obtained but 
no interaction was found (Ftreatment[1, 29]=12.3, p<0.01; Fstrain[2, 29]=40.4, p<0.0001). 
Locomotor activity was decreased by MPH treatment during adolescence in all three 
strains (Fig 4), but the decrease was greater in MPH-treated SHR (75% of vehicle control; 
tSHR[10] = 3.00, p<0.05) than WKY and WIS (82% and 84%, respectively). Also, SHR was 
hyperactive compared to both WKY and WIS, and WKY were hypoactive compared to 
WIS. 
 
7.3.3 Methylphenidate treatment in adult rats on behavior during adulthood 
For experiment II, mean IRT distribution patterns for adult SHR, WKY and WIS 
under DRL5LH and DRL30 schedules were not different between MPH and vehicle 
administered groups (Figures S2). For  DRL5LH, evaluation of efficiency (Table 3), 
proportion of timed-IRTs (p; Fig 5A), proportion of burst-IRTs (q*(1-p); Fig 5B), mean 
timed-IRTs and mean burst IRTs (Table 4) revealed no interactions or main effects. 
Similarly, no effects were found for other modeling parameters and for the number of 
sessions to train from DRL5LH to DRL30 (Supplementary Table T2). Under DRL30 
schedule, efficiency was lower in SHR compared to WKY and WIS, and greater in WKY 
compared to WIS; however, no interaction or main effect of treatment was revealed 
(Table 3). With respect to modeling parameters, a main effect of strain was revealed for 
accuracy of timed-IRTs, such that SHR exhibited reduced accuracy compared to WKY and 
WIS, and WKY exhibited greater accuracy compared to WIS (Fstrain[2, 30] = 80.3, 
p<0.0001; Fig 5C). For proportion of burst-IRTs (1-p; Fig 5D) and mean burst-IRTs (Table 
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3) as well as for other dependent variable unrelated to impulsivity, no interactions or 
main effects were found (Supplementary Table T2). 
Locomotor activity was greater in SHR compared to WKY and WIS (Fstrain[2, 30] = 
49.7, p<0.0001; Fig 6); also activity in WKY was lower than WIS. However, no strain x 
treatment interaction or main effect of treatment was found. 
 
 
7.4 Discussion 
The current results reveal that in SHR, chronic MPH treatment during 
adolescence followed by discontinuation in early adulthood increased response 
inhibition deficits in a DRL schedule, modeling a facet of impulsivity. Although, these 
effects of MPH were not evident as changes in efficiency, mathematical modeling of the 
entire responding pattern under DRL revealed an increase in proportion of burst IRTs 
and a corresponding decrease in proportion of timed IRTs, and thus, these parameters 
were more sensitive to the effects of prior MPH treatment. In contrast, chronic MPH 
during adulthood did not alter these parameters of impulsivity in SHR suggesting an age-
dependent effect of MPH. Furthermore, the increased burst responding in MPH-treated 
SHR was not due to a generalized increase in activity. Thus, evidence is provided that 
chronic MPH treatment during adolescence increases impulsivity that persists into 
adulthood. Furthermore, ongoing chronic MPH treatment during adulthood did not alter 
impulsivity in adult rats. 
Clinical evidence indicates that with increasing age and MPH treatment during 
childhood and adolescence, ADHD symptoms including hyperactivity and impulsivity 
decrease in severity leading to discontinuation of treatment (Faraone et al, 2006; 
Mannuzza et al, 1998; McCarthy et al, 2009). In animal models, treatment with acute or 
several injections of a therapeutically-relevant dose of MPH during adolescence reduced 
hyperactivity in both adolescent outbred Sprague-Dawley and SHR (Kuczenski et al, 
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2002; Umehara et al, 2013a; Umehara et al, 2013b). Consistent with clinical 
observations, the current study shows that chronic oral MPH treatment during 
adolescence (P28-55) resulted in a decreased locomotor activity in adult SHR, providing 
further support for the SHR model of ADHD. 
MPH is an efficacious therapeutic for reducing both hyperactivity and impulsivity 
exhibited in adults with ADHD (Boonstra et al, 2005; Castells et al, 2011). In SHR treated 
during adulthood, neither acute nor chronic MPH reduced hyperactivity in an open field 
(van den Bergh et al, 2006; Yang et al, 2011), suggesting that the adult SHR may not 
adequately model this symptom of ADHD. Consistent with these previous findings, the 
current results show no change in hyperactivity in adult SHR administered chronic oral 
MPH. With respect to impulsivity, both acute and chronic MPH administration to adult 
SHR have been reported to increase choice for a larger delayed reinforcer, and reduce 
choice for a smaller immediate reinforcer in a delay-discounting task, suggesting that 
MPH reduced impulsive choice in adult SHR (Slezak and Anderson, 2011). In the current 
study, acute but not chronic MPH produced a modest, but significant, increase in 
efficiency in the DRL5LH schedule in the adult SHR. However, the modest effect of MPH 
on efficiency, taken together with the absence of effect following chronic MPH, is 
interpreted as insufficient evidence to suggest a reliable reduction in impulsivity using 
the DRL5LH schedule. Moreover, acute and chronic MPH treatment in adult SHR did not 
reduce response inhibition deficits, indicating a lack of effect in this model of impulsivity 
(Ferguson et al, 2007; Orduna et al, 2009; van den Bergh et al, 2006; Yang et al, 2011). 
In the current study, chronic MPH treatment in adult SHR similarly did not alter either 
efficiency or the mathematically-modeled parameters of impulsivity using the DRL5LH 
and DRL30 schedules.  Thus, adult SHR appear to have limited utility for translational 
studies evaluting effects of ADHD pharmacotherpeutics for behavior such as 
hyperacitivity and response inhibition deficits.   
Impulsivity, including that measured as response inhibition deficits under DRL 
schedules, has been associated with decreased dopaminergic function in prefrontal 
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cortex of adult outbred rats (Antonelli et al, 2013; Pardey et al, 2013; Simon et al, 2013; 
Sokolowski et al, 1994).  Age-dependent decreases in impulsivity have been associated 
with developmental maturation of prefrontal cortex, particularly with respect to the 
dopaminergic system (Brenhouse et al, 2008; Burton et al, 2012; Doremus-Fitzwater et 
al, 2012; Rothmond et al, 2012; Somerville et al, 2011). Repeated peripheral 
administration of low doses of MPH from the juvenile period through adolescence 
resulted in long-lasting changes in firing patterns of prefrontal cortical pyramidal cells 
that persisted into adulthood in outbreds (Fumagalli et al, 2010; Urban et al, 2012). The 
neurochemical mechanism by which chronic MPH treatment during adolescence alters 
the developmental trajectory of the prefrontal cortex in SHR has not been elucidated in 
detail.  However, some evidence suggests that chronic MPH treatment during 
adolescence (P28-55) increased dopamine transporter function in medial prefrontal 
cortex (mPFC) of adult SHR relative to vehicle control (Somkuwar et al, 2013a). 
Importantly, chronic MPH did not alter transporter function in mPFC of WKY and WIS 
controls (Somkuwar et al, 2013a). Taken together with the current findings, the mPFC 
dopaminergic system likely contributes to the underlying mechanism responsible for the 
increased response inhibition deficits observed herein in the MPH-treated SHR. 
Furthermore, the increased response inhibition deficit may be the behavioral 
mechanism underlying the enhanced cocaine self-administration following chronic MPH 
treatment during adolescence (Harvey et al, 2011). Thus, the current study advances the 
understanding of the impact of MPH treatment during adolescence on outcomes during 
adulthood in ADHD. 
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7.5 Tables 
 
Table 7.1 Experimental design and methods summary 
Two separate cohorts (n=6/group/experiment) of male Spontaneously Hypertensive 
Rats, Wistar-Kyoto and Wistar rats were used for the current study. For experiment I, 
rats were administered methylphenidate (1.5mg/kg/day, p.o.) or vehicle (water, 1 
ml/kg/day, p.o. in oyster-crackers) Monday to Friday between P28 to P55. After P55, 
methylphenidate treatment ended. From P77, the rats were evaluated on the 
behavioral assays. Rats were trained to stability on differential reinforcement of low-
rates (DRL) of responding with 5-sec with limited-hold (DRL5LH), followed by DRL with 
30-sec (DRL30) and then evaluated on open-field locomotor activity for 3 days. In 
experiment II, rats were administered methylphenidate or vehicle from P77 onwards 
and thirty minutes later evaluated in the behavioral assays, i.e. DRL5LH, DRL30 and 
locomotor activity, in that order. 
 P28     P55  P77     P130 
 Adolescence  Adulthood 
Exp I Methylphenidate or vehicle  DRL5LH → DRL30 → Locomotor 
activity 
Exp II   Methylphenidate or vehicle 
DRL5LH → DRL30 → Locomotor 
activity 
 
 
 
  
 
 
 
 
Table 7.2 Therapeutically relevant low doses of MPH (0.3 - 5.0 mg/kg, p.o.) increased efficiency (% responses reinforced) in 
SHR and WKY, but not WIS under DRL5LH schedule of reinforcements. 
 
Vehicle 0.3 0.75 1.5 3.0 5.0 F-statistics b 
SHR 22.5 ± 1.48 a 25.1 ± 1.28 25.1 ± 1.06 24.8 ± 1.21 22.4 ± 1.54 23.6 ± 1.38 2.50 * 
WKY 25.6 ± 1.72 27.4 ± 1.40 28.9 ± 1.10 27.7 ± 1.17 28.1 ± 1.19 24.1 ± 1.25 2.40 * 
WIS 25.5 ± 1.34 24.5 ± 1.71 25.5 ± 1.88 25.6 ± 1.99 23.9 ± 1.28 25.8 ± 0.97 0.704 
a All values are mean ± S.E.M.;  
b For all the statistics, the within-subject degrees of freedom = 5, and residual degrees of freedom = 55. 
*Significant main effect of MPH, p < 0.05
2
57
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Table 7.3 SHR exhibited reduced efficiency (% responses reinforced) compared to 
controls, but chronic methylphenidate (MPH) treatment during adolescence or 
adulthood did not alter efficiency  in adult SHR, WKY and WIS rats under DRL5LH and 
DRL30 schedules. 
 
  Efficiency under DRL5LH Efficiency under DRL30 
  VEH MPH VEH MPH 
Experiment I SHR 23.2 ± 1.00 a 22.6 ± 0.92 2.52 ± 0.83 2.81 ± 0.92 
 WKY 25.7 ± 1.56 29.7 ± 1.59 33.8 ± 6.86 41.6 ± 7.60 
 WIS 27.1 ± 1.06 28.0 ± 0.96 10.8 ± 2.86 12.4 ± 2.43 
 Fstrain 
F[2,29] = 10.5 s*; SHR < WIS = 
WKY 
F[2,29] = 32.9 s*; SHR < WIS < 
WKY 
Experiment II SHR 27.1 ± 2.18  24.7 ± 0.37 5.35 ± 0.41 4.65 ± 0.84 
 WKY 26.8 ± 1.76 26.2 ± 1.35 45.9 ± 2.47 50.3 ± 3.29 
 WIS 25.3 ± 0.55 26.0 ± 1.09 17.9 ± 5.73 15.9 ± 4.84 
 Fstrain F[2,30] = 0.208 
F[2,30] = 80.3 s*; SHR < WIS < 
WKY 
a All values are mean ± S.E.M.;  
s* Significant main effect of strain, p < 0.05 
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Table 7.4 Chronic MPH treatment during adolescence or adulthood did not alter 
accuracy of timed-IRTs and mean burst IRT under DRL5LH schedule for adult SHR, WKY 
and WIS rats. 
Under DRL5LH, methylphenidate (MPH) treatment and rat strain did not alter accuracy 
of timed-IRTs as well as mean duration of burst IRTs in adult SHR, WKY and WIS. Chronic 
MPH treatment during adolescence or adulthood did not alter precision of timed-IRTs as 
well as mean duration and proportion of task-delinquent responses under DRL5LH in 
adult SHR, WKY and WIS; strain differences have been tabulated (Supplementary Table 
S1 and S2). 
 
  
Accuracy of timed-IRTs under 
DRL5LH 
Mean burst IRTs under 
DRL5LH (sec) 
  VEH MPH VEH MPH 
Experiment 
I 
SHR 0.94 ± 0.04 a 0.97 ± 0.03 2.3 ± 1.1 2.1 ± 0.8 
 WKY 0.97 ± 0.09 1.05 ± 0.07 5.8 ± 1.1 8.7 ± 2.9 
 WIS 1.03 ± 0.05 1.01 ± 0.02 3.1 ± 1.2 4.8 ± 1.4 
 Fstrain F[2,29] = 0.866 F[2,29] = 0.879 
Experiment 
II 
SHR 1.01 ± 0.06 0.96 ± 0.03 2.5 ± 1.2 3.2 ± 1.3 
 WKY 0.96 ± 0.06 0.91 ± 0.05 3.7 ± 2.1 3.4 ± 1.7 
 WIS 0.97 ± 0.01 0.97 ± 0.01 1.8 ± 0.8 1.7 ± 1.0 
 Fstrain F[2,30] = 0.805 F[2,30] = 0.825 
a All values are mean ± S.E.M. 
  
 260 
 
Table 7.5 Chronic MPH treatment during adolescence or adulthood did not alter 
accuracy of timed-IRTs or mean burst IRT under DRL30 schedule for adult SHR, WKY 
and WIS rats. 
Under DRL30, methylphenidate (MPH) treatment did not alter accuracy of timed-IRTs as 
well as mean duration of burst IRTs in adult SHR, WKY and WIS; main effects of strain 
are tabulated below. Chronic methylphenidate treatment did not alter precision of 
timed-IRTs under DRL30; strain differences have been tabulated (Supplementary Table 
S1 and S2). 
  Mean burst IRTs under DRL30 (sec) 
  VEH MPH 
Experiment I SHR 2.4 ± 1.7a 1.9 ± 1.0 
 WKY 1.7 ± 0.34 1.6 ± 0.50 
 WIS 0.81 ± 0.30 1.5 ± 0.64 
 Fstrain F[2,29] = 0.662 
Experiment II SHR 4.7 ± 1.9 2.7 ± 1.5 
 WKY 11.3 ± 6.1 2.2 ± 1.8 
 WIS 15.4 ± 7.0 10.1 ± 8.2 
 Fstrain F[2,30] = 0.288 
a All values are mean ± S.E.M. 
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7.6 Figures 
 
Figure 7.1 
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Fig 7.1: At a therapeutically relevant dose, methylphenidate (MPH) increased efficiency 
(% responses reinforced) in adult Spontaneously Hypertensive Rat (SHR) under a DRL5LH 
schedule. Values are number of pellets earned (mean ± S.E.M.), expressed as a % of 
responses on the active lever by adult SHR under DRL5LH schedule, evaluated between 
45-60 min after oral administration of one of the six doses of MPH (0-5.0 mg/kg, p.o.) 
using a randomized Latin-square design. n= 12; *p < 0.05 compared to vehicle (0 mg/kg). 
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Figure 7.2 
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Fig 7.2: Under DRL5LH, discontinuation of chronic methylphenidate (MPH) treatment 
during adolescence did not alter response inhibition capacity in adult Spontaneously 
Hypertensive Rat (SHR). (A) Mean inter-response time (IRT) distributions were not 
different between MPH (dotted curves) and vehicle (VEH, solid curves) groups, except 
for Wistar-Kyoto (WKY; middle panel). (B) Proportion of timed IRTs (mean ± S.E.M.) was 
increased in adult WKY following discontinuation of adolescent treatment with MPH 
(grey bars) compared to its VEH control (open bars). (C) Proportion of burst IRTs (mean 
± S.E.M.) was not different between adult SHR, WKY and Wistar (WIS) under DRL5LH 
schedule following discontinuation of adolescent treatment with MPH and VEH.  Mean 
IRT distributions are presented as 1-sec moving averages of IRTs for SHR, WKY and WIS 
under DRL5LH. n = 5-6/ group; ε p ≤ 0.05 compared to the respective VEH control. # p ≤ 
0.05 main effect of strain, different from WIS. 
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Figure 7.3 
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Fig 7.3: Under DRL30, discontinuation of chronic methylphenidate (MPH) treatment 
during adolescence increased response inhibition deficit in adult Spontaneously 
Hypertensive Rat (SHR). (A) In adult SHR (right panel), but not in control strains, 
discontinuation of adolescent treatment with MPH (dotted curves) altered inter-
response time (IRT) distribution by increasing  burst IRTs and proportionately decreasing 
timed IRTs. (B) Compared to Wistar-Kyoto (WKY) and Wistar (WIS) rats, adult SHR under 
the DRL30 schedule exhibited reduced accuracy of timed IRTs (mean ± S.E.M.) 
irrespective of adolescent treatment with MPH (grey bars) or vehicle (VEH, open bars). 
Also, compared to WIS, accuracy of timed IRTs was greater for WKY. (C) Compared to 
WKY and WIS, adult SHR administered VEH during adolescence emitted greater 
proportion of burst IRTs (mean ± S.E.M.), and MPH treatment during adolescence 
further increased burst IRTs during adulthood. Mean IRT distributions are presented as 
5-sec moving averages of IRTs for SHR, WKY and WIS under DRL30. n = 5-6/ group; * p ≤ 
0.05 compared to the respective VEH control as well as MPH-treated WKY and WIS; ^ p 
≤ 0.05 compared to VEH-treated WKY and WIS; s* p ≤ 0.05 main effect of strain, different 
from WKY and WIS; # p ≤ 0.05 main effect of strain, different from WIS. 
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Figure 7.4 
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Fig 7.4: Discontinuation of chronic methylphenidate (MPH) treatment during 
adolescence decreased locomotor activity in in adult Spontaneously Hypertensive Rat 
(SHR). SHR exhibited greater horizontal activity (mean ± S.E.M.) in open-field chambers 
compared to Wistar-Kyoto (WKY) and Wistar (WIS) rats. Further, horizontal activity in 
adult WKY was reduced compared to WIS. Discontinuation of adolescent treatment with 
MPH (grey bars) decreased horizontal activity in adult rats compared to vehicle control 
(VEH, open bars). n = 5-6/ group; ε p ≤ 0.05 compared to the respective VEH control; t* p 
≤ 0.05 main effect of treatment; s* p ≤ 0.05 main effect of strain, different from WKY and 
WIS; # p ≤ 0.05 main effect of strain, different from WIS. 
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Figure 7.5 
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Fig 7.5. Chronic methylphenidate (MPH) treatment during adulthood did not alter 
response inhibition capacity in adult Wistar (WIS), Wistar-Kyoto (WKY) rats and 
Spontaneously Hypertensive Rats (SHRs). Mean inter-response time (IRT) distributions 
were not different between MPH and vehicle (VEH) groups (Supplementary Materials 
Fig 2). For SHR, WKY and WIS rats under the DRL5LH schedule, (A) proportion of timed 
IRTs (mean ± S.E.M.) and (B) proportion of burst IRTs did not differ between MPH- and 
VEH-treated groups. (C) Under the DRL30 schedule, adult SHR exhibited reduced 
accuracy of timed IRTs (mean ± S.E.M.) compared to WKY and WIS, irrespective of 
adolescent treatment with MPH (grey bars) or vehicle (VEH, open bars). Also, compared 
to WIS, accuracy of timed IRTs was greater for WKY. (D) For SHR, WKY and WIS rats 
under the DRL30 schedule, proportion of burst IRTs (mean ± S.E.M.) did not differ 
between MPH- and VEH-treated groups. n = 6/ group; s* p ≤ 0.05 main effect of strain, 
different from WKY and WIS; # p ≤ 0.05 main effect of strain, different from WIS. 
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Figure 7.6 
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Fig 7.6: Chronic methylphenidate (MPH) treatment during adulthood did not alter 
locomotor activity in adult Wistar (WIS), Wistar-Kyoto (WKY) rats and Spontaneously 
Hypertensive Rats (SHRs). SHR exhibited greater horizontal activity (mean ± S.E.M.) in 
open-field chambers compared to WKY and WIS rats. Further, horizontal activity in adult 
WKY was reduced compared to WIS. n = 6/ group; s* p ≤ 0.05 main effect of strain, 
different from WKY and WIS; # p ≤ 0.05 main effect of strain, different from WIS. 
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7.7 Supplementary Materials 
 
Preliminary studies for optimizing the dose of methylphenidate (MPH) 
For animal models of ADHD, a face-validity criterion posits that low doses of 
MPH should reduce impulsivity (Willner, 1986). In previous work, therapeutically 
relevant doses of MPH (0.5-2 mg/kg, i.p.) increased reinforcers/hr in WIS rats in a 
response-withholding task, employing a fixed minimum interval schedule (Hill et al, 
2012a). In another response withholding task, the 5-choice serial reaction time task, 
MPH (0.1 mg/kg, i.p.) reduced premature responses in WIS. In contrast, higher doses of 
MPH in WIS reduced efficiency, peak time and response threshold (θ) (Emmett-Oglesby 
et al, 1980; Orduna et al, 2009; van den Bergh et al, 2006). Thus, MPH appears to 
produce a U-shaped dose-response curve for reducing impulsivity in outbred rats. The 
current pilot study was aimed at identifying the dose of MPH that reduced impulsivity in 
the SHR rat model of ADHD.  
Supplementary Methods 
Apparatus 
Differential reinforcement of low rate (DRL) experiments were conducted in 
operant conditioning chambers (ENV-001; MED Associates, St. Albans, VT, USA) housed 
in sound attenuating compartments (ENV-018 M, MED Associates). Operant chambers 
were connected to a PC interface (SG-6080D, MED Associates) and operated using MED-
PC TM software. Chambers were equipped with a 5 cm × 4.2 cm recessed food 
receptacle, two retractable metal levers located on either side of the food tray and 7.3 
cm above a metal grid floor, and a house light mounted on the wall opposite the food 
receptacle. Food pellet reinforcers (45-mg Noyes Precision Pellets; Research Diets, Inc., 
New Brunswick, NJ, USA) were delivered via a dispenser (ENV-203, MED Associates) 
mounted outside of the operant chamber. 
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Locomotor activity was assessed in acrylic open-field locomotor chambers 
(42 × 42 × 30 cm), each with a 16 × 16 grid of photobeam sensors with monitoring 
system (AccuScan Instruments Inc., Columbus, OH). Locomotor activity was recorded 
and was expressed as total number of horizontal beam breaks recorded over each 1-
hour session. 
Differential reinforcement of low rate schedules details 
Starting from P77, rats from experiment I and experiment II were trained on 
daily 55-min sessions of DRL5LH, followed by DRL30 schedule as published previously 
(Sanabria et al, 2008).  
Protocol for training from DRL5LH to DRL30: Following stable performance on 
DRL5LH, the rats from experiment I and II were trained to DRL30 by gradually increasing 
the schedule requirement by 0.75% within-session following each reinforced response. 
The adjusted DRL interval was carried over from session to session until DRL30 was 
reached.  
Stability criteria the DRL schedules: Stability under both DRL5LH and DRL30 
schedules was defined as less than a 20% change in IRT at 5 and 30 sec, respectively, 
across 5 consecutive sessions.  
Modified temporal regulation (TR) model  
Two non-linear mathematical models were utilized to evaluate impulsivity in SHR (Hill et 
al, 2012a; Mika et al, 2012; Sanabria et al, 2008).  Both models were fit to the IRT 
distribution data across 5 sessions of stable responding. The first model posits that the 
distribution of IRTs is a mixture of two independent probability distributions (see 
equation 1).  One distribution is sensitive to the DRL contingency (timed-IRTs) and 
predicted by a gamma function theoretically centered near the DRL target time 
(Supplemental Fig. S1).  The other distribution is not sensitive to the DRL contingency 
(non-timed-IRTs), and is predicted by an exponential function. The second model (see 
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equation 2) posits that the distribution of non-timed IRTs is a composite of two 
processes.  One process results in burst responses characterized by an exponential 
function with a high rate-of-decay (Supplemental Fig. S1).   The second process results in 
task delinquent behavior characterized by an exponential function with a low rate-of-
decay (Supplemental Fig. S2). 
  (     )     (       )   (   )    (   )                                                           
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Supplementary Fig. S1 Theoretical data representing the individual components of 
equation 2; a timing-IRT gamma-function (dashed line) that is typically centered on the 
DRL wait time, a fast-decaying exponential function (solid line) describing burst 
responding and a slow-decaying exponential function (beaded line) describing iterative 
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behavior with long pauses between subsequent lever responses. For equation 1, a single 
exponential function describes both burst and task-delinquent responding 
(representation not shown). 
Statistical analysis: Analysis was conducted using SPSS Statistics Version 19 (SPSS Inc., 
IBM Company, Armonk, NY). The IRT frequency distribution for each session was 
determined as a fraction of total number of active lever responses using the equation 
below. 
                   
                        
                    
 
The frequency distribution was then smoothed out (reduce noise due to the session-to-
session variation) using moving averages for 0.5 sec intervals and then averaged over 5 
sessions of stable performance for each individual rat. The IRT frequency distributions 
are reported as mean of the moving averages of IRT distributions response for rats in 
each group; n represents the number of rats per group.  
 
Supplementary Results 
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Supplementary  Figure S2:  IRT distributions for adult WIS, WKY and SHR treated with 
chronic methylphenidate (MPH, 1.5 mg/kg/day, p.o.) or vehicle (VEH, water 1 ml/kg/day 
in oyster crackers, p.o.) administered 30 minutes before testing under DRL5LH (top) and 
DRL30 (bottom) schedules. The values are mean moving averages for each group, 
n=6/group. The dotted line represents the DRL interval; all responses to the left of the 
line lead to loss of reinforcement due to some form of impulsivity. Under DRL30, area 
under the curve for responses right of the dotted line represent “efficiency” of earning 
reinforcers.  
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Table 1: Chronic MPH treatment during adolescence or adulthood did not alter latency 
to respond under DRL5LH and number of sessions to train to DRL30 for adult SHR, 
WKY and WIS rats. MPH treatment did not alter latency of responding following 
reinforcer delivery as well as number of sessions to train from DRL5LH to DRL30 in 
either of the two cohorts of rats.  
  
Latency to respond in DRL5LH 
(sec) 
Session to train to DRL30 
  VEH MPH VEH MPH 
Experiment I SHR 16 ± 1.1 a 14 ± 1.8 12 ± 1.8 8.7 ± 1.1 
 WKY 13 ± 1.3 12 ± 0.69 6.0 ± 0.3 6.2 ± 0.3 
 WIS 10 ± 0.65 9.7 ± 0.70 6.0 ± 0.9 5.3 ± 0.4 
 Fstrain F[2,29] = 11.1 s*; SHR > WIS 
F[2,29] = 12.3 s*; SHR > WIS = 
WKY 
Experiment II SHR 14 ± 1.0 14 ± 0.32 6.2 ± 0.3 5.8 ±0.4 
 WKY 9.8 ± 1.3 12 ± 0.58 6.5 ± 0.5 6.3 ± 0.6 
 WIS 10 ± 0.24 10 ± 0.52 5.2 ± 0.3 5.3 ± 0.3 
 Fstrain 
F[2,30] = 15.8 s*; SHR > WIS = 
WKY 
F[2,30] = 3.85 s*; WKY > WIS 
a All values are mean ± S.E.M.;  
s* Significant main effect of strain, p < 0.05
  
Supplementary Table 2: Other dependent variables for adult SHR, WKY and WIS rats under DRL5LH and DRL30 schedules in 
experiment I. Chronic MPH treatment did not alter efficiency of earning reinforcers, accuracy and precision of timing and 
mean duration of burst responses under either DRL5LH or DRL30. MPH treatment during adolescence did not alter latency of 
responding following reinforcer delivery as well as mean duration and proportion of task-delinquent responses under 
DRL5LH in adult SHR, WKY and WIS. Strain differences in latency of responding, precision of timing and mean duration of 
delinquency under DRL5LH schedule as well as in sessions to reach DRL30, efficiency of earning reinforcers and accuracy of 
estimating 30 sec under DRL30 schedule have been described. 
   WIS WKY SHR Finteraction Fstrain 
DRL5LH Latency (in s) VEH 10 ± 0.24 a 9.8 ± 1.3 14 ± 1.0 F[2,30] = 0.907 F[2,30] = 15.8 * 
  MPH 10 ± 0.52 12 ± 0.58 14 ± 0.32  SHR >WIS, WKY 
 Precision (ω) VEH 0.30  0.022 0.52  0.035 0.47 ± 0.077 F[2,30] = 0.270 F[2,30] = 9.32* 
 (in sec) MPH 0.31  0.014 0.47  0.031 0.44 ± 0.065  SHR, WKY>WIS 
 Delinquency VEH 0.084 ± 0.012 0.098 ± 0.032 0.055 ± 0.021 F[2,30] = 0.005 F[2,30] = 1.79 
 (1-p)*(1-q) MPH 0.085 ± 0.019 0.103 ± 0.030 0.059 ± 0.020   
 1/L’ (in sec) VEH 20.8 ± 1.4 268 ± 125 85.5 ± 18.5 F[2,26] = 1.32 F[2,26] = 9.86* 
  MPH 30.1 ± 8.1 87.2 ± 37.8 64.4 ± 22.8  SHR,WKY>WIS 
DRL30 Session to  VEH 5.2 ± 0.3 6.5 ± 0.5 6.2 ± 0.3 F[2,30] = 0.179 F[2,30] = 3.85* 
 reach DRL30 MPH 5.3 ± 0.3 6.3 ± 0.6 5.8 ±0.4  WKY > WIS 
 Precision (ω) VEH 0.50 ± 0.029 0.46 ± 0.048 0.44 ± 0.018 F[2,30] = 1.81 F[2,30] = 0.146 
 (in sec) MPH 0.44 ± 0.038 0.53 ± 0.055 0.51 ± 0.051   
a Values are mean ± S.E.M. 
* p < 0.05 
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Supplementary Table 3: Other dependent variables for adult WIS, WKY and SHR rats in experiment II. Chronic MPH 
treatment did not alter efficiency of earning reinforcers, accuracy and precision of timing and mean duration of burst 
responses under either DRL5LH or DRL30 in WIS, WKY or SHR. Methylphenidate treatment during adulthood did not alter 
latency of responding following reinforcer delivery as well as mean duration and proportion of task-delinquent responses 
under DRL5LH in adult, WIS, WKY or SHR. Strain differences in latency of responding, efficiency of earning reinforcers and 
mean duration of task-delinquency under DRL5LH schedule as well as in sessions to reach DRL30, efficiency of earning 
reinforcers under DRL30 schedule and accuracy of estimating 30 sec have been described.   
   WIS WKY SHR Finteraction Fstrain 
DRL5LH Latency (in s) VEH 10 ± 0.65a 13 ± 1.3 16 ± 1.1 F[2,29] = 0.471 F[2,29] = 11.1 * 
  MPH 9.7 ± 0.70 12 ± 0.69 14 ± 1.8  SHR >WIS 
 Precision (ω) VEH 0.32 ± 0.04 0.47 ± 0.12 0.37 ± 0.02 F[2,29] = 0.843 F[2,29] = 6.89* 
 (in s) MPH 0.27 ± 0.01 0.48 ± 0.08 0.34 ± 0.01  SHR, WIS>WKY 
 Delinquency VEH 0.098 ± 0.033 0.041 ± 0.007 0.071 ± 0.024 F[2,29] = 0.081 F[2,29] = 2.24 
 (1-p)*(1-q) MPH 0.075 ± 0.022 0.034 ± 0.006 0.062 ± 0.023   
 1/L’ (in s) VEH 36.4 ± 7.2 200 ± 27.9 30.6 ± 5.9 F[2,29] = 0.159 F[2,29] = 8.15 * 
  MPH 43.5 ± 15.4 222 ± 39.9 27.9 ± 6.2  SHR, WIS<WKY 
DRL30 Session to  VEH 6.0 ± 0.9 6.0 ± 0.3 12 ± 1.8 F[2,29] = 1.31 F[2,29] = 12.3* 
 reach DRL30 MPH 5.3 ± 0.4 6.2 ± 0.3 8.7 ± 1.1  SHR > WIS,WKY 
 Precision (ω) VEH 0.51 ± 0.03 0.47 ± 0.06 0.47 ± 0.02 F[2,29] = 2.60 F[2,29] = 0.615 
 (in s) MPH 0.46 ± 0.01 0.59 ± 0.03 0.55 ± 0.07   
a Values are mean ± S.E.M. 
* p < 0.05 
Copyright © Sucharita S. Somkuwar 2013 
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8 CHAPTER EIGHT: OVERALL DISCUSSION 
8.1 Review 
Although several advances have been made in ADHD research, the etiology 
underlying the disorder is not clearly understood (Tripp et al, 2009). The most widely 
accepted theory suggests that ADHD is a consequence of catecholaminergic 
dysregulation particularly in the prefrontal cortex (PFC; Arnsten, 2009). ADHD is typically 
treated with stimulant medications such as methylphenidate (MPH), or with non-
stimulant medications like ATO. These drugs inhibit dopamine transporters (DAT) and/or 
norepinephrine transporter (NET), and thus enhance dopaminergic and noradrenergic 
neurotransmission in the PFC (Arnsten, 2009; Levy, 2008). However, controversy exists 
as to whether chronic treatments with modulators of catecholamine neurotransmitter 
systems are completely safe, especially in children and adolescents (Kollins, 2008b).  
A major concern in evaluating therapeutic strategies for ADHD is the high 
substance use liability in ADHD. ADHD children are twice as likely as their non-ADHD 
counterparts to develop substance use disorders, including cocaine abuse, later in life 
(Lee et al, 2011). The prevalence of cocaine abuse is 35% greater in ADHD individuals 
compared to non-ADHD individuals (Carroll et al, 1993). However, the factors mediating 
the high comorbidity of cocaine abuse and ADHD are unclear. Concerns have been 
raised regarding MPH because the pharmacological profile and mechanism of action of 
the therapeutic is comparable to cocaine (Kollins et al, 2001; Volkow et al, 1995). 
Further, MPH treatment may potentiate susceptibility for cocaine abuse, because 
repeated administration of MPH produces the similar neuroadaptations as does cocaine 
(Brandon and Steiner, 2003; Zahniser et al, 2009). For example, cocaine and MPH, both 
increase neuronal activation in the dorsal striatum (Brandon et al, 2003), a component 
of the frontostriatal attention circuitry affected in ADHD as well as in drug abuse 
(Robbins et al, 1998). MPH is efficacious by inhibiting DAT and NET function (Berridge et 
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al, 2006; Oades et al, 2005). Cocaine produces its addictive properties by enhancing 
dopaminergic neurotransmission also via inhibition of DAT. Further, cocaine enhances 
noradrenergic neurotransmission via inhibition of NET function, which is thought to play 
a modulatory role in addiction (Koob et al, 2010; Steiner and Van Waes, 2013; Wee et al, 
2008). However, clinical studies evaluating the effects of MPH treatment on future 
cocaine abuse outcomes have been inconclusive and controversial. While some studies 
suggest that MPH treatment is protective against future cocaine abuse liability (Wilens 
et al, 2003), others indicate that the treatment does not exacerbate the comorbidity of 
ADHD and cocaine abuse (Molina et al, 2013). Another study reported a positive 
correlation between age of initiation of MPH treatment and future cocaine abuse 
liability (Mannuzza et al, 2008). Specifically, when treatment was initiated late, i.e. 
during early adolescence instead of childhood, cocaine abuse liability was elevated in 
adulthood.  
Adolescence appears to be a developmentally critical period during, which MPH 
treatment produces lasting alterations that increase the reinforcing properties of 
cocaine in adulthood in Sprague-Dawley rats (Brandon et al, 2001). In contrast, MPH 
treatment during peri-adolescence reduces the sensitivity to cocaine as well as natural 
rewards (Andersen et al, 2002; Bolanos et al, 2003; Carlezon et al, 2003). However, 
these studies are limited since the experimental models employed do not account for 
the preexisting deficits associated with ADHD.  
Neurobehavioral deficits in ADHD further enhance the susceptibility of ADHD 
individuals to drug abuse. Altered processing of rewards and mechanisms of 
reinforcement in ADHD have been suggested to confer the drug abuse vulnerability in 
ADHD individuals (Sagvolden et al, 1998a). Enhanced impulsivity, a hallmark of ADHD, is 
also a well-established predictor of cocaine abuse liability. Individuals with comorbid 
ADHD and cocaine dependence are more impulsive than ADHD individuals without this 
comorbidity (Crunelle et al, 2013; Groman et al, 2009).  Further, ADHD etiology and 
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cocaine abuse impinge on overlapping neurological substrates. PFC subregions including 
medial prefrontal cortex (mPFC) and orbitofrontal cortex (OFC) regulate cognitive and 
executive function and working memory, which when impaired, increase cocaine 
seeking and cocaine taking behavior (Di Pietro et al, 2004; Di Pietro et al, 2006; Grakalic 
et al, 2010). Taken together, these results emphasize the importance of the use of an 
animal model of ADHD to evaluate the impact of ADHD therapeutics on future cocaine 
abuse liability. 
Our previous studies using the Spontaneously Hypertensive Rats (SHR) model of 
ADHD demonstrate greater cocaine self-administration in SHR compared to control 
strains Wistar-Kyoto and Wistar (Harvey et al, 2011). Treatment during adolescence 
(postnatal day 28-55) with a therapeutically relevant dose of MPH (1.5 mg/kg/day, p.o.; 
Gerasimov et al, 2000; Kuczenski et al, 2002), followed by treatment discontinuation in 
early adulthood led to an enhanced cocaine self-administration during adulthood (>77 
days old) in the MPH-treated SHR compared to control (Harvey et al, 2011). Importantly, 
cocaine self-administration was not altered in MPH-treated Wistar-Kyoto (WKY; inbred 
control) and Wistar (WIS; outbred control) rats compared to the respective vehicle 
controls (Harvey et al, 2011). Taken together, these results established SHRs as a model 
for the clinically observed comorbidity of ADHD and cocaine abuse and for the enhanced 
cocaine abuse liability observed in ADHD individuals who initiated MPH treatment 
during adolescence (Klein et al, 2012; Mannuzza et al, 2008). The purpose of the current 
study was to delineate the neurochemical and behavioral mechanisms potentially 
underlying with the increased cocaine self-administration in MPH-treated SHR. 
The first and second aims of this dissertation (Chapters 2 and 3, respectively) 
determined the effects of treatment during adolescence with MPH and ATO on DAT 
function and cellular distribution in mPFC, OFC and striatum during adulthood. The 
maximal velocity of [3H]dopamine uptake (Vmax) and cellular distribution of DAT did not 
differ between vehicle administered SHR, WKY and WIS (Chapters 2 and 3). Importantly, 
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Vmax was increased in MPH-treated SHR compared to vehicle control and MPH-treated 
Wistar-Kyoto and Wistar rats (Chapter 2). Further the increased DAT function was not 
associated with a corresponding increase in surface DAT, suggesting that the effects of 
MPH were trafficking independent (Fig 8.1). On the other hand, treatment with the non-
stimulant ATO did not increase either cocaine-self administration in SHR (Somkuwar et 
al, 2013b) or DAT function in mPFC, OFC and striatum (Chapter 3). In contrast, DAT 
function in the OFC and striatum obtained from ATO-treated SHRs was decreased 
compared to controls. Furthermore, the decreased DAT function in OFC was associated 
with a corresponding decrease in cell surface expression of DAT (Fig 8.2), indicating that 
the effects of ATO were trafficking independent in the OFC. Also, the decreased DAT 
function in the striatum was associated with no difference in cell surface expression 
DAT; however total DAT expression in the striatum was increased (Fig 8.3) which is also 
suggestive of trafficking mediated mechanisms. Taken together, MPH treatment during 
adolescence increased DAT function in mPFC which may contribute to the enhanced 
cocaine self-administration in SHR. Also, ATO’s protection from enhanced cocaine self-
administration (compared to MPH) may be due to the reduced DAT function in the OFC 
and striatum. 
The third aim determined the effects of MPH during adolescence on NET 
function in mPFC and OFC during adulthood (Chapter 4). In the PFC, NET is involved in 
clearance of both norepinephrine and dopamine (Moron et al, 2002). Thus, changes in 
NET function will have implications on extracellular norepinephrine as well as dopamine 
in PFC. NET function was assessed using in vivo voltammetry in anesthetized rats to 
quantify the clearance kinetics of exogenously applied norepinephrine. NET function 
was measured using two parameters: 1) Uptake rate, defined as the peak amplitude of 
norepinephrine (or Amax) X first-order removal kinetics of norepinephrine (k-1), and 2) 
Clearance, defined as the amount of norepinephrine applied/area under curve for the 
norepinephrine signal. In SHR, NET function in the mPFC in adults was not different from 
WKY and WIS and was not altered by MPH treatment during adolescence. These results 
 282 
 
suggest that the increased DAT function in mPFC of MPH-treated SHR (Chapter 2) was 
neither accentuated nor compensated by a change in NET function. In contrast to mPFC, 
in the OFC, specifically the lateral OFC (LO), NET function was greater in SHR compared 
to WKY and WIS. The elevated NET function in lateral OFC may contribute to the 
behavioral deficits in SHR such as impulsivity, inattention, impaired behavioral flexibility 
and working memory (Harvey et al, 2013; Kantak et al, 2008; Sagvolden, 2006; 
Winstanley et al, 2006b; Zeeb et al, 2010). MPH treatment during adolescence followed 
by treatment discontinuation normalized NET function in SHR lateral OFC (Chapter 4; Fig 
8.4), potentially normalizing the disrupted noradrenergic as well dopaminergic function 
in lateral OFC.  Thus, some of the beneficial effects of MPH treatment during 
adolescence persist well into adulthood, even after treatment is discontinued.  One 
example of a lasting beneficial behavioral effect of MPH treatment during adolescence 
identified in the current study was a reduction of the hyperactivity in SHR (Chapter 7). 
However, empirical evidence is not available currently to ascribe this decreased 
hyperactivity with the decreased NET function in the lateral OFC of the MPH-treated 
SHR. 
The fourth aim was to determine the effects of MPH treatment during 
adolescence on sensitivity to cocaine-induced psychomotor response. The results 
indicate that while the sensitivity to acute cocaine-induced locomotor activation was 
least in SHR, the magnitude of locomotor sensitization to repeated cocaine 
administration was greatest in SHR (Chapter 5). The association between strain-
dependent differences in cocaine self-administration and psychomotor sensitization to 
cocaine suggests that subjects that readily develop sensitization to cocaine are more 
likely to demonstrate greater motivation for cocaine (Mandt et al, 2008). However, 
contrary to the hypothesis, MPH treatment during adolescence, followed by treatment 
discontinuation, increased motivation for cocaine (Harvey et al, 2011), but did not 
increase sensitivity to the psychomotor effects of cocaine in adult SHR.  
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The fifth aim was to determine the effects of MPH during adolescence on 
impulsivity during adulthood evaluated using differential reinforcement of low-rate 
(DRL) schedules. The DRL schedule investigates the response inhibition deficit, a facet of 
impulsivity that is thought to mediate the comorbidity of substance abuse and ADHD 
(Groman et al, 2009; Orduna et al, 2009). The fifth specific aim was executed through 
two experiments; the first experiment was aimed at optimizing a behavioral preparation 
and analytical technique to identify effects of strain as well as MPH treatment on 
response inhibition capacity (Chapter 6). The second aim applied the optimized 
procedure to determine whether MPH treatment during adolescence produced 
persistent alterations in response inhibition capacity in SHR (Chapter 7). 
The first set of experiments revealed strain differences between adult SHR, 
Wistar-Kyoto and Wistar under DRL 5 sec with limited hold (DRL5LH) and DRL 30 sec 
(DRL30) schedules (Chapter 6). Compared to Wistar-Kyoto and Wistar rats, adult SHR 
exhibited a greater frequency of burst responding and fewer timed responses under 
both schedules, indicating that SHRs have reduced response inhibition capacity 
compared to controls. Further, adult SHRs exhibited reduced accuracy of timing 
(reduced response threshold) under the DRL30 schedule, suggesting that response 
inhibition deficits in SHR become more evident under schedules where waiting is more 
challenging.  
Adolescent rats are known to be more impulsive than adult rats (Burton et al, 
2012; Sagvolden, 2011). Previous studies revealed that chronic MPH treatment in 
adolescent SHR improved behavioral flexibility and working memory compared to 
control (Harvey et al, 2013; Kantak et al, 2008).  In the current study, the effects of 
chronic MPH treatment on responding under DRL schedules were evaluated in a 
separate cohort of adolescent rats (Chapter 6). Under the DRL5LH schedule, chronic 
MPH treatment increased burst responding and decreased proportion of timed 
responding in all three strains of adolescent rats. Under the DRL30 schedule, burst 
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responding was increased and accuracy of timing was decreased in all three strains, but 
the effects were most pronounced in the SHR. In contrast, response latency was 
decreased in MPH treated SHR, suggesting an increased motivation for earning the 
reinforcer (Mattila et al, 2011; Meyer et al, 2012). These results suggest that MPH 
produces mixed effects on SHR behavior.  That is, MPH treatment decreased response 
inhibition capacity while simultaneously improving motivation to work for 
reinforcement (Chapter 6). 
The second set of experiments evaluated whether MPH treatment during 
adolescence altered response inhibition capacity in adult rats. The results revealed that 
only in SHR, MPH treatment during adolescence, followed by treatment discontinuation, 
further increase in burst responding and decrease timed responding under the DRL30 
schedule (Chapter 7). These results suggest that, in accordance with the hypothesis of 
the current experiment, chronic MPH treatment during adolescence increases response 
inhibition deficits in adult SHR. Furthermore, chronic MPH treatment during adulthood 
did not alter response inhibition capacity in adult SHRs. Taken together, MPH when 
administered during the developmentally vulnerable period (adolescence) is associated 
with this deleterious sequel. Finally, the enhanced response inhibition deficit may 
underlie the previously observed enhanced cocaine self-administration in MPH-treated 
SHR. 
  
Table 8.1 Summary of results of methylphenidate (MPH) or atomoxetine (ATO) treatment during adolescence, followed by 
treatment discontinuation, on neurobehavioral outcomes during adulthood 
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Str OFC mPFC OFC mPFC 
WIS VEH             
 MPH ↓↓ A ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ * ↔ ↔ ↔ 
              
WKY VEH             
 MPH ↔ ↑↑ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ 
              
SHR VEH ↑ ↓ ↑ ↑ ↑ ↑ ↑ ↔ ↔ ↔ ↑ ↔ 
 MPH ↑↑ A    ↑↑  ↓↓ * * ↑↑ A ↓↓  
↔ not different between strains or treatment groups; ↑ higher than control WKY and WIS rats; ↑↑ increased with 
MPH treatment; ↓↓ decreased with MPH treatment; A not changed with non-stimulant ATO treatment; * decreased 
with ATO treatment, ↑↑ increased with ATO treatment  
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Figure 8.1 Dopaminergic terminals in the medial prefrontal cortex of adult SHR 
 
Graphical illustration: MPH treatment during adolescence increases dopamine transporter function in the medial prefrontal 
cortex of adult SHR without increasing the cell surface expression of dopamine transporters, indicating a trafficking-
independent mechanism of regulation by MPH. MPH treatment did not alter dopamine transporter function in the 
orbitofrontal cortex or striatum of adult SHR. As such, the increase in dopamine transporter function in the medial prefrontal 
cortex may underlie the enhanced cocaine self-administration in MPH-treated SHRs. 
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Figure 8.2 Dopaminergic terminals in the orbitofrontal cortex of adult SHR 
 
 
Graphical illustration: Treatment with atomoxetine (ATO) during adolescence decreases dopamine transporter function and 
cell surface expression in the orbitofrontal cortex of adult SHR, indicating a trafficking-dependent mechanism of regulation 
by ATO. ATO treatment did not alter dopamine transporter function in the medial prefrontal cortex of adult SHR, and did not 
increase cocaine self-administration in adult SHR. 
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Figure 8.3 Dopaminergic terminals in the striatum of adult SHR 
 
 
Graphical illustration: Atomoxetine (ATO) treatment during adolescence decreases dopamine transporter function in the 
striatum of adult SHR. The decreased transporter function is associated with an increase in total expression of dopamine 
transporters, indicating a compensatory mechanism.  
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Figure 8.4 Noradrenergic terminals in the lateral orbitofrontal cortex of adult SHR 
 
 
Graphical illustration: Treatment with MPH during adolescence decreases norepinephrine transporter function in the lateral 
orbitofrontal cortex of adult SHR. In the vehicle administered-SHR, norepinephrine transporter function in the lateral 
orbitofrontal cortex was greater than that in WKY and WIS controls. Also, MPH treatment did not alter norepinephrine 
transporter function in the medial prefrontal cortex of adult SHR. 
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8.2 Integration of results 
8.2.1 DAT function in mPFC, OFC and striatum and behavior 
Evidence that mPFC, OFC and striatum are critically involved in cocaine self-
administration comes from studies in which local inactivation or lesions decreased 
cocaine-seeking and taking behavior (Di Ciano et al, 2008; Di Pietro et al, 2006; Grakalic 
et al, 2010). Following MPH treatment during adolescence, the observed increase in 
mPFC DAT function (Chapter 2) would be expected to decrease extracellular dopamine 
concentration in mPFC. Previous studies show that mPFC DA depletion results in an 
increased motivation for and increased sensitivity to cocaine (McGregor et al, 1996; 
Schenk et al, 1991). Thus, increased DAT function in mPFC may underlie the increased 
cocaine self-administration observed following adolescent MPH treatment (Harvey et al, 
2011). Furthermore, reduced dopamine in the mPFC was associated with increased 
burst responding on a DRL30 schedule (Sokolowski et al, 1994). Taken together, these 
results suggest that increased DAT function in the mPFC leads to increased response 
inhibition deficits in MPH-treated SHR (Chapter 7), and the increased response 
inhibition deficits may underlie the enhanced cocaine self-administration, as evidenced 
by upward shifts in FR and PR responding (Harvey et al, 2011) as well as greater cocaine 
intake during adulthood (Jordan et al, submitted). 
The relative protection rendered by ATO may be mediated partially by the 
absence of effects on DAT function in mPFC (Chapter 3). The decrease in DAT function in 
the OFC and striatum was not associated with alterations in rate of acquisition of 
cocaine self-administration or dose response functions for cocaine self-administration 
under FR and PR schedules (Somkuwar et al, 2013b). The OFC is known to process 
information regarding the reinforcing value of cocaine (Kantak et al, 2009). Specifically, 
OFC inactivation results in a right-shift in the cocaine dose-response under FR schedules. 
Therefore, the lack of effect of ATO treatment on cocaine self-administration 
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(Somkuwar et al, 2013b) despite the decreased DAT function in the OFC of ATO-treated 
SHR (Chapter 3) was unexpected. One explanation for the apparent disconnect between 
cocaine self-administration and DAT function in the OFC may be that OFC codes 
information regarding reward value by modulating specific post-synaptic dopaminergic 
receptor and not via modulation of DAT function per se (Zeeb et al, 2010). Further 
support for this idea comes from the DRL experiments (Chapter 6). The rank order for 
the decrease in accuracy of estimating waiting time from DRL5 to DRL30 was SHR > WIS 
> WKY, suggesting that SHR are most sensitive to the delay of reinforcement, a function 
mediated by OFC (Dalley et al, 2004). However, no strain differences were observed 
with respect to OFC DAT function (Chapter 2 and 3). Furthermore, decreased OFC 
dopamine receptor expression and/or activation increases impulsive choice in delay 
discounting schedules, but have limited effects on response inhibition deficits as 
measured using the 5-choice serial reaction time (5-CSRT) task (Winstanley et al, 2010b; 
Zeeb et al, 2010). Therefore, OFC may mediate impulsivity observed in the current study 
(Chapter 6) in conjunction with other neurotransmitter systems such as norepinephrine 
and serotonin (Bari et al, 2011; Jupp et al, 2013a; Wischhof et al, 2011). 
The dorsal striatum is involved in habit learning as well as habitual drug seeking 
as evaluated using instrumental learning paradigms (Everitt and Robbins, 2005; Yin et al, 
2004). Decreasing dopamine signal in the dorsal striatum alters acquisition of second-
order responding, but decreases responding once the behavior is established (Taylor 
and Robbins, 1986; Vanderschuren et al, 2005). Furthermore, responding for a 
conditioned stimulus is concurrent with increases in extracellular dopamine in the 
dorsal striatum (Ito et al, 2002). In the current study, ATO treatment during adolescence 
followed by treatment discontinuation in early adulthood decreased DAT function in the 
striatum of adult SHR (Chapter 3). The decreased striatal DAT function in the ATO-
treated may result in elevated extracellular dopamine during adulthood which may 
therefore, blunt the dopaminergic signal while responding for cocaine cues in adult 
SHRs. Taken together, the attenuated signal to noise ratio in the striatum of adult SHR 
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may underlie the observed decrease in cocaine cue-reactivity under second-order 
schedule in ATO-treated SHR (Jordan et al, submitted).  
In conclusion, the increased DAT function in the MPH-treated SHR may underlie 
the increased response inhibition deficits as well as cocaine self-administration during 
adulthood (Fig 8.5). In contrast, the decreased DAT function in the OFC and dorsal 
striatum of ATO-treated SHR may underlie the decreased cocaine cue-reactivity as well 
as the protection from further increase in cocaine abuse risk.  
Figure 8.5  Potential mechanism integrating changes in DAT function with behavioral 
outcomes in adult SHR 
 
Schematic representation of potential dopaminergic mechanism contributing to the 
opposite effects of methylphenidate (MPH) and atomoxetine (ATO) treatments during 
adolescence on cocaine abuse during adulthood evaluated using a heuristically useful 
model of ADHD (SHR). 
 
8.2.2 NET function in mPFC and OFC and behavior 
Hyperactivity is a hallmark of ADHD (American Psychiatric Association., 2013a). 
Hyperactivity as well as other behavioral deficits in ADHD decrease in severity with 
increasing age (Faraone et al, 2006; Mannuzza et al, 1998; Mannuzza et al, 2002). Also, 
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individuals with ADHD show delayed cortical maturation that is associated with 
impaired control of inappropriate behavior (Eshel et al, 2007; McLaughlin et al, 2010). In 
the current study, adolescent and adult SHR showed greater locomotor activity in open-
field chambers compared to control Wistar-Kyoto and Wistar rats (Chapter 6 and 7). 
These results were consistent with previous reports (van den Bergh et al, 2006; Yang et 
al, 2011). Previous studies suggest that in SHR, open-field activity did not decrease till 6 
months after birth, while in Wistar-Kyoto, locomotor activity decreased from 1 to 3 
months (Hsieh and Yang, 2008). In contrast, low doses of MPH (0.3, and 1 mg/kg, i.p.) 
administered acutely, reduced open-field activity in adolescent SHRs, but not WKY and 
WIS (Umehara et al, 2013a; Umehara et al, 2013b). In the current study, locomotor 
activity was decreased by the age of ~3.5 months in adult SHRs that were administered 
MPH during adolescence (Chapter 7). These current results complement the clinical 
findings that MPH treatment during development, in part, may be responsible for the 
age-dependent decrease in ADHD symptoms.  
Mechanistically, the MPH-induced decrease in hyperactivity in adolescent SHRs 
was blocked by idazoxan, an α2A receptor antagonist, at doses that were sufficient to 
block MPH-induced cognitive enhancement (Gamo et al, 2010; Umehara et al, 2013b). 
Further guanfacine, α2A agonist, reduced open-field activity while A-68930, a selective 
D1 agonist increased activity in SHR (Langen et al, 2011). Taken together, these current 
results and those from the literature suggest that attenuation of hyperactivity by MPH is 
mediated by activation α2A noradrenergic receptors. In the current study, NET function 
in the lateral orbitofrontal cortex of SHR was elevated compared to Wistar-Kyoto and 
Wistar. Chronic MPH treatment during adolescence normalized NET function in the 
lateral orbitofrontal cortex of SHRs (Chapter 4; Fig 8.4). Normalization of NET function in 
the lateral orbitofrontal cortex may increase extracellular norepinephrine 
concentrations and thereby enhance post-synaptic α2A receptor signaling, which may 
have contributed to the reduced hyperactivity in adult SHR following discontinuation of 
adolescent treatment with MPH. 
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In conclusion, NET function is elevated in the lateral orbitofrontal cortex of SHR 
compared to Wistar-Kyoto and Wistar. MPH treatment during adolescence followed by 
treatment discontinuation in early adulthood normalized of NET function in lateral 
orbitofrontal cortex of SHR, which may contribute to the reduced locomotor activity in 
adult SHR compared to vehicle control (Fig 8.6). 
 
Figure 8.6 Potential mechanism integrating changes in NET function with hyperactivity 
in adult SHR following methylphenidate treatment 
 
Schematic representation of potential noradrenergic mechanism contributing to the 
decreased hyperactivity in adult SHR that were administered methylphenidate (MPH) 
during adolescence. 
 
8.2.3 Differences in neuropsychopharmacology of methylphenidate and 
atomoxetine 
The current in vitro neurochemistry results show that MPH and ATO have 
distinct profiles for altering DAT function and expression in mPFC, OFC and striatum. 
MPH treatment during adolescence resulted in an increase in DAT function in the mPFC 
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of adult SHR (Chapter 2). Since clearance of extracellular dopamine is regulated by DAT 
localized at the cell surface of dopaminergic neurons (Zahniser and Sorkin, 2004), the 
cell surface expression of DAT was expected to be altered in the direction corresponding 
with the change in DAT function in the MPH and ATO treated-SHR. However, in the 
current study, DAT cell surface expression was not altered by MPH during adolescence 
(Chapter 2). Previous studies reported that chronic exposure to DAT inhibitors results in 
post-translational modifications or protein-protein associations that alter transporter 
function without changing cell-surface expression of DAT (Foster et al, 2008; 
Ramamoorthy et al, 2010). Taken together, MPH treatment during adolescence 
increased DAT function in adult SHR in a trafficking-independent manner. 
In contrast to effects of MPH, ATO decreased DAT function in OFC and striatum 
of SHR in a trafficking-dependent manner (Chapter 3). The effect of ATO, a selective NET 
inhibitor, on DAT in OFC was not surprising since the dose of ATO used in the current 
studies increases extracellular dopamine in the prefrontal cortex by inhibiting dopamine 
clearance via NET (Bymaster et al, 2002; Moron et al, 2002). As expected with the 
current treatment regimen, chronic ATO has been shown to persistently increase 
extracellular dopamine in the PFC (Koda et al, 2010). Further, repeated exposure to DAT 
substrates, including dopamine results in persistent trafficking-dependent 
downregulation of the transporter (Zahniser et al, 2009). Taken together, chronic ATO 
treatment during adolescence inhibits dopamine clearance by NET, which persistently 
increased extracellular dopamine and consequently, resulted in reduced DAT function 
and surface expression in the OFC (Chapter 3). In contrast, the effect of ATO on DAT in 
the striatum was not expected. However, frontostriatal cortical networks in OFC send 
extensive projections to the ventromedial caudate nucleus of the dorsal striatum 
(Alvarez and Emory, 2006) and are responsible for decision making and regulation of 
impulsivity (Feil et al, 2010). Thus, in the current study, the decreased DAT function in 
the OFC following chronic ATO treatment during adolescence may alter the connectivity 
between OFC and dorsal striatum and thereby, contribute to the decreased DAT 
function in the dorsal striatum.  
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Cocaine self-administration results also showed distinct profiles following 
discontinuation of MPH and ATO treatments in SHR. MPH treatment adolescence results 
in increased cocaine self-administration in adult SHR, while ATO treatment during 
adolescence was protective against the further increase in cocaine self-administration 
during adulthood (Harvey et al, 2011; Somkuwar et al, 2013b). These results suggest 
that MPH, but not ATO, treatment during adolescence may increase cocaine abuse 
liability in adults with ADHD. One of the hallmark features of addiction is that drug-
paired cues and context induces persistent drug-seeking behavior (Robinson et al, 
1993). Conditioned stimuli (or cues) paired with drugs of abuse induce craving and 
contribute to relapse (Ehrman et al, 1992; Kosten et al, 2006). Another set of 
experiments conducted in collaboration with the current studies compared the effects 
of MPH and atomoxetine treatments during adolescence on cues paired with cocaine 
self-administration using a second-order schedule of responding during adulthood 
(Jordan et al, submitted). Second-order schedules of reinforcement were used to 
evaluate differential reactivity for cues that predict availability of a drug between strain 
and treatment groups (Di Ciano et al, 2005; Schindler et al, 2002). Under the second 
order schedules, animals learn a complex sequence of responding; each step in the 
sequence is reinforced by a conditioned reinforcer (e.g., cue-light) and completion of 
the sequence results in delivery of the primary reinforcer (Cain et al, 2004). As such, the 
conditioned stimulus reinforces the operant responding and more importantly, signal 
that completion of the successive steps will result in the delivery of the drug of abuse. 
The current study used a fixed interval 5 min – fixed ratio 5 (FI5 min [FR5:S]) schedule; 
every 5th response on the lever (i.e., fixed ratio) resulted in the presentation of a cue-
light (stimulus; S). This continued for 5 min (i.e. fixed interval), after which the 5th 
response on the lever resulted in the presentation of the cue-light and the delivery of 
the primary reinforcer (i.e., cocaine; Kantak et al, 2001). During extinction of second-
order responding, neither cocaine nor cue-light were presented during operant 
responding. During cue-reinstatement, every 5th response resulted in the presentation 
of cue-light; however, cocaine was not available to the rats (Kantak et al, 2002). Results 
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revealed that SHR earned more cocaine infusions during the maintenance of cocaine 
responding under the FI5min[FR5:S] schedule, required greater number of sessions to 
reach extinction criterion, and reinstated cue-induced cocaine seeking to a greater 
extent than control WKY and WIS (Jordan et al, submitted). Further, MPH treatment 
during adolescence increased the number of cocaine infusions earned during the 
maintenance, but did not alter extinction of responding or cue-reinstatement of cocaine 
seeking. In contrast, ATO did not alter responding during maintenance or extinction, but 
attenuated cue-induced reinstatement of cocaine seeking.  These results are in 
agreement with the current study which shows that SHR sensitize to cocaine-induced 
locomotor activation more readily than WKY and WIS, but MPH treatment does not 
alter cocaine sensitization (Chapter 5). The effect of chronic ATO treatment on cocaine 
sensitization has not been evaluated, and would be interesting to pursue in future 
studies. Previous studies suggest a relation between sensitization and relapse, such that 
greater sensitization is associated with robust reinstatement of responding for context 
and cues associated with the drug of abuse through a process termed as incentive 
sensitization (Robinson et al, 2001). Although data supporting this hypothesis are 
debatable at present (Robinson et al, 2008b), the current study found that compared to 
control Wistar-Kyoto and Wistar rats, SHR sensitize more readily to repeated cocaine 
administration and exhibit increased conditioned response in the cocaine-paired context 
(Chapter 5). MPH treatment during adolescence did not alter cocaine sensitization or 
conditioning the adult SHR (Chapter 5), nor did it alter cocaine cue-reactivity under the 
second-order schedule (Jordan et al, submitted). Taken together, these results lend 
support to the incentive sensitization theory by showing that strain differences in 
sensitization is associated with robust reinstatement of responding for cocaine cues and 
context.  
In conclusion, SHR exhibit enhanced sensitivity for cocaine and cocaine-cues 
compared to Wistar-Kyoto and Wistar rats. MPH treatment during adolescence did not 
alter sensitization to cocaine or cocaine cue-reactivity in adult SHR, but increased DAT 
function in the mPFC in a trafficking independent manner. In contrast, ATO treatment 
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during adolescence decreased cocaine cue-reactivity and decreased DAT function in the 
OFC and dorsal striatum of adult SHR.  
 
8.3 Implications 
8.3.1 How can the results with SHR be used to improve treatment outcomes in 
ADHD? 
ADHD individuals with comorbid cocaine dependence were found to be more 
impulsive than non-cocaine dependent ADHD individuals and demographically-matched 
healthy controls (Crunelle et al, 2013). However, prospective experimental design is 
needed to evaluate whether preexisting differences in impulsivity led to cocaine 
dependence in individuals with ADHD or whether cocaine abuse contributed to the 
increased impulsivity. Using an animal model of ADHD, the current study reported that 
MPH treatment during adolescence increased burst responses in adult SHR under DRL30 
schedule (Chapter 7), suggesting that MPH treatment increased response inhibition 
deficit in SHR. By extrapolation, increased response inhibition deficit following MPH 
treatment during adolescence may underlie increased cocaine abuse (Lambert et al, 
1998; Mannuzza et al, 2008). Furthermore, the increased response inhibition deficit as 
evaluated by increased burst responding may be a behavioral marker for increased 
cocaine abuse liability in individuals with ADHD who were treated with MPH during 
adolescence. However, human subjects learn the DRL schedule of reinforcement to 
100% efficiency in a matter of hours (Stewart et al, 2006). Thus, in clinical laboratory 
studies, individuals exhibit suboptimal performance on DRL schedules for a very limited 
time during which the differences between individuals with comorbid ADHD and 
cocaine dependence and those without the comorbid cocaine dependence may be 
apparent. The mathematical modeling approach optimized herein (Chapter 6) may be 
able to identify individual differences in responding under the DRL schedule within a 
limited time-window, and thus facilitate clinical research with DRL schedules. Further, 
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DRL schedules coupled with mathematical modeling approach may be developed as a 
behavioral assay or marker to identify individuals with ADHD in whom MPH treatment 
during adolescence increased cocaine abuse liability.  
ADHD-like symptoms are often presented by individuals with neurogenetic 
disorders such as Tuberous Sclerosis Complex, Neurofibromatosis I, Williams Syndrome, 
and Fragile X Syndrome. These clinical comorbidities clearly indicate that the down-
stream effects of these varied genetic abnormalities converge upon common biological 
pathways or neural circuits (Curatolo et al, 2010; Lo-Castro et al, 2011), thus giving rise 
to the concept of endophenotypes. Endophenotypes are proximal markers of gene 
action, and comorbid conditions may help identify such genetically homogeneous 
subgroups (Bearden et al, 2004; Gottesman et al, 2003). Furthermore, 
pharmacogenomics research in ADHD for predicting response to treatment and side 
effects of treatment has been lagging (Kieling et al, 2010). Improved understanding of 
the effects of ADHD therapeutics on endophenotypes will advance the field of ADHD 
pharmacogenomics. Impulsivity under DRL schedules may isolate potential 
endophenotypes associated with the increased cocaine abuse liablility in individuals 
with ADHD (Almasy et al, 2001; Bearden et al, 2004; Crosbie et al, 2008; Winstanley et 
al, 2010a). With the two DRL schedules used herein, response inhibition deficits (burst 
responding) and sensitivity to delayed reinforcement (accuracy of estimating wait-time) 
were identified as two facets of impulsivity that may underlie the comorbidity between 
ADHD and cocaine abuse. A key finding of the current study was that MPH treatment 
during adolescence resulted in decreased response inhibition (increased burst 
responding, Chapter 7) in adulthood. Furthermore, converging evidence from the DAT 
function assays presented herein and studies from the literature reporting effects of 6 -
hydroxydopamine lesion suggest that reduced dopaminergic signaling in the mPFC may 
be the neurological basis for reduced response inhibition. Taken together, increased 
burst responding under DRL30 and the associated decreased dopaminergic signaling in 
the mPFC may be the neurobehavioral marker for the increased cocaine abuse liability. 
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The current results have several implications for clinical practice of therapeutic 
strategies for ADHD. Firstly, given the causal relation between reduced response 
inhibition and increased cocaine abuse liability (Fillmore et al, 2002; Li et al, 2006), our 
studies suggest that the increased cocaine abuse liability in adulthood following MPH 
treatment during adolescence (Mannuzza et al, 2008) may be mediated by decreased 
response inhibition in the ADHD individuals. Thus, therapeutic approaches that reduce 
response inhibition deficits will be protective against cocaine abuse liability in MPH-
treated ADHD individuals. 
Secondly, an improved understanding of the underlying neurochemistry 
associated with discontinuation of MPH treatment may enable identification of 
appropriate therapeutic strategies for ADHD individuals with comorbid cocaine abuse. In 
the current study, SHR displayed elevated NET function in the lateral orbitofrontal 
cortex (Chapter 4), which is expected to lead to decreased norepinephrine transmission 
as well as decreased dopamine transmission by inhibiting dopamine clearance via NET 
(Moron et al, 2002). MPH treatment during adolescence normalized NET function in SHR 
(Chapter 4), suggesting that both norepinephrine and dopamine transmission in the OFC 
are normalized. Therefore, OFC mediated function such as attention, working memory 
and impulsive decision making are expected to be normalized following MPH treatment 
during adolescence (Harvey et al, 2013; Kantak et al, 2008; Sun et al, 2012; Zeeb et al, 
2010). Prophylactic strategies that capitalize on these behavioral facets may provide 
better outcomes in terms of reducing cocaine abuse risk in individuals with ADHD who 
had been treated with MPH during adolescence. 
Dopaminergic function in the OFC is implicated in ascribing the relative ‘value’ of 
a larger delayed reward compared to a smaller immediate reward (Kheramin et al, 2004; 
Kheramin et al, 2002). In delay discounting studies, inhibition of D1 and/or D2 receptors 
in the OFC increases the choice for small immediate reward over a delayed but larger 
reward, and increasing D1/D2 receptor activation produced the opposite effect (Pardey 
et al, 2013; Wade et al, 2000). In the current study, ATO treatment during adolescence 
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did not increase DAT function in the mPFC, but decreased DAT function in the OFC of 
SHR during adulthood (Chapter 3). Thus, an ATO-induced decrease in DAT function in 
the OFC of SHR would be expected to decrease impulsive choice. A previous study 
reported that chronic ATO administration to adolescent outbred rats decreased 
impulsivity on a delay discounting assay, that was associated with changes in neuronal 
plasticity markers in the OFC (Sun et al, 2012). Thus, the protective effect of ATO against 
further increasing cocaine self-administration (Somkuwar et al, 2013b) may be mediated 
partially by decreased impulsivity. However, whether ATO treatment during 
adolescence is associated with decreased impulsive choice during adulthood needs to 
be empirically evaluated in future work. Importantly, ATO decreased cue-induced 
reinstatement of second order responding (Jordan et al, submitted), which was 
associated with a decreased striatal DAT function (Chapter 3). Taken together, ATO may 
be a safer treatment alternative for ADHD adolescents in whom cocaine abuse liability is 
a concern. 
 
 
8.3.2 Predictions for future studies  
8.3.2.1 Other facets of impulsivity 
SHR show greater sensitivity to delayed reinforcement (reduced response 
threshold under DRL30; Chapter 7) compared to WKY and WIS, which is consistent with 
strain differences in delay discounting studies (Wooters et al, 2011). MPH treatment 
during adolescence does not alter sensitivity to delayed reinforcement in adult SHR 
under DRL schedules (Chapter 7). However, the effects of MPH treatment on SHR 
behavior under delay discounting schedules, including a ‘choice’ to obtain a smaller 
reinforcement as opposed to a delayed larger reward has not been evaluated.  
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The neurochemical results in the current study reveal that MPH treatment 
increased DAT function in mPFC and normalized the previously elevated NET function in 
the OFC in SHR (Chapters 2 and 4, respectively). The role of mPFC dopaminergic 
signaling on impulsive choice is complex. Previous studies report that D1 antagonists as 
well as high doses D1 agonists applied into the mPFC increase impulsive choice, i.e. 
choice of a the smaller immediate reinforcement (Loos et al, 2010; Pardey et al, 2013). 
Thus, tonic D1 activation promotes choice of delayed larger reward; decreased D1 
receptor activation increases impulsive choice due to ineffective suppression of cortical 
inputs (i.e. noise; Arnsten et al, 2005). In the current study, increased DAT function in 
the mPFC of MPH-treated SHR may lead to impulsive choice in this ADHD model. 
On the other hand, inhibition of D1 and/or D2 receptors in OFC increase the 
choice of the small immediate reward over delayed but larger reward, and increasing 
D1/D2 receptor signaling by increasing extracellular dopamine has the opposite effect 
on impulsive choice (Pardey et al, 2013; Wade et al, 2000). In the current study, NET 
function was greater in the OFC of SHR compared to Wistar-Kyoto and Wistar rats 
(Chapter 4). Since NET in cortical areas is responsible for regulating extracellular 
dopamine (Moron et al, 2002), the increased NET function in the OFC of SHR reported 
herein may be the neurochemical basis for the previously reported increased impulsive 
choice in SHR (Wooters et al, 2011). Furthermore, MPH treatment during adolescence 
normalized NET function in the OFC of adult SHR (Chapter 4). Therefore, MPH-treated 
SHR are expected to exhibit reduced impulsivity on a delay discounting paradigm during 
adulthood. 
 
8.3.2.2 Other neurochemical mechanisms 
Compared to adult WKY and WIS, SHR display several behavioral deficits that 
may underlie increased cocaine self-administration in SHR (Harvey et al, 2011; 
Somkuwar et al, 2013b). SHR display reduced response inhibition during the DRL30 
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schedule (increased bursts, Chapters 6 and 7), as well as an elevated sensitivity to 
delayed reinforcement under DRL schedules (reduced response threshold under DRL30, 
Chapter 6 and 7) and delayed reward choice paradigms (Slezak et al, 2011; Wooters et 
al, 2011), all of which confer the vulnerability for acquiring drug-taking behavior in SHR. 
Further studies are required to obtain a more comprehensive understanding of the 
neurochemical basis for the strain differences between SHR and control in sensitivity to 
delayed reinforcement (accuracy of estimating wait-time), cocaine self-administration as 
well as cocaine sensitization. Catecholaminergic receptors, other neurotransmitter 
systems (e.g. serotonin) as well as other brain regions (e.g., nucleus accumbens; NAc) 
have been implicated in these behaviors (Pattij and Vanderschuren, 2008).  
Increased sensitization to the  psychomotor effects of cocaine has been 
suggested to mediate the transition from recreational drug use to addiction (Ferrario et 
al, 2005; Robinson et al, 2001; but see Ahmed et al, 2006). Compared to Wistar-Kyoto 
and Wistar, SHR were less sensitive to the locomotor-activating effect of cocaine, but 
readily sensitized to repeated cocaine administration and reinstated responding for 
cocaine cues (Chapter 5 and Jordan et al, submitted). Dopamine in the NAc is implicated 
in cocaine sensitization and cue-induced reinstatement of cocaine seeking behavior (Di 
Ciano et al, 2008; Pierce et al, 1996a; Pierce et al, 1996b; Robinson et al, 1993). 
Compared to WKY controls, SHR show attenuated dopamine release in the NAc that was 
reversed by D2 receptor antagonists to a greater extent in SHR than in WKY (Russell et 
al, 1995, 1998). Dopamine in the mPFC modulates dopamine release in the NAc (Beyer 
et al, 1999). Following MPH treatment during adolescence, DAT function in the mPFC 
and cocaine self-administration were both increased (Chapter 2; Harvey et al, 2011; 
Somkuwar et al, 2013a). Surprisingly, locomotor sensitization to cocaine and second 
order reinstatement for cocaine cues were not altered by MPH treatment (Chapter 5 
and Jordan et al, submitted). Self-administration may be modulated by phasic dopamine 
release in the mPFC, while sensitization and cue-reactivity may be modulated by tonic 
dopamine through D2 receptor-mediated mechanisms. Support for this hypothesis is 
that decreased D2 function in the mPFC facilitated development of sensitization by 
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increasing glutamatergic signaling in the mPFC and NAc (Liu et al, 2011). D2 antagonists 
did not alter cocaine-induced reinstatement but attenuated cue-induced reinstatement 
(Capriles et al, 2003; Cervo et al, 2003). Taken together, SHR may have lower D2 
function in mPFC and greater D2 function in the NAc compared to control. Also, the lack 
of effect of MPH on sensitization and cue-reactivity suggests that MPH treatment does 
not alter D2 function in either areas of the brain.   
The dorsolateral subregion of the striatum is implicated in cue-reactivity under 
second-order schedules (Vanderschuren et al, 2005), and dopaminergic cross-talk 
between the dorsolateral striatum and NAc modulates cocaine cue-reactivity (Belin and 
Everitt, 2008a). ATO treatment during adolescence decreased striatal DAT function in 
SHR (Chapter 3), which may underlie the attenuated cocaine cue-reactivity during 
adulthood. In the current study, strain differences in striatal DAT function were not 
obtained (Chapter 2 and 3), but SHR exhibited greater cocaine cue-reactivity compared 
to Wistar-Kyoto and Wistar rats (Jordan et al, submitted). In contrast to the results for 
striatal DAT function reported herein, a recent study using in vivo voltammetry 
suggested that compared to Wistar-Kyoto and outbred rats, SHR exhibit differences in 
DAT function within the subregions of the dorsal striatum (Miller et al, 2012). The latter 
study evaluated uptake of exogenously applied dopamine for three depths of the dorsal 
striatum and for NAc. SHR exhibited faster dopamine uptake in the NAc and in the 
ventral portions of the dorsal striatum, while DAT function did not differ in the dorsal 
coordinates of dorsal striatum. Taken together, the increased DAT function in the 
ventral portions of the striatum and in the NAc may underlie the increased cocaine cue-
reactivity in SHR compared to controls. Extending these results to the increased cocaine 
abuse liability in individuals with ADHD suggests that hypodopaminergic striatum and 
accumbens may contribute to increased sensitivity for cocaine cues. 
Serotonergic tone and receptor function also have been implicated in impulsivity 
(Dalley et al, 2002; Perry et al, 2011; Winstanley et al, 2006b). A dysfunctional 
serotonergic system is not thought to underlie ADHD, since serotonergic modulators do 
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not ameliorate ADHD symptoms (Adriani et al, 2004; Winstanley et al, 2006a). As a 
consequence, serotonergic involvement ADHD etiopathology has not been investigated 
extensively. However, a recent genetic association study suggests that serotoninergic 
receptor systems may be involved in ADHD and substance use disorder comorbidity 
(Sanchez-Mora et al, 2013). Although, serotonin transporters have not been associated 
with response inhibition deficits (Jupp et al, 2013b), serotonin transporter 
polymorphisms have been associated with greater impulsive choice in delay discounting 
paradigms in individuals with ADHD (Sonuga-Barke et al, 2011). Furthermore, individuals 
with comorbid ADHD and cocaine dependence are a more impulsive subpopulation of 
adults with ADHD (Crunelle et al, 2013). Taken together, these results suggest that 
serotonergic mechanisms need to be evaluated further with respect to control of 
impulsivity in ADHD, which also may be a valuable therapeutic strategy for managing 
comorbid ADHD and cocaine abuse. 
 
8.3.3 Implications of the 5th edition of Diagnostic and Statistical Manual of Mental 
Disorders (DSM V, American Psychiatric Association., 2013b) 
In the new edition of the DSM-V, the age of expression of ADHD symptoms was 
increased from 7 years to 12 years. The increase in age of diagnosis is of particular 
concern taking into account the results of the current study that shows that MPH 
treatment initiation during adolescence is associated with several deleterious 
consequences with respect to future cocaine abuse liability. However, the current study 
does not eliminate the possibility that the behavioral and neurochemical sequel of MPH 
treatment during adolescence was a consequence of ‘discontinuation’ of the treatment. 
Clinical report suggests that continued stimulant treatment may be protective against 
development of future cocaine abuse liability (Biederman et al, 1999b).  
A recent study reported that in 15 to 21 year old individuals with ADHD, the 
prescription rate of MPH and ATO declines more rapidly than the rate of decline of 
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ADHD symptoms (McCarthy et al, 2009). These results suggest the possibility that 
treatment is prematurely discontinued in some young adults. One reason for these 
clinical practices may be the reluctance of clinicians to diagnose ADHD in older 
adolescents due to the unclear definitions of remission in DSM IV (American Psychiatric 
Association., 2000). In DSM IV, partial remission status was applied for individuals who 
exhibited symptoms that “no longer meet full criteria” (American Psychiatric 
Association., 2000).  In the DSM V, the definition and diagnostic criteria for ADHD have 
been updated to facilitate characterization of ADHD in older adolescents (age >17 years) 
and adults (American Psychiatric Association., 2013b). Specifically, partial remission was 
applied when individuals who met the full ADHD criteria in the past (i.e., during 
childhood or adolescence) exhibited fewer symptoms than the full criteria for the past 6 
months, and the symptoms still contribute to impaired function in social, academic and 
occupational settings. Furthermore, provisions have been included to specify the 
severity of the impairments under the new DSM V. Again, studies using the SHR model 
may reveal whether continued MPH treatment leads to different outcomes in terms of 
abuse liability evaluated using cocaine self-administration, response inhibition deficit 
and DAT function in the mPFC.  
 
8.4 Limitations 
8.4.1 General limitations of the overall experimental design 
One limitation of the overall experimental design was that single doses of MPH 
and ATO were evaluated in the current study. MPH dose was chosen based on previous 
studies that demonstrated efficacy as well as therapeutically relevant plasma levels of 
MPH in rats (Berridge et al, 2006; Harvey et al, 2011; Kantak et al, 2008; Kuczenski et al, 
2002; Umehara et al, 2013b). Unlike MPH, the ATO dose employed may not be referred 
to as being ‘therapeutically relevant’ because the plasma concentration of ATO in rats 
has not been empirically compared with the therapeutically efficacious plasma levels 
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observed in the clinical studies. However, the dose used herein was established as 
pharmacologically efficacious and mechanistically relevant as an ADHD therapeutic 
(Bymaster et al, 2002; Levy, 2008; Robinson et al, 2008a; Swanson et al, 2006). 
Specifically, ATO at 0.3 mg/kg, i.p. increased extracellular dopamine and norepinephrine 
in the PFC, decreased hyperactivity and impulsivity and increased attention in rats 
(Bymaster et al, 2002; Gamo et al, 2010; Robinson et al, 2008a; Umehara et al, 2013a).  
The oral route of administration is clinically relevant for both MPH and ATO. 
Therefore, the oral dosing regimen of MPH used in the current study closely resembles 
the clinical situation (Gerasimov et al, 2000). However, ATO was administered via 
intraperitoneal injection in the current study. Oral bioavailability of ATO in rats is 4% of 
intravenous administration (Mattiuz et al, 2003), and hence the intraperitoneal route of 
administration was used in our studies to better control dosing. Taken together, 
although ther are always limitations, the dose and route of administration of MPH and 
ATO were optimal for addressing the objectives of the current study. 
 
8.4.2 Limitations in translational value of the impulsivity study 
The current study revealed that in adolescent SHR, chronic treatment with a 
therapeutically-relevant dose of MPH did not decrease response inhibition deficit 
(Chapter 6 and 7). Compared to vehicle control, burst responding was increased and 
response threshold was decrease with chronic MPH in adolescent SHRs (Chapter 6). 
These results were surprising since MPH reduces impulsivity in individuals with ADHD. 
One explanation may be limitations of the SHR model of ADHD (van den Bergh et al, 
2006). SHR, though inbred and genetically homogeneous, have been suggested to have 
impulsive and non-impulsive subpopulations that differ in their response to MPH under 
delay discounting schedules (Adriani et al, 2003). In contrast to effects on response 
inhibition capacity, comparable dose of MPH improved several ADHD-related behavioral 
deficits in SHRs, including working memory, behavioral flexibility, hyperactivity as well 
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as impulsive decision making (Adriani et al, 2003; Harvey et al, 2013; Harvey et al, 2011; 
Kantak et al, 2008; Umehara et al, 2013b). Furthermore, in agreement with previous 
reports, the current study found reduced latency for responding and no change in 
locomotor activity with chronic MPH treatment (Harvey et al, 2013; Yang et al, 2011). 
Taken together, these results suggest SHR may capture limited aspects of ADHD and 
other models also should be explored. 
Another explanation for the unexpected effects of MPH on response inhibition 
capacity may be that the experimental preparations for rats do not model the clinical 
measures of response inhibition capacity. Another schedule evaluating response 
inhibition capacity is the 5-choice serial reaction time task. In this preparation, MPH and 
d-amphetamine administered at therapeutically relevant low doses reproducibly 
increased premature responses (Economidou et al, 2012; Navarra et al, 2008; Paterson 
et al, 2011).These results are in agreement with the results from the current study that 
proportion of burst responding was increased and the proportion of timed responding 
was decreased in MPH-treated adolescent rats (Chapter 6). In contrast to stimulants, 
the NET inhibitor ATO was reported to reduce premature responding (Navarra et al, 
2008; Paterson et al, 2011). Taken together, response inhibition tasks in rodents may be 
particularly sensitive to the ‘stimulant’ properties of MPH, and thus, these tasks have 
limited translational utility.  
 
8.4.3 Limitations of an animal model approach 
The high comorbidity of cocaine abuse in ADHD individuals is well documented in 
the clinical literature (see section 1.4; Carroll et al, 1993; Levin et al, 1999; Szobot et al, 
2007). While the current study empirically evaluated mechanisms that contribute to this 
comorbidity, they have inherent limitations. These reductionist approach using animal 
models cannot capture the inherent complexity of psychiatric comorbidities being 
modeled. Factors such as prenatal drug exposure, environmental factors, and complex 
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social interactions need to be individually modeled in comparable studies to increase 
our understanding of the comorbidity of ADHD and cocaine abuse liability. 
One of the most widely debated and highly controversial topics in the 
comorbidity of ADHD and cocaine abuse has been the effects of MPH treatment on 
cocaine abuse liability in individuals with ADHD (Kollins, 2008b). One of the early studies 
reporting that MPH treatment during adolescence increased the risk substance abuse 
and dependence (Lambert et al, 1998) was heavily criticized (Mick et al, 2000). A 
particular concern was that the authors did not control for comorbid conduct disorder in 
their subjects, which is an independent predictor for problem drug use (Burke et al, 
2001), also see section 1.4.1 A later study found that MPH treatment during childhood 
was associated with a greater likelihood of ever using cocaine by adulthood only in the 
presence of comorbid conduct disorder (Barkley et al, 2003). In contrast, a study that 
excluded children with conduct disorder found a positive correlation between age of 
initiation of MPH treatment and cocaine abuse during adulthood (Mannuzza et al, 
2008), such that lifetime rates of cocaine abuse were higher when treatment was 
initiated in early adolescence. Taken together, the effect of MPH treatment on the 
comorbidity of ADHD and cocaine abuse, appears to depend on a complex relation 
between age of treatment initiation and presence of comorbid conditions and the 
current model does not capture these complexities in its entirity.  
 
8.5 Future directions 
To complete the profile of ATO as an alternative therapeutic strategy for ADHD 
adolescents at a higher risk for cocaine abuse, effects of discontinuation of ATO 
treatments on cocaine sensitization, response inhibition capacity as well as NET function 
in the mPFC and OFC needs to be evaluated. Due to the non-stimulant profile, ATO may 
be particularly useful for individuals with ADHD and comorbid substance use disorders 
(Garnock-Jones et al, 2010). However, ATO is not efficacious in about 25% ADHD 
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children and 40% ADHD adults (Spencer et al, 2001; Surman et al, 2010); therefore other 
therapeutic options also need to be explored. 
The treatment discontinuation model is clinically relevant because delayed 
initiation of MPH treatment has been associated with increased discontinuation of 
treatment (Chen et al, 2011). Furthermore, a recent review documented high rates of 
non-adherence to ADHD medications and noted peak rates of discontinuation of MPH 
after 5 years of treatment initiation in children and adolescents (Adler et al, 2010). 
Therefore, whether the elevated risk for cocaine abuse liability was an outcome of MPH 
treatment itself or of treatment discontinuation needs to be addressed in future studies. 
The impact of discontinuation of MPH treatment on drug abuse liability needs to be 
evaluated to inform new treatment strategies for ADHD individuals at an elevated risk 
for cocaine abuse. 
Strain differences between adult SHR, WKY and WIS revealed several behavioral 
mechanisms that underlie the elevated cocaine self-administration in SHRs such as 
greater impulsivity, sensitivity to cocaine cues and context, and greater reinforcing 
efficacy of cocaine. Dopaminergic function in the NAc and serotonergic function in the 
mPFC and OFC maybe mechanisms that also contribute to the increased cocaine abuse 
vulnerability in ADHD individuals (Koob et al, 2010; Pattij et al, 2008) and should be 
evaluated in the future.  
The current model of MPH treatment and discontinuation in SHR was 
established as a valuable model for delineating the neurobehavioral mechanisms 
associated the comorbidity of ADHD and cocaine abuse as well as the MPH-treatment 
mediated increase in future cociane abuse liability. Based on the results of the current 
study, this model is recommended for future studies to identify additional 
neurochemical and behavioral mechanisms to assist in developing therapeutic strategies 
to protect individuals with ADHD from developing cocaine abuse as well as to identify 
measures to attenuate the risk of escalating cocaine abuse in individuals with ADHD 
who have been treated with methylpheniate during adolescence. 
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8.6 Final comments 
The current study delineates the neurochemical and behavioral mechanisms 
associated with the increased cocaine self-administration in MPH-treated SHR. The 
results demonstrate that SHR were more impulsive and more sensitive to repeated 
cocaine administration compared to control, thus making SHR more vulnerable to 
cocaine self- administration and more reactive to cocaine cues, respectively. Also, SHR 
exhibit increased NET function in the OFC which may partially underlie the increased 
impulsivity and cocaine self-administration in SHR. MPH treatment during adolescence 
increased impulsivity and mPFC DAT function during adulthood, providing 
neurobehavioral mechanisms for the increased cocaine self-administration in SHR.  In 
contrast, ATO treatment during adolescence decreased DAT function in the OFC and 
striatum thus providing neurochemical mechanism for reduced cocaine cue-reactivity 
and suggesting a decrease in impulsivity in SHRs. Also, MPH normalized NET function in 
the OFC and decreased locomotor activity in adult SHR, suggesting that MPH treatment 
during adolescence may produce some persistent neurobehavioral improvements in 
ADHD. Pharmacological and behavioral interventions counteracting the increased mPFC 
DAT function and impulsivity in MPH-treated ADHD individuals may provide protection 
against cocaine abuse liability. Furthermore, interventions that reduce DAT function in 
the PFC may provide additional protection against cocaine abuse liability in ADHD 
individuals.   
 
 
 
 
Copyright © Sucharita S. Somkuwar 2013 
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